CA2385172A1 - Ab5 toxin b subunit mutants with altered chemical conjugation characteristics - Google Patents
Ab5 toxin b subunit mutants with altered chemical conjugation characteristics Download PDFInfo
- Publication number
- CA2385172A1 CA2385172A1 CA002385172A CA2385172A CA2385172A1 CA 2385172 A1 CA2385172 A1 CA 2385172A1 CA 002385172 A CA002385172 A CA 002385172A CA 2385172 A CA2385172 A CA 2385172A CA 2385172 A1 CA2385172 A1 CA 2385172A1
- Authority
- CA
- Canada
- Prior art keywords
- protein
- subunit
- toxin
- amino acid
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000126 substance Substances 0.000 title claims description 18
- 230000021615 conjugation Effects 0.000 title description 98
- 231100000765 toxin Toxicity 0.000 title description 43
- 239000003053 toxin Substances 0.000 title description 42
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 310
- 235000018102 proteins Nutrition 0.000 claims abstract description 232
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 232
- 108010049048 Cholera Toxin Proteins 0.000 claims abstract description 227
- 102000009016 Cholera Toxin Human genes 0.000 claims abstract description 226
- 230000035772 mutation Effects 0.000 claims abstract description 103
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 88
- 238000000034 method Methods 0.000 claims abstract description 77
- 230000002163 immunogen Effects 0.000 claims abstract description 69
- 238000007385 chemical modification Methods 0.000 claims abstract description 31
- 235000018417 cysteine Nutrition 0.000 claims abstract description 14
- 239000003446 ligand Substances 0.000 claims abstract description 14
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 6
- 235000001014 amino acid Nutrition 0.000 claims description 171
- 230000027455 binding Effects 0.000 claims description 116
- 150000001413 amino acids Chemical class 0.000 claims description 108
- 238000006467 substitution reaction Methods 0.000 claims description 81
- 238000012217 deletion Methods 0.000 claims description 74
- 230000037430 deletion Effects 0.000 claims description 74
- 230000004048 modification Effects 0.000 claims description 52
- 238000012986 modification Methods 0.000 claims description 52
- 150000001875 compounds Chemical class 0.000 claims description 50
- 230000000975 bioactive effect Effects 0.000 claims description 49
- 238000003780 insertion Methods 0.000 claims description 41
- 230000037431 insertion Effects 0.000 claims description 41
- 101710182223 Toxin B Proteins 0.000 claims description 36
- 241000588724 Escherichia coli Species 0.000 claims description 32
- 238000004519 manufacturing process Methods 0.000 claims description 31
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 29
- 230000014509 gene expression Effects 0.000 claims description 28
- 108010081690 Pertussis Toxin Proteins 0.000 claims description 27
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 24
- 239000002671 adjuvant Substances 0.000 claims description 24
- 239000013598 vector Substances 0.000 claims description 22
- 239000004472 Lysine Substances 0.000 claims description 20
- 108020004705 Codon Proteins 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 108010079723 Shiga Toxin Proteins 0.000 claims description 18
- 230000028993 immune response Effects 0.000 claims description 15
- 108091026890 Coding region Proteins 0.000 claims description 14
- 239000003431 cross linking reagent Substances 0.000 claims description 14
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 13
- 108020001507 fusion proteins Proteins 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 125000000524 functional group Chemical group 0.000 claims description 9
- 230000004927 fusion Effects 0.000 claims description 9
- 231100000710 AB5 toxin Toxicity 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 8
- 230000005875 antibody response Effects 0.000 claims description 7
- 230000007423 decrease Effects 0.000 claims description 7
- 230000001965 increasing effect Effects 0.000 claims description 7
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 6
- 230000024932 T cell mediated immunity Effects 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 230000002519 immonomodulatory effect Effects 0.000 claims description 3
- 102220571113 Carboxypeptidase M_F25K_mutation Human genes 0.000 claims description 2
- 102220516191 Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial_N21C_mutation Human genes 0.000 claims description 2
- 102220241096 rs1555523987 Human genes 0.000 claims description 2
- 102220008905 rs34227486 Human genes 0.000 claims description 2
- 102220176286 rs771811712 Human genes 0.000 claims description 2
- 102220094196 rs876660097 Human genes 0.000 claims description 2
- 102220645246 Orofacial cleft 1 candidate gene 1 protein_K34G_mutation Human genes 0.000 claims 2
- 102220624465 Phospholemman_K63G_mutation Human genes 0.000 claims 2
- 102000035118 modified proteins Human genes 0.000 claims 2
- 108091005573 modified proteins Proteins 0.000 claims 2
- 102220561803 Sodium/potassium-transporting ATPase subunit beta-1-interacting protein 4_K91Q_mutation Human genes 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 abstract description 53
- 235000018977 lysine Nutrition 0.000 abstract description 20
- 238000005859 coupling reaction Methods 0.000 abstract description 9
- 230000008878 coupling Effects 0.000 abstract description 8
- 238000010168 coupling process Methods 0.000 abstract description 8
- 230000003993 interaction Effects 0.000 abstract description 6
- 230000005847 immunogenicity Effects 0.000 abstract description 3
- 150000001945 cysteines Chemical class 0.000 abstract 1
- 150000002669 lysines Chemical class 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 description 128
- 150000002270 gangliosides Chemical class 0.000 description 81
- 125000003275 alpha amino acid group Chemical group 0.000 description 79
- 108700012359 toxins Proteins 0.000 description 41
- 239000000427 antigen Substances 0.000 description 31
- 102000036639 antigens Human genes 0.000 description 31
- 108091007433 antigens Proteins 0.000 description 31
- 230000002939 deleterious effect Effects 0.000 description 29
- 239000012634 fragment Substances 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 26
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 26
- 108010071207 serylmethionine Proteins 0.000 description 21
- 238000007792 addition Methods 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 241000607626 Vibrio cholerae Species 0.000 description 19
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 18
- VNYMOTCMNHJGTG-JBDRJPRFSA-N Ala-Ile-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O VNYMOTCMNHJGTG-JBDRJPRFSA-N 0.000 description 18
- 239000000872 buffer Substances 0.000 description 18
- 150000002339 glycosphingolipids Chemical class 0.000 description 18
- 230000002209 hydrophobic effect Effects 0.000 description 18
- 239000012528 membrane Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 210000004379 membrane Anatomy 0.000 description 15
- 230000013823 prenylation Effects 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- ONNSECRQFSTMCC-XKBZYTNZSA-N Thr-Glu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ONNSECRQFSTMCC-XKBZYTNZSA-N 0.000 description 12
- 239000008363 phosphate buffer Substances 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 108091033319 polynucleotide Proteins 0.000 description 12
- 102000040430 polynucleotide Human genes 0.000 description 12
- 239000002157 polynucleotide Substances 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 241000277307 Esox Species 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 108010017391 lysylvaline Proteins 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 231100000419 toxicity Toxicity 0.000 description 11
- 230000001988 toxicity Effects 0.000 description 11
- MDNAVFBZPROEHO-UHFFFAOYSA-N Ala-Lys-Val Natural products CC(C)C(C(O)=O)NC(=O)C(NC(=O)C(C)N)CCCCN MDNAVFBZPROEHO-UHFFFAOYSA-N 0.000 description 10
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 10
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 10
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 10
- LMKSBGIUPVRHEH-FXQIFTODSA-N Met-Ala-Asn Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(N)=O LMKSBGIUPVRHEH-FXQIFTODSA-N 0.000 description 10
- DRXODWRPPUFIAY-DCAQKATOSA-N Met-Asn-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCCN DRXODWRPPUFIAY-DCAQKATOSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- GMWNQSGWWGKTSF-LFSVMHDDSA-N Phe-Thr-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O GMWNQSGWWGKTSF-LFSVMHDDSA-N 0.000 description 10
- HZWPGKAKGYJWCI-ULQDDVLXSA-N Tyr-Val-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(C)C)C(O)=O HZWPGKAKGYJWCI-ULQDDVLXSA-N 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 238000012412 chemical coupling Methods 0.000 description 10
- 238000005755 formation reaction Methods 0.000 description 10
- 238000002703 mutagenesis Methods 0.000 description 10
- 231100000350 mutagenesis Toxicity 0.000 description 10
- 230000002588 toxic effect Effects 0.000 description 10
- HJCGDIGVVWETRO-ZPFDUUQYSA-N Asp-Lys-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC(O)=O)C(O)=O HJCGDIGVVWETRO-ZPFDUUQYSA-N 0.000 description 9
- BBFCMGBMYIAGRS-AUTRQRHGSA-N Gln-Val-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O BBFCMGBMYIAGRS-AUTRQRHGSA-N 0.000 description 9
- WXLYNEHOGRYNFU-URLPEUOOSA-N Ile-Thr-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N WXLYNEHOGRYNFU-URLPEUOOSA-N 0.000 description 9
- WCTCIIAGNMFYAO-DCAQKATOSA-N Leu-Cys-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O WCTCIIAGNMFYAO-DCAQKATOSA-N 0.000 description 9
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 9
- DMWNPLOERDAHSY-MEYUZBJRSA-N Tyr-Leu-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DMWNPLOERDAHSY-MEYUZBJRSA-N 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 9
- APHUDFFMXFYRKP-CIUDSAMLSA-N Asn-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N APHUDFFMXFYRKP-CIUDSAMLSA-N 0.000 description 8
- IBLAOXSULLECQZ-IUKAMOBKSA-N Asn-Ile-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC(N)=O IBLAOXSULLECQZ-IUKAMOBKSA-N 0.000 description 8
- QUMKPKWYDVMGNT-NUMRIWBASA-N Asn-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O QUMKPKWYDVMGNT-NUMRIWBASA-N 0.000 description 8
- AITKTFCQOBRJTG-CIUDSAMLSA-N Asp-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)O)N AITKTFCQOBRJTG-CIUDSAMLSA-N 0.000 description 8
- DFHVLUKTTVTCKY-PBCZWWQYSA-N His-Asn-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CN=CN1)N)O DFHVLUKTTVTCKY-PBCZWWQYSA-N 0.000 description 8
- JDAWAWXGAUZPNJ-ZPFDUUQYSA-N Ile-Glu-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N JDAWAWXGAUZPNJ-ZPFDUUQYSA-N 0.000 description 8
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 8
- JGAMUXDWYSXYLM-SRVKXCTJSA-N Lys-Arg-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O JGAMUXDWYSXYLM-SRVKXCTJSA-N 0.000 description 8
- YYEIFXZOBZVDPH-DCAQKATOSA-N Met-Lys-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O YYEIFXZOBZVDPH-DCAQKATOSA-N 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 8
- 102000007365 Sialoglycoproteins Human genes 0.000 description 8
- 108010032838 Sialoglycoproteins Proteins 0.000 description 8
- AMXMBCAXAZUCFA-RHYQMDGZSA-N Thr-Leu-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AMXMBCAXAZUCFA-RHYQMDGZSA-N 0.000 description 8
- IMDMLDSVUSMAEJ-HJGDQZAQSA-N Thr-Leu-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IMDMLDSVUSMAEJ-HJGDQZAQSA-N 0.000 description 8
- SJLVYVZBFDTRCG-DCAQKATOSA-N Val-Lys-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)O)N SJLVYVZBFDTRCG-DCAQKATOSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 108010092854 aspartyllysine Proteins 0.000 description 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 8
- 108010069495 cysteinyltyrosine Proteins 0.000 description 8
- -1 for GM-1 Chemical class 0.000 description 8
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 108010054155 lysyllysine Proteins 0.000 description 8
- 108010029020 prolylglycine Proteins 0.000 description 8
- CKLDHDOIYBVUNP-KBIXCLLPSA-N Ala-Ile-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O CKLDHDOIYBVUNP-KBIXCLLPSA-N 0.000 description 7
- AYOAHKWVQLNPDM-HJGDQZAQSA-N Asn-Lys-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O AYOAHKWVQLNPDM-HJGDQZAQSA-N 0.000 description 7
- ZVGRHIRJLWBWGJ-ACZMJKKPSA-N Asp-Ser-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZVGRHIRJLWBWGJ-ACZMJKKPSA-N 0.000 description 7
- KQOPMGBHNQBCEL-HVTMNAMFSA-N Gln-His-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KQOPMGBHNQBCEL-HVTMNAMFSA-N 0.000 description 7
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical group NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 7
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 7
- DCQMJRSOGCYKTR-GHCJXIJMSA-N Ile-Asp-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O DCQMJRSOGCYKTR-GHCJXIJMSA-N 0.000 description 7
- NGKPIPCGMLWHBX-WZLNRYEVSA-N Ile-Tyr-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N NGKPIPCGMLWHBX-WZLNRYEVSA-N 0.000 description 7
- LZDNBBYBDGBADK-UHFFFAOYSA-N L-valyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-UHFFFAOYSA-N 0.000 description 7
- WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 7
- IIKJNQWOQIWWMR-CIUDSAMLSA-N Leu-Cys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)N IIKJNQWOQIWWMR-CIUDSAMLSA-N 0.000 description 7
- PNUCWVAGVNLUMW-CIUDSAMLSA-N Leu-Cys-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O PNUCWVAGVNLUMW-CIUDSAMLSA-N 0.000 description 7
- XOQMURBBIXRRCR-SRVKXCTJSA-N Lys-Lys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN XOQMURBBIXRRCR-SRVKXCTJSA-N 0.000 description 7
- BDFHWFUAQLIMJO-KXNHARMFSA-N Lys-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N)O BDFHWFUAQLIMJO-KXNHARMFSA-N 0.000 description 7
- 102000008300 Mutant Proteins Human genes 0.000 description 7
- 108010021466 Mutant Proteins Proteins 0.000 description 7
- 108010066427 N-valyltryptophan Proteins 0.000 description 7
- 201000005702 Pertussis Diseases 0.000 description 7
- XNMYNGDKJNOKHH-BZSNNMDCSA-N Phe-Ser-Tyr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XNMYNGDKJNOKHH-BZSNNMDCSA-N 0.000 description 7
- MSSXKZBDKZAHCX-UNQGMJICSA-N Phe-Thr-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O MSSXKZBDKZAHCX-UNQGMJICSA-N 0.000 description 7
- DXTOOBDIIAJZBJ-BQBZGAKWSA-N Pro-Gly-Ser Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(O)=O DXTOOBDIIAJZBJ-BQBZGAKWSA-N 0.000 description 7
- 108050002653 Retinoblastoma protein Proteins 0.000 description 7
- LKJCABTUFGTPPY-HJGDQZAQSA-N Thr-Pro-Gln Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O LKJCABTUFGTPPY-HJGDQZAQSA-N 0.000 description 7
- YEGMNOHLZNGOCG-UBHSHLNASA-N Trp-Asn-Asn Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O YEGMNOHLZNGOCG-UBHSHLNASA-N 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 238000004132 cross linking Methods 0.000 description 7
- 239000000147 enterotoxin Substances 0.000 description 7
- 231100000655 enterotoxin Toxicity 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 108010003700 lysyl aspartic acid Proteins 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 230000016379 mucosal immune response Effects 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 230000009885 systemic effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- ROLXPVQSRCPVGK-XDTLVQLUSA-N Ala-Glu-Tyr Chemical compound N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O ROLXPVQSRCPVGK-XDTLVQLUSA-N 0.000 description 6
- NYDIVDKTULRINZ-AVGNSLFASA-N Arg-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NYDIVDKTULRINZ-AVGNSLFASA-N 0.000 description 6
- JSNWZMFSLIWAHS-HJGDQZAQSA-N Asp-Thr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O JSNWZMFSLIWAHS-HJGDQZAQSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 241000588832 Bordetella pertussis Species 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- JRHPEMVLTRADLJ-AVGNSLFASA-N Gln-Lys-Lys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N JRHPEMVLTRADLJ-AVGNSLFASA-N 0.000 description 6
- KEBACWCLVOXFNC-DCAQKATOSA-N Glu-Arg-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O KEBACWCLVOXFNC-DCAQKATOSA-N 0.000 description 6
- DTLLNDVORUEOTM-WDCWCFNPSA-N Glu-Thr-Lys Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DTLLNDVORUEOTM-WDCWCFNPSA-N 0.000 description 6
- NTHIHAUEXVTXQG-KKUMJFAQSA-N Glu-Tyr-Arg Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O NTHIHAUEXVTXQG-KKUMJFAQSA-N 0.000 description 6
- YADRBUZBKHHDAO-XPUUQOCRSA-N His-Gly-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](C)C(O)=O YADRBUZBKHHDAO-XPUUQOCRSA-N 0.000 description 6
- VTZYMXGGXOFBMX-DJFWLOJKSA-N His-Ile-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O VTZYMXGGXOFBMX-DJFWLOJKSA-N 0.000 description 6
- HZMLFETXHFHGBB-UGYAYLCHSA-N Ile-Asn-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N HZMLFETXHFHGBB-UGYAYLCHSA-N 0.000 description 6
- QSPLUJGYOPZINY-ZPFDUUQYSA-N Ile-Asp-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N QSPLUJGYOPZINY-ZPFDUUQYSA-N 0.000 description 6
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 6
- LFSQWRSVPNKJGP-WDCWCFNPSA-N Leu-Thr-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(O)=O LFSQWRSVPNKJGP-WDCWCFNPSA-N 0.000 description 6
- NFLFJGGKOHYZJF-BJDJZHNGSA-N Lys-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN NFLFJGGKOHYZJF-BJDJZHNGSA-N 0.000 description 6
- PINHPJWGVBKQII-SRVKXCTJSA-N Lys-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCCN)N PINHPJWGVBKQII-SRVKXCTJSA-N 0.000 description 6
- UGCIQUYEJIEHKX-GVXVVHGQSA-N Lys-Val-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O UGCIQUYEJIEHKX-GVXVVHGQSA-N 0.000 description 6
- QGQGAIBGTUJRBR-NAKRPEOUSA-N Met-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCSC QGQGAIBGTUJRBR-NAKRPEOUSA-N 0.000 description 6
- 108010079364 N-glycylalanine Proteins 0.000 description 6
- DGHFNYXVIXNNMC-GUBZILKMSA-N Ser-Gln-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N DGHFNYXVIXNNMC-GUBZILKMSA-N 0.000 description 6
- VMVNCJDKFOQOHM-GUBZILKMSA-N Ser-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N VMVNCJDKFOQOHM-GUBZILKMSA-N 0.000 description 6
- SJRUJQFQVLMZFW-WPRPVWTQSA-N Val-Pro-Gly Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O SJRUJQFQVLMZFW-WPRPVWTQSA-N 0.000 description 6
- LNWSJGJCLFUNTN-ZOBUZTSGSA-N Val-Trp-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)O)N LNWSJGJCLFUNTN-ZOBUZTSGSA-N 0.000 description 6
- 108010045350 alanyl-tyrosyl-alanine Proteins 0.000 description 6
- 108010070944 alanylhistidine Proteins 0.000 description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 6
- 235000011130 ammonium sulphate Nutrition 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000013599 cloning vector Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 238000002741 site-directed mutagenesis Methods 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 5
- BLIMFWGRQKRCGT-YUMQZZPRSA-N Ala-Gly-Lys Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN BLIMFWGRQKRCGT-YUMQZZPRSA-N 0.000 description 5
- OKEWAFFWMHBGPT-XPUUQOCRSA-N Ala-His-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CN=CN1 OKEWAFFWMHBGPT-XPUUQOCRSA-N 0.000 description 5
- PNALXAODQKTNLV-JBDRJPRFSA-N Ala-Ile-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O PNALXAODQKTNLV-JBDRJPRFSA-N 0.000 description 5
- JJHBEVZAZXZREW-LFSVMHDDSA-N Ala-Thr-Phe Chemical compound C[C@@H](O)[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](Cc1ccccc1)C(O)=O JJHBEVZAZXZREW-LFSVMHDDSA-N 0.000 description 5
- DJAIOAKQIOGULM-DCAQKATOSA-N Arg-Glu-Met Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O DJAIOAKQIOGULM-DCAQKATOSA-N 0.000 description 5
- HJDNZFIYILEIKR-OSUNSFLBSA-N Arg-Ile-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HJDNZFIYILEIKR-OSUNSFLBSA-N 0.000 description 5
- NPZJLGMWMDNQDD-GHCJXIJMSA-N Asn-Ser-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NPZJLGMWMDNQDD-GHCJXIJMSA-N 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 5
- ATFSDBMHRCDLBV-BPUTZDHNSA-N Cys-Val-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CS)N ATFSDBMHRCDLBV-BPUTZDHNSA-N 0.000 description 5
- 101710146739 Enterotoxin Proteins 0.000 description 5
- GIVHPCWYVWUUSG-HVTMNAMFSA-N Gln-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)N)N GIVHPCWYVWUUSG-HVTMNAMFSA-N 0.000 description 5
- JKGHMESJHRTHIC-SIUGBPQLSA-N Gln-Ile-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N JKGHMESJHRTHIC-SIUGBPQLSA-N 0.000 description 5
- RMWAOBGCZZSJHE-UMNHJUIQSA-N Glu-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N RMWAOBGCZZSJHE-UMNHJUIQSA-N 0.000 description 5
- CSMYMGFCEJWALV-WDSKDSINSA-N Gly-Ser-Gln Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O CSMYMGFCEJWALV-WDSKDSINSA-N 0.000 description 5
- COWHUQXTSYTKQC-RWRJDSDZSA-N Ile-Thr-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N COWHUQXTSYTKQC-RWRJDSDZSA-N 0.000 description 5
- QNTJIDXQHWUBKC-BZSNNMDCSA-N Leu-Lys-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QNTJIDXQHWUBKC-BZSNNMDCSA-N 0.000 description 5
- SQUFDMCWMFOEBA-KKUMJFAQSA-N Leu-Ser-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 SQUFDMCWMFOEBA-KKUMJFAQSA-N 0.000 description 5
- HQVDJTYKCMIWJP-YUMQZZPRSA-N Lys-Asn-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O HQVDJTYKCMIWJP-YUMQZZPRSA-N 0.000 description 5
- KWUKZRFFKPLUPE-HJGDQZAQSA-N Lys-Asp-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWUKZRFFKPLUPE-HJGDQZAQSA-N 0.000 description 5
- RRIHXWPHQSXHAQ-XUXIUFHCSA-N Met-Ile-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(O)=O RRIHXWPHQSXHAQ-XUXIUFHCSA-N 0.000 description 5
- JCMMNFZUKMMECJ-DCAQKATOSA-N Met-Lys-Asn Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O JCMMNFZUKMMECJ-DCAQKATOSA-N 0.000 description 5
- MFQXSDWKUXTOPZ-DZKIICNBSA-N Phe-Gln-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)N MFQXSDWKUXTOPZ-DZKIICNBSA-N 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- OQSQCUWQOIHECT-YJRXYDGGSA-N Ser-Tyr-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OQSQCUWQOIHECT-YJRXYDGGSA-N 0.000 description 5
- VGYVVSQFSSKZRJ-OEAJRASXSA-N Thr-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@H](O)C)CC1=CC=CC=C1 VGYVVSQFSSKZRJ-OEAJRASXSA-N 0.000 description 5
- UEHRGZCNLSWGHK-DLOVCJGASA-N Val-Glu-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UEHRGZCNLSWGHK-DLOVCJGASA-N 0.000 description 5
- 108010047495 alanylglycine Proteins 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 108010055409 ganglioside receptor Proteins 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- MDNAVFBZPROEHO-DCAQKATOSA-N Ala-Lys-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O MDNAVFBZPROEHO-DCAQKATOSA-N 0.000 description 4
- ZJLORAAXDAJLDC-CQDKDKBSSA-N Ala-Tyr-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O ZJLORAAXDAJLDC-CQDKDKBSSA-N 0.000 description 4
- UBCPNBUIQNMDNH-NAKRPEOUSA-N Arg-Ile-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O UBCPNBUIQNMDNH-NAKRPEOUSA-N 0.000 description 4
- QISZHYWZHJRDAO-CIUDSAMLSA-N Asn-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N QISZHYWZHJRDAO-CIUDSAMLSA-N 0.000 description 4
- 101150027801 CTA1 gene Proteins 0.000 description 4
- 101100273295 Candida albicans (strain SC5314 / ATCC MYA-2876) CAT1 gene Proteins 0.000 description 4
- 206010008631 Cholera Diseases 0.000 description 4
- ILWHFUZZCFYSKT-AVGNSLFASA-N Glu-Lys-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O ILWHFUZZCFYSKT-AVGNSLFASA-N 0.000 description 4
- GUOWMVFLAJNPDY-CIUDSAMLSA-N Glu-Ser-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(O)=O GUOWMVFLAJNPDY-CIUDSAMLSA-N 0.000 description 4
- BNMRSWQOHIQTFL-JSGCOSHPSA-N Gly-Val-Phe Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 BNMRSWQOHIQTFL-JSGCOSHPSA-N 0.000 description 4
- XINDHUAGVGCNSF-QSFUFRPTSA-N His-Ala-Ile Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O XINDHUAGVGCNSF-QSFUFRPTSA-N 0.000 description 4
- HERITAGIPLEJMT-GVARAGBVSA-N Ile-Ala-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HERITAGIPLEJMT-GVARAGBVSA-N 0.000 description 4
- AXNGDPAKKCEKGY-QPHKQPEJSA-N Ile-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N AXNGDPAKKCEKGY-QPHKQPEJSA-N 0.000 description 4
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 4
- UILIPCLTHRPCRB-XUXIUFHCSA-N Leu-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)N UILIPCLTHRPCRB-XUXIUFHCSA-N 0.000 description 4
- RIHIGSWBLHSGLV-CQDKDKBSSA-N Leu-Tyr-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O RIHIGSWBLHSGLV-CQDKDKBSSA-N 0.000 description 4
- ZXFRGTAIIZHNHG-AJNGGQMLSA-N Lys-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCCCN)N ZXFRGTAIIZHNHG-AJNGGQMLSA-N 0.000 description 4
- KPVLLNDCBYXKNV-CYDGBPFRSA-N Met-Val-Ile Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KPVLLNDCBYXKNV-CYDGBPFRSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- XZONQWUEBAFQPO-HJGDQZAQSA-N Pro-Gln-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XZONQWUEBAFQPO-HJGDQZAQSA-N 0.000 description 4
- PZZJMBYSYAKYPK-UWJYBYFXSA-N Ser-Ala-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O PZZJMBYSYAKYPK-UWJYBYFXSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- VGYBYGQXZJDZJU-XQXXSGGOSA-N Thr-Glu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O VGYBYGQXZJDZJU-XQXXSGGOSA-N 0.000 description 4
- JAJOFWABAUKAEJ-QTKMDUPCSA-N Thr-Pro-His Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N)O JAJOFWABAUKAEJ-QTKMDUPCSA-N 0.000 description 4
- VHRLUTIMTDOVCG-PEDHHIEDSA-N Val-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H](C(C)C)N VHRLUTIMTDOVCG-PEDHHIEDSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 230000007541 cellular toxicity Effects 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 108010049041 glutamylalanine Proteins 0.000 description 4
- 108010090037 glycyl-alanyl-isoleucine Proteins 0.000 description 4
- 108010040030 histidinoalanine Proteins 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 150000003141 primary amines Chemical class 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 108010038196 saccharide-binding proteins Proteins 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 108010061238 threonyl-glycine Proteins 0.000 description 4
- 230000024033 toxin binding Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- HXNNRBHASOSVPG-GUBZILKMSA-N Ala-Glu-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O HXNNRBHASOSVPG-GUBZILKMSA-N 0.000 description 3
- FEGOCLZUJUFCHP-CIUDSAMLSA-N Ala-Pro-Gln Chemical compound [H]N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O FEGOCLZUJUFCHP-CIUDSAMLSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- CQGBSALYGOXQPE-HTUGSXCWSA-N Glu-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O CQGBSALYGOXQPE-HTUGSXCWSA-N 0.000 description 3
- QSDKBRMVXSWAQE-BFHQHQDPSA-N Gly-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN QSDKBRMVXSWAQE-BFHQHQDPSA-N 0.000 description 3
- CLNSYANKYVMZNM-UWVGGRQHSA-N Gly-Lys-Arg Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CCCN=C(N)N CLNSYANKYVMZNM-UWVGGRQHSA-N 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 description 3
- ZJZNLRVCZWUONM-JXUBOQSCSA-N Leu-Thr-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O ZJZNLRVCZWUONM-JXUBOQSCSA-N 0.000 description 3
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 3
- SBQDRNOLGSYHQA-YUMQZZPRSA-N Lys-Ser-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SBQDRNOLGSYHQA-YUMQZZPRSA-N 0.000 description 3
- GAELMDJMQDUDLJ-BQBZGAKWSA-N Met-Ala-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O GAELMDJMQDUDLJ-BQBZGAKWSA-N 0.000 description 3
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 3
- RMKGXGPQIPLTFC-KKUMJFAQSA-N Phe-Lys-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O RMKGXGPQIPLTFC-KKUMJFAQSA-N 0.000 description 3
- DIFXZGPHVCIVSQ-CIUDSAMLSA-N Pro-Gln-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O DIFXZGPHVCIVSQ-CIUDSAMLSA-N 0.000 description 3
- WDXYVIIVDIDOSX-DCAQKATOSA-N Ser-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N WDXYVIIVDIDOSX-DCAQKATOSA-N 0.000 description 3
- SFTZTYBXIXLRGQ-JBDRJPRFSA-N Ser-Ile-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O SFTZTYBXIXLRGQ-JBDRJPRFSA-N 0.000 description 3
- UGGWCAFQPKANMW-FXQIFTODSA-N Ser-Met-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O UGGWCAFQPKANMW-FXQIFTODSA-N 0.000 description 3
- 108010017898 Shiga Toxins Proteins 0.000 description 3
- PZSDPRBZINDEJV-HTUGSXCWSA-N Thr-Phe-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O PZSDPRBZINDEJV-HTUGSXCWSA-N 0.000 description 3
- NYQIZWROIMIQSL-VEVYYDQMSA-N Thr-Pro-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O NYQIZWROIMIQSL-VEVYYDQMSA-N 0.000 description 3
- LVFZXRQQQDTBQH-IRIUXVKKSA-N Tyr-Thr-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O LVFZXRQQQDTBQH-IRIUXVKKSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 108010070783 alanyltyrosine Proteins 0.000 description 3
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 108010013835 arginine glutamate Proteins 0.000 description 3
- 108010047857 aspartylglycine Proteins 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 230000012202 endocytosis Effects 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 108010000761 leucylarginine Proteins 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 230000000869 mutational effect Effects 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 108010048818 seryl-histidine Proteins 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 108010003137 tyrosyltyrosine Proteins 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- QEIFSLUFHRCVQL-UHFFFAOYSA-N (5-bromo-4-chloro-1h-indol-3-yl) hydrogen phosphate;(4-methylphenyl)azanium Chemical compound CC1=CC=C(N)C=C1.C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QEIFSLUFHRCVQL-UHFFFAOYSA-N 0.000 description 2
- UZDMJOILBYFRMP-UHFFFAOYSA-N 2-[2-[2-[(2-amino-3-methylpentanoyl)amino]propanoylamino]propanoylamino]-3-methylpentanoic acid Chemical compound CCC(C)C(N)C(=O)NC(C)C(=O)NC(C)C(=O)NC(C(O)=O)C(C)CC UZDMJOILBYFRMP-UHFFFAOYSA-N 0.000 description 2
- IADQVXRMSNIUEL-UHFFFAOYSA-N 3,4-dihydroxyphenylacetaldehyde Chemical compound OC1=CC=C(CC=O)C=C1O IADQVXRMSNIUEL-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- PUBLUECXJRHTBK-ACZMJKKPSA-N Ala-Glu-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O PUBLUECXJRHTBK-ACZMJKKPSA-N 0.000 description 2
- QCTFKEJEIMPOLW-JURCDPSOSA-N Ala-Ile-Phe Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QCTFKEJEIMPOLW-JURCDPSOSA-N 0.000 description 2
- XUCHENWTTBFODJ-FXQIFTODSA-N Ala-Met-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O XUCHENWTTBFODJ-FXQIFTODSA-N 0.000 description 2
- AENHOIXXHKNIQL-AUTRQRHGSA-N Ala-Tyr-Ala Chemical compound [O-]C(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H]([NH3+])C)CC1=CC=C(O)C=C1 AENHOIXXHKNIQL-AUTRQRHGSA-N 0.000 description 2
- PGNNQOJOEGFAOR-KWQFWETISA-N Ala-Tyr-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=C(O)C=C1 PGNNQOJOEGFAOR-KWQFWETISA-N 0.000 description 2
- ZTKHZAXGTFXUDD-VEVYYDQMSA-N Arg-Asn-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZTKHZAXGTFXUDD-VEVYYDQMSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CQMQJWRCRQSBAF-BPUTZDHNSA-N Asn-Arg-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)N)N CQMQJWRCRQSBAF-BPUTZDHNSA-N 0.000 description 2
- CTQIOCMSIJATNX-WHFBIAKZSA-N Asn-Gly-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O CTQIOCMSIJATNX-WHFBIAKZSA-N 0.000 description 2
- HFPXZWPUVFVNLL-GUBZILKMSA-N Asn-Leu-Gln Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O HFPXZWPUVFVNLL-GUBZILKMSA-N 0.000 description 2
- CJUKAWUWBZCTDQ-SRVKXCTJSA-N Asp-Leu-Lys Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O CJUKAWUWBZCTDQ-SRVKXCTJSA-N 0.000 description 2
- GKWFMNNNYZHJHV-SRVKXCTJSA-N Asp-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC(O)=O GKWFMNNNYZHJHV-SRVKXCTJSA-N 0.000 description 2
- RRIJEABIXPKSGP-FXQIFTODSA-N Cys-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CS RRIJEABIXPKSGP-FXQIFTODSA-N 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- ZNTDJIMJKNNSLR-RWRJDSDZSA-N Gln-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N ZNTDJIMJKNNSLR-RWRJDSDZSA-N 0.000 description 2
- JJKKWYQVHRUSDG-GUBZILKMSA-N Glu-Ala-Lys Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O JJKKWYQVHRUSDG-GUBZILKMSA-N 0.000 description 2
- HUFCEIHAFNVSNR-IHRRRGAJSA-N Glu-Gln-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUFCEIHAFNVSNR-IHRRRGAJSA-N 0.000 description 2
- LZMQSTPFYJLVJB-GUBZILKMSA-N Glu-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N LZMQSTPFYJLVJB-GUBZILKMSA-N 0.000 description 2
- ZQYZDDXTNQXUJH-CIUDSAMLSA-N Glu-Met-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)N ZQYZDDXTNQXUJH-CIUDSAMLSA-N 0.000 description 2
- XOEKMEAOMXMURD-JYJNAYRXSA-N Glu-Tyr-His Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O XOEKMEAOMXMURD-JYJNAYRXSA-N 0.000 description 2
- GQGAFTPXAPKSCF-WHFBIAKZSA-N Gly-Ala-Cys Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)O GQGAFTPXAPKSCF-WHFBIAKZSA-N 0.000 description 2
- PYUCNHJQQVSPGN-BQBZGAKWSA-N Gly-Arg-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)CN)CN=C(N)N PYUCNHJQQVSPGN-BQBZGAKWSA-N 0.000 description 2
- FZQLXNIMCPJVJE-YUMQZZPRSA-N Gly-Asp-Leu Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O FZQLXNIMCPJVJE-YUMQZZPRSA-N 0.000 description 2
- UWQDKRIZSROAKS-FJXKBIBVSA-N Gly-Met-Thr Chemical compound [H]NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UWQDKRIZSROAKS-FJXKBIBVSA-N 0.000 description 2
- FOKISINOENBSDM-WLTAIBSBSA-N Gly-Thr-Tyr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O FOKISINOENBSDM-WLTAIBSBSA-N 0.000 description 2
- ONSARSFSJHTMFJ-STQMWFEESA-N Gly-Trp-Ser Chemical compound [H]NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CO)C(O)=O ONSARSFSJHTMFJ-STQMWFEESA-N 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- NKVZTQVGUNLLQW-JBDRJPRFSA-N Ile-Ala-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)O)N NKVZTQVGUNLLQW-JBDRJPRFSA-N 0.000 description 2
- GVKKVHNRTUFCCE-BJDJZHNGSA-N Ile-Leu-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)O)N GVKKVHNRTUFCCE-BJDJZHNGSA-N 0.000 description 2
- FGBRXCZYVRFNKQ-MXAVVETBSA-N Ile-Phe-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)O)N FGBRXCZYVRFNKQ-MXAVVETBSA-N 0.000 description 2
- YCKPUHHMCFSUMD-IUKAMOBKSA-N Ile-Thr-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N YCKPUHHMCFSUMD-IUKAMOBKSA-N 0.000 description 2
- DGTOKVBDZXJHNZ-WZLNRYEVSA-N Ile-Thr-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N DGTOKVBDZXJHNZ-WZLNRYEVSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 2
- DZQMXBALGUHGJT-GUBZILKMSA-N Leu-Glu-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O DZQMXBALGUHGJT-GUBZILKMSA-N 0.000 description 2
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 2
- YWKNKRAKOCLOLH-OEAJRASXSA-N Leu-Phe-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=CC=C1 YWKNKRAKOCLOLH-OEAJRASXSA-N 0.000 description 2
- ISSAURVGLGAPDK-KKUMJFAQSA-N Leu-Tyr-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O ISSAURVGLGAPDK-KKUMJFAQSA-N 0.000 description 2
- AAORVPFVUIHEAB-YUMQZZPRSA-N Lys-Asp-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O AAORVPFVUIHEAB-YUMQZZPRSA-N 0.000 description 2
- GIKFNMZSGYAPEJ-HJGDQZAQSA-N Lys-Thr-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O GIKFNMZSGYAPEJ-HJGDQZAQSA-N 0.000 description 2
- YRAWWKUTNBILNT-FXQIFTODSA-N Met-Ala-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YRAWWKUTNBILNT-FXQIFTODSA-N 0.000 description 2
- AETNZPKUUYYYEK-CIUDSAMLSA-N Met-Glu-Asn Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O AETNZPKUUYYYEK-CIUDSAMLSA-N 0.000 description 2
- HAQLBBVZAGMESV-IHRRRGAJSA-N Met-Lys-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O HAQLBBVZAGMESV-IHRRRGAJSA-N 0.000 description 2
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- SCKXGHWQPPURGT-KKUMJFAQSA-N Phe-Lys-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O SCKXGHWQPPURGT-KKUMJFAQSA-N 0.000 description 2
- FQUUYTNBMIBOHS-IHRRRGAJSA-N Phe-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N FQUUYTNBMIBOHS-IHRRRGAJSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- PEYNRYREGPAOAK-LSJOCFKGSA-N Pro-His-Ala Chemical compound C([C@@H](C(=O)N[C@@H](C)C([O-])=O)NC(=O)[C@H]1[NH2+]CCC1)C1=CN=CN1 PEYNRYREGPAOAK-LSJOCFKGSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 101710149951 Protein Tat Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- WBINSDOPZHQPPM-AVGNSLFASA-N Ser-Glu-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)N)O WBINSDOPZHQPPM-AVGNSLFASA-N 0.000 description 2
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 description 2
- FUMGHWDRRFCKEP-CIUDSAMLSA-N Ser-Leu-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O FUMGHWDRRFCKEP-CIUDSAMLSA-N 0.000 description 2
- GVMUJUPXFQFBBZ-GUBZILKMSA-N Ser-Lys-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O GVMUJUPXFQFBBZ-GUBZILKMSA-N 0.000 description 2
- CUXJENOFJXOSOZ-BIIVOSGPSA-N Ser-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CO)N)C(=O)O CUXJENOFJXOSOZ-BIIVOSGPSA-N 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- CAGTXGDOIFXLPC-KZVJFYERSA-N Thr-Arg-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CCCN=C(N)N CAGTXGDOIFXLPC-KZVJFYERSA-N 0.000 description 2
- NLSNVZAREYQMGR-HJGDQZAQSA-N Thr-Asp-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NLSNVZAREYQMGR-HJGDQZAQSA-N 0.000 description 2
- GARULAKWZGFIKC-RWRJDSDZSA-N Thr-Gln-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O GARULAKWZGFIKC-RWRJDSDZSA-N 0.000 description 2
- PAXANSWUSVPFNK-IUKAMOBKSA-N Thr-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N PAXANSWUSVPFNK-IUKAMOBKSA-N 0.000 description 2
- UUSQVWOVUYMLJA-PPCPHDFISA-N Thr-Lys-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O UUSQVWOVUYMLJA-PPCPHDFISA-N 0.000 description 2
- NZRUWPIYECBYRK-HTUGSXCWSA-N Thr-Phe-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O NZRUWPIYECBYRK-HTUGSXCWSA-N 0.000 description 2
- TZXFLDNBYYGLKA-BZSNNMDCSA-N Tyr-Asp-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 TZXFLDNBYYGLKA-BZSNNMDCSA-N 0.000 description 2
- CNLKDWSAORJEMW-KWQFWETISA-N Tyr-Gly-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](C)C(O)=O CNLKDWSAORJEMW-KWQFWETISA-N 0.000 description 2
- YIKDYZDNRCNFQB-KKUMJFAQSA-N Tyr-His-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O YIKDYZDNRCNFQB-KKUMJFAQSA-N 0.000 description 2
- ZXAGTABZUOMUDO-GVXVVHGQSA-N Val-Glu-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N ZXAGTABZUOMUDO-GVXVVHGQSA-N 0.000 description 2
- XBRMBDFYOFARST-AVGNSLFASA-N Val-His-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N XBRMBDFYOFARST-AVGNSLFASA-N 0.000 description 2
- HPANGHISDXDUQY-ULQDDVLXSA-N Val-Lys-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N HPANGHISDXDUQY-ULQDDVLXSA-N 0.000 description 2
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 2
- WUFHZIRMAZZWRS-OSUNSFLBSA-N Val-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)N WUFHZIRMAZZWRS-OSUNSFLBSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 238000007818 agglutination assay Methods 0.000 description 2
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 2
- 108010005233 alanylglutamic acid Proteins 0.000 description 2
- 108010044940 alanylglutamine Proteins 0.000 description 2
- 108010011559 alanylphenylalanine Proteins 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 2
- 230000006229 amino acid addition Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 150000001735 carboxylic acids Chemical group 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 101150005152 ctb gene Proteins 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 2
- 201000002491 encephalomyelitis Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 108010089804 glycyl-threonine Proteins 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 229930186900 holotoxin Natural products 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000035987 intoxication Effects 0.000 description 2
- 231100000566 intoxication Toxicity 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 108010031424 isoleucyl-prolyl-proline Proteins 0.000 description 2
- 108010027338 isoleucylcysteine Proteins 0.000 description 2
- 108010034529 leucyl-lysine Proteins 0.000 description 2
- 108010057821 leucylproline Proteins 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 108010056582 methionylglutamic acid Proteins 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 102220237183 rs1006228968 Human genes 0.000 description 2
- 102200055059 rs121909790 Human genes 0.000 description 2
- 102200102602 rs62635018 Human genes 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 108010026333 seryl-proline Proteins 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 150000004043 trisaccharides Chemical class 0.000 description 2
- 108010017949 tyrosyl-glycyl-glycine Proteins 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 108010073969 valyllysine Proteins 0.000 description 2
- VZMUZTBFPAWECJ-HOTGVXAUSA-N (2r)-2-[(4-azidobenzoyl)amino]-3-[[(2r)-2-[(4-azidobenzoyl)amino]-2-carboxyethyl]disulfanyl]propanoic acid Chemical compound N([C@@H](CSSC[C@@H](C(=O)O)NC(=O)C=1C=CC(=CC=1)N=[N+]=[N-])C(O)=O)C(=O)C1=CC=C(N=[N+]=[N-])C=C1 VZMUZTBFPAWECJ-HOTGVXAUSA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 1
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- ZIWNJZLXPXFNGN-GXTQQWMXSA-N (z)-7-[(3r,4s)-3-[(e,3s)-3-hydroxyoct-1-enyl]-4-bicyclo[3.1.1]heptanyl]hept-5-enoic acid Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)CC2CC1C2 ZIWNJZLXPXFNGN-GXTQQWMXSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- HATJHXCDGADERG-HGTLKWEASA-N 1-o-[2-[(5-azido-2-hydroxy-3-iodanylbenzoyl)amino]ethyl] 4-o-(2,5-dioxopyrrolidin-1-yl) butanedioate Chemical compound OC1=C([125I])C=C(N=[N+]=[N-])C=C1C(=O)NCCOC(=O)CCC(=O)ON1C(=O)CCC1=O HATJHXCDGADERG-HGTLKWEASA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- GIVUILZPMLYAFS-UHFFFAOYSA-N 2-(4-azidophenyl)isoindole-1,3-dione Chemical compound C1=CC(N=[N+]=[N-])=CC=C1N1C(=O)C2=CC=CC=C2C1=O GIVUILZPMLYAFS-UHFFFAOYSA-N 0.000 description 1
- LAHCMYYCRFQUHP-UHFFFAOYSA-N 2-(4-azidophenyl)sulfanylisoindole-1,3-dione Chemical compound C1=CC(N=[N+]=[N-])=CC=C1SN1C(=O)C2=CC=CC=C2C1=O LAHCMYYCRFQUHP-UHFFFAOYSA-N 0.000 description 1
- PPINMSZPTPRQQB-NHCYSSNCSA-N 2-[[(2s)-1-[(2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]acetic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PPINMSZPTPRQQB-NHCYSSNCSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- NNDLQUNWZOIESH-UHFFFAOYSA-N 8-hydroxy-7-[[7-[(8-hydroxy-5-sulfoquinoline-7-carbonyl)amino]-4-[3-[(8-hydroxy-5-sulfoquinoline-7-carbonyl)amino]propyl]heptyl]carbamoyl]quinoline-5-sulfonic acid Chemical compound C1=CC=NC2=C(O)C(C(=O)NCCCC(CCCNC(=O)C=3C(=C4N=CC=CC4=C(C=3)S(O)(=O)=O)O)CCCNC(=O)C3=C(C4=NC=CC=C4C(=C3)S(O)(=O)=O)O)=CC(S(O)(=O)=O)=C21 NNDLQUNWZOIESH-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- ODWSTKXGQGYHSH-FXQIFTODSA-N Ala-Arg-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O ODWSTKXGQGYHSH-FXQIFTODSA-N 0.000 description 1
- XQGIRPGAVLFKBJ-CIUDSAMLSA-N Ala-Asn-Lys Chemical compound N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)O XQGIRPGAVLFKBJ-CIUDSAMLSA-N 0.000 description 1
- WQVYAWIMAWTGMW-ZLUOBGJFSA-N Ala-Asp-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N WQVYAWIMAWTGMW-ZLUOBGJFSA-N 0.000 description 1
- LSLIRHLIUDVNBN-CIUDSAMLSA-N Ala-Asp-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN LSLIRHLIUDVNBN-CIUDSAMLSA-N 0.000 description 1
- IKKVASZHTMKJIR-ZKWXMUAHSA-N Ala-Asp-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O IKKVASZHTMKJIR-ZKWXMUAHSA-N 0.000 description 1
- HWPXGQCMZITGFN-XVYDVKMFSA-N Ala-Cys-His Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N HWPXGQCMZITGFN-XVYDVKMFSA-N 0.000 description 1
- LGFCAXJBAZESCF-ACZMJKKPSA-N Ala-Gln-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O LGFCAXJBAZESCF-ACZMJKKPSA-N 0.000 description 1
- FUSPCLTUKXQREV-ACZMJKKPSA-N Ala-Glu-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O FUSPCLTUKXQREV-ACZMJKKPSA-N 0.000 description 1
- ZVFVBBGVOILKPO-WHFBIAKZSA-N Ala-Gly-Ala Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O ZVFVBBGVOILKPO-WHFBIAKZSA-N 0.000 description 1
- BTBUEVAGZCKULD-XPUUQOCRSA-N Ala-Gly-His Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BTBUEVAGZCKULD-XPUUQOCRSA-N 0.000 description 1
- LMFXXZPPZDCPTA-ZKWXMUAHSA-N Ala-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N LMFXXZPPZDCPTA-ZKWXMUAHSA-N 0.000 description 1
- PCIFXPRIFWKWLK-YUMQZZPRSA-N Ala-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N PCIFXPRIFWKWLK-YUMQZZPRSA-N 0.000 description 1
- QHASENCZLDHBGX-ONGXEEELSA-N Ala-Gly-Phe Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QHASENCZLDHBGX-ONGXEEELSA-N 0.000 description 1
- HJGZVLLLBJLXFC-LSJOCFKGSA-N Ala-His-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(O)=O HJGZVLLLBJLXFC-LSJOCFKGSA-N 0.000 description 1
- CFPQUJZTLUQUTJ-HTFCKZLJSA-N Ala-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](C)N CFPQUJZTLUQUTJ-HTFCKZLJSA-N 0.000 description 1
- TZDNWXDLYFIFPT-BJDJZHNGSA-N Ala-Ile-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O TZDNWXDLYFIFPT-BJDJZHNGSA-N 0.000 description 1
- XCZXVTHYGSMQGH-NAKRPEOUSA-N Ala-Ile-Met Chemical compound C[C@H]([NH3+])C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C([O-])=O XCZXVTHYGSMQGH-NAKRPEOUSA-N 0.000 description 1
- CCDFBRZVTDDJNM-GUBZILKMSA-N Ala-Leu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O CCDFBRZVTDDJNM-GUBZILKMSA-N 0.000 description 1
- AWZKCUCQJNTBAD-SRVKXCTJSA-N Ala-Leu-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN AWZKCUCQJNTBAD-SRVKXCTJSA-N 0.000 description 1
- VHVVPYOJIIQCKS-QEJZJMRPSA-N Ala-Leu-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 VHVVPYOJIIQCKS-QEJZJMRPSA-N 0.000 description 1
- SUHLZMHFRALVSY-YUMQZZPRSA-N Ala-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)NCC(O)=O SUHLZMHFRALVSY-YUMQZZPRSA-N 0.000 description 1
- IHMCQESUJVZTKW-UBHSHLNASA-N Ala-Phe-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=CC=C1 IHMCQESUJVZTKW-UBHSHLNASA-N 0.000 description 1
- DCVYRWFAMZFSDA-ZLUOBGJFSA-N Ala-Ser-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DCVYRWFAMZFSDA-ZLUOBGJFSA-N 0.000 description 1
- DYXOFPBJBAHWFY-JBDRJPRFSA-N Ala-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N DYXOFPBJBAHWFY-JBDRJPRFSA-N 0.000 description 1
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 1
- NZGRHTKZFSVPAN-BIIVOSGPSA-N Ala-Ser-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N NZGRHTKZFSVPAN-BIIVOSGPSA-N 0.000 description 1
- VRTOMXFZHGWHIJ-KZVJFYERSA-N Ala-Thr-Arg Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VRTOMXFZHGWHIJ-KZVJFYERSA-N 0.000 description 1
- IYKVSFNGSWTTNZ-GUBZILKMSA-N Ala-Val-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IYKVSFNGSWTTNZ-GUBZILKMSA-N 0.000 description 1
- DHONNEYAZPNGSG-UBHSHLNASA-N Ala-Val-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 DHONNEYAZPNGSG-UBHSHLNASA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 101000878595 Arabidopsis thaliana Squalene synthase 1 Proteins 0.000 description 1
- HULHGJZIZXCPLD-FXQIFTODSA-N Arg-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N HULHGJZIZXCPLD-FXQIFTODSA-N 0.000 description 1
- VBFJESQBIWCWRL-DCAQKATOSA-N Arg-Ala-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VBFJESQBIWCWRL-DCAQKATOSA-N 0.000 description 1
- XEPSCVXTCUUHDT-AVGNSLFASA-N Arg-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCCN=C(N)N XEPSCVXTCUUHDT-AVGNSLFASA-N 0.000 description 1
- FBLMOFHNVQBKRR-IHRRRGAJSA-N Arg-Asp-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FBLMOFHNVQBKRR-IHRRRGAJSA-N 0.000 description 1
- UFBURHXMKFQVLM-CIUDSAMLSA-N Arg-Glu-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O UFBURHXMKFQVLM-CIUDSAMLSA-N 0.000 description 1
- PNIGSVZJNVUVJA-BQBZGAKWSA-N Arg-Gly-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O PNIGSVZJNVUVJA-BQBZGAKWSA-N 0.000 description 1
- RFXXUWGNVRJTNQ-QXEWZRGKSA-N Arg-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N RFXXUWGNVRJTNQ-QXEWZRGKSA-N 0.000 description 1
- WVNFNPGXYADPPO-BQBZGAKWSA-N Arg-Gly-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O WVNFNPGXYADPPO-BQBZGAKWSA-N 0.000 description 1
- GXXWTNKNFFKTJB-NAKRPEOUSA-N Arg-Ile-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O GXXWTNKNFFKTJB-NAKRPEOUSA-N 0.000 description 1
- MTYLORHAQXVQOW-AVGNSLFASA-N Arg-Lys-Met Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(O)=O MTYLORHAQXVQOW-AVGNSLFASA-N 0.000 description 1
- RIQBRKVTFBWEDY-RHYQMDGZSA-N Arg-Lys-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RIQBRKVTFBWEDY-RHYQMDGZSA-N 0.000 description 1
- OISWSORSLQOGFV-AVGNSLFASA-N Arg-Met-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CCCN=C(N)N OISWSORSLQOGFV-AVGNSLFASA-N 0.000 description 1
- DTBPLQNKYCYUOM-JYJNAYRXSA-N Arg-Met-Phe Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 DTBPLQNKYCYUOM-JYJNAYRXSA-N 0.000 description 1
- LXMKTIZAGIBQRX-HRCADAONSA-N Arg-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O LXMKTIZAGIBQRX-HRCADAONSA-N 0.000 description 1
- HGKHPCFTRQDHCU-IUCAKERBSA-N Arg-Pro-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O HGKHPCFTRQDHCU-IUCAKERBSA-N 0.000 description 1
- NGYHSXDNNOFHNE-AVGNSLFASA-N Arg-Pro-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O NGYHSXDNNOFHNE-AVGNSLFASA-N 0.000 description 1
- VENMDXUVHSKEIN-GUBZILKMSA-N Arg-Ser-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O VENMDXUVHSKEIN-GUBZILKMSA-N 0.000 description 1
- ZPWMEWYQBWSGAO-ZJDVBMNYSA-N Arg-Thr-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZPWMEWYQBWSGAO-ZJDVBMNYSA-N 0.000 description 1
- QMQZYILAWUOLPV-JYJNAYRXSA-N Arg-Tyr-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CC1=CC=C(O)C=C1 QMQZYILAWUOLPV-JYJNAYRXSA-N 0.000 description 1
- BDMIFVIWCNLDCT-CIUDSAMLSA-N Asn-Arg-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O BDMIFVIWCNLDCT-CIUDSAMLSA-N 0.000 description 1
- XQQVCUIBGYFKDC-OLHMAJIHSA-N Asn-Asp-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XQQVCUIBGYFKDC-OLHMAJIHSA-N 0.000 description 1
- HLTLEIXYIJDFOY-ZLUOBGJFSA-N Asn-Cys-Asn Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O HLTLEIXYIJDFOY-ZLUOBGJFSA-N 0.000 description 1
- OKZOABJQOMAYEC-NUMRIWBASA-N Asn-Gln-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OKZOABJQOMAYEC-NUMRIWBASA-N 0.000 description 1
- KLKHFFMNGWULBN-VKHMYHEASA-N Asn-Gly Chemical compound NC(=O)C[C@H](N)C(=O)NCC(O)=O KLKHFFMNGWULBN-VKHMYHEASA-N 0.000 description 1
- YGHCVNQOZZMHRZ-DJFWLOJKSA-N Asn-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC(=O)N)N YGHCVNQOZZMHRZ-DJFWLOJKSA-N 0.000 description 1
- FVKHEKVYFTZWDX-GHCJXIJMSA-N Asn-Ile-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N FVKHEKVYFTZWDX-GHCJXIJMSA-N 0.000 description 1
- JWKDQOORUCYUIW-ZPFDUUQYSA-N Asn-Lys-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JWKDQOORUCYUIW-ZPFDUUQYSA-N 0.000 description 1
- BKFXFUPYETWGGA-XVSYOHENSA-N Asn-Phe-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BKFXFUPYETWGGA-XVSYOHENSA-N 0.000 description 1
- PLTGTJAZQRGMPP-FXQIFTODSA-N Asn-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(N)=O PLTGTJAZQRGMPP-FXQIFTODSA-N 0.000 description 1
- HPASIOLTWSNMFB-OLHMAJIHSA-N Asn-Thr-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O HPASIOLTWSNMFB-OLHMAJIHSA-N 0.000 description 1
- FMNBYVSGRCXWEK-FOHZUACHSA-N Asn-Thr-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O FMNBYVSGRCXWEK-FOHZUACHSA-N 0.000 description 1
- XOQYDFCQPWAMSA-KKHAAJSZSA-N Asn-Val-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XOQYDFCQPWAMSA-KKHAAJSZSA-N 0.000 description 1
- PBVLJOIPOGUQQP-CIUDSAMLSA-N Asp-Ala-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O PBVLJOIPOGUQQP-CIUDSAMLSA-N 0.000 description 1
- KVMPVNGOKHTUHZ-GCJQMDKQSA-N Asp-Ala-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KVMPVNGOKHTUHZ-GCJQMDKQSA-N 0.000 description 1
- SDHFVYLZFBDSQT-DCAQKATOSA-N Asp-Arg-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N SDHFVYLZFBDSQT-DCAQKATOSA-N 0.000 description 1
- RDRMWJBLOSRRAW-BYULHYEWSA-N Asp-Asn-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O RDRMWJBLOSRRAW-BYULHYEWSA-N 0.000 description 1
- BFOYULZBKYOKAN-OLHMAJIHSA-N Asp-Asp-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BFOYULZBKYOKAN-OLHMAJIHSA-N 0.000 description 1
- KVPHTGVUMJGMCX-BIIVOSGPSA-N Asp-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CC(=O)O)N)C(=O)O KVPHTGVUMJGMCX-BIIVOSGPSA-N 0.000 description 1
- HAFCJCDJGIOYPW-WDSKDSINSA-N Asp-Gly-Gln Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O HAFCJCDJGIOYPW-WDSKDSINSA-N 0.000 description 1
- SWTQDYFZVOJVLL-KKUMJFAQSA-N Asp-His-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(=O)O)N)O SWTQDYFZVOJVLL-KKUMJFAQSA-N 0.000 description 1
- VSMYBNPOHYAXSD-GUBZILKMSA-N Asp-Lys-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O VSMYBNPOHYAXSD-GUBZILKMSA-N 0.000 description 1
- WQSXAPPYLGNMQL-IHRRRGAJSA-N Asp-Met-Tyr Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CC(=O)O)N WQSXAPPYLGNMQL-IHRRRGAJSA-N 0.000 description 1
- UEFODXNXUAVPTC-VEVYYDQMSA-N Asp-Thr-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O UEFODXNXUAVPTC-VEVYYDQMSA-N 0.000 description 1
- VHUKCUHLFMRHOD-MELADBBJSA-N Asp-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)O)N)C(=O)O VHUKCUHLFMRHOD-MELADBBJSA-N 0.000 description 1
- PLOKOIJSGCISHE-BYULHYEWSA-N Asp-Val-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O PLOKOIJSGCISHE-BYULHYEWSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- GRNOCLDFUNCIDW-ACZMJKKPSA-N Cys-Ala-Glu Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CS)N GRNOCLDFUNCIDW-ACZMJKKPSA-N 0.000 description 1
- PRXCTTWKGJAPMT-ZLUOBGJFSA-N Cys-Ala-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O PRXCTTWKGJAPMT-ZLUOBGJFSA-N 0.000 description 1
- SBMGKDLRJLYZCU-BIIVOSGPSA-N Cys-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)N)C(=O)O SBMGKDLRJLYZCU-BIIVOSGPSA-N 0.000 description 1
- QCUJUETWTSWPNZ-NAKRPEOUSA-N Cys-Ile-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CS)N QCUJUETWTSWPNZ-NAKRPEOUSA-N 0.000 description 1
- FANFRJOFTYCNRG-JYBASQMISA-N Cys-Thr-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CS)N)O FANFRJOFTYCNRG-JYBASQMISA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- DBAKFASWICGISY-DASCVMRKSA-N Dexchlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 DBAKFASWICGISY-DASCVMRKSA-N 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 101000738180 Euglena gracilis Chaperonin CPN60, mitochondrial Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101710154643 Filamentous hemagglutinin Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- HHWQMFIGMMOVFK-WDSKDSINSA-N Gln-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O HHWQMFIGMMOVFK-WDSKDSINSA-N 0.000 description 1
- UWZLBXOBVKRUFE-HGNGGELXSA-N Gln-Ala-His Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)N)N UWZLBXOBVKRUFE-HGNGGELXSA-N 0.000 description 1
- WMOMPXKOKASNBK-PEFMBERDSA-N Gln-Asn-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WMOMPXKOKASNBK-PEFMBERDSA-N 0.000 description 1
- NVEASDQHBRZPSU-BQBZGAKWSA-N Gln-Gln-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O NVEASDQHBRZPSU-BQBZGAKWSA-N 0.000 description 1
- JHPFPROFOAJRFN-IHRRRGAJSA-N Gln-Glu-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N)O JHPFPROFOAJRFN-IHRRRGAJSA-N 0.000 description 1
- JZOYFBPIEHCDFV-YUMQZZPRSA-N Gln-His Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 JZOYFBPIEHCDFV-YUMQZZPRSA-N 0.000 description 1
- NROSLUJMIQGFKS-IUCAKERBSA-N Gln-His-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N NROSLUJMIQGFKS-IUCAKERBSA-N 0.000 description 1
- DAAUVRPSZRDMBV-KBIXCLLPSA-N Gln-Ile-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)N)N DAAUVRPSZRDMBV-KBIXCLLPSA-N 0.000 description 1
- MLSKFHLRFVGNLL-WDCWCFNPSA-N Gln-Leu-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MLSKFHLRFVGNLL-WDCWCFNPSA-N 0.000 description 1
- FNAJNWPDTIXYJN-CIUDSAMLSA-N Gln-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCC(N)=O FNAJNWPDTIXYJN-CIUDSAMLSA-N 0.000 description 1
- KUBFPYIMAGXGBT-ACZMJKKPSA-N Gln-Ser-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KUBFPYIMAGXGBT-ACZMJKKPSA-N 0.000 description 1
- XKPACHRGOWQHFH-IRIUXVKKSA-N Gln-Thr-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XKPACHRGOWQHFH-IRIUXVKKSA-N 0.000 description 1
- RDPOETHPAQEGDP-ACZMJKKPSA-N Glu-Asp-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O RDPOETHPAQEGDP-ACZMJKKPSA-N 0.000 description 1
- JRCUFCXYZLPSDZ-ACZMJKKPSA-N Glu-Asp-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O JRCUFCXYZLPSDZ-ACZMJKKPSA-N 0.000 description 1
- KVBPDJIFRQUQFY-ACZMJKKPSA-N Glu-Cys-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O KVBPDJIFRQUQFY-ACZMJKKPSA-N 0.000 description 1
- ZJFNRQHUIHKZJF-GUBZILKMSA-N Glu-His-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(O)=O ZJFNRQHUIHKZJF-GUBZILKMSA-N 0.000 description 1
- PJBVXVBTTFZPHJ-GUBZILKMSA-N Glu-Leu-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)N PJBVXVBTTFZPHJ-GUBZILKMSA-N 0.000 description 1
- HRBYTAIBKPNZKQ-AVGNSLFASA-N Glu-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O HRBYTAIBKPNZKQ-AVGNSLFASA-N 0.000 description 1
- AOCARQDSFTWWFT-DCAQKATOSA-N Glu-Met-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O AOCARQDSFTWWFT-DCAQKATOSA-N 0.000 description 1
- GMAGZGCAYLQBKF-NHCYSSNCSA-N Glu-Met-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(O)=O GMAGZGCAYLQBKF-NHCYSSNCSA-N 0.000 description 1
- WVWZIPOJECFDAG-AVGNSLFASA-N Glu-Phe-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N WVWZIPOJECFDAG-AVGNSLFASA-N 0.000 description 1
- IDEODOAVGCMUQV-GUBZILKMSA-N Glu-Ser-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IDEODOAVGCMUQV-GUBZILKMSA-N 0.000 description 1
- HAGKYCXGTRUUFI-RYUDHWBXSA-N Glu-Tyr-Gly Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)O)N)O HAGKYCXGTRUUFI-RYUDHWBXSA-N 0.000 description 1
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 1
- LZEUDRYSAZAJIO-AUTRQRHGSA-N Glu-Val-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LZEUDRYSAZAJIO-AUTRQRHGSA-N 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- PUUYVMYCMIWHFE-BQBZGAKWSA-N Gly-Ala-Arg Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PUUYVMYCMIWHFE-BQBZGAKWSA-N 0.000 description 1
- YMUFWNJHVPQNQD-ZKWXMUAHSA-N Gly-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN YMUFWNJHVPQNQD-ZKWXMUAHSA-N 0.000 description 1
- PHONXOACARQMPM-BQBZGAKWSA-N Gly-Ala-Met Chemical compound [H]NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O PHONXOACARQMPM-BQBZGAKWSA-N 0.000 description 1
- MZZSCEANQDPJER-ONGXEEELSA-N Gly-Ala-Phe Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MZZSCEANQDPJER-ONGXEEELSA-N 0.000 description 1
- QIZJOTQTCAGKPU-KWQFWETISA-N Gly-Ala-Tyr Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)N[C@H](C([O-])=O)CC1=CC=C(O)C=C1 QIZJOTQTCAGKPU-KWQFWETISA-N 0.000 description 1
- GWCRIHNSVMOBEQ-BQBZGAKWSA-N Gly-Arg-Ser Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O GWCRIHNSVMOBEQ-BQBZGAKWSA-N 0.000 description 1
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 1
- QPDUVFSVVAOUHE-XVKPBYJWSA-N Gly-Gln-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CN)C(O)=O QPDUVFSVVAOUHE-XVKPBYJWSA-N 0.000 description 1
- STVHDEHTKFXBJQ-LAEOZQHASA-N Gly-Glu-Ile Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O STVHDEHTKFXBJQ-LAEOZQHASA-N 0.000 description 1
- MBOAPAXLTUSMQI-JHEQGTHGSA-N Gly-Glu-Thr Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MBOAPAXLTUSMQI-JHEQGTHGSA-N 0.000 description 1
- OLPPXYMMIARYAL-QMMMGPOBSA-N Gly-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)CN OLPPXYMMIARYAL-QMMMGPOBSA-N 0.000 description 1
- SWQALSGKVLYKDT-UHFFFAOYSA-N Gly-Ile-Ala Natural products NCC(=O)NC(C(C)CC)C(=O)NC(C)C(O)=O SWQALSGKVLYKDT-UHFFFAOYSA-N 0.000 description 1
- AAHSHTLISQUZJL-QSFUFRPTSA-N Gly-Ile-Ile Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AAHSHTLISQUZJL-QSFUFRPTSA-N 0.000 description 1
- FHQRLHFYVZAQHU-IUCAKERBSA-N Gly-Lys-Gln Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O FHQRLHFYVZAQHU-IUCAKERBSA-N 0.000 description 1
- GMTXWRIDLGTVFC-IUCAKERBSA-N Gly-Lys-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMTXWRIDLGTVFC-IUCAKERBSA-N 0.000 description 1
- WDEHMRNSGHVNOH-VHSXEESVSA-N Gly-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)CN)C(=O)O WDEHMRNSGHVNOH-VHSXEESVSA-N 0.000 description 1
- BBTCXWTXOXUNFX-IUCAKERBSA-N Gly-Met-Arg Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O BBTCXWTXOXUNFX-IUCAKERBSA-N 0.000 description 1
- MDKCBHZLQJZOCJ-STQMWFEESA-N Gly-Met-Tyr Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)CN MDKCBHZLQJZOCJ-STQMWFEESA-N 0.000 description 1
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 1
- MYXNLWDWWOTERK-BHNWBGBOSA-N Gly-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN)O MYXNLWDWWOTERK-BHNWBGBOSA-N 0.000 description 1
- WRFOZIJRODPLIA-QWRGUYRKSA-N Gly-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)CN)O WRFOZIJRODPLIA-QWRGUYRKSA-N 0.000 description 1
- NGRPGJGKJMUGDM-XVKPBYJWSA-N Gly-Val-Gln Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O NGRPGJGKJMUGDM-XVKPBYJWSA-N 0.000 description 1
- ZVXMEWXHFBYJPI-LSJOCFKGSA-N Gly-Val-Ile Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ZVXMEWXHFBYJPI-LSJOCFKGSA-N 0.000 description 1
- COZMNNJEGNPDED-HOCLYGCPSA-N Gly-Val-Trp Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O COZMNNJEGNPDED-HOCLYGCPSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 101710086934 Guanine nucleotide-binding protein subunit beta-like protein Proteins 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- BDFCIKANUNMFGB-PMVVWTBXSA-N His-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1 BDFCIKANUNMFGB-PMVVWTBXSA-N 0.000 description 1
- SYIPVNMWBZXKMU-HJPIBITLSA-N His-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC2=CN=CN2)N SYIPVNMWBZXKMU-HJPIBITLSA-N 0.000 description 1
- YAALVYQFVJNXIV-KKUMJFAQSA-N His-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CN=CN1 YAALVYQFVJNXIV-KKUMJFAQSA-N 0.000 description 1
- AYUOWUNWZGTNKB-ULQDDVLXSA-N His-Phe-Arg Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AYUOWUNWZGTNKB-ULQDDVLXSA-N 0.000 description 1
- CCUSLCQWVMWTIS-IXOXFDKPSA-N His-Thr-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O CCUSLCQWVMWTIS-IXOXFDKPSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- RWIKBYVJQAJYDP-BJDJZHNGSA-N Ile-Ala-Lys Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN RWIKBYVJQAJYDP-BJDJZHNGSA-N 0.000 description 1
- QYZYJFXHXYUZMZ-UGYAYLCHSA-N Ile-Asn-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N QYZYJFXHXYUZMZ-UGYAYLCHSA-N 0.000 description 1
- RPZFUIQVAPZLRH-GHCJXIJMSA-N Ile-Asp-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)O)N RPZFUIQVAPZLRH-GHCJXIJMSA-N 0.000 description 1
- NZOCIWKZUVUNDW-ZKWXMUAHSA-N Ile-Gly-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O NZOCIWKZUVUNDW-ZKWXMUAHSA-N 0.000 description 1
- URWXDJAEEGBADB-TUBUOCAGSA-N Ile-His-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N URWXDJAEEGBADB-TUBUOCAGSA-N 0.000 description 1
- UIEZQYNXCYHMQS-BJDJZHNGSA-N Ile-Lys-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)O)N UIEZQYNXCYHMQS-BJDJZHNGSA-N 0.000 description 1
- HQEPKOFULQTSFV-JURCDPSOSA-N Ile-Phe-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)O)N HQEPKOFULQTSFV-JURCDPSOSA-N 0.000 description 1
- UYNXBNHVWFNVIN-HJWJTTGWSA-N Ile-Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@@H](C)CC)CC1=CC=CC=C1 UYNXBNHVWFNVIN-HJWJTTGWSA-N 0.000 description 1
- VOCZPDONPURUHV-QEWYBTABSA-N Ile-Phe-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N VOCZPDONPURUHV-QEWYBTABSA-N 0.000 description 1
- XQLGNKLSPYCRMZ-HJWJTTGWSA-N Ile-Phe-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)O)N XQLGNKLSPYCRMZ-HJWJTTGWSA-N 0.000 description 1
- JZNVOBUNTWNZPW-GHCJXIJMSA-N Ile-Ser-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)O)N JZNVOBUNTWNZPW-GHCJXIJMSA-N 0.000 description 1
- AGGIYSLVUKVOPT-HTFCKZLJSA-N Ile-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N AGGIYSLVUKVOPT-HTFCKZLJSA-N 0.000 description 1
- DRCKHKZYDLJYFQ-YWIQKCBGSA-N Ile-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DRCKHKZYDLJYFQ-YWIQKCBGSA-N 0.000 description 1
- NAFIFZNBSPWYOO-RWRJDSDZSA-N Ile-Thr-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N NAFIFZNBSPWYOO-RWRJDSDZSA-N 0.000 description 1
- ANTFEOSJMAUGIB-KNZXXDILSA-N Ile-Thr-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N ANTFEOSJMAUGIB-KNZXXDILSA-N 0.000 description 1
- NURNJECQNNCRBK-FLBSBUHZSA-N Ile-Thr-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NURNJECQNNCRBK-FLBSBUHZSA-N 0.000 description 1
- PRTZQMBYUZFSFA-XEGUGMAKSA-N Ile-Tyr-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)NCC(=O)O)N PRTZQMBYUZFSFA-XEGUGMAKSA-N 0.000 description 1
- ZUWSVOYKBCHLRR-MGHWNKPDSA-N Ile-Tyr-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)O)N ZUWSVOYKBCHLRR-MGHWNKPDSA-N 0.000 description 1
- HODVZHLJUUWPKY-STECZYCISA-N Ile-Tyr-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@@H](C)CC)CC1=CC=C(O)C=C1 HODVZHLJUUWPKY-STECZYCISA-N 0.000 description 1
- WRDTXMBPHMBGIB-STECZYCISA-N Ile-Tyr-Val Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=C(O)C=C1 WRDTXMBPHMBGIB-STECZYCISA-N 0.000 description 1
- YJRSIJZUIUANHO-NAKRPEOUSA-N Ile-Val-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)O)N YJRSIJZUIUANHO-NAKRPEOUSA-N 0.000 description 1
- DLEBSGAVWRPTIX-PEDHHIEDSA-N Ile-Val-Ile Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)[C@@H](C)CC DLEBSGAVWRPTIX-PEDHHIEDSA-N 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102100034353 Integrase Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- KVRKAGGMEWNURO-CIUDSAMLSA-N Leu-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)N KVRKAGGMEWNURO-CIUDSAMLSA-N 0.000 description 1
- XBBKIIGCUMBKCO-JXUBOQSCSA-N Leu-Ala-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XBBKIIGCUMBKCO-JXUBOQSCSA-N 0.000 description 1
- HXWALXSAVBLTPK-NUTKFTJISA-N Leu-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(C)C)N HXWALXSAVBLTPK-NUTKFTJISA-N 0.000 description 1
- SENJXOPIZNYLHU-IUCAKERBSA-N Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-IUCAKERBSA-N 0.000 description 1
- GRZSCTXVCDUIPO-SRVKXCTJSA-N Leu-Arg-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O GRZSCTXVCDUIPO-SRVKXCTJSA-N 0.000 description 1
- FJUKMPUELVROGK-IHRRRGAJSA-N Leu-Arg-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N FJUKMPUELVROGK-IHRRRGAJSA-N 0.000 description 1
- VCSBGUACOYUIGD-CIUDSAMLSA-N Leu-Asn-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VCSBGUACOYUIGD-CIUDSAMLSA-N 0.000 description 1
- HIZYETOZLYFUFF-BQBZGAKWSA-N Leu-Cys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CS)C(O)=O HIZYETOZLYFUFF-BQBZGAKWSA-N 0.000 description 1
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 1
- QVFGXCVIXXBFHO-AVGNSLFASA-N Leu-Glu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O QVFGXCVIXXBFHO-AVGNSLFASA-N 0.000 description 1
- FIYMBBHGYNQFOP-IUCAKERBSA-N Leu-Gly-Gln Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)N FIYMBBHGYNQFOP-IUCAKERBSA-N 0.000 description 1
- VWHGTYCRDRBSFI-ZETCQYMHSA-N Leu-Gly-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(O)=O VWHGTYCRDRBSFI-ZETCQYMHSA-N 0.000 description 1
- CCQLQKZTXZBXTN-NHCYSSNCSA-N Leu-Gly-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O CCQLQKZTXZBXTN-NHCYSSNCSA-N 0.000 description 1
- KEVYYIMVELOXCT-KBPBESRZSA-N Leu-Gly-Phe Chemical compound CC(C)C[C@H]([NH3+])C(=O)NCC(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 KEVYYIMVELOXCT-KBPBESRZSA-N 0.000 description 1
- YFBBUHJJUXXZOF-UWVGGRQHSA-N Leu-Gly-Pro Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O YFBBUHJJUXXZOF-UWVGGRQHSA-N 0.000 description 1
- AVEGDIAXTDVBJS-XUXIUFHCSA-N Leu-Ile-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AVEGDIAXTDVBJS-XUXIUFHCSA-N 0.000 description 1
- LCPYQJIKPJDLLB-UWVGGRQHSA-N Leu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C LCPYQJIKPJDLLB-UWVGGRQHSA-N 0.000 description 1
- LVTJJOJKDCVZGP-QWRGUYRKSA-N Leu-Lys-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O LVTJJOJKDCVZGP-QWRGUYRKSA-N 0.000 description 1
- KPYAOIVPJKPIOU-KKUMJFAQSA-N Leu-Lys-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O KPYAOIVPJKPIOU-KKUMJFAQSA-N 0.000 description 1
- VCHVSKNMTXWIIP-SRVKXCTJSA-N Leu-Lys-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O VCHVSKNMTXWIIP-SRVKXCTJSA-N 0.000 description 1
- YUTNOGOMBNYPFH-XUXIUFHCSA-N Leu-Pro-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O YUTNOGOMBNYPFH-XUXIUFHCSA-N 0.000 description 1
- KWLWZYMNUZJKMZ-IHRRRGAJSA-N Leu-Pro-Leu Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O KWLWZYMNUZJKMZ-IHRRRGAJSA-N 0.000 description 1
- IRMLZWSRWSGTOP-CIUDSAMLSA-N Leu-Ser-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O IRMLZWSRWSGTOP-CIUDSAMLSA-N 0.000 description 1
- IZPVWNSAVUQBGP-CIUDSAMLSA-N Leu-Ser-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O IZPVWNSAVUQBGP-CIUDSAMLSA-N 0.000 description 1
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 1
- SVBJIZVVYJYGLA-DCAQKATOSA-N Leu-Ser-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O SVBJIZVVYJYGLA-DCAQKATOSA-N 0.000 description 1
- VDIARPPNADFEAV-WEDXCCLWSA-N Leu-Thr-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O VDIARPPNADFEAV-WEDXCCLWSA-N 0.000 description 1
- JGKHAFUAPZCCDU-BZSNNMDCSA-N Leu-Tyr-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=C(O)C=C1 JGKHAFUAPZCCDU-BZSNNMDCSA-N 0.000 description 1
- BTEMNFBEAAOGBR-BZSNNMDCSA-N Leu-Tyr-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)O)N BTEMNFBEAAOGBR-BZSNNMDCSA-N 0.000 description 1
- UFPLDOKWDNTTRP-ULQDDVLXSA-N Leu-Tyr-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)CC1=CC=C(O)C=C1 UFPLDOKWDNTTRP-ULQDDVLXSA-N 0.000 description 1
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- MPOHDJKRBLVGCT-CIUDSAMLSA-N Lys-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N MPOHDJKRBLVGCT-CIUDSAMLSA-N 0.000 description 1
- YKIRNDPUWONXQN-GUBZILKMSA-N Lys-Asn-Gln Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N YKIRNDPUWONXQN-GUBZILKMSA-N 0.000 description 1
- HKCCVDWHHTVVPN-CIUDSAMLSA-N Lys-Asp-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O HKCCVDWHHTVVPN-CIUDSAMLSA-N 0.000 description 1
- OVIVOCSURJYCTM-GUBZILKMSA-N Lys-Asp-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(O)=O OVIVOCSURJYCTM-GUBZILKMSA-N 0.000 description 1
- RZHLIPMZXOEJTL-AVGNSLFASA-N Lys-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)N RZHLIPMZXOEJTL-AVGNSLFASA-N 0.000 description 1
- SLQJJFAVWSZLBL-BJDJZHNGSA-N Lys-Ile-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN SLQJJFAVWSZLBL-BJDJZHNGSA-N 0.000 description 1
- IUWMQCZOTYRXPL-ZPFDUUQYSA-N Lys-Ile-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O IUWMQCZOTYRXPL-ZPFDUUQYSA-N 0.000 description 1
- QBEPTBMRQALPEV-MNXVOIDGSA-N Lys-Ile-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN QBEPTBMRQALPEV-MNXVOIDGSA-N 0.000 description 1
- KEPWSUPUFAPBRF-DKIMLUQUSA-N Lys-Ile-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O KEPWSUPUFAPBRF-DKIMLUQUSA-N 0.000 description 1
- VMTYLUGCXIEDMV-QWRGUYRKSA-N Lys-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN VMTYLUGCXIEDMV-QWRGUYRKSA-N 0.000 description 1
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 1
- GAHJXEMYXKLZRQ-AJNGGQMLSA-N Lys-Lys-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O GAHJXEMYXKLZRQ-AJNGGQMLSA-N 0.000 description 1
- GHKXHCMRAUYLBS-CIUDSAMLSA-N Lys-Ser-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O GHKXHCMRAUYLBS-CIUDSAMLSA-N 0.000 description 1
- CUHGAUZONORRIC-HJGDQZAQSA-N Lys-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N)O CUHGAUZONORRIC-HJGDQZAQSA-N 0.000 description 1
- RMOKGALPSPOYKE-KATARQTJSA-N Lys-Thr-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O RMOKGALPSPOYKE-KATARQTJSA-N 0.000 description 1
- USPJSTBDIGJPFK-PMVMPFDFSA-N Lys-Tyr-Trp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O USPJSTBDIGJPFK-PMVMPFDFSA-N 0.000 description 1
- VWPJQIHBBOJWDN-DCAQKATOSA-N Lys-Val-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O VWPJQIHBBOJWDN-DCAQKATOSA-N 0.000 description 1
- MDDUIRLQCYVRDO-NHCYSSNCSA-N Lys-Val-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN MDDUIRLQCYVRDO-NHCYSSNCSA-N 0.000 description 1
- VKCPHIOZDWUFSW-ONGXEEELSA-N Lys-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN VKCPHIOZDWUFSW-ONGXEEELSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- NKDSBBBPGIVWEI-RCWTZXSCSA-N Met-Arg-Thr Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NKDSBBBPGIVWEI-RCWTZXSCSA-N 0.000 description 1
- OXHSZBRPUGNMKW-DCAQKATOSA-N Met-Gln-Arg Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O OXHSZBRPUGNMKW-DCAQKATOSA-N 0.000 description 1
- JYCQGAGDJQYEDB-GUBZILKMSA-N Met-Gln-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O JYCQGAGDJQYEDB-GUBZILKMSA-N 0.000 description 1
- OOSPRDCGTLQLBP-NHCYSSNCSA-N Met-Glu-Val Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OOSPRDCGTLQLBP-NHCYSSNCSA-N 0.000 description 1
- PZUUMQPMHBJJKE-AVGNSLFASA-N Met-Leu-Arg Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCNC(N)=N PZUUMQPMHBJJKE-AVGNSLFASA-N 0.000 description 1
- OSZTUONKUMCWEP-XUXIUFHCSA-N Met-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC OSZTUONKUMCWEP-XUXIUFHCSA-N 0.000 description 1
- IRVONVRHHJXWTK-RWMBFGLXSA-N Met-Lys-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N IRVONVRHHJXWTK-RWMBFGLXSA-N 0.000 description 1
- QLESZRANMSYLCZ-CYDGBPFRSA-N Met-Pro-Ile Chemical compound [H]N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O QLESZRANMSYLCZ-CYDGBPFRSA-N 0.000 description 1
- FIZZULTXMVEIAA-IHRRRGAJSA-N Met-Ser-Phe Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FIZZULTXMVEIAA-IHRRRGAJSA-N 0.000 description 1
- MIXPUVSPPOWTCR-FXQIFTODSA-N Met-Ser-Ser Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MIXPUVSPPOWTCR-FXQIFTODSA-N 0.000 description 1
- GMMLGMFBYCFCCX-KZVJFYERSA-N Met-Thr-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O GMMLGMFBYCFCCX-KZVJFYERSA-N 0.000 description 1
- CIIJWIAORKTXAH-FJXKBIBVSA-N Met-Thr-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O CIIJWIAORKTXAH-FJXKBIBVSA-N 0.000 description 1
- NDJSSFWDYDUQID-YTWAJWBKSA-N Met-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N)O NDJSSFWDYDUQID-YTWAJWBKSA-N 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101150004094 PRO2 gene Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- HTTYNOXBBOWZTB-SRVKXCTJSA-N Phe-Asn-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N HTTYNOXBBOWZTB-SRVKXCTJSA-N 0.000 description 1
- NKLDZIPTGKBDBB-HTUGSXCWSA-N Phe-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)N)O NKLDZIPTGKBDBB-HTUGSXCWSA-N 0.000 description 1
- HBGFEEQFVBWYJQ-KBPBESRZSA-N Phe-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 HBGFEEQFVBWYJQ-KBPBESRZSA-N 0.000 description 1
- YCCUXNNKXDGMAM-KKUMJFAQSA-N Phe-Leu-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YCCUXNNKXDGMAM-KKUMJFAQSA-N 0.000 description 1
- OQTDZEJJWWAGJT-KKUMJFAQSA-N Phe-Lys-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O OQTDZEJJWWAGJT-KKUMJFAQSA-N 0.000 description 1
- GPLWGAYGROGDEN-BZSNNMDCSA-N Phe-Phe-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O GPLWGAYGROGDEN-BZSNNMDCSA-N 0.000 description 1
- MGLBSROLWAWCKN-FCLVOEFKSA-N Phe-Phe-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MGLBSROLWAWCKN-FCLVOEFKSA-N 0.000 description 1
- IPFXYNKCXYGSSV-KKUMJFAQSA-N Phe-Ser-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N IPFXYNKCXYGSSV-KKUMJFAQSA-N 0.000 description 1
- MVIJMIZJPHQGEN-IHRRRGAJSA-N Phe-Ser-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@H](CO)NC(=O)[C@@H]([NH3+])CC1=CC=CC=C1 MVIJMIZJPHQGEN-IHRRRGAJSA-N 0.000 description 1
- GLUYKHMBGKQBHE-JYJNAYRXSA-N Phe-Val-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 GLUYKHMBGKQBHE-JYJNAYRXSA-N 0.000 description 1
- BQMFWUKNOCJDNV-HJWJTTGWSA-N Phe-Val-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BQMFWUKNOCJDNV-HJWJTTGWSA-N 0.000 description 1
- JTKGCYOOJLUETJ-ULQDDVLXSA-N Phe-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 JTKGCYOOJLUETJ-ULQDDVLXSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- DZZCICYRSZASNF-FXQIFTODSA-N Pro-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 DZZCICYRSZASNF-FXQIFTODSA-N 0.000 description 1
- XQLBWXHVZVBNJM-FXQIFTODSA-N Pro-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 XQLBWXHVZVBNJM-FXQIFTODSA-N 0.000 description 1
- XROLYVMNVIKVEM-BQBZGAKWSA-N Pro-Asn-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O XROLYVMNVIKVEM-BQBZGAKWSA-N 0.000 description 1
- FUVBEZJCRMHWEM-FXQIFTODSA-N Pro-Asn-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O FUVBEZJCRMHWEM-FXQIFTODSA-N 0.000 description 1
- CJZTUKSFZUSNCC-FXQIFTODSA-N Pro-Asp-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1 CJZTUKSFZUSNCC-FXQIFTODSA-N 0.000 description 1
- NGNNPLJHUFCOMZ-FXQIFTODSA-N Pro-Asp-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1 NGNNPLJHUFCOMZ-FXQIFTODSA-N 0.000 description 1
- ODPIUQVTULPQEP-CIUDSAMLSA-N Pro-Gln-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]1CCCN1 ODPIUQVTULPQEP-CIUDSAMLSA-N 0.000 description 1
- UPJGUQPLYWTISV-GUBZILKMSA-N Pro-Gln-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UPJGUQPLYWTISV-GUBZILKMSA-N 0.000 description 1
- HAAQQNHQZBOWFO-LURJTMIESA-N Pro-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1 HAAQQNHQZBOWFO-LURJTMIESA-N 0.000 description 1
- QEWBZBLXDKIQPS-STQMWFEESA-N Pro-Gly-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O QEWBZBLXDKIQPS-STQMWFEESA-N 0.000 description 1
- LNOWDSPAYBWJOR-PEDHHIEDSA-N Pro-Ile-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LNOWDSPAYBWJOR-PEDHHIEDSA-N 0.000 description 1
- RUDOLGWDSKQQFF-DCAQKATOSA-N Pro-Leu-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O RUDOLGWDSKQQFF-DCAQKATOSA-N 0.000 description 1
- XYSXOCIWCPFOCG-IHRRRGAJSA-N Pro-Leu-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O XYSXOCIWCPFOCG-IHRRRGAJSA-N 0.000 description 1
- MZNUJZBYRWXWLQ-AVGNSLFASA-N Pro-Met-His Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@@H]2CCCN2 MZNUJZBYRWXWLQ-AVGNSLFASA-N 0.000 description 1
- DYMPSOABVJIFBS-IHRRRGAJSA-N Pro-Phe-Cys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CS)C(=O)O DYMPSOABVJIFBS-IHRRRGAJSA-N 0.000 description 1
- PCWLNNZTBJTZRN-AVGNSLFASA-N Pro-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 PCWLNNZTBJTZRN-AVGNSLFASA-N 0.000 description 1
- MKGIILKDUGDRRO-FXQIFTODSA-N Pro-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 MKGIILKDUGDRRO-FXQIFTODSA-N 0.000 description 1
- GBUNEGKQPSAMNK-QTKMDUPCSA-N Pro-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@@H]2CCCN2)O GBUNEGKQPSAMNK-QTKMDUPCSA-N 0.000 description 1
- IALSFJSONJZBKB-HRCADAONSA-N Pro-Tyr-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N3CCC[C@@H]3C(=O)O IALSFJSONJZBKB-HRCADAONSA-N 0.000 description 1
- FIDNSJUXESUDOV-JYJNAYRXSA-N Pro-Tyr-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O FIDNSJUXESUDOV-JYJNAYRXSA-N 0.000 description 1
- OQSGBXGNAFQGGS-CYDGBPFRSA-N Pro-Val-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O OQSGBXGNAFQGGS-CYDGBPFRSA-N 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 241000169446 Promethis Species 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- UGJRQLURDVGULT-LKXGYXEUSA-N Ser-Asn-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UGJRQLURDVGULT-LKXGYXEUSA-N 0.000 description 1
- BTPAWKABYQMKKN-LKXGYXEUSA-N Ser-Asp-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BTPAWKABYQMKKN-LKXGYXEUSA-N 0.000 description 1
- UJTZHGHXJKIAOS-WHFBIAKZSA-N Ser-Gln Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O UJTZHGHXJKIAOS-WHFBIAKZSA-N 0.000 description 1
- GWMXFEMMBHOKDX-AVGNSLFASA-N Ser-Gln-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 GWMXFEMMBHOKDX-AVGNSLFASA-N 0.000 description 1
- UICKAKRRRBTILH-GUBZILKMSA-N Ser-Glu-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)N UICKAKRRRBTILH-GUBZILKMSA-N 0.000 description 1
- MIJWOJAXARLEHA-WDSKDSINSA-N Ser-Gly-Glu Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O MIJWOJAXARLEHA-WDSKDSINSA-N 0.000 description 1
- GZFAWAQTEYDKII-YUMQZZPRSA-N Ser-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO GZFAWAQTEYDKII-YUMQZZPRSA-N 0.000 description 1
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 1
- RIAKPZVSNBBNRE-BJDJZHNGSA-N Ser-Ile-Leu Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O RIAKPZVSNBBNRE-BJDJZHNGSA-N 0.000 description 1
- ZOPISOXXPQNOCO-SVSWQMSJSA-N Ser-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CO)N ZOPISOXXPQNOCO-SVSWQMSJSA-N 0.000 description 1
- IAORETPTUDBBGV-CIUDSAMLSA-N Ser-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N IAORETPTUDBBGV-CIUDSAMLSA-N 0.000 description 1
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 1
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 1
- AXOHAHIUJHCLQR-IHRRRGAJSA-N Ser-Met-Tyr Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CO)N AXOHAHIUJHCLQR-IHRRRGAJSA-N 0.000 description 1
- ADJDNJCSPNFFPI-FXQIFTODSA-N Ser-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO ADJDNJCSPNFFPI-FXQIFTODSA-N 0.000 description 1
- JLKWJWPDXPKKHI-FXQIFTODSA-N Ser-Pro-Asn Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CO)N)C(=O)N[C@@H](CC(=O)N)C(=O)O JLKWJWPDXPKKHI-FXQIFTODSA-N 0.000 description 1
- PJIQEIFXZPCWOJ-FXQIFTODSA-N Ser-Pro-Asp Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O PJIQEIFXZPCWOJ-FXQIFTODSA-N 0.000 description 1
- XGQKSRGHEZNWIS-IHRRRGAJSA-N Ser-Pro-Tyr Chemical compound N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O XGQKSRGHEZNWIS-IHRRRGAJSA-N 0.000 description 1
- OZPDGESCTGGNAD-CIUDSAMLSA-N Ser-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CO OZPDGESCTGGNAD-CIUDSAMLSA-N 0.000 description 1
- SQHKXWODKJDZRC-LKXGYXEUSA-N Ser-Thr-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O SQHKXWODKJDZRC-LKXGYXEUSA-N 0.000 description 1
- PURRNJBBXDDWLX-ZDLURKLDSA-N Ser-Thr-Gly Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CO)N)O PURRNJBBXDDWLX-ZDLURKLDSA-N 0.000 description 1
- ZSDXEKUKQAKZFE-XAVMHZPKSA-N Ser-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N)O ZSDXEKUKQAKZFE-XAVMHZPKSA-N 0.000 description 1
- PQEQXWRVHQAAKS-SRVKXCTJSA-N Ser-Tyr-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)N)CC1=CC=C(O)C=C1 PQEQXWRVHQAAKS-SRVKXCTJSA-N 0.000 description 1
- PMTWIUBUQRGCSB-FXQIFTODSA-N Ser-Val-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O PMTWIUBUQRGCSB-FXQIFTODSA-N 0.000 description 1
- IAOHCSQDQDWRQU-GUBZILKMSA-N Ser-Val-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IAOHCSQDQDWRQU-GUBZILKMSA-N 0.000 description 1
- PCMZJFMUYWIERL-ZKWXMUAHSA-N Ser-Val-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O PCMZJFMUYWIERL-ZKWXMUAHSA-N 0.000 description 1
- MFQMZDPAZRZAPV-NAKRPEOUSA-N Ser-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N MFQMZDPAZRZAPV-NAKRPEOUSA-N 0.000 description 1
- YEDSOSIKVUMIJE-DCAQKATOSA-N Ser-Val-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O YEDSOSIKVUMIJE-DCAQKATOSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- NJEMRSFGDNECGF-GCJQMDKQSA-N Thr-Ala-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O NJEMRSFGDNECGF-GCJQMDKQSA-N 0.000 description 1
- LVHHEVGYAZGXDE-KDXUFGMBSA-N Thr-Ala-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)O)N)O LVHHEVGYAZGXDE-KDXUFGMBSA-N 0.000 description 1
- VFEHSAJCWWHDBH-RHYQMDGZSA-N Thr-Arg-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O VFEHSAJCWWHDBH-RHYQMDGZSA-N 0.000 description 1
- WFUAUEQXPVNAEF-ZJDVBMNYSA-N Thr-Arg-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CCCN=C(N)N WFUAUEQXPVNAEF-ZJDVBMNYSA-N 0.000 description 1
- QNJZOAHSYPXTAB-VEVYYDQMSA-N Thr-Asn-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O QNJZOAHSYPXTAB-VEVYYDQMSA-N 0.000 description 1
- PQLXHSACXPGWPD-GSSVUCPTSA-N Thr-Asn-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PQLXHSACXPGWPD-GSSVUCPTSA-N 0.000 description 1
- NOWXWJLVGTVJKM-PBCZWWQYSA-N Thr-Asp-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N)O NOWXWJLVGTVJKM-PBCZWWQYSA-N 0.000 description 1
- QWMPARMKIDVBLV-VZFHVOOUSA-N Thr-Cys-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O QWMPARMKIDVBLV-VZFHVOOUSA-N 0.000 description 1
- BECPPKYKPSRKCP-ZDLURKLDSA-N Thr-Glu Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O BECPPKYKPSRKCP-ZDLURKLDSA-N 0.000 description 1
- XOTBWOCSLMBGMF-SUSMZKCASA-N Thr-Glu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XOTBWOCSLMBGMF-SUSMZKCASA-N 0.000 description 1
- IMULJHHGAUZZFE-MBLNEYKQSA-N Thr-Gly-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O IMULJHHGAUZZFE-MBLNEYKQSA-N 0.000 description 1
- AYCQVUUPIJHJTA-IXOXFDKPSA-N Thr-His-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O AYCQVUUPIJHJTA-IXOXFDKPSA-N 0.000 description 1
- XOWKUMFHEZLKLT-CIQUZCHMSA-N Thr-Ile-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O XOWKUMFHEZLKLT-CIQUZCHMSA-N 0.000 description 1
- GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 description 1
- ODXKUIGEPAGKKV-KATARQTJSA-N Thr-Leu-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)O)N)O ODXKUIGEPAGKKV-KATARQTJSA-N 0.000 description 1
- MEJHFIOYJHTWMK-VOAKCMCISA-N Thr-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)O MEJHFIOYJHTWMK-VOAKCMCISA-N 0.000 description 1
- KKPOGALELPLJTL-MEYUZBJRSA-N Thr-Lys-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 KKPOGALELPLJTL-MEYUZBJRSA-N 0.000 description 1
- UGFSAPWZBROURT-IXOXFDKPSA-N Thr-Phe-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CS)C(=O)O)N)O UGFSAPWZBROURT-IXOXFDKPSA-N 0.000 description 1
- BDYBHQWMHYDRKJ-UNQGMJICSA-N Thr-Phe-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)O)N)O BDYBHQWMHYDRKJ-UNQGMJICSA-N 0.000 description 1
- QOLYAJSZHIJCTO-VQVTYTSYSA-N Thr-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O QOLYAJSZHIJCTO-VQVTYTSYSA-N 0.000 description 1
- XKWABWFMQXMUMT-HJGDQZAQSA-N Thr-Pro-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XKWABWFMQXMUMT-HJGDQZAQSA-N 0.000 description 1
- MXDOAJQRJBMGMO-FJXKBIBVSA-N Thr-Pro-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O MXDOAJQRJBMGMO-FJXKBIBVSA-N 0.000 description 1
- GVMXJJAJLIEASL-ZJDVBMNYSA-N Thr-Pro-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O GVMXJJAJLIEASL-ZJDVBMNYSA-N 0.000 description 1
- VUXIQSUQQYNLJP-XAVMHZPKSA-N Thr-Ser-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N)O VUXIQSUQQYNLJP-XAVMHZPKSA-N 0.000 description 1
- QYDKSNXSBXZPFK-ZJDVBMNYSA-N Thr-Thr-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYDKSNXSBXZPFK-ZJDVBMNYSA-N 0.000 description 1
- QJIODPFLAASXJC-JHYOHUSXSA-N Thr-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N)O QJIODPFLAASXJC-JHYOHUSXSA-N 0.000 description 1
- UMFLBPIPAJMNIM-LYARXQMPSA-N Thr-Trp-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)N)O UMFLBPIPAJMNIM-LYARXQMPSA-N 0.000 description 1
- LXXCHJKHJYRMIY-FQPOAREZSA-N Thr-Tyr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O LXXCHJKHJYRMIY-FQPOAREZSA-N 0.000 description 1
- JAWUQFCGNVEDRN-MEYUZBJRSA-N Thr-Tyr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N)O JAWUQFCGNVEDRN-MEYUZBJRSA-N 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- FOAJSVIXYCLTSC-PJODQICGSA-N Trp-Ala-Met Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N FOAJSVIXYCLTSC-PJODQICGSA-N 0.000 description 1
- GRQCSEWEPIHLBI-JQWIXIFHSA-N Trp-Asn Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O)=CNC2=C1 GRQCSEWEPIHLBI-JQWIXIFHSA-N 0.000 description 1
- ZPZNQAZHMCLTOA-PXDAIIFMSA-N Trp-Tyr-Ile Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CC=C(O)C=C1 ZPZNQAZHMCLTOA-PXDAIIFMSA-N 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
- 241001467018 Typhis Species 0.000 description 1
- DLZKEQQWXODGGZ-KWQFWETISA-N Tyr-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DLZKEQQWXODGGZ-KWQFWETISA-N 0.000 description 1
- TVOGEPLDNYTAHD-CQDKDKBSSA-N Tyr-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 TVOGEPLDNYTAHD-CQDKDKBSSA-N 0.000 description 1
- HTHCZRWCFXMENJ-KKUMJFAQSA-N Tyr-Arg-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O HTHCZRWCFXMENJ-KKUMJFAQSA-N 0.000 description 1
- OEVJGIHPQOXYFE-SRVKXCTJSA-N Tyr-Asn-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O OEVJGIHPQOXYFE-SRVKXCTJSA-N 0.000 description 1
- PEVVXUGSAKEPEN-AVGNSLFASA-N Tyr-Asn-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PEVVXUGSAKEPEN-AVGNSLFASA-N 0.000 description 1
- JWHOIHCOHMZSAR-QWRGUYRKSA-N Tyr-Asp-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JWHOIHCOHMZSAR-QWRGUYRKSA-N 0.000 description 1
- HVHJYXDXRIWELT-RYUDHWBXSA-N Tyr-Glu-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O HVHJYXDXRIWELT-RYUDHWBXSA-N 0.000 description 1
- UNUZEBFXGWVAOP-DZKIICNBSA-N Tyr-Glu-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UNUZEBFXGWVAOP-DZKIICNBSA-N 0.000 description 1
- ZQOOYCZQENFIMC-STQMWFEESA-N Tyr-His Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)C1=CC=C(O)C=C1 ZQOOYCZQENFIMC-STQMWFEESA-N 0.000 description 1
- MVYRJYISVJWKSX-KBPBESRZSA-N Tyr-His-Gly Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)NCC(=O)O)N)O MVYRJYISVJWKSX-KBPBESRZSA-N 0.000 description 1
- USYGMBIIUDLYHJ-GVARAGBVSA-N Tyr-Ile-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 USYGMBIIUDLYHJ-GVARAGBVSA-N 0.000 description 1
- NHOVZGFNTGMYMI-KKUMJFAQSA-N Tyr-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NHOVZGFNTGMYMI-KKUMJFAQSA-N 0.000 description 1
- SYFHQHYTNCQCCN-MELADBBJSA-N Tyr-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O SYFHQHYTNCQCCN-MELADBBJSA-N 0.000 description 1
- PWKMJDQXKCENMF-MEYUZBJRSA-N Tyr-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O PWKMJDQXKCENMF-MEYUZBJRSA-N 0.000 description 1
- CLEGSEJVGBYZBJ-MEYUZBJRSA-N Tyr-Thr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CLEGSEJVGBYZBJ-MEYUZBJRSA-N 0.000 description 1
- MQUYPYFPHIPVHJ-MNSWYVGCSA-N Tyr-Trp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)O MQUYPYFPHIPVHJ-MNSWYVGCSA-N 0.000 description 1
- AGDDLOQMXUQPDY-BZSNNMDCSA-N Tyr-Tyr-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O AGDDLOQMXUQPDY-BZSNNMDCSA-N 0.000 description 1
- DJIJBQYBDKGDIS-JYJNAYRXSA-N Tyr-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(C)C)C(O)=O DJIJBQYBDKGDIS-JYJNAYRXSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 208000025609 Urogenital disease Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- VDPRBUOZLIFUIM-GUBZILKMSA-N Val-Arg-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N VDPRBUOZLIFUIM-GUBZILKMSA-N 0.000 description 1
- VMRFIKXKOFNMHW-GUBZILKMSA-N Val-Arg-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N VMRFIKXKOFNMHW-GUBZILKMSA-N 0.000 description 1
- NWDOPHYLSORNEX-QXEWZRGKSA-N Val-Asn-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCSC)C(=O)O)N NWDOPHYLSORNEX-QXEWZRGKSA-N 0.000 description 1
- FPCIBLUVDNXPJO-XPUUQOCRSA-N Val-Cys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O FPCIBLUVDNXPJO-XPUUQOCRSA-N 0.000 description 1
- QHFQQRKNGCXTHL-AUTRQRHGSA-N Val-Gln-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O QHFQQRKNGCXTHL-AUTRQRHGSA-N 0.000 description 1
- VVZDBPBZHLQPPB-XVKPBYJWSA-N Val-Glu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O VVZDBPBZHLQPPB-XVKPBYJWSA-N 0.000 description 1
- ROLGIBMFNMZANA-GVXVVHGQSA-N Val-Glu-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N ROLGIBMFNMZANA-GVXVVHGQSA-N 0.000 description 1
- JZWZACGUZVCQPS-RNJOBUHISA-N Val-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N JZWZACGUZVCQPS-RNJOBUHISA-N 0.000 description 1
- MYLNLEIZWHVENT-VKOGCVSHSA-N Val-Ile-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](C(C)C)N MYLNLEIZWHVENT-VKOGCVSHSA-N 0.000 description 1
- BTWMICVCQLKKNR-DCAQKATOSA-N Val-Leu-Ser Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C([O-])=O BTWMICVCQLKKNR-DCAQKATOSA-N 0.000 description 1
- VIKZGAUAKQZDOF-NRPADANISA-N Val-Ser-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O VIKZGAUAKQZDOF-NRPADANISA-N 0.000 description 1
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 1
- CEKSLIVSNNGOKH-KZVJFYERSA-N Val-Thr-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](C(C)C)N)O CEKSLIVSNNGOKH-KZVJFYERSA-N 0.000 description 1
- MNSSBIHFEUUXNW-RCWTZXSCSA-N Val-Thr-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N MNSSBIHFEUUXNW-RCWTZXSCSA-N 0.000 description 1
- YQYFYUSYEDNLSD-YEPSODPASA-N Val-Thr-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O YQYFYUSYEDNLSD-YEPSODPASA-N 0.000 description 1
- VBTFUDNTMCHPII-UHFFFAOYSA-N Val-Trp-Tyr Natural products C=1NC2=CC=CC=C2C=1CC(NC(=O)C(N)C(C)C)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 VBTFUDNTMCHPII-UHFFFAOYSA-N 0.000 description 1
- LLJLBRRXKZTTRD-GUBZILKMSA-N Val-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N LLJLBRRXKZTTRD-GUBZILKMSA-N 0.000 description 1
- JVGDAEKKZKKZFO-RCWTZXSCSA-N Val-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)O JVGDAEKKZKKZFO-RCWTZXSCSA-N 0.000 description 1
- 108010081404 acein-2 Proteins 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
- 108010041407 alanylaspartic acid Proteins 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 108010069926 arginyl-glycyl-serine Proteins 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 108010036533 arginylvaline Proteins 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 108010010430 asparagine-proline-alanine Proteins 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 108010060199 cysteinylproline Proteins 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 1
- 239000012969 di-tertiary-butyl peroxide Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 150000002256 galaktoses Chemical class 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 102000025871 ganglioside binding proteins Human genes 0.000 description 1
- 108091009149 ganglioside binding proteins Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000012817 gel-diffusion technique Methods 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 125000002350 geranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002686 geranylgeranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000020415 glioma susceptibility 1 Diseases 0.000 description 1
- 108010080575 glutamyl-aspartyl-alanine Proteins 0.000 description 1
- 108010079547 glutamylmethionine Proteins 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 108010075431 glycyl-alanyl-phenylalanine Proteins 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- 108010050475 glycyl-leucyl-tyrosine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 108010071185 leucyl-alanine Proteins 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- 108010051673 leucyl-glycyl-phenylalanine Proteins 0.000 description 1
- 108010091798 leucylleucine Proteins 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000005427 lymphocyte apoptotic process Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 108010022588 methionyl-lysyl-proline Proteins 0.000 description 1
- MBAXWTVHCRPVFW-UHFFFAOYSA-N methyl 3-[(3-imino-3-methoxypropyl)disulfanyl]propanimidate Chemical compound COC(=N)CCSSCCC(=N)OC MBAXWTVHCRPVFW-UHFFFAOYSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000008775 paternal effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N pentanal Chemical compound CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 108010012581 phenylalanylglutamate Proteins 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 238000013197 protein A assay Methods 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000031998 transcytosis Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 108700004896 tripeptide FEG Proteins 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 108010072644 valyl-alanyl-prolyl-glycine Proteins 0.000 description 1
- 108010009962 valyltyrosine Proteins 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
A recombinant AB5 B subunit protein including at least one mutation, wherein the mutation alters the number of amino acid residues available for chemical modification as compared to a wild type AB5 B subunit protein, and wherein said recombinant protein retains an effective target ligand bind affinity. F or example, specifically designed mutations are produced in the cholera Toxin B subunit (CTB) such that it can still bind with high affinity to its receptor , Gm-1, but can be specifically covalently linked at lysines or cysteines to a n immunogen or vaccine. The vaccine produced from this coupling is a mucosal vaccine which has high immunogenicity due to the interaction with the CTB. T he vaccine can be produced inexpensively and easily. Alternatively, a technique is disclosed for treating CTB such that non-covalent coupling to a vaccine o r immunogen can occur.
Description
ABS TOXIN B SUBUNIT MUTANTS WITH
ALTERED CHEMICAL CONJUGATION CHARACTERISTICS
FIELD OF THE INVENTION
This invention relates to methods of creating mutants in AB5 toxin B subunit proteins, such as cholera toxin B subunit (CTB), with altered chemical conjugation characteristics.
Compositions comprising the mutant AB5 toxin B subunit proteins are also discussed. Further, use of these compositions as vaccines and bioactive molecule delivery agents is also discussed.
BACKGROUND OF THE INVENTION
MucosalImmunity Most licensed vaccines are delivered parenterally, a route of immunization that, in general, is extremely effective at inducing systemic protection against invasive disease. However, as many pathogens replicate or invade at mucosal surfaces, the efficacy of vaccines against these organisms may be improved if both systemic and mucosal immune responses were induced.
Vaccines may have to be administered at a mucosal site, for example by oral or nasal delivery, in order to induce mucosal immune responses. Indeed, this may be a prerequisite for the production of vaccines against certain pathogens for which no vaccine is currently available (e.g., respiratory syncytial virus and even possibly HIV). An additional potential advantage of mucosal vaccines is that they would be easier to deliver, an extremely important consideration in mass immunization programs.
Unfortunately, delivery of many antigens via mucosal routes is often characterized by low immune responsiveness, due in part to inefficient uptake of antigen. As a result, various strategies for effective delivery of antigens by mucosal routes have been investigated.
Antigens that are successfully delivered across the barrier of epithelial cells lining mucosal tracts stimulate underlying inductive sites of the mucosa-associated lymphoid tissue (MALT).
Antigen-specific lymphocytes that are sensitized in the MALT migrate through the circulatory system to populate distant mucosal sites, thus mucosal immunization may provide both local and systemic protection.
Because many microorganisms invade their hosts via mucosal membrane surfaces, the development of a protective mucosal immune response can provide a preemptory line of defense against a variety of infectious diseases. Successful oral vaccination must induce the production of mucosal antibodies and/or cellular immunity. However, oral administration of many purified antigens fails to result in any substantial immune response.
Use of cholera toxin in mucosal immunity Cholera toxin (CT) has long been considered responsible for inducing an effective, long-lasting protective mucosal immune response to subsequent cholera infection and disease. It was soon discovered that an enhanced mucosal immune response to orally administered antigens can be achieved when the antigens are mixed with CT or conjugated to cholera toxin B
protein (CTB).
The ability of CT and CTB to act as mucosal adjuvants may stem from the adhesive and epithelial cell membrane-permeabilizing effects of these proteins; however, it appears that active toxin is more effective than the B subunit in exerting this immunostimulatory activity.
It is therefore important to determine the events associated with CTB-membrane interaction and to identify mechanisms related to the potential translocational pathways of CTAI .
Cholera Toxin The overt symptoms of cholera are well-known and the cellular events responsible for toxicity of the Vibrio cholerae enterotoxin (CT) have been thoroughly described. In contrast, molecular details of how the different subunits of the hexameric ABS complex of CT act together to initiate cellular toxicity remain poorly understood. What is known is that CT (Mr = 85 620) binds to gangliosides on the apical surface of intestinal epithelial cells via its homopentameric B
subunit (CTB). The unusually strong avidity of CTB for gangliosides, particularly for GM-1, is most likely due to the cooperative affinities of each of the monomeric subunits in their pentameric form. Upon binding, CTB forms a planar ring structure on the membrane surface which possesses a highly polar central pore that interacts intimately with the A subunit of CT. The A subunit is composed of a toxic CTAI subunit linked to the CTA2 subunit by a disulfide bond. Liberation of CTA1 by reduction of this disulfide linkage occurs during transcytosis through the cell to its basolateral membrane. This leads to permanent activation of adenylate cyclase and ribosylation of the GTP-binding regulatory protein GSa. These events result in the activation of sodium pumps via cAMP-dependent protein kinases and subsequent expulsion of sodium and water into the intestinal lumen. While CTB is clearly responsible for toxin binding to ganglioside GM-I
receptors, an essential step in cholera toxicity, the mechanism for transport of CTAl into the cytoplasmic compartment of target cells, remains unclear.
Studies of CT-membrane interactions have shown that CTB binding to GM-I
incorporated into lipid bilayers induces the formation of membrane channels. These findings suggest that CTAI
is translocated into the target cell cytoplasm by passing through a protein-lined pore that traverses the membrane. However, on the basis of investigations using membrane-imbedded photoactivatable probes, as well as low-resolution structural studies, it does not appear that CTB
enters the membrane following its association with GM-1 receptors. These studies could indicate that CT binds with CTA1 oriented toward the cell surface, thereby forcing CTAI
into and through the membrane upon CTB-GM-1 interaction; however, such a mechanism is not consistent with the crystal structures of CT, CTB, and the closely related heat-labile enterotoxin of Escherichia coli (LT). High-resolution structural analyses show that if the B pentamer of the toxin were bound with the AI polypeptide oriented toward the membrane, a significant portion of the B subunit would also have to enter the membrane. Moreover, recent evidence has demonstrated that functional CT
binds with CTA1 facing away from the cell surface. These observations and the fact that CT does not appear to undergo significant structural changes upon receptor association have prompted many questions concerning the mechanism by which CTAI moves from a site that is some distance from the cell surface to a position within the target cell cytoplasm.
Evidence is now accumulating that supports a model in which endocytosis plays a major role in mediating cellular toxicity by CT. The role of endocytosis in mediating CT intoxication is not entirely clear; however, endosomal processing appears to involve CT
migration to the Golgi and possibly other membrane-lined regions of the target cell cytoplasm. It now appears that endocytosis allows CT to encounter environmental stimuli that influence the course of cellular toxicity. The precise nature of these signals remains to be clearly established, but temperature sensitivity and pH have been suggested to be important in CT intoxication of rat hepatocytes and lung epithelial cell lines and may influence the cytoplasmic routing of CTB.
Moreover, low pH
has been suggested to have a role in cellular toxicity by other ABS toxins.
IS The mechanisms responsible for CTA1 transport are important because, in addition to its well-known toxic effect, CT possesses potent mucosal adjuvant properties that can be exploited in oral and other immunization strategies.
Production of mucosal vaccines using CT: previous strategies One strategy to develop mucosal vaccines has been to employ bacterial enterotoxins such as cholera toxin (CT) from Vibrio cholera and the related E. coli heat-labile enterotoxin (LT), which are highly immunogenic when delivered mucosally and which can act as carriers to potentiate responses to non-related antigens. Both biotoxins are composed of an ADP-ribosylating A subunit which mediates toxicity, linked to a cyclic pentamer of B subunits which interacts specifically with monosialoganglioside (GM-I) sugars expressed on eukaryotic cells. During a natural infection, the function of the B subunits is to facilitate the binding and entry of the attached A subunit into GM-1-expressing cells. Although the holotoxins are potent adjuvants for a range of antigens and can modulate different immune functions including antigen presentation, cytokine production, and B-cell switching, their practical use is limited by the toxicity of the A subunit.
Attempts to diminish toxicity through mutations to the A subunit have raised considerable debate over the direct relationship between the toxicity and adjuvanticity of this subunit. If successful, these adjuvants would be relatively simple to formulate. Other attempts to solve the toxicity problem have included an attempt to develop non-toxic subunits as adjuvants. While vaccines incorporating B subunits appear to enhance the toxin's adjuvant activity by diminishing the toxin dosages required, B subunits have failed to gain popularity. Many investigations, however, only consider the B subunits as adjuvants, rather than as vehicles for antigen delivery.
_,_ Recent evidence indicates that B subunits might effectively serve to deliver antigen to the mucosal immune system when physically coupled to that antigen. In such case, the B
subunit is known to significantly enhance the mucosal immune response to the carried antigen.
It is assumed that some of the adjuvant properties of LTB and CTB can be explained by the increased uptake of B subunit across GM-I-expressing epithelial cells lining mucosal tracts, thereby enhancing the amount of antigen passively delivered to the MALT
inductive sites and the subsequent stimulation of antigen-specific B- and T-lymphocytes. LTB can also modulate immune activities such as cytokine production, lymphocyte apoptosis, and expression of B-cell activation molecules. These properties may also add to their effectiveness as adjuvants.
What is clear is that the highly immunogenic nature of LTB and CTB and their ability to modulate lymphocyte activity is dependent upon their ability to bind GM-1.
Antigens can be physically attached to BS subunits by either genetic or chemical means.
Genetic fusion of epitopes to LTB has been successful in some cases, but genetic coupling of heterologous epitopes can interfere with the structure, secretion, GM-1-binding and immunogenicity of the LTB fusion proteins. Also, there are limitations to the size and type of antigen that can be attached to LTB by genetic fusion. An alternative and more flexible approach is chemical coupling, which may be used to attach larger and a wider range of antigens, including polysaccharides. CTB has been chemically coupled to antigens such as whole Sendai virus and purified AgI/II from Streptococcus mutarTS and these conjugates have been shown to stimulate strong immune responses at mucosal sites (gut, respiratory tract, genital tract) and in the circulation.
O'Dowd et al., 1999, Vaccine 17, pp. 1442-1453 generated a panel of LTB fusion proteins in which individual amino acids within an epitope tag were replaced with cysteine. Horseradish peroxidase (HRP) was chemically coupled to these cysteine residues. Following intranasal administration, high titer mucosal and systemic antibody responses to HRP were generated when HRP was chemically coupled to LTB. There was no antibody response when HRP was co-administered with LTB.
SUMMARY OF THE INVENTION
The invention provides novel sequence modifications to recombinant CTB or other AB;-type BS subunit proteins through site directed mutations, deletions or additions. The invention also contemplates a method for producing said proteins which can be cross-linked chemically, hydrophobically, or genetically, or otherwise associated with an immunogen adjuvant, microcapsule, drug or immune response modifier in a manner in which the CTB
product or other ABS-type BS retains ganglioside specificity. In one embodiment, the recombinant B subunit proteins are specifically altered so that chemical conjugation to an immunogen, drug or immune response modifier occurs in a residue specific manner and can be attached without eliminating the ganglioside affinity of the resultant conjugate. The recombinant B subunit proteins can be expressed and isolated in large amounts. This allows for a conjugate that is more homogeneous in composition and is known to bind to the ganglioside with an acceptable affinity. The vaccines) derived from this conjugate thereby target the mucosal tissues and promote both systemic and mucosal immune responses. The preferred embodiment of this invention is particularly advantageous for the recruitment of immunity to the predominant site of infection for infectious diseases, most of which typically colonize mucosal tissue surfaces.
One embodiment of the invention is a novel plasmid construct of a BS
expression system in which a BS protein is expressed at high levels. In one embodiment, a recombinant cholera toxin B (rCTB) subunit protein including at least one mutation, addition, or deletion of residues between positions 1-103 of CTB is disclosed. Advantageously, the alteration allows chemical conjugation of said recombinant protein without interference to the ganglioside binding of CTB. In one embodiment, the mutation diminishes the ability of rCTB to combine at that site with any compound, drug, immunogen, immunomodulatory molecule, adjuvant or other bioactive molecule.
However, the compound can bind more specifically at another site and deliver these compounds to the mucosal epithelium. Preferably, the mutation, deletion or addition is to positions 1-103 of wild type CTB.
In a further embodiment, at least one mutation includes K23U, K34U, K43U, K62U, K63U, K69U, K81U, K84U, C86U or K9lU; wherein "U" is any amino acid that fails to promote chemical modification at those sites or wherein "U" represents the deletion of the residue, and the deletion of the amino acid results in a rCTB protein with a reduced ability to be covalently modified at those sites.
In one embodiment, advantageously, the at least one mutation, deletion or addition facilitates rCTB to combine at the site of the mutation, deletion or addition with any compound, drug, immunogen, immunomodulatory molecule, adjuvant or other bioactive molecule and to deliver the complex to the mucosal epithelium. Advantageously, the mutation, deletion or addition is to positions 1-103 of wild type CTB.
A further embodiment of the invention is a recombinant cholera toxin B (rCTB) subunit protein including at least one mutation or deletion that reduces the number of potential chemical modification sites in the recombinant protein as compared to a wild type CTB
protein. Preferably, the mutation or deletion is at positions 1-103 of CTB. Advantageously, at least one mutation or addition increases the number of potential chemical modification sites in the recombinant protein at the mutation sites as compared to a wild type CTB protein. In one aspect of the invention, the mutations or additions are at positions 1-103 of CTB.
A further embodiment of the invention is a method of making a recombinant cholera toxin B (rCTB) subunit gene encoding a rCTB protein with a reduced number of modification sites as compared to a wild type CTB protein. The method includes providing a cholera toxin B (CTB) subunit gene encoding a CTB protein; selecting codons encoding amino acid residues favoring chemical modification of the CTB protein; and mutating or deleting the codons such that the resulting amino acid residues are unfavorable for chemical modification.
A further embodiment of the invention is a method of making a recombinant cholera toxin B (rCTB) subunit gene encoding a rCTB protein with an increase in chemical modification sites as compared to a wild type CTB protein, comprising providing a cholera toxin B
(CTB) subunit gene encoding a CTB protein; selecting codons encoding amino acid residues unfavorable to chemical modification of the CTB protein; and mutating or adding said codons such that the resulting rCTB
protein possesses favorable chemical modification capabilities; selecting codons encoding amino acid residues favorable to chemical modification of the CTB protein; and mutating or deleting said codons such that the resulting amino acids are incapable of chemical modification.
I S A further embodiment of the invention is a method of producing a recombinant cholera toxin B (rCTB) subunit gene encoding a rCTB protein with decreased chemical modification sites as compared to a wild type CTB protein, comprising providing a cholera toxin B
(CTB) subunit gene encoding a CTB protein; selecting codons encoding amino acid residues unfavorable to chemical modification of the CTB protein; mutating or adding said codons such that the resulting rCTB protein possesses favorable chemical modification capabilities; selecting codons encoding amino acid residues favorable to chemical modification of the CTB protein; and mutating or deleting said codons such that the resulting amino acids are incapable of chemical modification.
A further embodiment of the invention is a method for producing a recombinant cholera toxin B (rCTB) subunit protein including the steps of obtaining a gene encoding an rCTB protein or mutated protein of the invention, adding a promoter, thereby producing an expression cassette;
introducing the expression cassette into a suitable host cell, and cultivating the host cell under conditions whereby the expression cassette is translated into protein.
A further embodiment of the invention is a gene construct for producing a recombinant binding subunit protein of cholera toxin (CTB), having a promoter and a DNA
sequence which encodes a rCTB protein operably linked in the proper reading frame.
A further embodiment of the invention is a method for producing a recombinant binding sub-unit protein of cholera toxin (CTB). The method includes expressing a gene construct in a suitable host cell and recovering CTB or mutations thereof.
A further embodiment of the invention is the creation of complexes of rCTB or variants thereof and compounds of whole or part, live, killed or reconstituted bacterium or virus, virus-like particle, protein, peptide, glycoprotein, carbohydrate, polysaccharide, phospholipid, DNA, drug, biological response modifier, microparticles or adjuvant by genetic, covalent, hydrophobic or associative mechanisms.
A further embodiment of the invention is a gene fusion vector which includes a promoter, a DNA sequence encoding the cholera toxin binding subunit protein or mutant rCTB of the invention and an immunogenic peptide coding sequence, wherein the cholera toxin binding protein subunit and the immunogenic peptide coding sequences are operably linked in the proper reading frame, whereby a gene fusion protein results, and the gene fusion protein is expressed and secreted within inclusion bodies or medium.
A further embodiment of the invention is a method of generating an antibody or cellular immune response to an immunogen or immunogenic complex. Advantageously, the method includes providing the recombinant CTB protein of the invention, modifying the protein covalently with a heterobifunctional cross-linking reagent with a first and a second functional groups, wherein the first functional group is in chemical association with the recombinant CTB
protein, covalently I S modifying the second functional group covalently with the immunogen, and administering the CTB protein modified in such a way that the animal generates an immune response.
A further embodiment of the invention is a method of generating an antibody or cellular immune response to an immunogen or immunogenic complex including providing the recombinant CTB protein of the invention, modifying the protein with a dimeric cross-linking reagent with a first and a second functional groups, wherein the first functional group is in chemical association with the recombinant CTB protein, covalently modifying the second functional group with an epitope, and administering the protein to the host until an immune response is generated.
A further embodiment of the invention is a method of generating an antibody or cellular immune response to an immunogen or immunogenic complex which includes providing the recombinant CTB protein of the invention, modifying the protein hydrophobically by prenylation or by covalent linkage in a CTB site directed manner to an amphipathic side group, mixing with an immunogenic complex containing any lipid or phospholipid micellar formulation, and administering the CTB-immunogen to the host until an immune response is generated.
A further embodiment of the invention is an rCTB expression vector including an MS-0 vector, and SEQ ID NO:1. The vector may be pML-CTBtacl .
A further embodiment of the invention is a method for generating an immune response to an immunogen comprising providing a recombinant ABS toxin B protein, prenylating the toxin B
protein, mixing the prenylated toxin B protein with an immunogen to produce a hydrophobically coupled protein, and administering the protein to an animal to generate an antibody or cellular response. In one embodiment, the ABS toxin B protein may be cholera toxin B
protein (CTB), E.
coli heat labile toxin B protein (LTB), LT type IIa B protein, LT type IIb B
protein, Shiga toxin B
protein, Shiga-like toxin B protein, or pertussis toxin B protein. Preferably, the ABS toxin B
protein is cholera toxin B protein (CTB).
A further embodiment of the invention is a method of making a recombinant ABS
toxin B
(rB) subunit gene encoding a rB protein with an enhanced number of modifications sites as compared to the wild type rB protein, comprising providing a B subunit gene encoding a B protein, selecting codons encoding amino acid residues not involved in covalent modification of the B
protein, and mutating said codons such that the resulting rB protein possesses enhanced modification capabilities.
A further embodiment of the invention is a method of making a recombinant ABS
toxin B
(rB) subunit gene encoding a rB protein with altered chemical modification capabilities as compared to the wild type B protein, including providing a toxin B (B) subunit gene encoding a B
protein, selecting codons encoding amino acid residues which favor covalent modification of the B
protein, mutating the codons such that the resulting rB protein possesses enhanced chemical I S modification capabilities at that site, selecting codons encoding amino acid residues which favor chemical modification of the B protein; and mutating the codons such that the resulting amino acids do not favor chemical modification at that site. In one embodiment, the rB protein is cholera toxin B protein (CTB), E. coli heat labile toxin B protein (LTB), LT type IIa B protein, LT type IIb B protein, Shiga toxin B protein, Shiga-like toxin B protein, or pertussis toxin B protein. In a further embodiment, the rB protein is cholera toxin B protein (CTB).
Advantageously, the mutations include changing lysine, histidine, arginine or cysteine residues to any other amino acid residues. In a further embodiment, the mutations include changing any amino acid to lysine, histidine, arginine or cysteine.
A further embodiment of the invention is a gene fusion vector comprising a promoter, a DNA sequence encoding an ABS toxin ganglioside binding subunit protein and an immunogenic peptide coding sequence, wherein said ABS toxin ganglioside binding protein subunit and said immunogenic peptide coding sequences are operably linked in the proper reading frame, whereby a gene fusion protein results; and said gene fusion protein is expressed and secreted within inclusion bodies or medium.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is the translated coding sequence of the rCTB protein produced by the (Maxim Secretory -0) genetic expression vector (SEQ ID NOs:l and 2). The encoded protein is identical to the wild-type sequence from V. cholera strain 569B.
Figure 2 is a plasmid map illustrating the MS-0 plasmid.
_g_ Figure 3 is the amino acid sequence of rCTB (SEQ ID N0:2), further illustrating the predicted secondary structure, position of lysine residues, and regions involved in binding to GM-1.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The invention contemplates introducing mutations, such as amino acid additions or deletions. throughout the nucleic acid sequence of the B subunits from the family of ABS toxins (hereinafter ABS B subunit proteins) to produce mutant proteins that possess enhanced conjugation characteristics. The term "enhanced conjugation characteristics'' refers to an ABj B subunit protein that can be conjugated by chemical or other means to drugs, immunogens, cytokines or other bioactive compounds such that the conjugated compound possesses increased bioactivity.
Specifically, enhanced conjugation characteristics in an ABS B subunit protein results from the mutations taught here that are designed to decrease steric hinderance or the formation of inappropriate quaternary structures as a consequence of the process of conjugation. In this way, these mutations maximize the availability of the ligand binding sites on the mutant ABS B subunit proteins an conjugates composed thereof. One benefit of using such mutant AB5 B subunit proteins is to improve the yield of bioactive structures following conjugation.
The invention describes mutants of ABS B subunit proteins comprising single or multiple amino acid substitutions, deletions, or insertions, throughout its sequence that result in novel, predictable spatial orientations of the molecules to be conjugated relative to one another. The invention further contemplates mutant ABS B subunit proteins with enhanced or altered conjugation characteristics that enhance the bioactivity of the resulting conjugate. Such a mutant ABS B subunit protein coupled to an immunogen or other bioactive compound serves to enhance the compound's activity in a subject to whom the mutant protein conjugate is administered.
ABS toxins consist of hexameric assemblies comprising a single catalytically active A-subunit and a pentamer of B-subunits. The B-pentamer of these toxins is capable of target cell recognition and binding even in the absence of the A-subunit. The toxin pentamers bind to saccharides, either to the olgosaccaride moieties of gangliosides in the cell membrane or to glycosylated proteins at the cell surface. The class of ABS toxins may be subdivided into families on the basis of sequence homology and catalytic activity. One family, the cholera toxin (CT) family includes, in addition to CT itself, the E. coli heat-labile enterotoxins LT and LT-lI, and a less well-characterized toxin from Campylobacter jejuni. Another family, the shiga toxin family, comprises a number of toxins from Shigella dyserrteriae and the shiga-like toxins (also known as verotoxins) from E.coli. Other ABS toxins include pertussis toxin from B.
pertussis and the eukaryotic toxin ricin.
The AB5 toxin LTB illustrates one relationship between this family of proteins. LTB
shares extensive homology with CTB. The two toxins share 80% amino acid sequence identity, similar receptor specificity, catalytic activity, and immunological properties. Those AB5 proteins with little sequence identity such as the shiga and pertussis toxins still share a high degree of structural similarity. This was determined based on the structure of the toxins in complex with the pentasaccharide from the toxin receptor and based on crystallographically determined details of toxin-receptor binding interactions (see Merritt et al. Current Opinion in Structural Biology, 1995, 5:165-171 ). Therefore, although other BS subunit proteins can be distinct in amino acid sequence, they still possess comparable functional specificity. Some BS holotoxins of this type are LT type fIa and IIb. Additionally. Shiga toxin, shiga-like toxin and Pertussis toxin share a similar receptor specificity of BS subunits. Further, mutations such as those set out herein for rCTB, to these subunits would create delivery molecules enhanced in their ability to bind other bioactive compounds but which still retain ganglioside specificity. The concepts taught in this application for rCTB may be applied to all examples of B5 subunits, some of which are shown below in Table 1.
TABLE 1: AB5 TOXIN SEQUENCES
AB5 family Protein NCBI accession SEQ ID NO.
#
CTB
CTB GI:209555 32 GI:758351 4 GI:1827850 5 GI:808900 6 GI:229616 7 GI:998409 8 GI:2144685 9 GI:1421511 10 CTB classic (596B)GI:48890 11 CTB Ogawa 41 GI:2781121 12 CTB Ogawa 4l R35D ~ GI:1421525 13 LTB
Classic LTB GI:3062900 15 GI:1169505 16 ABS family Protein NCBI accession SEQ ID NO.
#
6I:1395122 61:145833 18 LT87 61:1648865 19 GI:223254 20 GI:408996 21 GI:494265 22 GI:69630 23 LT-IIa GI:146671 24 LT-Ilb GI:576584 25 Shiga toxin Shiga toxin beta 61:152784 26 subunit Shiga-like toxin Shiga-like from E. 61:4877349 27 coli Pertussis Pertussis toxin GI:144070 28 chain S2 S3 GI:144070 29 S4 GI:144070 30 SS 61:144070 31 In many cases several toxin variants that differ in amino acid sequence have been characterized. The first CTB sequence shown (SEQ ID NO: 33) is the original sequence published by Sanchez and Holmgren that is identical to the one used in this application, except for the amino terminus. (SEQ ID N0:2). The first LTB sequence (SEQ ID NO:15) is derived from the sequence of the cloned gene. The other sequences listed in the table are variants of either CTB or LTB
found in the NCBI gene bank. The list is not intended to show all variants, but to demonstrate the natural variation among these toxins.
Polvnucleotides Encoding Mutant ABS B Subunit Proteins The invention also relates to nucleic acids molecules comprising polynucleotide sequences encoding mutant ABS B subunit proteins, fragments or derivatives thereof. In one embodiment, the ABS B subunit proteins, fragments or derivatives contemplated for use with the invention possess mucosal tissue binding or association capabilities. These sequences generally contain at least one base insertion, deletion or substitution, or combinations thereof that result in single or multiple amino acid addition, deletion and substitution relative to the wild type ABS B
subunit protein.
Due to the degeneracy of nucleotide coding sequences, any other DNA sequences that encode the same amino acid sequence for a mutant subunit may be used in the practice of the invention.
These include but are not limited to nucleotide sequences comprising all or portions of the coding region of a ABS B subunit which are altered by the substitution of different codons that encode the same amino acid residue within the sequence, thus producing a silent change.
ABS B Subunit Gene Cloning Polynucleotides encoding ABS B subunits can be obtained by standard procedures from sources of cloned DNA, as would be represented by a "library" of biological clones, by chemical synthesis, by cDNA cloning. or by the cloning of genomic DNA purified from a desired cell type.
Methods useful for conducting these procedures have been detailed by Sambrook et al., in Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989); by Glover, D.M. (ed.), in DNA Cloning: A Practical Approach, MRL Press, Ltd., Oxford, U.K. (1985); and by Current Protocols irr Molecular Biology, Eds.
Ausubel, et al., John Wiley & Sons, Inc. (1998). The polymerase chain reaction (PCR) can be used to amplify sequences encoding an ABS B subunit in a genomic or cDNA library. Synthetic oligonucleotides can be utilized as primers in a PCR protocol using RNA or DNA, or a cDNA library, as a source of target sequences.
The nucleic acid sequence being amplified can include cDNA or genomic DNA from any ABS B
toxin producing bacterium. After successful isolation or amplification of a polynucleotide encoding a segment of an ABS B subunit, that segment can be molecularly cloned and sequenced, and utilized as a probe to isolate a complete cDNA or genomic clone. This, in turn, will permit characterization of the nucleotide sequence of the ABS B subunit-encoding polynucleotide, and the production of the ABS B subunit protein product for functional analysis and/or therapeutic or diagnostic use.
Alternatives to isolating the coding regions for the subunits include chemically synthesizing the gene sequence itself from the published sequence. Other methods are possible and within the scope of the invention. The above-methods are not meant to limit performance of the methods by which mutants of the BS subunits may be obtained.
The identified and isolated polynucleotide can be inserted into an appropriate cloning vector for amplification of the gene sequence. A large number of vector-host systems known in the art may be used for this purpose. Possible vectors include plasmids or modified viruses. Of course, the vector system must be compatible with the host cell used in these procedures. Such vectors include bacteriophages such as lambda derivatives, or plasmids such as pBR322 or pUC
plasmid derivatives or the pBLUESCRIPT vector (Stratagene, La Jolla, CA). The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment of interest into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. In an alternative method, the cleaved vector and mutant subunit gene may be modified by homopolymeric tailing.
Recombinant molecules can be introduced into host cells via transformation.
transfection, infection or electroporation so that the copies of the vector containing the gene sequence of interest is increased.
In an alternative method, the desired gene may be identified and isolated after insertion into a suitable cloning vector in a "shot gun" approach. Enrichment for the desired gene, for example, by size fractionation, can be done before insertion into the cloning vector.
In specific embodiments, transformation of host cells with recombinant DNA
molecules that comprise the mutant subunit gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene. Thus, the ABS B subunit-encoding polynucleotide may be obtained in large quantities by growing transformed host organisms, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA. Copies of the gene are used in mutagenesis experiments to study the structure and function of mutant ABS B subunit proteins.
Muta~enesis The mutations present in mutant ABS B subunits, fragments and derivatives of the invention can be produced by various methods known in the art. The manipulations which result in their production can occur at the gene or protein level. For example, the cloned coding region of the subunits can be modified by any of numerous strategies known in the art (see Sambrook et al., 1990, Molecular Cloning, A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York). The polynucleotide sequence can be cleaved at appropriate sites using restriction endonucleases, followed by further enzymatic modification if desired, isolated, and ligated in vitro.
In the production of a mutant subunit, care should be taken to ensure that the modified gene remains within the same translational reading frame, uninterrupted by translational stop signals in the gene region where the subunit is encoded.
Additionally, the polynucleotide sequence encoding the subunits can be mutated in vitro or in vivo, to create variations in coding regions (e.g. amino acid substitutions), and/or to create and/or destroy translation, initiation, and/or termination sequences, and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further in vitro modification. Any technique for mutagenesis known in the art can be used, including but not limited to, chemical mutagenesis, in vitro site-directed mutagenesis (Hutchinson, C., et al., 1978, J. Biol. Chem 253:6551), PCR-based overlap extension (Ho et al., 1989, Gene 77:51-59), PCR-based megaprimer mutagenesis (Sarkar et al., 1990, Biotechniques, 8:404-407), or similar methods. The presence of mutations can be confirmed by double stranded dideoxy DNA sequencing.
Manipulations of the mutant subunit sequence may also be made at the protein level.
Included within the scope of the invention are mutant ABS B subunits that are differentially modified during or after translation, e.g., by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand. Any of numerous chemical modifications may be carried out by kIlOWi7 techniques, including but not limited to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH4; acetylation, formylation, oxidation, reduction; or metabolic synthesis in the presence of tunicamycin.
In addition. mutant ABj B peptide sequences or chemical analogs can be synthesized. For example, a peptide corresponding to a portion of a mutant subunit which comprises the desired mutated domain can be synthesized using an automated peptide synthesizer.
Optionally, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the mutant subunit sequence. Non-classical amino acids include but are not limited to the D-isomers of the common amino acids, a-amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, y-Abu, E-Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, (3-alanine, fluoro-amino acids, designer amino acids such as (3-methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L
(levorotary).
Expression of Mutant ABS B Subunit-Encoding Polynucleotides The polynucleotide sequence encoding a mutant subunit of CTB or a functionally active fragment or other derivative thereof can be inserted into an appropriate expression vector. In the context of the invention, appropriate expression vectors will contain the necessary elements for the transcription and translation of the inserted protein-coding sequence. The necessary transcriptional and translational signals may also be supplied by the native ABS B subunit cDNA or gene, and/or genomic sequences flanking the subunit gene. A variety of host-vector systems may be utilized to express the protein-coding sequence. These include established or experimental bacterial expression systems; mammalian cell systems infected with a recombinant virus such as a vaccinia virus or adenovirus, insect cell systems infected with a virus such as a recombinant baculovirus, and microorganisms such as yeast containing vectors capable of replication in yeast.
The expression elements of vectors vary in their strengths and specificities.
Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used. In specific embodiments, a mutant subunit coding region or a sequence encoding a mutated and functionally active portion of the respective mutant subunit is expressed.
Any of the methods previously described for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/translational control signals and the protein coding sequences. These methods may include ij~ vitro recombinant DNA synthetic techniques. Expression of polynucleotide sequences encoding mutant ABS B subunits or peptide fragments thereof may be regulated by a second polynucleotide sequence so that the mutant subunit(s) or peptide is expressed in a host transformed with the recombinant DNA molecule. For example, expression of a mutant ABS B
subunit or peptide fragments thereof may be controlled by any promoter/enhancer element known 117 the art. Promoters which may be used include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al.. 1980. Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proe. Ncrtl. Acad Sci. U.S.A. 78:1441-1440, and the regulatory sequences of the metallothionein gene (Brinster et al., 1982, Nature 296:39-42).
In a specific embodiment, a vector is used that comprises a promoter operably linked to the coding region of a mutant ABS B subunit, and one or more selectable markers (e.g., an antibiotic resistance gene).
A host cell strain may be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired.
Expression from certain promoters can be elevated in the presence of cel-tain inducers. In this matter, expression of the genetically engineered mutant subunits may be controlled. Furthermore, different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, phosphorylation of proteins). Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed.
Expression in mammalian cells can be used to ensure "native" glycosylation of a heterologous protein. Furthermore, different vector/host expression systems may effect processing reactions to different extents.
Once a recombinant host cell which expresses the mutant subunit gene sequences) is identified, the gene products) can be purified and analyzed. The analysis is achieved by assays based on the physical or functional properties of the product, including radioactive labelling of the product followed by analysis by gel electrophoresis, immunoassay or other techniques useful for detecting the biological activity of the mutant subunit.
Production of Antibodies to Mutant Subunits and Analogs Thereof According to the invention, mutant ABS B subunits, fragments or other derivatives thereof, alone or conjugated to an immunogenic molecule or some other protein of interest may be used as an immunogen to generate antibodies which immunospecifically bind such an immunogen. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library. In a specific embodiment, antibodies to a mutant ABS B
subunit, such as CTB, are produced. In another embodiment antibodies to a domain of a mutant subunit are produced. In another embodiment, antibodies to the immunogen are produced.
Various procedures known Ill the art may be used for the production of polyclonal antibodies directed against mutant ABS B subunits, fragments. or other derivatives thereof. For the production of antibodies, various host animals can be immunized by injection with the mutant subunits produced with the methods described herein. Appropriate host animals include rabbits, mice, rats, other mammals, as well as birds such as chickens. Various adjuvants may be used to increase the immunological response, depending on the host species, and including but not limited to Freund's adjuvant (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, caprylic acid glycerides, peptides, polyoxyethylene sorbitan monoesters, oil and water emulsions, liposomes, poly-L-lactide co glycolide (PLG) microspheres, protein carriers such as keyhole limpet hemocyanin or diphtheria toxin mutants, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette Guerin) and corynebacterium parvum.
For preparation of monoclonal antibodies directed against mutant ABS B
subunits, its fragments, or other derivatives thereof, any technique which provides for the production of antibody molecules by continuous cell lines in culture can be used. For example. the hybridoma technique originally developed by Kohler and Milstein (1975, Nature 256:495-497), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals utilizing recent technology (PCT/US90/02545). Human antibodies can be used and can be obtained by using human hybridomas (Cote et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:2026-2030) or by transforming human B cells with EBV virus in vitro (Cole et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, pp. 77-96). In fact, techniques developed for the production of "chimeric antibodies" (Morrison et al., 1984, Proc. Natl. Acad. Sci. U.S.A.
81:6851-6855; Neuberger et al., 1984, Nature 312:604-608; Takeda et al., 1985, Nature 314:452-454) by splicing the genes from a mouse antibody molecule specific for the epitope together with genes from a human antibody molecule of appropriate biological activity can be used. The antibody products of these techniques fall within the scope of this invention.
According to the invention, techniques described for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce specific single chain antibodies against ABS B
subunits, fragments, or derivatives thereof. An additional embodiment of the invention utilizes the techniques described for the construction of Fab expression libraries (Huse et al., 1989, Science 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.
Antibody fragments which contain the idiotype of the molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')2 fragment which can be produced by pepsin digestion of the antibody molecule, the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab')2 fragment, the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent, and Fv fragments.
In the production of antibodies, screening for the desired antibody can be accomplished using standard techniques known in the art. For example, the ELISA (enzyme-linked immunosorbent assay) would be an appropriate screening technique. For example, to select antibodies which recognize a specific domain of a mutant subunit, one may assay hybridomas for a product which binds to a fragment of a mutant subunit containing such domain. For selection of an antibody that specifically binds a mutant ABS B subunit, but which does not specifically bind the wild type protein, one can select on the basis of positive binding to the mutant and a lack of binding to the wild type protein. Antibodies specific for a domain of a mutant ABS B subunit, or fragment thereof are also provided by the invention.
The foregoing antibodies can be used in methods known in the art relating to the localization and activity of the mutant ABS B subunits of the invention. These methods can involve labeling of the proteins, measuring levels thereof in appropriate physiological samples in diagnostic methods.
Structure and Function Analysis of Mutant ABS B Subunits Described herein are methods for analyzing the structure and function of mutant ABS B
subunits and for analyzing the in vitro activities and in vivo biological functions of the foregoing.
Once a mutant ABS B subunit is identified, it can be isolated and purified by standard methods including chromatography (e.g., ion exchange, affinity, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique useful for purifying proteins.
Functional properties of the protein can be evaluated using any suitable assay, including immunological, immunochemcial, biochemical and biological assays.
_ 17-Alternatively, once a mutant ABS B subunit produced by a recombinant host cell is identified, the amino acid sequence of the subunit(s) can be determined using standard techniques for protein sequencing, including the use of an automated amino acid sequencer.
The functional activity of a mutant ABS B subunit, derivatives and fragments thereof can be assayed by various methods known in the art. For example, where a mutant ABS B
subunit or fragment thereof is assayed for its ability to bind or compete with the corresponding wild type ABS B
subunit. Alternatively, when ABS B subunits are assayed for antibody binding, various immunoassays known in the art can be used. These immunoassays include competitive and non competitive assay systems using techniques such as radio-immunoassays, ELISA, "sandwich"
immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, if? situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), Western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays. Antibody binding can be detected by detecting a label on the I S primary antibody. Alternatively, the primary antibody can be detected by detecting binding of a secondary antibody or reagent to the primary antibody, particularly where the secondary antibody is labeled.
One of ordinary skill in the art may use the various assays discussed above to measure the binding affinity of a mutant ABS B subunit for its target ligand. Binding affinities for the mutant ABS B subunits may be reduced by one, two, three, four, or five, orders of magnitudes. A mutant AB5 B subunit protein remains acceptable so long as the binding affinity of the mutant protein does not eliminate delivery of the mutant protein complex in vivo. The binding affinity of wild type CTB
for Gm-1 has been calculated at approximately 4.6 x 10-12 as determined by BIAcor analysis (Duziemdo, et al. 1996, Biochem. 35:6375-6384). Mutants of CTB with altered modification characteristics may demonstrate reduced binding affinities for GM-I, however, wild type affinity is so strong that significant reductions of affinity following mutation may not reduce the in vivo delivery of the mutant protein complexes. Accordingly, mutant CTB proteins with binding affinities of approximately 10-12, 10-11, 10-10, 10-9, 10-8, 10-7 are considered acceptable.
Mutant ABS B subunit proteins as vaccines Mutant ABS B subunit proteins can be used as vaccines. When used in this manner, a mutant ABS B subunit may be coupled to an immunogen of choice. The mutant ABS B
subunit proteins described herein are combined in a desired weight ratio so as to produce a vaccine that can elicit an optimal protective mucosal and systemic immune response from an immunized subject. In one embodiment, the mutant ABS B subunit and the immunogen component are mixed in a ratio in which the proportion of carrier component exceeds that of the immunogen, for example, at a molecular weight ratio of about 500,000:1. In another embodiment of the invention, the mutant ABS B subunit and the immunogenic component are mixed in a molecular weight ratio of about 100,000:1. In still another embodiment the mutant ABS B subunit and the immunogen are mixed in a molecular weight ratio of about 1000:1, or 100:1, or 10:1. And in yet another embodiment, the molecular weight ratio can be that of 1:1. Alternatively, the components of the vaccine can also be combined in a ratio where the proportion of carrier component is less than that of the immunogen.
For example, small compounds or peptides conjugated to a mutant rCtB described herein can be conjugated at a ratio of 1 rCtB homopentamer to 5, 10 or more immunogenic molecules.
Cross-linking reagents for use with mutant ABS B subunits There are a variety of cross-linking procedures and reagents available to conjugate bioactive compounds, such as immunogens and vaccines to mutant ABS B subunits. Cross-linking procedures generally employ bifunctional reagents that modify amino acid side-chains.
Typical amino acids modified include cysteine, lysine, and histamine, although any modifiable amino acid is contemplated for use with the invention. Bifunctional reagents are often classified on the basis of (i) chemical specificity; (ii) length of cross-bridge formed; (iii) whether the compound is a homo-bifunctional or hetero-bifunctional compound; (iv) whether the groups are chemically or photochemically reactive;
and (v) whether the reagents contain a cleavable bond.
Frequently, cross-linking reagents are reactive with amino- groups or sulphydryl- containing side chains of amino acids, for example, as with lysine or cysteine side chains. The choice of a cross-linking reagent will depend on the target amino acid in both the ligand to be cross-linked and the target ABS B subunit. Cross-linking reagents for use with the invention modify target amino acid residues, produce a cross-link between the immunogen of choice and a mutant ABS B subunit that produces an immunogenic product, and does not substantially reduce the ligand binding affinity of the mutant ABS B subunit. An example of a cross-linking technique for lysine and cysteine residues is shown in Example 5.
A number of reagents are available to cross-link proteins. Examples of suitable cross-linking reagents include cleavable and non-cleavable cross-linking reagents.
Some suitable cleavable cross-linking reagents that primarily react with primary amines such as lysine side chains include: dimethyl-3,3'-dithiobispropionimidate (DTBP), 2-iminothiolane (2-IT), N succinimidyl-(4-azidophenyl)-1,3-dithiopropionate (SADP), ethyl-4-azidophenyl-1,4-dithiobutyrimidiate (EADB), I-[n-2-hydroxy-5-azidobenzoyl)-2-aminoethyl]-4-(N hydroxysuccinimidyl)-succinate (HAHS), and N [-4 p-azidophenylazo)benzoyl]-3-aminopropyl-lV'-oxysulphosuccinimide ester. A
suitable non-cleavable cross-linking agent that is specific for primary amines is succinimidyl trans-4-(maleimidylmethyl) cyclohexane-1-carbodylate (SMCC). Examples of suitable cleavable cross-linking reagents that are specific for cysteine side chains include: N (4-azidophenyl)phthalimide (APTP), N [4-(p-azidosalicylamido)butyl]-3'-(2'-pyridyldithio)propionamide (APDP), N,N'-bis(4-azidobenzoyl)cystine (ABC)2, and N-(4-azidobenzoylglycl)-S-(2-thiopyridyl)cysteine (AGTC).
Cross-linking with mutant ABS B subunit proteins can be induced with an aldehyde. For example, suitable aldehydes include glutaraldehyde, formaldehyde, glyceraldehyde, acetaldehyde, phenylaldehyde, valeraldehyde, or 3,4-dihydroxyphenylacetaldehyde. In another aspect of the invention, ketones can be used to modify and cross-link the vaccine components. Suitable ketones would include acetone, methyl ethyl ketone, 3-pentanone, or any other ketone known to one of ordinary skill in the art. Use of other cross-linking or conjugation agents is also contemplated, including N-succinimidyl 3-[2-pyridyldithio] propionate (SPDP), ultraviolet cross-linking and other protein cross-linking methods known in the art.
Mutants of ABS B subunit proteins Three-dimensional structural analysis A number of mutational analysis studies have been conducted to understand the component residues involved in either the ganglioside receptor or the toxic activity of ABS toxins. Mutations to the A subunit of LT have attempted to eliminate toxicity while maintaining adjuvant activity. The toxicity of CT and LT requires the binding of the toxin to a cell through the B subunit and activation of the toxic A1 subunit by cleavage from the A2 subunit. Mutations to the A
subunit either prevent cleavage of the toxic A1 from the A2 subunit or alter the active residues of the A1 enzymatic site.
Numerous and varied mutations of LTA at residues A7, 561, QI 12, Gl 18, A146 or A192 have been claimed to retain adjuvant activity concurrent with the loss of toxic activity (Komase et al. 1998 Vaccine 16:248-254). The adjuvant activity of many of these mutants is enhanced however, by the addition of rLTB (Verweij et al. 1998. vaccine 16:2069-2076.) Mutations to the ganglioside binding sites of the B subunits of the ABS toxins might adversely affect the ganglioside affinity characteristics of the protein. In fact, several mutations to CTB subunit residues influence receptor binding. For example, the mutation G33D ablates ganglioside affinity yet appears to retain polyglycosylceramide affinity (Backstrom et al. 1997 Mol Microbiol 24:489-497). Surprisingly, G33R mutations retain ganglioside affinity (Merritt et al. 1995 Structure 3:561-570).
Alternative substitutions may have surprising effects on the quaternary structure of CTB. For example, G35D substitutions diminish homopentamer formation (Merritt et al.
1995. Structure 3:561-570). Further, an affinity of the CTB residues between 10-14, particularly H13, for the ganglioside receptor of CTB has been suggested to lead to pentamer-pentamer formations (Merritt et al. 1995.
Structure 3:561-570). His 13 has also been crucially implicated in the affinity of rCTB for Zn+2 (Dertzbaugh et al. 1998 Prot Eng 11: 577-581). In contrast, substitution of several novel peptide sequences for positions 55-64 failed to influence ganglioside affinity (Backstrom et al. 1995. Gene 165:163-171 ).
In another example, site specific mutagenesis of the B subunit of LT-IIa enterotoxin at positions T13 and T14 significantly diminished GDIa ganglioside affinity.
Similarly, mutagenesis of the LT-IIb positions T13, T14 and additionally T34 diminished ligand affinity.
Interestingly, only serine substitutions at these sites allowed the retention of ligand affinity (Connell and Holmes. 1995.
Mol Microbiol 16:21-31). Thus, mutation of residues known to be involved with ligand affinity may still be accomplished without loss of activity. Conversely, mutations (insertions, deletions, substitutions) of residues not known to be involved with ligand affinity may influence receptor activity. Site directed mutational analysis must therefore be conducted on a site by site basis.
A number of mutational analysis studies have been conducted to understand the component residues involved in either the ganglioside receptor or the toxic activity of ABS toxins. Mutations to the A subunit of LT attempt to eliminate toxicity while maintaining adjuvant activity. The toxicity of CT and LT requires the binding of the toxin to a cell through the B subunit and activation of the toxic A1 subunit by cleavage from the A2 subunit. Mutations to the A subunit either prevent cleavage of the toxic A1 from the A2 subunit or alter the active residues of the A1 enzymatic site. Numerous and varied mutations of LTA at residues A7, S61, Q112, 6118, A146 or A192 have been claimed to retain adjuvant activity concurrent with the loss of toxic activity (Komase et al. 1998 Vaccine 16:248-254). The adjuvant activity of many of these mutants is enhanced by the addition of rLTB (Verweij et al. 1998. Vaccine 16:2069-2076.) Mutations to the ganglioside binding sites of the B subunits of the ABS toxins can adversely affect the ganglioside affinity characteristics CTB. Several mutations to CTB
subunit residues influence receptor binding. For example, the mutation G33D ablates ganglioside affinity yet appears to retain polyglycosylceramide affinity (Backstrom et al. 1997. Mol Microbiol 24:489-497).
Surprisingly, G33R mutations retain ganglioside affinity (Merritt et al. 1995.
Structure 3:561-570).
Alternative substitutions may have surprising effects on the quaternary structure of CTB. For example, G35D substitutions diminish homopentamer formation (Merritt et al.
1995. Structure 3:561-570). Further, an affinity of the CTB residues between 10-14, particularly H13, for the ganglioside binding site of CTB has been suggested to lead to pentamer-pentamer formations (Merritt et al. 1995, Structure 3:561-570). His 13 has also been crucially implicated in the affinity of rCTB
for Z.n+2 (Dertzbaugh et al. 1998, Prot Eng 11: 577-581 ). In contrast, substitution of several novel peptide sequences for positions 55-64 failed to influence ganglioside affinity (Backstrom et al. 1995, Gene 165:163-171).
ALTERED CHEMICAL CONJUGATION CHARACTERISTICS
FIELD OF THE INVENTION
This invention relates to methods of creating mutants in AB5 toxin B subunit proteins, such as cholera toxin B subunit (CTB), with altered chemical conjugation characteristics.
Compositions comprising the mutant AB5 toxin B subunit proteins are also discussed. Further, use of these compositions as vaccines and bioactive molecule delivery agents is also discussed.
BACKGROUND OF THE INVENTION
MucosalImmunity Most licensed vaccines are delivered parenterally, a route of immunization that, in general, is extremely effective at inducing systemic protection against invasive disease. However, as many pathogens replicate or invade at mucosal surfaces, the efficacy of vaccines against these organisms may be improved if both systemic and mucosal immune responses were induced.
Vaccines may have to be administered at a mucosal site, for example by oral or nasal delivery, in order to induce mucosal immune responses. Indeed, this may be a prerequisite for the production of vaccines against certain pathogens for which no vaccine is currently available (e.g., respiratory syncytial virus and even possibly HIV). An additional potential advantage of mucosal vaccines is that they would be easier to deliver, an extremely important consideration in mass immunization programs.
Unfortunately, delivery of many antigens via mucosal routes is often characterized by low immune responsiveness, due in part to inefficient uptake of antigen. As a result, various strategies for effective delivery of antigens by mucosal routes have been investigated.
Antigens that are successfully delivered across the barrier of epithelial cells lining mucosal tracts stimulate underlying inductive sites of the mucosa-associated lymphoid tissue (MALT).
Antigen-specific lymphocytes that are sensitized in the MALT migrate through the circulatory system to populate distant mucosal sites, thus mucosal immunization may provide both local and systemic protection.
Because many microorganisms invade their hosts via mucosal membrane surfaces, the development of a protective mucosal immune response can provide a preemptory line of defense against a variety of infectious diseases. Successful oral vaccination must induce the production of mucosal antibodies and/or cellular immunity. However, oral administration of many purified antigens fails to result in any substantial immune response.
Use of cholera toxin in mucosal immunity Cholera toxin (CT) has long been considered responsible for inducing an effective, long-lasting protective mucosal immune response to subsequent cholera infection and disease. It was soon discovered that an enhanced mucosal immune response to orally administered antigens can be achieved when the antigens are mixed with CT or conjugated to cholera toxin B
protein (CTB).
The ability of CT and CTB to act as mucosal adjuvants may stem from the adhesive and epithelial cell membrane-permeabilizing effects of these proteins; however, it appears that active toxin is more effective than the B subunit in exerting this immunostimulatory activity.
It is therefore important to determine the events associated with CTB-membrane interaction and to identify mechanisms related to the potential translocational pathways of CTAI .
Cholera Toxin The overt symptoms of cholera are well-known and the cellular events responsible for toxicity of the Vibrio cholerae enterotoxin (CT) have been thoroughly described. In contrast, molecular details of how the different subunits of the hexameric ABS complex of CT act together to initiate cellular toxicity remain poorly understood. What is known is that CT (Mr = 85 620) binds to gangliosides on the apical surface of intestinal epithelial cells via its homopentameric B
subunit (CTB). The unusually strong avidity of CTB for gangliosides, particularly for GM-1, is most likely due to the cooperative affinities of each of the monomeric subunits in their pentameric form. Upon binding, CTB forms a planar ring structure on the membrane surface which possesses a highly polar central pore that interacts intimately with the A subunit of CT. The A subunit is composed of a toxic CTAI subunit linked to the CTA2 subunit by a disulfide bond. Liberation of CTA1 by reduction of this disulfide linkage occurs during transcytosis through the cell to its basolateral membrane. This leads to permanent activation of adenylate cyclase and ribosylation of the GTP-binding regulatory protein GSa. These events result in the activation of sodium pumps via cAMP-dependent protein kinases and subsequent expulsion of sodium and water into the intestinal lumen. While CTB is clearly responsible for toxin binding to ganglioside GM-I
receptors, an essential step in cholera toxicity, the mechanism for transport of CTAl into the cytoplasmic compartment of target cells, remains unclear.
Studies of CT-membrane interactions have shown that CTB binding to GM-I
incorporated into lipid bilayers induces the formation of membrane channels. These findings suggest that CTAI
is translocated into the target cell cytoplasm by passing through a protein-lined pore that traverses the membrane. However, on the basis of investigations using membrane-imbedded photoactivatable probes, as well as low-resolution structural studies, it does not appear that CTB
enters the membrane following its association with GM-1 receptors. These studies could indicate that CT binds with CTA1 oriented toward the cell surface, thereby forcing CTAI
into and through the membrane upon CTB-GM-1 interaction; however, such a mechanism is not consistent with the crystal structures of CT, CTB, and the closely related heat-labile enterotoxin of Escherichia coli (LT). High-resolution structural analyses show that if the B pentamer of the toxin were bound with the AI polypeptide oriented toward the membrane, a significant portion of the B subunit would also have to enter the membrane. Moreover, recent evidence has demonstrated that functional CT
binds with CTA1 facing away from the cell surface. These observations and the fact that CT does not appear to undergo significant structural changes upon receptor association have prompted many questions concerning the mechanism by which CTAI moves from a site that is some distance from the cell surface to a position within the target cell cytoplasm.
Evidence is now accumulating that supports a model in which endocytosis plays a major role in mediating cellular toxicity by CT. The role of endocytosis in mediating CT intoxication is not entirely clear; however, endosomal processing appears to involve CT
migration to the Golgi and possibly other membrane-lined regions of the target cell cytoplasm. It now appears that endocytosis allows CT to encounter environmental stimuli that influence the course of cellular toxicity. The precise nature of these signals remains to be clearly established, but temperature sensitivity and pH have been suggested to be important in CT intoxication of rat hepatocytes and lung epithelial cell lines and may influence the cytoplasmic routing of CTB.
Moreover, low pH
has been suggested to have a role in cellular toxicity by other ABS toxins.
IS The mechanisms responsible for CTA1 transport are important because, in addition to its well-known toxic effect, CT possesses potent mucosal adjuvant properties that can be exploited in oral and other immunization strategies.
Production of mucosal vaccines using CT: previous strategies One strategy to develop mucosal vaccines has been to employ bacterial enterotoxins such as cholera toxin (CT) from Vibrio cholera and the related E. coli heat-labile enterotoxin (LT), which are highly immunogenic when delivered mucosally and which can act as carriers to potentiate responses to non-related antigens. Both biotoxins are composed of an ADP-ribosylating A subunit which mediates toxicity, linked to a cyclic pentamer of B subunits which interacts specifically with monosialoganglioside (GM-I) sugars expressed on eukaryotic cells. During a natural infection, the function of the B subunits is to facilitate the binding and entry of the attached A subunit into GM-1-expressing cells. Although the holotoxins are potent adjuvants for a range of antigens and can modulate different immune functions including antigen presentation, cytokine production, and B-cell switching, their practical use is limited by the toxicity of the A subunit.
Attempts to diminish toxicity through mutations to the A subunit have raised considerable debate over the direct relationship between the toxicity and adjuvanticity of this subunit. If successful, these adjuvants would be relatively simple to formulate. Other attempts to solve the toxicity problem have included an attempt to develop non-toxic subunits as adjuvants. While vaccines incorporating B subunits appear to enhance the toxin's adjuvant activity by diminishing the toxin dosages required, B subunits have failed to gain popularity. Many investigations, however, only consider the B subunits as adjuvants, rather than as vehicles for antigen delivery.
_,_ Recent evidence indicates that B subunits might effectively serve to deliver antigen to the mucosal immune system when physically coupled to that antigen. In such case, the B
subunit is known to significantly enhance the mucosal immune response to the carried antigen.
It is assumed that some of the adjuvant properties of LTB and CTB can be explained by the increased uptake of B subunit across GM-I-expressing epithelial cells lining mucosal tracts, thereby enhancing the amount of antigen passively delivered to the MALT
inductive sites and the subsequent stimulation of antigen-specific B- and T-lymphocytes. LTB can also modulate immune activities such as cytokine production, lymphocyte apoptosis, and expression of B-cell activation molecules. These properties may also add to their effectiveness as adjuvants.
What is clear is that the highly immunogenic nature of LTB and CTB and their ability to modulate lymphocyte activity is dependent upon their ability to bind GM-1.
Antigens can be physically attached to BS subunits by either genetic or chemical means.
Genetic fusion of epitopes to LTB has been successful in some cases, but genetic coupling of heterologous epitopes can interfere with the structure, secretion, GM-1-binding and immunogenicity of the LTB fusion proteins. Also, there are limitations to the size and type of antigen that can be attached to LTB by genetic fusion. An alternative and more flexible approach is chemical coupling, which may be used to attach larger and a wider range of antigens, including polysaccharides. CTB has been chemically coupled to antigens such as whole Sendai virus and purified AgI/II from Streptococcus mutarTS and these conjugates have been shown to stimulate strong immune responses at mucosal sites (gut, respiratory tract, genital tract) and in the circulation.
O'Dowd et al., 1999, Vaccine 17, pp. 1442-1453 generated a panel of LTB fusion proteins in which individual amino acids within an epitope tag were replaced with cysteine. Horseradish peroxidase (HRP) was chemically coupled to these cysteine residues. Following intranasal administration, high titer mucosal and systemic antibody responses to HRP were generated when HRP was chemically coupled to LTB. There was no antibody response when HRP was co-administered with LTB.
SUMMARY OF THE INVENTION
The invention provides novel sequence modifications to recombinant CTB or other AB;-type BS subunit proteins through site directed mutations, deletions or additions. The invention also contemplates a method for producing said proteins which can be cross-linked chemically, hydrophobically, or genetically, or otherwise associated with an immunogen adjuvant, microcapsule, drug or immune response modifier in a manner in which the CTB
product or other ABS-type BS retains ganglioside specificity. In one embodiment, the recombinant B subunit proteins are specifically altered so that chemical conjugation to an immunogen, drug or immune response modifier occurs in a residue specific manner and can be attached without eliminating the ganglioside affinity of the resultant conjugate. The recombinant B subunit proteins can be expressed and isolated in large amounts. This allows for a conjugate that is more homogeneous in composition and is known to bind to the ganglioside with an acceptable affinity. The vaccines) derived from this conjugate thereby target the mucosal tissues and promote both systemic and mucosal immune responses. The preferred embodiment of this invention is particularly advantageous for the recruitment of immunity to the predominant site of infection for infectious diseases, most of which typically colonize mucosal tissue surfaces.
One embodiment of the invention is a novel plasmid construct of a BS
expression system in which a BS protein is expressed at high levels. In one embodiment, a recombinant cholera toxin B (rCTB) subunit protein including at least one mutation, addition, or deletion of residues between positions 1-103 of CTB is disclosed. Advantageously, the alteration allows chemical conjugation of said recombinant protein without interference to the ganglioside binding of CTB. In one embodiment, the mutation diminishes the ability of rCTB to combine at that site with any compound, drug, immunogen, immunomodulatory molecule, adjuvant or other bioactive molecule.
However, the compound can bind more specifically at another site and deliver these compounds to the mucosal epithelium. Preferably, the mutation, deletion or addition is to positions 1-103 of wild type CTB.
In a further embodiment, at least one mutation includes K23U, K34U, K43U, K62U, K63U, K69U, K81U, K84U, C86U or K9lU; wherein "U" is any amino acid that fails to promote chemical modification at those sites or wherein "U" represents the deletion of the residue, and the deletion of the amino acid results in a rCTB protein with a reduced ability to be covalently modified at those sites.
In one embodiment, advantageously, the at least one mutation, deletion or addition facilitates rCTB to combine at the site of the mutation, deletion or addition with any compound, drug, immunogen, immunomodulatory molecule, adjuvant or other bioactive molecule and to deliver the complex to the mucosal epithelium. Advantageously, the mutation, deletion or addition is to positions 1-103 of wild type CTB.
A further embodiment of the invention is a recombinant cholera toxin B (rCTB) subunit protein including at least one mutation or deletion that reduces the number of potential chemical modification sites in the recombinant protein as compared to a wild type CTB
protein. Preferably, the mutation or deletion is at positions 1-103 of CTB. Advantageously, at least one mutation or addition increases the number of potential chemical modification sites in the recombinant protein at the mutation sites as compared to a wild type CTB protein. In one aspect of the invention, the mutations or additions are at positions 1-103 of CTB.
A further embodiment of the invention is a method of making a recombinant cholera toxin B (rCTB) subunit gene encoding a rCTB protein with a reduced number of modification sites as compared to a wild type CTB protein. The method includes providing a cholera toxin B (CTB) subunit gene encoding a CTB protein; selecting codons encoding amino acid residues favoring chemical modification of the CTB protein; and mutating or deleting the codons such that the resulting amino acid residues are unfavorable for chemical modification.
A further embodiment of the invention is a method of making a recombinant cholera toxin B (rCTB) subunit gene encoding a rCTB protein with an increase in chemical modification sites as compared to a wild type CTB protein, comprising providing a cholera toxin B
(CTB) subunit gene encoding a CTB protein; selecting codons encoding amino acid residues unfavorable to chemical modification of the CTB protein; and mutating or adding said codons such that the resulting rCTB
protein possesses favorable chemical modification capabilities; selecting codons encoding amino acid residues favorable to chemical modification of the CTB protein; and mutating or deleting said codons such that the resulting amino acids are incapable of chemical modification.
I S A further embodiment of the invention is a method of producing a recombinant cholera toxin B (rCTB) subunit gene encoding a rCTB protein with decreased chemical modification sites as compared to a wild type CTB protein, comprising providing a cholera toxin B
(CTB) subunit gene encoding a CTB protein; selecting codons encoding amino acid residues unfavorable to chemical modification of the CTB protein; mutating or adding said codons such that the resulting rCTB protein possesses favorable chemical modification capabilities; selecting codons encoding amino acid residues favorable to chemical modification of the CTB protein; and mutating or deleting said codons such that the resulting amino acids are incapable of chemical modification.
A further embodiment of the invention is a method for producing a recombinant cholera toxin B (rCTB) subunit protein including the steps of obtaining a gene encoding an rCTB protein or mutated protein of the invention, adding a promoter, thereby producing an expression cassette;
introducing the expression cassette into a suitable host cell, and cultivating the host cell under conditions whereby the expression cassette is translated into protein.
A further embodiment of the invention is a gene construct for producing a recombinant binding subunit protein of cholera toxin (CTB), having a promoter and a DNA
sequence which encodes a rCTB protein operably linked in the proper reading frame.
A further embodiment of the invention is a method for producing a recombinant binding sub-unit protein of cholera toxin (CTB). The method includes expressing a gene construct in a suitable host cell and recovering CTB or mutations thereof.
A further embodiment of the invention is the creation of complexes of rCTB or variants thereof and compounds of whole or part, live, killed or reconstituted bacterium or virus, virus-like particle, protein, peptide, glycoprotein, carbohydrate, polysaccharide, phospholipid, DNA, drug, biological response modifier, microparticles or adjuvant by genetic, covalent, hydrophobic or associative mechanisms.
A further embodiment of the invention is a gene fusion vector which includes a promoter, a DNA sequence encoding the cholera toxin binding subunit protein or mutant rCTB of the invention and an immunogenic peptide coding sequence, wherein the cholera toxin binding protein subunit and the immunogenic peptide coding sequences are operably linked in the proper reading frame, whereby a gene fusion protein results, and the gene fusion protein is expressed and secreted within inclusion bodies or medium.
A further embodiment of the invention is a method of generating an antibody or cellular immune response to an immunogen or immunogenic complex. Advantageously, the method includes providing the recombinant CTB protein of the invention, modifying the protein covalently with a heterobifunctional cross-linking reagent with a first and a second functional groups, wherein the first functional group is in chemical association with the recombinant CTB
protein, covalently I S modifying the second functional group covalently with the immunogen, and administering the CTB protein modified in such a way that the animal generates an immune response.
A further embodiment of the invention is a method of generating an antibody or cellular immune response to an immunogen or immunogenic complex including providing the recombinant CTB protein of the invention, modifying the protein with a dimeric cross-linking reagent with a first and a second functional groups, wherein the first functional group is in chemical association with the recombinant CTB protein, covalently modifying the second functional group with an epitope, and administering the protein to the host until an immune response is generated.
A further embodiment of the invention is a method of generating an antibody or cellular immune response to an immunogen or immunogenic complex which includes providing the recombinant CTB protein of the invention, modifying the protein hydrophobically by prenylation or by covalent linkage in a CTB site directed manner to an amphipathic side group, mixing with an immunogenic complex containing any lipid or phospholipid micellar formulation, and administering the CTB-immunogen to the host until an immune response is generated.
A further embodiment of the invention is an rCTB expression vector including an MS-0 vector, and SEQ ID NO:1. The vector may be pML-CTBtacl .
A further embodiment of the invention is a method for generating an immune response to an immunogen comprising providing a recombinant ABS toxin B protein, prenylating the toxin B
protein, mixing the prenylated toxin B protein with an immunogen to produce a hydrophobically coupled protein, and administering the protein to an animal to generate an antibody or cellular response. In one embodiment, the ABS toxin B protein may be cholera toxin B
protein (CTB), E.
coli heat labile toxin B protein (LTB), LT type IIa B protein, LT type IIb B
protein, Shiga toxin B
protein, Shiga-like toxin B protein, or pertussis toxin B protein. Preferably, the ABS toxin B
protein is cholera toxin B protein (CTB).
A further embodiment of the invention is a method of making a recombinant ABS
toxin B
(rB) subunit gene encoding a rB protein with an enhanced number of modifications sites as compared to the wild type rB protein, comprising providing a B subunit gene encoding a B protein, selecting codons encoding amino acid residues not involved in covalent modification of the B
protein, and mutating said codons such that the resulting rB protein possesses enhanced modification capabilities.
A further embodiment of the invention is a method of making a recombinant ABS
toxin B
(rB) subunit gene encoding a rB protein with altered chemical modification capabilities as compared to the wild type B protein, including providing a toxin B (B) subunit gene encoding a B
protein, selecting codons encoding amino acid residues which favor covalent modification of the B
protein, mutating the codons such that the resulting rB protein possesses enhanced chemical I S modification capabilities at that site, selecting codons encoding amino acid residues which favor chemical modification of the B protein; and mutating the codons such that the resulting amino acids do not favor chemical modification at that site. In one embodiment, the rB protein is cholera toxin B protein (CTB), E. coli heat labile toxin B protein (LTB), LT type IIa B protein, LT type IIb B protein, Shiga toxin B protein, Shiga-like toxin B protein, or pertussis toxin B protein. In a further embodiment, the rB protein is cholera toxin B protein (CTB).
Advantageously, the mutations include changing lysine, histidine, arginine or cysteine residues to any other amino acid residues. In a further embodiment, the mutations include changing any amino acid to lysine, histidine, arginine or cysteine.
A further embodiment of the invention is a gene fusion vector comprising a promoter, a DNA sequence encoding an ABS toxin ganglioside binding subunit protein and an immunogenic peptide coding sequence, wherein said ABS toxin ganglioside binding protein subunit and said immunogenic peptide coding sequences are operably linked in the proper reading frame, whereby a gene fusion protein results; and said gene fusion protein is expressed and secreted within inclusion bodies or medium.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is the translated coding sequence of the rCTB protein produced by the (Maxim Secretory -0) genetic expression vector (SEQ ID NOs:l and 2). The encoded protein is identical to the wild-type sequence from V. cholera strain 569B.
Figure 2 is a plasmid map illustrating the MS-0 plasmid.
_g_ Figure 3 is the amino acid sequence of rCTB (SEQ ID N0:2), further illustrating the predicted secondary structure, position of lysine residues, and regions involved in binding to GM-1.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The invention contemplates introducing mutations, such as amino acid additions or deletions. throughout the nucleic acid sequence of the B subunits from the family of ABS toxins (hereinafter ABS B subunit proteins) to produce mutant proteins that possess enhanced conjugation characteristics. The term "enhanced conjugation characteristics'' refers to an ABj B subunit protein that can be conjugated by chemical or other means to drugs, immunogens, cytokines or other bioactive compounds such that the conjugated compound possesses increased bioactivity.
Specifically, enhanced conjugation characteristics in an ABS B subunit protein results from the mutations taught here that are designed to decrease steric hinderance or the formation of inappropriate quaternary structures as a consequence of the process of conjugation. In this way, these mutations maximize the availability of the ligand binding sites on the mutant ABS B subunit proteins an conjugates composed thereof. One benefit of using such mutant AB5 B subunit proteins is to improve the yield of bioactive structures following conjugation.
The invention describes mutants of ABS B subunit proteins comprising single or multiple amino acid substitutions, deletions, or insertions, throughout its sequence that result in novel, predictable spatial orientations of the molecules to be conjugated relative to one another. The invention further contemplates mutant ABS B subunit proteins with enhanced or altered conjugation characteristics that enhance the bioactivity of the resulting conjugate. Such a mutant ABS B subunit protein coupled to an immunogen or other bioactive compound serves to enhance the compound's activity in a subject to whom the mutant protein conjugate is administered.
ABS toxins consist of hexameric assemblies comprising a single catalytically active A-subunit and a pentamer of B-subunits. The B-pentamer of these toxins is capable of target cell recognition and binding even in the absence of the A-subunit. The toxin pentamers bind to saccharides, either to the olgosaccaride moieties of gangliosides in the cell membrane or to glycosylated proteins at the cell surface. The class of ABS toxins may be subdivided into families on the basis of sequence homology and catalytic activity. One family, the cholera toxin (CT) family includes, in addition to CT itself, the E. coli heat-labile enterotoxins LT and LT-lI, and a less well-characterized toxin from Campylobacter jejuni. Another family, the shiga toxin family, comprises a number of toxins from Shigella dyserrteriae and the shiga-like toxins (also known as verotoxins) from E.coli. Other ABS toxins include pertussis toxin from B.
pertussis and the eukaryotic toxin ricin.
The AB5 toxin LTB illustrates one relationship between this family of proteins. LTB
shares extensive homology with CTB. The two toxins share 80% amino acid sequence identity, similar receptor specificity, catalytic activity, and immunological properties. Those AB5 proteins with little sequence identity such as the shiga and pertussis toxins still share a high degree of structural similarity. This was determined based on the structure of the toxins in complex with the pentasaccharide from the toxin receptor and based on crystallographically determined details of toxin-receptor binding interactions (see Merritt et al. Current Opinion in Structural Biology, 1995, 5:165-171 ). Therefore, although other BS subunit proteins can be distinct in amino acid sequence, they still possess comparable functional specificity. Some BS holotoxins of this type are LT type fIa and IIb. Additionally. Shiga toxin, shiga-like toxin and Pertussis toxin share a similar receptor specificity of BS subunits. Further, mutations such as those set out herein for rCTB, to these subunits would create delivery molecules enhanced in their ability to bind other bioactive compounds but which still retain ganglioside specificity. The concepts taught in this application for rCTB may be applied to all examples of B5 subunits, some of which are shown below in Table 1.
TABLE 1: AB5 TOXIN SEQUENCES
AB5 family Protein NCBI accession SEQ ID NO.
#
CTB
CTB GI:209555 32 GI:758351 4 GI:1827850 5 GI:808900 6 GI:229616 7 GI:998409 8 GI:2144685 9 GI:1421511 10 CTB classic (596B)GI:48890 11 CTB Ogawa 41 GI:2781121 12 CTB Ogawa 4l R35D ~ GI:1421525 13 LTB
Classic LTB GI:3062900 15 GI:1169505 16 ABS family Protein NCBI accession SEQ ID NO.
#
6I:1395122 61:145833 18 LT87 61:1648865 19 GI:223254 20 GI:408996 21 GI:494265 22 GI:69630 23 LT-IIa GI:146671 24 LT-Ilb GI:576584 25 Shiga toxin Shiga toxin beta 61:152784 26 subunit Shiga-like toxin Shiga-like from E. 61:4877349 27 coli Pertussis Pertussis toxin GI:144070 28 chain S2 S3 GI:144070 29 S4 GI:144070 30 SS 61:144070 31 In many cases several toxin variants that differ in amino acid sequence have been characterized. The first CTB sequence shown (SEQ ID NO: 33) is the original sequence published by Sanchez and Holmgren that is identical to the one used in this application, except for the amino terminus. (SEQ ID N0:2). The first LTB sequence (SEQ ID NO:15) is derived from the sequence of the cloned gene. The other sequences listed in the table are variants of either CTB or LTB
found in the NCBI gene bank. The list is not intended to show all variants, but to demonstrate the natural variation among these toxins.
Polvnucleotides Encoding Mutant ABS B Subunit Proteins The invention also relates to nucleic acids molecules comprising polynucleotide sequences encoding mutant ABS B subunit proteins, fragments or derivatives thereof. In one embodiment, the ABS B subunit proteins, fragments or derivatives contemplated for use with the invention possess mucosal tissue binding or association capabilities. These sequences generally contain at least one base insertion, deletion or substitution, or combinations thereof that result in single or multiple amino acid addition, deletion and substitution relative to the wild type ABS B
subunit protein.
Due to the degeneracy of nucleotide coding sequences, any other DNA sequences that encode the same amino acid sequence for a mutant subunit may be used in the practice of the invention.
These include but are not limited to nucleotide sequences comprising all or portions of the coding region of a ABS B subunit which are altered by the substitution of different codons that encode the same amino acid residue within the sequence, thus producing a silent change.
ABS B Subunit Gene Cloning Polynucleotides encoding ABS B subunits can be obtained by standard procedures from sources of cloned DNA, as would be represented by a "library" of biological clones, by chemical synthesis, by cDNA cloning. or by the cloning of genomic DNA purified from a desired cell type.
Methods useful for conducting these procedures have been detailed by Sambrook et al., in Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989); by Glover, D.M. (ed.), in DNA Cloning: A Practical Approach, MRL Press, Ltd., Oxford, U.K. (1985); and by Current Protocols irr Molecular Biology, Eds.
Ausubel, et al., John Wiley & Sons, Inc. (1998). The polymerase chain reaction (PCR) can be used to amplify sequences encoding an ABS B subunit in a genomic or cDNA library. Synthetic oligonucleotides can be utilized as primers in a PCR protocol using RNA or DNA, or a cDNA library, as a source of target sequences.
The nucleic acid sequence being amplified can include cDNA or genomic DNA from any ABS B
toxin producing bacterium. After successful isolation or amplification of a polynucleotide encoding a segment of an ABS B subunit, that segment can be molecularly cloned and sequenced, and utilized as a probe to isolate a complete cDNA or genomic clone. This, in turn, will permit characterization of the nucleotide sequence of the ABS B subunit-encoding polynucleotide, and the production of the ABS B subunit protein product for functional analysis and/or therapeutic or diagnostic use.
Alternatives to isolating the coding regions for the subunits include chemically synthesizing the gene sequence itself from the published sequence. Other methods are possible and within the scope of the invention. The above-methods are not meant to limit performance of the methods by which mutants of the BS subunits may be obtained.
The identified and isolated polynucleotide can be inserted into an appropriate cloning vector for amplification of the gene sequence. A large number of vector-host systems known in the art may be used for this purpose. Possible vectors include plasmids or modified viruses. Of course, the vector system must be compatible with the host cell used in these procedures. Such vectors include bacteriophages such as lambda derivatives, or plasmids such as pBR322 or pUC
plasmid derivatives or the pBLUESCRIPT vector (Stratagene, La Jolla, CA). The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment of interest into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. In an alternative method, the cleaved vector and mutant subunit gene may be modified by homopolymeric tailing.
Recombinant molecules can be introduced into host cells via transformation.
transfection, infection or electroporation so that the copies of the vector containing the gene sequence of interest is increased.
In an alternative method, the desired gene may be identified and isolated after insertion into a suitable cloning vector in a "shot gun" approach. Enrichment for the desired gene, for example, by size fractionation, can be done before insertion into the cloning vector.
In specific embodiments, transformation of host cells with recombinant DNA
molecules that comprise the mutant subunit gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene. Thus, the ABS B subunit-encoding polynucleotide may be obtained in large quantities by growing transformed host organisms, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA. Copies of the gene are used in mutagenesis experiments to study the structure and function of mutant ABS B subunit proteins.
Muta~enesis The mutations present in mutant ABS B subunits, fragments and derivatives of the invention can be produced by various methods known in the art. The manipulations which result in their production can occur at the gene or protein level. For example, the cloned coding region of the subunits can be modified by any of numerous strategies known in the art (see Sambrook et al., 1990, Molecular Cloning, A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York). The polynucleotide sequence can be cleaved at appropriate sites using restriction endonucleases, followed by further enzymatic modification if desired, isolated, and ligated in vitro.
In the production of a mutant subunit, care should be taken to ensure that the modified gene remains within the same translational reading frame, uninterrupted by translational stop signals in the gene region where the subunit is encoded.
Additionally, the polynucleotide sequence encoding the subunits can be mutated in vitro or in vivo, to create variations in coding regions (e.g. amino acid substitutions), and/or to create and/or destroy translation, initiation, and/or termination sequences, and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further in vitro modification. Any technique for mutagenesis known in the art can be used, including but not limited to, chemical mutagenesis, in vitro site-directed mutagenesis (Hutchinson, C., et al., 1978, J. Biol. Chem 253:6551), PCR-based overlap extension (Ho et al., 1989, Gene 77:51-59), PCR-based megaprimer mutagenesis (Sarkar et al., 1990, Biotechniques, 8:404-407), or similar methods. The presence of mutations can be confirmed by double stranded dideoxy DNA sequencing.
Manipulations of the mutant subunit sequence may also be made at the protein level.
Included within the scope of the invention are mutant ABS B subunits that are differentially modified during or after translation, e.g., by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand. Any of numerous chemical modifications may be carried out by kIlOWi7 techniques, including but not limited to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH4; acetylation, formylation, oxidation, reduction; or metabolic synthesis in the presence of tunicamycin.
In addition. mutant ABj B peptide sequences or chemical analogs can be synthesized. For example, a peptide corresponding to a portion of a mutant subunit which comprises the desired mutated domain can be synthesized using an automated peptide synthesizer.
Optionally, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the mutant subunit sequence. Non-classical amino acids include but are not limited to the D-isomers of the common amino acids, a-amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, y-Abu, E-Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, (3-alanine, fluoro-amino acids, designer amino acids such as (3-methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L
(levorotary).
Expression of Mutant ABS B Subunit-Encoding Polynucleotides The polynucleotide sequence encoding a mutant subunit of CTB or a functionally active fragment or other derivative thereof can be inserted into an appropriate expression vector. In the context of the invention, appropriate expression vectors will contain the necessary elements for the transcription and translation of the inserted protein-coding sequence. The necessary transcriptional and translational signals may also be supplied by the native ABS B subunit cDNA or gene, and/or genomic sequences flanking the subunit gene. A variety of host-vector systems may be utilized to express the protein-coding sequence. These include established or experimental bacterial expression systems; mammalian cell systems infected with a recombinant virus such as a vaccinia virus or adenovirus, insect cell systems infected with a virus such as a recombinant baculovirus, and microorganisms such as yeast containing vectors capable of replication in yeast.
The expression elements of vectors vary in their strengths and specificities.
Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used. In specific embodiments, a mutant subunit coding region or a sequence encoding a mutated and functionally active portion of the respective mutant subunit is expressed.
Any of the methods previously described for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/translational control signals and the protein coding sequences. These methods may include ij~ vitro recombinant DNA synthetic techniques. Expression of polynucleotide sequences encoding mutant ABS B subunits or peptide fragments thereof may be regulated by a second polynucleotide sequence so that the mutant subunit(s) or peptide is expressed in a host transformed with the recombinant DNA molecule. For example, expression of a mutant ABS B
subunit or peptide fragments thereof may be controlled by any promoter/enhancer element known 117 the art. Promoters which may be used include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al.. 1980. Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proe. Ncrtl. Acad Sci. U.S.A. 78:1441-1440, and the regulatory sequences of the metallothionein gene (Brinster et al., 1982, Nature 296:39-42).
In a specific embodiment, a vector is used that comprises a promoter operably linked to the coding region of a mutant ABS B subunit, and one or more selectable markers (e.g., an antibiotic resistance gene).
A host cell strain may be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired.
Expression from certain promoters can be elevated in the presence of cel-tain inducers. In this matter, expression of the genetically engineered mutant subunits may be controlled. Furthermore, different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, phosphorylation of proteins). Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed.
Expression in mammalian cells can be used to ensure "native" glycosylation of a heterologous protein. Furthermore, different vector/host expression systems may effect processing reactions to different extents.
Once a recombinant host cell which expresses the mutant subunit gene sequences) is identified, the gene products) can be purified and analyzed. The analysis is achieved by assays based on the physical or functional properties of the product, including radioactive labelling of the product followed by analysis by gel electrophoresis, immunoassay or other techniques useful for detecting the biological activity of the mutant subunit.
Production of Antibodies to Mutant Subunits and Analogs Thereof According to the invention, mutant ABS B subunits, fragments or other derivatives thereof, alone or conjugated to an immunogenic molecule or some other protein of interest may be used as an immunogen to generate antibodies which immunospecifically bind such an immunogen. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library. In a specific embodiment, antibodies to a mutant ABS B
subunit, such as CTB, are produced. In another embodiment antibodies to a domain of a mutant subunit are produced. In another embodiment, antibodies to the immunogen are produced.
Various procedures known Ill the art may be used for the production of polyclonal antibodies directed against mutant ABS B subunits, fragments. or other derivatives thereof. For the production of antibodies, various host animals can be immunized by injection with the mutant subunits produced with the methods described herein. Appropriate host animals include rabbits, mice, rats, other mammals, as well as birds such as chickens. Various adjuvants may be used to increase the immunological response, depending on the host species, and including but not limited to Freund's adjuvant (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, caprylic acid glycerides, peptides, polyoxyethylene sorbitan monoesters, oil and water emulsions, liposomes, poly-L-lactide co glycolide (PLG) microspheres, protein carriers such as keyhole limpet hemocyanin or diphtheria toxin mutants, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette Guerin) and corynebacterium parvum.
For preparation of monoclonal antibodies directed against mutant ABS B
subunits, its fragments, or other derivatives thereof, any technique which provides for the production of antibody molecules by continuous cell lines in culture can be used. For example. the hybridoma technique originally developed by Kohler and Milstein (1975, Nature 256:495-497), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals utilizing recent technology (PCT/US90/02545). Human antibodies can be used and can be obtained by using human hybridomas (Cote et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:2026-2030) or by transforming human B cells with EBV virus in vitro (Cole et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, pp. 77-96). In fact, techniques developed for the production of "chimeric antibodies" (Morrison et al., 1984, Proc. Natl. Acad. Sci. U.S.A.
81:6851-6855; Neuberger et al., 1984, Nature 312:604-608; Takeda et al., 1985, Nature 314:452-454) by splicing the genes from a mouse antibody molecule specific for the epitope together with genes from a human antibody molecule of appropriate biological activity can be used. The antibody products of these techniques fall within the scope of this invention.
According to the invention, techniques described for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce specific single chain antibodies against ABS B
subunits, fragments, or derivatives thereof. An additional embodiment of the invention utilizes the techniques described for the construction of Fab expression libraries (Huse et al., 1989, Science 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.
Antibody fragments which contain the idiotype of the molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')2 fragment which can be produced by pepsin digestion of the antibody molecule, the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab')2 fragment, the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent, and Fv fragments.
In the production of antibodies, screening for the desired antibody can be accomplished using standard techniques known in the art. For example, the ELISA (enzyme-linked immunosorbent assay) would be an appropriate screening technique. For example, to select antibodies which recognize a specific domain of a mutant subunit, one may assay hybridomas for a product which binds to a fragment of a mutant subunit containing such domain. For selection of an antibody that specifically binds a mutant ABS B subunit, but which does not specifically bind the wild type protein, one can select on the basis of positive binding to the mutant and a lack of binding to the wild type protein. Antibodies specific for a domain of a mutant ABS B subunit, or fragment thereof are also provided by the invention.
The foregoing antibodies can be used in methods known in the art relating to the localization and activity of the mutant ABS B subunits of the invention. These methods can involve labeling of the proteins, measuring levels thereof in appropriate physiological samples in diagnostic methods.
Structure and Function Analysis of Mutant ABS B Subunits Described herein are methods for analyzing the structure and function of mutant ABS B
subunits and for analyzing the in vitro activities and in vivo biological functions of the foregoing.
Once a mutant ABS B subunit is identified, it can be isolated and purified by standard methods including chromatography (e.g., ion exchange, affinity, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique useful for purifying proteins.
Functional properties of the protein can be evaluated using any suitable assay, including immunological, immunochemcial, biochemical and biological assays.
_ 17-Alternatively, once a mutant ABS B subunit produced by a recombinant host cell is identified, the amino acid sequence of the subunit(s) can be determined using standard techniques for protein sequencing, including the use of an automated amino acid sequencer.
The functional activity of a mutant ABS B subunit, derivatives and fragments thereof can be assayed by various methods known in the art. For example, where a mutant ABS B
subunit or fragment thereof is assayed for its ability to bind or compete with the corresponding wild type ABS B
subunit. Alternatively, when ABS B subunits are assayed for antibody binding, various immunoassays known in the art can be used. These immunoassays include competitive and non competitive assay systems using techniques such as radio-immunoassays, ELISA, "sandwich"
immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, if? situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), Western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays. Antibody binding can be detected by detecting a label on the I S primary antibody. Alternatively, the primary antibody can be detected by detecting binding of a secondary antibody or reagent to the primary antibody, particularly where the secondary antibody is labeled.
One of ordinary skill in the art may use the various assays discussed above to measure the binding affinity of a mutant ABS B subunit for its target ligand. Binding affinities for the mutant ABS B subunits may be reduced by one, two, three, four, or five, orders of magnitudes. A mutant AB5 B subunit protein remains acceptable so long as the binding affinity of the mutant protein does not eliminate delivery of the mutant protein complex in vivo. The binding affinity of wild type CTB
for Gm-1 has been calculated at approximately 4.6 x 10-12 as determined by BIAcor analysis (Duziemdo, et al. 1996, Biochem. 35:6375-6384). Mutants of CTB with altered modification characteristics may demonstrate reduced binding affinities for GM-I, however, wild type affinity is so strong that significant reductions of affinity following mutation may not reduce the in vivo delivery of the mutant protein complexes. Accordingly, mutant CTB proteins with binding affinities of approximately 10-12, 10-11, 10-10, 10-9, 10-8, 10-7 are considered acceptable.
Mutant ABS B subunit proteins as vaccines Mutant ABS B subunit proteins can be used as vaccines. When used in this manner, a mutant ABS B subunit may be coupled to an immunogen of choice. The mutant ABS B
subunit proteins described herein are combined in a desired weight ratio so as to produce a vaccine that can elicit an optimal protective mucosal and systemic immune response from an immunized subject. In one embodiment, the mutant ABS B subunit and the immunogen component are mixed in a ratio in which the proportion of carrier component exceeds that of the immunogen, for example, at a molecular weight ratio of about 500,000:1. In another embodiment of the invention, the mutant ABS B subunit and the immunogenic component are mixed in a molecular weight ratio of about 100,000:1. In still another embodiment the mutant ABS B subunit and the immunogen are mixed in a molecular weight ratio of about 1000:1, or 100:1, or 10:1. And in yet another embodiment, the molecular weight ratio can be that of 1:1. Alternatively, the components of the vaccine can also be combined in a ratio where the proportion of carrier component is less than that of the immunogen.
For example, small compounds or peptides conjugated to a mutant rCtB described herein can be conjugated at a ratio of 1 rCtB homopentamer to 5, 10 or more immunogenic molecules.
Cross-linking reagents for use with mutant ABS B subunits There are a variety of cross-linking procedures and reagents available to conjugate bioactive compounds, such as immunogens and vaccines to mutant ABS B subunits. Cross-linking procedures generally employ bifunctional reagents that modify amino acid side-chains.
Typical amino acids modified include cysteine, lysine, and histamine, although any modifiable amino acid is contemplated for use with the invention. Bifunctional reagents are often classified on the basis of (i) chemical specificity; (ii) length of cross-bridge formed; (iii) whether the compound is a homo-bifunctional or hetero-bifunctional compound; (iv) whether the groups are chemically or photochemically reactive;
and (v) whether the reagents contain a cleavable bond.
Frequently, cross-linking reagents are reactive with amino- groups or sulphydryl- containing side chains of amino acids, for example, as with lysine or cysteine side chains. The choice of a cross-linking reagent will depend on the target amino acid in both the ligand to be cross-linked and the target ABS B subunit. Cross-linking reagents for use with the invention modify target amino acid residues, produce a cross-link between the immunogen of choice and a mutant ABS B subunit that produces an immunogenic product, and does not substantially reduce the ligand binding affinity of the mutant ABS B subunit. An example of a cross-linking technique for lysine and cysteine residues is shown in Example 5.
A number of reagents are available to cross-link proteins. Examples of suitable cross-linking reagents include cleavable and non-cleavable cross-linking reagents.
Some suitable cleavable cross-linking reagents that primarily react with primary amines such as lysine side chains include: dimethyl-3,3'-dithiobispropionimidate (DTBP), 2-iminothiolane (2-IT), N succinimidyl-(4-azidophenyl)-1,3-dithiopropionate (SADP), ethyl-4-azidophenyl-1,4-dithiobutyrimidiate (EADB), I-[n-2-hydroxy-5-azidobenzoyl)-2-aminoethyl]-4-(N hydroxysuccinimidyl)-succinate (HAHS), and N [-4 p-azidophenylazo)benzoyl]-3-aminopropyl-lV'-oxysulphosuccinimide ester. A
suitable non-cleavable cross-linking agent that is specific for primary amines is succinimidyl trans-4-(maleimidylmethyl) cyclohexane-1-carbodylate (SMCC). Examples of suitable cleavable cross-linking reagents that are specific for cysteine side chains include: N (4-azidophenyl)phthalimide (APTP), N [4-(p-azidosalicylamido)butyl]-3'-(2'-pyridyldithio)propionamide (APDP), N,N'-bis(4-azidobenzoyl)cystine (ABC)2, and N-(4-azidobenzoylglycl)-S-(2-thiopyridyl)cysteine (AGTC).
Cross-linking with mutant ABS B subunit proteins can be induced with an aldehyde. For example, suitable aldehydes include glutaraldehyde, formaldehyde, glyceraldehyde, acetaldehyde, phenylaldehyde, valeraldehyde, or 3,4-dihydroxyphenylacetaldehyde. In another aspect of the invention, ketones can be used to modify and cross-link the vaccine components. Suitable ketones would include acetone, methyl ethyl ketone, 3-pentanone, or any other ketone known to one of ordinary skill in the art. Use of other cross-linking or conjugation agents is also contemplated, including N-succinimidyl 3-[2-pyridyldithio] propionate (SPDP), ultraviolet cross-linking and other protein cross-linking methods known in the art.
Mutants of ABS B subunit proteins Three-dimensional structural analysis A number of mutational analysis studies have been conducted to understand the component residues involved in either the ganglioside receptor or the toxic activity of ABS toxins. Mutations to the A subunit of LT have attempted to eliminate toxicity while maintaining adjuvant activity. The toxicity of CT and LT requires the binding of the toxin to a cell through the B subunit and activation of the toxic A1 subunit by cleavage from the A2 subunit. Mutations to the A
subunit either prevent cleavage of the toxic A1 from the A2 subunit or alter the active residues of the A1 enzymatic site.
Numerous and varied mutations of LTA at residues A7, 561, QI 12, Gl 18, A146 or A192 have been claimed to retain adjuvant activity concurrent with the loss of toxic activity (Komase et al. 1998 Vaccine 16:248-254). The adjuvant activity of many of these mutants is enhanced however, by the addition of rLTB (Verweij et al. 1998. vaccine 16:2069-2076.) Mutations to the ganglioside binding sites of the B subunits of the ABS toxins might adversely affect the ganglioside affinity characteristics of the protein. In fact, several mutations to CTB subunit residues influence receptor binding. For example, the mutation G33D ablates ganglioside affinity yet appears to retain polyglycosylceramide affinity (Backstrom et al. 1997 Mol Microbiol 24:489-497). Surprisingly, G33R mutations retain ganglioside affinity (Merritt et al. 1995 Structure 3:561-570).
Alternative substitutions may have surprising effects on the quaternary structure of CTB. For example, G35D substitutions diminish homopentamer formation (Merritt et al.
1995. Structure 3:561-570). Further, an affinity of the CTB residues between 10-14, particularly H13, for the ganglioside receptor of CTB has been suggested to lead to pentamer-pentamer formations (Merritt et al. 1995.
Structure 3:561-570). His 13 has also been crucially implicated in the affinity of rCTB for Zn+2 (Dertzbaugh et al. 1998 Prot Eng 11: 577-581). In contrast, substitution of several novel peptide sequences for positions 55-64 failed to influence ganglioside affinity (Backstrom et al. 1995. Gene 165:163-171 ).
In another example, site specific mutagenesis of the B subunit of LT-IIa enterotoxin at positions T13 and T14 significantly diminished GDIa ganglioside affinity.
Similarly, mutagenesis of the LT-IIb positions T13, T14 and additionally T34 diminished ligand affinity.
Interestingly, only serine substitutions at these sites allowed the retention of ligand affinity (Connell and Holmes. 1995.
Mol Microbiol 16:21-31). Thus, mutation of residues known to be involved with ligand affinity may still be accomplished without loss of activity. Conversely, mutations (insertions, deletions, substitutions) of residues not known to be involved with ligand affinity may influence receptor activity. Site directed mutational analysis must therefore be conducted on a site by site basis.
A number of mutational analysis studies have been conducted to understand the component residues involved in either the ganglioside receptor or the toxic activity of ABS toxins. Mutations to the A subunit of LT attempt to eliminate toxicity while maintaining adjuvant activity. The toxicity of CT and LT requires the binding of the toxin to a cell through the B subunit and activation of the toxic A1 subunit by cleavage from the A2 subunit. Mutations to the A subunit either prevent cleavage of the toxic A1 from the A2 subunit or alter the active residues of the A1 enzymatic site. Numerous and varied mutations of LTA at residues A7, S61, Q112, 6118, A146 or A192 have been claimed to retain adjuvant activity concurrent with the loss of toxic activity (Komase et al. 1998 Vaccine 16:248-254). The adjuvant activity of many of these mutants is enhanced by the addition of rLTB (Verweij et al. 1998. Vaccine 16:2069-2076.) Mutations to the ganglioside binding sites of the B subunits of the ABS toxins can adversely affect the ganglioside affinity characteristics CTB. Several mutations to CTB
subunit residues influence receptor binding. For example, the mutation G33D ablates ganglioside affinity yet appears to retain polyglycosylceramide affinity (Backstrom et al. 1997. Mol Microbiol 24:489-497).
Surprisingly, G33R mutations retain ganglioside affinity (Merritt et al. 1995.
Structure 3:561-570).
Alternative substitutions may have surprising effects on the quaternary structure of CTB. For example, G35D substitutions diminish homopentamer formation (Merritt et al.
1995. Structure 3:561-570). Further, an affinity of the CTB residues between 10-14, particularly H13, for the ganglioside binding site of CTB has been suggested to lead to pentamer-pentamer formations (Merritt et al. 1995, Structure 3:561-570). His 13 has also been crucially implicated in the affinity of rCTB
for Z.n+2 (Dertzbaugh et al. 1998, Prot Eng 11: 577-581 ). In contrast, substitution of several novel peptide sequences for positions 55-64 failed to influence ganglioside affinity (Backstrom et al. 1995, Gene 165:163-171).
Structural Features of CTB
Amino acids 2-7 form a loop on the outer surface of rCTB. Residues Gln 3, Asn 4, Thr 6, and Asn7, all possess polar side chains which face out from the molecule.
These side chains can be replaced with another amino acid to introduce a chemically modifiable amino acid side chains into this region. Residues 10-14 are reported to form an amino acid sequence with ganglioside receptor affinity. Mutations to this site, particularly H13, might create a more hydrophobic rCTB
(Merritt et al. 1995. Structure 3:561-570). Amino acids 14-20 are thought to form a /.sheet on the outer surface of rCTB with many of the side chains facing outward. Among these amino acids are many polar side chain groups, particularly His 18, which may be amenable to lysine additions.
Residues 2l-25 of CTB form a surface loop on the surface of rCTB. The loop is comprised of Asn 21, an uncharged polar amine, Asp 22, an acidic side chain, and Lys 23, a basic amine. Each side group is thought to face outward from the surface of the protein. The orientation of this residue suggests that it may play some role in structural stability of the monomer. Amino acid residue Phe 25 also faces outward from the molecular surface with its uncharged, nonpolar benzyl ring and might be mutated to introduce a modifiable amino acid into the sequence of the protein. Residues 25-30 form a /pleated sheet within the CTB monomer that is not accessible to the molecular surface. Mutations to this site might be expected to disrupt the quaternary structure of rCTB. Residues 31-35 are referenced within the specification with regard to the Gm-1 receptor.
Residues 36-40 of CTB are thought to form an internal (3-pleated sheet as in 25-30.
Residues 41-44 form a surface exposed loop containing Lys 43 next to Asn 44.
Asn 44 may be a good candidate for lysine due to its location, charge, and side chain similarity to Lys 43.
Residues 45-55 are thought to form a (3-pleated sheet within the monomer.
Residues 55-64 are thought to form an insert permissive site. Lysines at positions 62 and 63 within this region may be deleted or mutated without apparent adverse effect on the ganglioside binding affinity of rCTB
mutants (Backstrom et al. 1995, Gene 165:163-171). Residues 60-78 form an internal hydrophobic a-helix in the homopentamer. Significant changes to this sequence, particularly to residues 65-78, might be expected to interfere with homopentamer formation.
Residues 79-85 of CTB form a loop on the surface of the CTB monomer. Within the loop, Lys 81 and Lys 84 face outward from the monomeric structure. Lys 81 and 84 would appear to be an optimal target residues for conjugation due to their position contralateral to the receptor and surface location within the monomer.
CTB residues 86-95 form internalized side chains and inferior loop contact points with Gm-I, encompass the Lys 91 successfully produced and claimed herein. CTB
residues 96-103 form an internal sheet which ends with an optimally positioned Asn 103. This Asn 103 is a key target for Lys insertion due to its similar charge, structure and on the molecule.
In view of the structural analysis discussed above, it is clear that a large number of mutations can result in a mutant CTB protein with altered conjugation characteristics. Some mutants will preserve, enhance, or at least not detrimentally reduce the Gm-1 binding affinity of the mutant CTB proteins described herein. On the other hand, some loss of Gm-1 affinity is tolerable given the extraordinarily high initial affinity (4.6 x 10-12) of the cholera toxin B for the Gm-1 receptor. Binding affinity of the mutant proteins can be determined using a number of assays well known in the art.
Mutants of Recombinant cholera Toxin Subunit B (rCTB) The invention contemplates mutations, substitutions, deletions, or insertions of one, two, three, four or more amino acid residues in the amino acid sequence of cholera toxin subunit B. The full length amino acid sequence of wild type rCTB is shown in FIGURE 1 (SEQ ID
NO: 2).
The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB without deleterious effect to the ganglioside (Gm-1 ) binding affinity of the recombinantly produced molecule.
Such mutations include: T1X, P2X, Q3 X, N4X, ISX, T6X, D7X, LBX, C9X, AlOX, E11X, Y12X, H13X, N14X, T15X, Q16X, I17X, H18X, T19X, L20X, N21X, D22X, K23X, I24X, F25X, S26X, Y27X, T28X, E29X, 530X, L31X, A32X, 633X, K34X, R35X, E36X, M37X, A38X, I39X, I40X, T41X, F42X, K43X, N44X, G45X, A46X, T47X, F48X, Q49X, VSOX, ES1X, V52X, P53X, G54X, SSSX, Q56X, H57X, I58X, D59X, S60X, Q61X, K62X, K63X, A64X, I65X, E66X, R67X, M68X, K69X, D70X, T71X, L72X, R73X, I74X, A75X, Y76X, L77X, T78X, E79X, A80X, K81X, V82X, E83X, K84X, L85X, C86X, V87X, W88X, N89X, N90X, K91X, T92X, P93X, H94X, A95X, I96X, A97X, A98X, I99X, S 100X, M 1 O1 X, A 102X, N 103X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
Lvsine Substitutions in rCTB
Conjugation of rCTB to immunogens derived from infectious diseases can create vaccines which induce protection following mucosal delivery. Classic conjugation chemistry targets are reactive amino acid side chain groups such as primary amines, carboxylic acids, aldehydes, or sulfhydryls. The primary reactive amino acids in rCTB are lysines (see Figure 3). The B subunit of cholera toxin contains nine (9) lysine amino acid residues. A number of these residues are contemplated to play a role in facilitating conjugation of bioactive compounds to the rCTB protein.
These lysine residues are distributed at various places throughout the CTB
sequence. Those lysine residues that are near the Gm-1 binding site (e.g. K91 ) can couple to a bioactive compound of interest in a conformation which interferes with ganglioside binding. Further, any lysine residues to which the bioactive compound is coupled may induce a conformational change upon conjugation, which prevents or disrupts the formation of the quaternary structure required for ganglioside binding.
Accordingly, a number of mutant rCTB proteins with increased or decreased numbers of conjugation sites as compared to the wild type form of the protein are disclosed herein.
The present approach involves directing the covalent linkage of an ABS B
subunit carrier and a bioactive molecule such that the bioactive molecule does not interfere with the ganglioside site of CTB. Site directed mutagenesis was employed to create a panel of mutations at Lys91 of the rCTB coding sequence. These mutations resulted in several mutants which produce levels of protein, in vitro, comparable to those of the wild type and which can effectively deliver bioactive CTB-immunogen complexes to the mucosal immune system.
Accordingly, one embodiment discussed herein articulates a number of mutant rCTB proteins with amino acid substitutions that replace the lysine residues found in the wild type rCtB protein. Of the 9 lysine residues present in wild type CTB, the invention contemplates recombinant CTB proteins with one or more of the following amino acid substitutions: K23X, K34X, K43X, K62X, K63X, K69X, K81X, K84X, and K91X; wherein "X" is any amino acid that results in a rCTB protein with a reduced ability to conjugate at the mutant sites. These mutants are also contemplated to maintain a substantial degree of Gm-1 binding affinity as compared to the wild type or unmutated form of the protein. Moreover, as mentioned before, some loss of affinity is allowable due to the extraordinarily high initial affinity (4.6 x 10-12) of the wild type CTB for the Gm-1 receptor.
There are a number of lysine residues that are thought to result in particularly deleterious conjugation events given the proximity of these residues to the Gm-1 binding site. These residues include K34, K62, K63, and K91. Mutation of these residues favors conjugation events that will not interfere with Gm-1 binding affinity.
The invention further contemplates mutating the lysine residue at K69 to eliminate conjugation at this position. Lysine 69 is thought to be distal from the Gm-I
binding site; however, conjugation to this residue might reduce rCtB homopentamer self assembly.
Incomplete quaternary structure formation is known to diminish Gm-1 affinity and likely also diminishes the bioactivity of a rCTB conjugated molecule.
The remaining lysine residues in CTB are K23, K43, K81, and K84. Each of these residues are contemplated as acceptable sites for conjugation. One or more of these residues can be mutated to reduce the total number of sites for conjugation.
McCann et al. (Biochem. 1997, 36:9169) demonstrated that Lys91 was the most reactive of all lysine residues in CTB when reacted with "small" (fluorescent) molecular probes. When CTB
is bound to Gm-l, Lys91 is positioned proximal to the terminal galactose residue of Gm-1.
Therefore, conjugation of large molecular weight bioactive molecules is likely to result in steric hinderance of the Gm-1 binding site of rCTB. Similarly, reaction of larger molecular weight compounds with Lys69, which is located within the hydrophobic core of the pentamer, would disfavor reformation of bioactive CTB homopentamers.
Lys91 possesses a basic amino side chain with which the hydroxylated galactose of Gm-1 may interact and facilitate the affinity of rCTB for Gm-1. A knockout of Lys91 might therefore be expected to significantly decrease the affinity of the mutant rCTB for Gm-l and effect a decrease in recombinant production levels.
sine additions in rCTB
The invention further contemplates the addition of amino acid residues throughout the amino acid sequence of rCTB to direct conjugation of immunogens, immunomodulators, drugs, or other bioactive molecules, to specified sites within rCTB. Any residue of rCTB can be mutated to introduce an amino acid residue that promotes acceptable conjugation events.
Examples of these mutations include Q3X, N4X, T6X, N7X, H18X, N21X, F25X, N44X, MlOlX, and N103X
wherein "X" is any amino acid that results in the addition of an acceptable conjugation site. Specific examples of suitable amino acids for use at these sites include lysine and cysteine.
Accordingly, one or more of the following mutations: Q3K, N4K, T6K, N7K, H18K, N21K, F25K, N44K, M101K, N103K, Q3C, N4C, T6C, N7C, H18C, N21C, F25C, N44C, M101C, and N103C are contemplated.
Alternative Chemical Cross-linking Moieties A further approach to specific chemical coupling or site-directed chemical coupling is to create a site for chemical coupling using a cysteine residue rather than a lysine residue. Accordingly, the following cysteine insertions are created: H18C and MIO1C. The site-directed mutagenesis is performed as in Examples 1-2. Example 5 provides techniques for chemically coupling these residues to an immunogen of interest.
Mutants in the N-terminus of rCTB
The wild type amino acid sequence of rCTB is shown in Figure 1. The invention contemplates various mutations throughout the rCTB amino acid sequence. In one embodiment, one or more mutations are introduced into the N-terminus of the protein sequence.
For example, in one embodiment, an alanine residue is introduced at the first position of the rCTB
amino acid sequence.
Introduction of this particular amino acid creates a defined signal sequence cleavage site, as opposed to the threonine residue at the amino terminus of the wild type form of rCTB.
This cleavage site can be important in post-translational modifications.
Mutants of other CTB family members identified by NCBI accession number The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GI:758351 without deleterious effect to the ganglioside (Gm-1) binding affinity of the recombinantly produced molecule. Such mutants include: M1X, I2X, K3X, L4X, KSX, F6X, G7X, V8X, F9X, F10X, T11X, V12X, L13X, L14X, S15X, S16X, A17X, Y18X, A19X, H20X, 621X, T22X, P23X, Q24X, N25X, I26X, T27X, D28X, L29X, C30X, A31X, E32X, 533X, H34X, N35X, T36X, Q37X, I38X, Y39X, T40X, L41X, N42X, D43X, K44X, I45X, F46X, 547X, Y48X, T49X, ESOX, SS1X, L52X, A53X, G54X, KSSX, R56X, E57X, M58X, A59X, 160X, I61X, T62X, F63X, K64X, N65X, G66X, A67X, I68X, F69X, Q70X, V71X, E72X, V73X, P74X, S75X, S76X, Q77X, H78X, 179X, D80X, S81X, Q82X, K83X, K84X, A85X, I86X, E87X, 888X, M89X, K90X, D91X, T92X, L93X, R94X, I95X, A96X, Y97X, L98X, T99X, E100X, AlOlX, K102X, V103X, E104X, K105X, L106X, C107X, V108X, W109X, N110X, N111X, K112X, T113X, P114X, H115X, A116X, I117X, A118X, A119X, I120X, S121X, M122X, A123X, N124X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB
GI:758351 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GI:1827850 without deleterious effect to the ganglioside (Gm-1) binding affinity of the recombinantly produced molecule. Such mutants include: T1X, P2X, Q3X, N4X, ISX, T6X, D7X, L8X, C9X, AlOX, E11X, Y12X, H13X, N14X, T15X, Q16X, 117X, Y18X, T19X, L20X, N21X, D22X, K23X, I24X, F25X, S26X, Y27X, T28X, E29X, S30X, L31X, A32X, G33X, K34X, R35X, E36X, M37X. A38X, I39X, I40X, T41X, F42X, K43X, N44X, G45X, A46X, 147X, F48X, Q49X, VSOX, E51X, V52X, P53X, S54X, SSSX, Q56X, H57X, I58X, D59X, S60X, Q61X, K62X, K63X, A64X, I65X, E66X, R67X, M68X, K69X, D70X, T71X, L72X, R73X, I74X, A75X, Y76X, L77X, T78X, E79X, A80X, K81X, V82X, E83X, K84X, L85X, C86X, T87X, W88X, N89X, N90X, K91X, T92X, P93X, H94X, A95X, I96X, A97X, A98X, I99X, 5100X, M101X, A102X, N103X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB GI: 1827850 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB 61:808900 without deleterious effect to the ganglioside (Gm-I) binding affinity of the recombinantly produced molecule. Such mutations include: M1X, I2X, K3X, L4X, KSX, F6X, 67X, V8X, F9X, F10X, T11X, V12X, L13X, L14X, S15X, S16X, A17X, Y18X, A19X, H20X, 621X, T22X, P23X, Q24X, N25X, I26X, T27X, D28X, L29X, C30X, A31X, E32X, Y33X, H34X, N35X, T36X, Q37X, I38X, H39X, T40X, L41X, N42X, D43X, K44X, 145X, L46X, S47X, Y48X, T49X, ESOX, SS1X, L52X, A53X, 654X, NSSX, R56X; E57X, M58X, A59X, I60X, I61X, T62X, F63X, K64X, N65X, 666X, A67X, T68X, F69X, Q70X, V71X, E72X, V73X, P74X, 675X, S76X, Q77X, H78X, I79X, D80X, S81X, Q82X, K83X, K84X, A85X, I86X, E87X, R88X, M89X, K90X, D91X, T92X, L93X, R94X, I95X, A96X, Y97X, L98X, T99X, E100X, AlOlX, K102X, V103X, E104X, KlOSX, L106X, C107X, V108X, W109X, N110X, N111X, K112X, T113X, P114X, H115X, A116X, I117X, A 118X, A 1 I 9X, I 120X, S 121 X, M 122X, A 123X, N 124X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB
GI:808900 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-I binding activity.
The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GI:229616 without deleterious effect to the ganglioside (Gm-1) binding affinity of the recombinantly produced molecule. Such mutations include: T1 X, P2X, E3X, N4X, ISX, T6X, D7X, LBX, C9X, AIOX, EI 1X, Y12X, H13X, N14X, T15X, Q16X, I17X, H18X, T19X, L20X, N21X, N22X, K23X, I24X, F25X, S26X, Y27X, T28X, E29X, S30X, L31X, A32X, 633X, K34X, R35X, E36X, M37X, A38X, I39X, I40X, T41X, F42X, K43X, D44X, 645X, A46X, T47X, F48X, E49X, VSOX, ES1X, V52X, P53X, 654X, SSSX, E56X, H57X, I58X, D59X, S60X, E61X, K62X, K63X, A64X, I65X, E66X, R67X, M68X, K69X, D70X, T71X, L72X, R73X, I74X, A75X, Y76X, L77X, T78X, E79X, A80X, K81X, V82X, E83X, K84X, L85X, C86X, V87X, W88X, N89X, N90X, K91X, T92X, P93X, H94X, A95X, I96X, A97X, A98X, I99X, S100X, MlOlX, A102X, N103X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB GI: 229616 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GI:998409 without deleterious effect to the ganglioside (Gill-1 ) binding affinity of the recombinantly produced molecule. Such mutations include: T1X, P2X, Q3X, N4X, ISX, T6X, D7X, LBX, C9X, AlOX, E1 IX, Y12X, H13X, N14X, T15X, Q16X, I17X, Y18X, T19X, L20X, N21X, D22X, K23X, I24X, F25X, 526X, Y27X, T28X, E29X, S30X, L31X, A32X, G33X, K34X, R35X, E36X, M37X, A38X, 139X, I40X, T41X, F42X, K43X, N44X, 645X, A46X, I47X, F48X, Q49X, VSOX, ES1X, V52X. P53X, G54X, SSSX, Q56X, I-I57X, I58X. D59X, S60X, Q61X, K62X, K63X, A64X, I65X, E66X. R67X, M68X, K69X, D70X, T71X, L72X, R73X. 174X. A75X, Y76X, L77X. T78X, E79X, A80X, K81X, V82X, E83X. K84X, L85X, C86X, V87X. W88X. N89X. N90X, K91X, T92X, P93X, H94X, A95X, I96X, A97X, A98X, I99X, S 100X, M 1 O 1 X, A 102X, N 103X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB GI: 998409 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GI:2144685 without deleterious effect to the ganglioside (Gm-I ) binding affinity of the recombinantly produced molecule: Such mutations include: MIX, I2X, K3X, L4X, KSX, F6X, G7X, VBX, F9X, F10X, T11X, V12X, L13X, L14X, S15X, S16X, A17X, Y18X, A19X, H20X, G21X, T22X, P23X, Q24X, N25X, I26X, T27X, D28X. L29X, C30X, A31X, E32X, S33X, H34X, N35X, T36X, Q37X, I38X, Y39X, T40X, L41 X, N42X, D43X, K44X, 145X, F46X, S47X, Y48X, T49X, ESOX, SS 1 X, L52X, A53X, G54X, KSSX, 856X, E57X, M58X, A~9X, 160X, 161 X, T62X. F63X. K64X, N65X, G66X, A67X, I68X, F69X, Q70X, V71X, E72X, V73X, P74X, S75X, S76X, Q77X, H78X, I79X, D80X, 581X, Q82X, K83X, K84X, A85X, I86X, E87X, R88X, M89X, K90X, D91X, T92X, L93X, R94X, 195X, A96X, Y97X, L98X, T99X, EIOOX, AIOIX, K102X, V103X, E104X, K105X, L106X, C107X, V108X, W109X, N110X, N111X, K112X, T113X, P114X, H115X, A116X, I117X, A118X, Al 19X, I120X, 5121X, M122X, A123X, N124X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB
GI:2144685 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GI:1421511 without deleterious effect to the ganglioside (Gm-1) binding affinity of the recombinantly produced molecule. Such mutations include: T1X, P2X, Q3X, N4X, ISX, T6X, D7X, LBX, C9X, AlOX, E11X, Y12X, H13X, N14X, T15X, Q16X, I17X, H18X, T19X, L20X, N21X, D22X, K23X, I24X, F25X, 526X, Y27X, T28X, E29X, 530X, L31X, A32X, D33X, K34X, R35X, E36X, M37X, A38X, I39X, I40X, T41X, F42X, K43X, N44X, 645X, A46X, T47X, F48X, Q49X, VSOX, ES1X, V52X, P53X, G54X, SSSX, Q56X, H57X, I58X, D59X, S60X, Q61X, K62X, K63X, A64X, I65X, E66X, R67X, M68X, K69X, D70X, T71X, L72X, R73X, I74X, A75X, Y76X, L77X, T78X, E79X, A80X, K81X, V82X, E83X, K84X, L85X, C86X, V87X, W88X, N89X, N90X, K91X, T92X, P93X, H94X, A95X, 196X, A97X, A98X, I99X, 5100X, MlOlX, A102X, N103X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB GI: 1421511 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GI:48890 (classic 569B) without deleterious effect to the ganglioside (Gm-1) binding affinity of the recombinantly produced molecule. Such mutations include: M1X, I2X, K3X, L4X, KSX, F6X, G7X, VBX, F9X, F10X, T11X, V12X, L13X, L14X, 515X, S16X, A17X, Y18X, A19X, H20X. G21X, T22X, P23X, Q24X, N25X, I26X, T27X, D28X, L29X, C30X, A31X, E32X, Y33X, H34X, N35X, T36X, Q37X, I38X, H39X, T40X, L41X, N42X, D43X, K44X, I45X, F46X, S47X, Y48X, T49X, ESOX, SS1X, L52X, A53X, G54X, KSSX, R56X, E57X, M58X, A59X, I60X, I61X, T62X, F63X, K64X, N65X, G66X, A67X, T68X, F69X, Q70X, V71X, E72X, V73X, P74X, G75X, S76X, Q77X, H78X, I79X, D80X, 581X, Q82X, K83X, K84X, A85X, I86X, E87X, R88X, M89X, K90X, D91X, T92X, L93X, R94X, I95X, A96X, Y97X, L98X, T99X, E100X, AlOIX, K102X, V103X, E104X, K105X, L106X, C107X, V108X, W109X, N110X, NI11X, K112X, T113X, P114X, H115X, Al 16X, I117X, A 118X, A 119X, I120X, S 121 X, M 122X, A 123X, N 124X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB
GI: 48890 (classic 569B) with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GI:2781121 (Ogawa 4l) without deleterious effect to the ganglioside (Gm-1) binding affinity of the recombinantly produced molecule. Such mutations include: M1X, T2X, P3X, Q4X, NSX, I6X, T7X, D8X, L9X, C10X, A11X, E12X, Y13X, H14X, N15X, T16X, Q17X, I18X, H19X, T20X, L21X, N22X, D23X, K24X, I25X, F26X, S27X, Y28X, T29X, E30X, S31X, L32X, A33X, 634X, K35X, R36X, E37X, M38X, A39X, I40X, I41X, T42X, F43X, K44X, N45X, G46X, A47X, T48X, F49X, Q50X, V51X, E52X, V53X, P54X, G55X, S55X, Q56X, H57X, I58X, D59X, 560X, Q61X, K62X, K63X, A64X, I65X, E66X, R67X, M68X, K69X, D70X, T71X, L72X, R73X, I74X, A75X, Y76X, L77X, T78X, E79X, A80X, K81X, V82X, E83X, K84X, L85X, C86X, V87X, W88X, N89X, N90X, K91 X, T92X, P93X, H94X, A95X, I96X, A97X, A98X, 199X, S 100X, M 1 O 1 X, A102X, N103X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid,. The "X"
represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB GI: 2781121 (Ogawa 41) with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GI:1421525 (Ogawa 41 R35D) without deleterious effect to the ganglioside (Gm-I ) binding affinity of the recombinantly produced molecule. Such mutations include: T1 X, P2X, Q3X, N4X, ISX, T6X, D7X, L8X, C9X, AIOX, E11X, Y12X, H13X, N14X, T15X, Q16X, I17X, H18X, T19X, L20X, N21X, D22X, K23X, I24X, F25X, S26X, Y27X, T28X, E29X, S30X, L31X, A32X, G33X, K34X, D35X, E36X, M37X, A38X, I39X, I40X, T41X, F42X, K43X, N44X, G45X, A46X, T47X, F48X, Q49X, V50X, ES1X, V52X, P53X, G54X, 555X, Q56X, H57X. I58X, D59X, S60X, Q61X, K62X, K63X, A64X, I65X, E66X, R67X, M68X, K69X, D70X, T71X, L72X, R73X, I74X, A75X, Y76X, L77X, T78X, E79X, A80X, K81X, V82X, E83X, K84X, L85X, C86X, V87X, W88X, N89X, N90X, K91X, T92X, P93X, H94X, A95X, I96X, A97X, A98X, I99X, S 100X, M 1 O1 X, A I 02X, N
103 X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB GI: 1421525 (Ogawa 41 R35D) with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
Mutants of LTB and LTB family members identified by NCBI accession number The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GI:3062900 without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule. Such mutations include: M1X, N2X, K3X, V4X, KSX, C6X, Y7X, VBX, L9X. F10X, T11X, A12X, L13X, L14X, S15X, S16X, L17X, C18X, A19X, Y20X, 621X, A22X, P23X, Q24X, S25X, 126X, T27X, E28X, L29X, C30X, S31X, E32X, Y33X, R34X, N35X, T36X, Q37X, I38X, Y39X, T40X, I41X, N42X, D43X, K44X, I45X, L46X, S47X, Y48X, T49X, ESOX, SS1X, M52X, A53X, G54X, KSSX, 856X, E57X, M58X, V59X, I60X, I61X, T62X, F63X, K64X, S65X, G66X, A67X, T68X, F69X, Q70X, V71X, E72X, V73X, P74X, G75X, S76X, Q77X, H78X, I79X, D80X, S81X, Q82X, K83X, K84X, A85X, I86X, E87X, R88X, M89X, K90X, D91X, T92X, L93X, R94X, I95X, T96X, Y97X, L98X, T99X, EIOOX, T101X, K102X, I103X, D104X, K105X, L106X, C107X, V108X, W109X, N110X, Nl 11X, KI 12X. T113X, PI
14X, N115X, S116X, 1117X, A118X, A119X, I120X, S121X, M122X, E123X. N124X. wherein the first letter is the native amino acid appearing at the position of the indicated number. and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLTB GI:3062900 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside and glycosphingolipid binding activity.
The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GI:1169505 without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule. Such mutations include: MIX, N2X, K3X, V4X, KSX, C6X, Y7X, VBX, L9X, F10X, T11X, A12X, L13X, L14X, SISX, S16X, L17X, Y18X, A19X, H20X, G21X, A22X, P23X, Q24X, T25X, I26X, T27X, E28X, L29X, C30X, 531X, E32X, Y33X, R34X, N35X, T36X, Q37X, I38X, Y39X, T40X, I41X, N42X, D43X, K44X, I45X, L46X, 547X, Y48X, T49X, ESOX, SS1X, M52X, A53X, 654X, KSSX, R56X, E57X, M58X, V59X, I60X, I61X, T62X, F63X, K64X, S65X, 666X, E67X, T68X, F69X, Q70X, V71X, E72X, V73X, P74X, 675X, S76X, Q77X, H78X, I79X, D80X, 581X, Q82X, K83X, K84X, A85X, I86X, E87X, R88X, M89X, K90X, D91X, T92X, L93X, R94X, I95X, T96X, Y97X, L98X, T99X, E100X, T101X, K102X, I103X, D104X, K105X, L106X, C107X, V108X, W109X, N110X, N111X, Kl 12X, T113X, Pl 14X, N115X, 5116X, 1117X, A118X, A119X, I120X, 5121X, M122X, K123X, N124X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLTB GI:1169505 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside and glycosphingolipid binding activity.
The amino acid substitutions encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GI:1395122 without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule. Such mutations include: M1X, N2X, K3X, V4X, KSX, C6X, Y7X, VBX, L9X, FlOX, T11X, A12X, 1.13X, L14X, S15X, S16X, L17X, C18X, A19X, Y20X, G21X, A22X, P23X, Q24X, S25X, I26X, T27X, E28X, L29X, C30X, S31X, E32X, Y33X, R34X, N35X, T36X, Q37X, I38X, Y39X, T40X, I41X, N42X, D43X, K44X, 145X, L46X, S47X, Y48X, T49X, ESOX, SS1X, M52X, A53X, 654X, KSSX, R56X, E57X, M58X, V59X, 160X, I61X, T62X, F63X, K64X, 565X, 666X, A67X, T68X, F69X, Q70X, V71X, E72X, V73X, P74X, G75X, S76X, Q77X, H78X, I79X, D80X, S81X, Q82X, K83X, K84X, A85X, 186X, E87X, R88X, M89X, K90X, D91X, T92X, L93X, R94X, I95X, T96X, Y97X, L98X, T99X, E100X, T101X, K102X, I103X, D104X, K105X, L106X, C107X, V108X, W 109X, N 110X, N I 11 X, K I 12X, T113 X, P 114X, N I 15X, 5116X, 1117X, A l 18X, A l 19X, I 120X, M121X, E122X, N123X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLTB
GI:1395122 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside and glycosphingolipid binding activity.
The amino acid substitutions encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GI:145833 without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule. Such mutations include: MIX, N2X, K3X, V4X, KSX, C6X, Y7X, VBX, L9X, F10X, T11X, A12X, L13X, L14X, 515X, S16X, L17X, Y18X, A19X, H20X, G21X, A22X, P23X, Q24X, T25X, I26X, T27X, E28X, L29X, C30X, 531X, E32X, Y33X, R34X, N35X, T36X, Q37X, I38X, Y39X, T40X, 141X, N42X, D43X, K44X, I45X, L46X, S47X, Y48X, T49X, ESOX, SS1X, M52X, A53X, G54X, KSSX, R56X, E57X, M58X, V59X, I60X, I61X, T62X, F63X, K64X, S65X, G66X, E67X, T68X, F69X, Q70X, V71X, E72X, V73X, P74X, G75X, S76X, Q77X, H78X, I79X, D80X, 581X, Q82X, K83X, K84X, A85X, I86X, E87X, R88X, M89X, K90X, D91X, T92X, L93X, R94X, 195X, T96X, Y97X, L98X, T99X, E100X, TlOlX, K102X, I103X, D104X, K105X, L106X, C107X, V108X, W109X, N1 IOX, N111X, K112X, T113X, Pl 14X, N115X, 5116X, I117X, A118X, Al 19X, I120X, S121X, M122X, K123X, N124X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLTB GI:145833 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside and glycosphingolipid binding activity.
The amino acid substitutions encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GI:1648865 (LT87) without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule. Such mutations include: M1X, N2X, K3X, V4X, KSX, F6X, Y7X, VBX, L9X, F10X, T11X, A12X, L13X, L14X, SISX, S16X, L17X, C18X, A19X, H20X, G21X, A22X, P23X, Q24X, 525X, I26X, T27X, E28X, L29X, C30X, S31X, E32X, Y33X, H34X, N35X, T36X, Q37X, I38X, Y39X, T40X, I41X, N42X, D43X, K44X, I45X, L46X, 547X, Y48X, T49X, ESOX, SS1X, M52X, A53X, G54X, KSSX, R56X, E57X, M58X, V59X, I60X, I61X, T62X, F63X, K64X, S65X, G66X, A67X, T68X, F69X, Q70X, V71X, E72X, V73X, P74X, G75X, S76X, Q77X, H78X, 179X, D80X, S81X, Q82X, K83X, K84X, A85X, I86X, E87X, R88X, M89X, K90X, D91X, T92X, L93X, R94X, I95X, T96X, Y97X, L98X, T99X, E100X, T101X, K102X, I103X, D104X, K105X, L106X, C107X, V108X, W109X, N110X, N111X, K112X, T113X, P114X, N115X, Sl 16X, I117X, A118X, A119X, I120X, S121X, M122X, E123X, N124X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLTB GI:
1648865 (LT87) with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside and glycosphingolipid binding activity.
The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GI:223254 without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule. Such mutations include: M1X, N2X, K3X, V4X, KSX, C6X, Y7X, VBX, L9X, F10X, T11X, A12X, L13X, L14X, 515X, 516X, L17X, Y18X, A19X, H20X, 621X, A22X, P23X, Q24X, T25X, I26X, T27X, E28X, L29X, C30X, S31X, E32X, Y33X, R34X, N35X, T36X, Q37X, I38X. Y39X, T40X, I41X, N42X, D43X, K44X, I45X, L46X, S47X, Y48X, T49X, ESOX, SS1X, M52X, A53X, G54X, KSSX, R56X, E57X, M58X, V59X, I60X, I61X, T62X, F63X, M64X, S65X, G66X, E67X, T68X, F69X, Q70X, V71X, E72X, V73X, P74X, G75X, 576X, Q77X, H78X, I79X, D80X, 581X, Q82X, K83X, K84X, A85X, I86X, E87X, R88X, M89X, K90X, D91X, T92X, L93X, R94X, I95X, T96X, Y97X, L98X, T99X, E100X, T101X, K102X, I103X, D104X, K105X, L106X, C107X, V108X, W109X, N1 10X, N11 1X, K112X, T113X, Pl 14X, N115X, S 116X, I 117X, A 118X, A 119X, I 120X, S 121 X, M 122X, K 123 X, N 124X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLTB GI:223254 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside and glycosphingolipid binding activity.
The amino acid substitutions encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GI:408996 without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule. Such mutations include: M1X, N2X, K3X, V4X, KSX, C6X, Y7X, VBX, L9X, F10X, TI1X, A12X, L13X, L14X, S15X, S16X, L17X, C18X, A19X, Y20X, G21X, A22X, P23X, Q24X, 525X, I26X, T27X, E28X, L29X, C30X, 531X, E32X, Y33X, R34X, N35X, T36X, Q37X, I38X, Y39X, T40X, I41X, N42X, D43X, K44X, I45X, L46X, 547X. Y48X, T49X, E50X, S51X, M52X, A53X, 654X, K55X, R56X, E57X, M58X, V59X, I60X, I61X, T62X, F63X, K64X, S65X, G66X, A67X, T68X, F69X, Q70X, V71X, E72X, V73X, P74X, 675X, S76X, Q77X, H78X, I79X, D80X, 581X, Q82X, K83X, K84X, A85X, I86X, E87X, R88X, M89X, K90X, D91X, T92X, L93X, R94X, I95X, T96X, Y97X, L98X, T99X, E100X, T101X, K102X, I103X, D104X, K105X, L106X, C107X, V108X, W 109X, N l 1 OX, N 111 X, K 1 I 2X, T 113 X, P 114X, N 115 X, S 116X, I 117X, A 118X, A 119X, I 120X, 5121X, M122X, E123X, N124X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLTB GI:408996 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside and glycosphingolipid binding activity.
The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GI:494265 without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule. Such mutations include: A1 X, P2X, Q3 X, T4X, ISX, T6X, E7X, L8X, C9X, SIOX, E11X, Y12X, R13X, N14X, T15X, Q16X, I17X, Y18X, T19X, I20X, N21X, D22X, K23X, I24X, L25X, S26X, Y27X, T28X, E29X, S30X, M31X, A32X, G33X, K34X, R35X, E36X, M37X, V38X, I39X, I40X, T41X, F42X, K43X, 544X, 645X, E46X, T47X, F48X, Q49X, VSOX, E51X, V52X, P53X, G54X, S55X, Q56X, H57X, I58X, D59X, S60X, Q61X, K62X, K63X, A64X, I65X, E66X, R67X, M68X, K69X, D70X, T71X, L72X, R73X, I74X, T75X, Y76X, L77X, T78X, E79X, T80X, K81X, I82X, D83X, K84X, L85X, C86X, V87X, W88X, N89X, N90X, K91X, T92X, P93X, N94X, S95X, I96X, A97X, A98X, I99X, S100X, M101X, K102X, N103X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLTB 61:494265 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside and glycosphingolipid binding activity.
The amino acid substitutions encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GI:69630 without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule. Such mutations include: M1X, N2X, K3X, V4X, KSX, C6X, Y7X, V8X, L9X, F10X, T11X, A12X, L13X, L14X, 515X, S16X, L17X, Y18X, A19X, H20X, 621X, A22X, P23X, Q24X, T25X, I26X, T27X, Q28X, L29X, C30X, 531X, E32X, Y33X, R34X, N35X, T36X, Q37X, I38X, Y39X, T40X, I41X, N42X, D43X, K44X, I45X, L46X, S47X, Y48X, T49X, ESOX, SS1X, M52X, A53X, 654X, KSSX, R56X, E57X, M58X, V59X, I60X, I61X, T62X, F63X, M64X, S65X, 666X, E67X, T68X, F69X, Q70X, V71X, E72X, V73X, P74X, 675X, S76X, Q77X, H78X, 179X, D80X, S81X, Q82X, K83X, K84X, A85X, 186X, E87X, R88X, M89X, K90X, D91X, T92X, L93X, R94X, I95X, T96X, Y97X, L98X, T99X, E100X, T101X, K102X, I103X, D104X, K105X, L106X, C107X, V108X, W109X, N110X, N111X, K112X, T113X, P114X, N115X, S116X, I117X, A118X, A119X, I120X, 5121X, M122X, K123X, N124X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid,. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLTB GI:69630 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside and glycosphingolipid binding activity.
Mutants of LT-IIa The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLT-IIa NCBI Accession No. 6I:146671 without deleterious effect to the ganglioside (GDI b, among others) binding affinity of the recombinantly produced molecule. Such mutations include: M1X, S2X, S3X, K4X, KSX, I6X, I7X, 68X, A9X, F 1 OX, V 11 X, L 12X, M 13 X, T 14X, G l SX, I 16X, L 17X, S
18X, G 19X, Q20X, V21X, Y22X, A23X, 624X, V25X, 526X, E27X, H28X, F29X, R30X, N31X, I32X, C33X, N34X, Q35X, T36X, T37X, A38X, D39X, I40X, V41X, A42X, 643X, V44X, Q45X, L46X, K47X, K48X, Y49X, ISOX, AS1X, D52X, V53X, N54X, TSSX, N56X, T57X, R58X, 659X, I60X, Y61X, V62X, V63X, S64X, N65X, T66X, G67X, G68X, V69X, W70X, Y71X, I72X, P73X, G74X, G75X, R76X, D77X, Y78X, P79X, D80X, N81X, F82X, L83X, S84X, G85X, E86X, I87X, R88X, K89X, T90X, A91X, M92X, A93X, A94X, I95X, L96X, S97X, D98X, T99X, KIOOX, V101X, N102X, L103X, C104X, AlOSX, K106X, T107X, 5108X, S109X, 5110X, P111X, N112X, H113X, I114X, W115X, A116X, M117X, El 18X, L119X, D120X, R121X, E122X, S123X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLT-IIa with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its GD1 b binding activity.
Mutants of LT-IIb The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLT-IIb NCBI accession no. GI:576584 without deleterious effect to the ganglioside (GDIa among others) binding affinity of the recombinantly produced molecule. Such mutations include: MIX, 52X, F3X, K4X, KSX, I6X, I7X, KBX, A9X, F I OX, V 11 X, I 12X, M I 3X, A 14X, A 1 SX, L 16X, V 17X, S
18X, V 19X, Q20X, A21X, H22X, A23X, 624X, A25X, S26X, Q27X, F28X, F29X, K30X, D31X, N32X, C33X, N34X, R35X, T36X, T37X, A38X, S39X, L40X, V41X, E42X, G43X, V44X, E45X, L46X, T47X, K48X, Y49X, ISOX, SS1X, D52X, I53X, N54X, NSSX, N56X, T57X, D58X, G59X, M60X, Y61X, V62X, V63X, 564X, S65X, T66X, G67X, 668X, V69X, W70X, R71X, I72X, S73X, R74X, A75X, K76X. D77X, Y78X, P79X, D80X, N81X, V82X, M83X, T84X, A85X, E86X, M87X, R88X, K89X, I90X, A91X, M92X, A93X. A94X, V95X, L96X, S97X, 698X, M99X, R100X, V101X, N102X, M103X, C104X, AlOSX, S106X, P107X, A108X, S109X, S110X, P111X, N112X, V113X, I114X, W115X, A116X, I117X, E118X, L119X, E120X, A121X, E122X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLT-IIb with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside GDIa binding activity.
Mutants of Shiya toxin Beta subunit The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of Shiga toxin Beta subunit NCBI Accession No. GI:152784 without deleterious effect to the carbohydrate binding affinity of the recombinantly produced molecule for Gal alpha 1----4Ga1 beta 1 ----4Glc and globotrioside trisaccharides. Such mutations include: M1X, K2X, K3X, T4X, LSX, L6X, I7X, ABX, A9X, SlOX, L11X, 512X, F13X, F14X, S15X, A16X, S17X, A18X, L19X, A20X, T21X, P22X, D23X, C24X, V25X, T26X, 627X, K28X, V29X, E30X, Y31 X, T32X, K33X, Y34X, N35X, D36X, D37X, D38X, T39X, F40X, T41X, V42X, K43X, V44X, 645X, D46X, K47X, E48X, L49X, F50X, T51X, N52X, R53X, W54X, N55X, L56X, Q57X, 558X, L59X, L60X, L61X, S62X, A63X, Q64X, I65X, T66X, G67X, M68X, T69X, V70X, T71X, I72X, K73X, T74X, N75X, A76X, C77X, H78X, N79X, .G80X, G81X, G82X, F83X, S84X, E85X, V86X, I87X, F88X, R89X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X'' represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant Shiga toxin Beta subunit with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its carbohydrate binding activity.
Mutants of verotoxin (Shiya-like toxin) beta subunit from E. coli The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of Shiga-like toxin Beta subunit from E. coli NCBI Accession No. G1:4877349 without deleterious effect to the carbohydrate binding affinity for globotriaosyl ceramide, Gb3 or blood group P1 antigenic trisaccharide of the recombinantly produced molecule. Such mutations include: M1X, K2X, K3X, I4X, FSX, V6X, A7X, ABX, L9X, F10X, AllX, F12X, V13X, 514X, V15X, N16X, A17X, M18X, A19X, A20X, D21X, C22X, A23X, K24X, G25X, K26X, I27X, E28X, F29X, S30X, K31X, Y32X, N33X, E34X, N35X, D36X, T37X, F38X, T39X, V40X, K41X, V42X, A43X, G44X, K45X, E46X, Y47X, W48X, T49X, N50X, R51 X, W52X, N53X, L54X, Q55X, P56X, L57X, L58X, Q59X, S60X, A61X, Q62X, L63X, T64X, 665X, M66X, T67X, V68X, T69X, I70X, K71X, S72X, N73X, T74X, C75X, A76X, S77X, G78X, S79X, G80X, FBIX, A82X, E83X, V84X, Q85X, F86X, N87X, N88X, D89X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X"
represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant Shiga-like toxin Beta subunit from E. coli with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its carbohydrate binding activity.
Mutants of ~ertussis toxin B subunits The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of pertussis toxin S2 subunit NCBI Accession No. GI:144070 without deleterious effect to the ganglioside (sialoglycoproteins) binding affinity of the recombinantly produced molecule.
Such mutations include: MlX, P2X, I3X, D4X, RSX, K6X, T7X, LBX, C9X, H10X, L11X, L12X, S13X, V14X, L15X, P16X, L17X, A18X, L19X, L20X, 621X, S22X, H23X, V24X, A25X, 826X, A27X, 528X, T29X, P30X, 631X, I32X, V33X, I34X, P35X, P36X, Q37X, E38X, Q39X, I40X, T41X, Q42X, H43X, 644X, S45X, P46X, Y47X, 648X, 849X, CSOX, A51X, N52X, K53X, T54X, RSSX, A56X, L57X, T58X, V59X, A60X, E61X, L62X, 863X, 664X, S65X, 666X, D67X, L68X, Q69X, E70X, Y71X, L72X, 873X, H74X, V75X, T76X, 877X, 678X, W79X, S80X, I81X, F82X, A83X; L84X, Y85X, D86X, 687X, T88X, Y89X, L90X, 691X, 692X, E93X, Y94X, 695X, 696X, V97X, I98X, K99X, D 100X, G 1 O l X, T 102X, P 103 X, G 104X, G 105X, A
106X, F 107X, D108X, L109X, K110X, T111X, T112X, F113X, C114X, I115X, M116X, T117X, T118X, 8119X, N120X, T121X, 6122X, Q123X, P124X, A125X, T126X, D127X, H128X, Y129X, Y130X, S131X, N132X, V133X, T134X, A135X, T136X, 8137X, L138X, L139X, 5140X, 5141X, T142X, N143X, S144X, 8145X, L146X, C147X, A148X, V149X, FISOX, V151X, 8152X, S153X, 6154X, Q155X, P156X, V157X, I158X, 6159X, A160X, C161X, T162X, S163X, P164X, Y165X, D166X, 6167X, K 168X, Y 169X, W 170X, S 171 X, M 172X, Y 173 X, S 174X, 8175X, L 176X, 8177X, K 178X, M 179X, L 180X, Y 181 X, L I 82X, I 183X, Y 184X, V 185 X, A I 86X, G 187X, I
188X, S 189X, V 190X, R I 91 X, V 192X, H 193X, V 194X, S 195X, K 196X, E 197X, E 198X, Q 199X, Y200X, Y201 X, D202X, Y203X, E204X, D205X, A206X, T207X, F208X, E209X, T210X, Y211X, A212X, L213X, T214X, 6215X, I216X, S217X, I218X, C219X, N220X, P221X, 6222X, 5223X, S224X, L225X, C226X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant pertussis toxin S2 subunit with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside (sialoglycoproteins) binding activity.
The amino acid substitutions encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of pertussis toxin S3 subunit NCBI Accession No.
6I:144070 without deleterious effect to the ganglioside (sialoglycoproteins) binding affinity of the recombinantly produced molecule. Such mutations include: MIX, L2X, I3X, N4X, NSX, K6X, K7X, LBX, L9X, H10X, H11X, I12X, L13X, P14X, I15X, L16X, V17X, L18X, A19X, L20X, L21X, 622X, M23X, 824X, T25X, A26X, Q27X, A28X, V29X, A30X, P31X, 632X, I33X, V34X. I35X, P36X, P37X, K38X, A39X, L40X, F41X. T42X, Q43X, Q44X, 645X, 646X, A47X, Y48X, 649X, RS OX, CS1X, P52X, N53X, 654X, TSSX, 856X, A57X, L58X, T59X, V60X, A61X, E62X, L63X, 864X, 665X, N66X, A67X, E68X, L69X, Q70X, T71X, Y72X, L73X, 874X, Q75X, I76X, T77X, P78X, 679X, W80X, S81X, I82X, Y83X, 684X, L85X, Y86X, D87X, 688X, T89X, Y90X, L91X, 692X, Q93X, A94X, Y95X, 696X, 697X, I98X, I99X, K100X, DlOlX, A102X, P103X, P104X, 6105X, A106X, 6107X, F108X, I109X, Y110X, R111X, E112X, T113X, F114X, C115X, I116X, T117X, T118X, I119X, Y120X, K121X, T122X, 6123X, Q124X, P125X, A126X, A127X, D128X, H129X, Y130X, Y131X, S132X, K133X, V134X, T135X, A136X, T137X, R138X, L139X, L140X, A141X, S142X, T143X, N144X, 5145X, R146X, L147X, C148X, A149X, V150X, F151X, V152X, R153X, D154X, 6155X, Q156X, 5157X, V158X, I159X, 6160X, A161X, C162X, A163X, 5164X, P165X, Y166X, E167X, 6168X, R169X, Y170X, R171X, D172X, M173X, Y174X, D175X, A176X, L177X, R178X, R179X, L180X, L181X, Y182X, M183X, I184X, Y 185X, M I 86X, S 187X, G 188X, L I 89X, A 190X, V 19 I X, R 192X, V 193 X, H
194X, V 195X, S 196X, K196X, E197X, E198X, Q199X, Y200X, Y201X, D202X, Y203X, E204X, D205X, A206X, T207X, F208X, Q209X, T210X, Y211 X, A212X, L213X, T214X, 6215X, I216X, S217X, L218X, C219X, N220X, P221X, A222X, A223X, S224X, I225X, C226X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant pertussis toxin S3 subunit with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside (sialoglycoproteins) binding activity.
The amino acid substitutions further encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of pertussis toxin S4 subunit NCBI Accession No. 6I:144070 without deleterious effect to the ganglioside (sialoglycoproteins) binding affinity of the recombinantly produced molecule. Such mutations include: MIX, L2X, R3 X, R4X, FSX, P6X, T7X, RBX, T9X, T10X, Al IX, P12X, 63X, Q14X, 615X, 616X, A17X, R18X, R19X, S20X, R21X, V22X, R23X, A24X, L25X, A26X, W27X, L28X, L29X, A30X, S31X, 632X, A33X, M34X, T35X, H36X, L37X, S38X, P39X, A40X, L41X, A42X, D43X, V44X, P45X, Y46X, V47X, L48X, V49X, K50X, T51X, N52X, M53X, V54X, V55X, T56X, S57X, V58X, A59X, M60X, K61X, P62X, Y63X, E64X, V65X, T66X, P67X, T68X, R69X, M70X, L71X, V72X, C73X, 674X, I75X, A76X, A77X, K78X, L79X, 680X, A81X, A82X, A83X, S84X, 585X, P86X, D87X, A88X, H89X, V90X, P91X, F92X, C93X, F94X, 695X, K96X, D97X, L98X, K99X, R100X, P101X, 6102X, S103X, S104X, P105X, M106X, E107X, V108X, M109X, L110X, R111X, A112X, Vl 13X, F114X, M115X, Q116X, Q117X, R118X, P119X, L120X, R121X, M122X, F123X, L124X, 6125X, P126X, K127X, Q128X, L129X, T130X, F131X, E132X, 6133X, K134X, P135X, A136X, L137X, E138X, L139X, 1140X, R141X, M142X, V143X, E144X, C145X, S146X, 6147X, K148X, Q149X, DISOX, C151X, P152X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant pertussis toxin S4 subunit with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside (sialoglycoproteins) binding activity.
The amino acid substitutions contemplated in the invention likewise encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of pertussis toxin SS subunit NCBI Accession No. 61:144070 without deleterious effect to the ganglioside (sialoglycoproteins) blildlllg affinity of the recombinantly produced molecule. Such mutations include: M1X, Q2X, R3X, Q4X, ASX, 66X, L7X, PBX, L9X, K10X, A11X, N12X, Pl3X, M14X, H15X, T16X, I17X, A18X, S19X, I20X, L21X, L22X, S23X, V24X, L25X, 626X, I27X, Y28X, S29X, P30X, A31X, D32X, V33X, A34X, 635X, L36X, P37X, T38X, H39X, L40X, Y41X, K42X, N43X, F44X, T45X, V46X, Q47X, E48X, L49X, ASOX, LSIX, K52X, L53X, K54X, GSSX, K56X, N57X, Q58X, E59X, F60X, C61X, L62X, T63X, A64X, F65X, M66X, 567X, 668X, R69X, S70X, L71 X, V72X, R73X, A74X, C75X, L76X, S77X, D78X, A79X, 680X, H81X, E82X, H83X, D84X, T85X, W86X, F87X, D88X, T89X, M90X, L91X, 692X, F93X, A94X, I95X, S96X, A97X, Y98X, A99X, L100X, KIO1X, S102X, R103X, 1104X, AIOSX, L106X, T107X, V108X, E109X, D110X, S111X, P112X, Y113X, P114X, GI15X, T116X, P117X, 6118X, D119X, L120X, L121X, E122X, L123X, Q124X, I125X, C126X, P127X, L128X, N129X, 6130X, Y131X, C132X, E133X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant pertussis toxin SS subunit with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site. retains its ganglioside (sialoglycoproteins) binding activity.
Lysine Substitutions in the rCTB, rLTB, ShiQa, Shiga-like, and pertussis family Conjugation of members of the rCTB, rLTB, Shiga, Shiga-like, and pertussis family to immunogens derived from infectious diseases can create vaccines which induce protection following mucosal delivery. Classic conjugation chemistry targets are reactive amino acid side chain groups such as primary amines, carboxylic acids, aldehydes, or sulfllydryls. The lysine residues are distributed at various places throughout the sequence. Those lysine residues that are near the Gm-1 binding site can couple to the ligand in a conformation which interferes with ganglioside binding. Accordingly, the invention articulates a number of mutant conjugation characteristics, primarily at lysine residues found in the rCTB protein family.
Therefore, the present approach involves the idea of directing the covalent linkage of carrier and immunogen away from the ganglioside receptor of CTB family. Site directed mutagenesis is employed to create a panel of mutations at various lysines of the rCTB family coding sequences. These mutations will result in mutants which produce variable levels of protein, in vitro, comparable to those of the wild type and which can effectively deliver bioactive CTB-immunogen complexes to the mucosal immune system.
Accordingly, the invention articulates a number of mutant rCTB family proteins that with amino acid substitutions that replace the lysine residues found in the wild type rCTB family protein.
Preferably, the following amino acid substitutions are contemplated for rCTB
family proteins GI:758351, 808900, 2144685, and 48890 (wherein "X" is any amino acid that results in a rCTB
protein with a reduced ability to conjugate at the mutant sites): K44X, KSSX, K64X, K83X, K84X, K90X, K102X, K105X, and KI 12X. For rCTB family proteins 61:1827850, 998409, and 142151 l, preferably K34X, K43X, K62X, K63X, K69X, K81X, K84X, and K91X. For rCTB family proteins GI: 229616, preferably K43X, K63X, K69X, K81, K84X, and K91X. For rCTB family protein GI:
2781121, preferably K35X, K44X, K62X, K69X, K81X, K84X, and K91X. For rCTB
family protein GI:1421525. preferably K43X, K62X, K63X, K69X. K81X, K91X. For all rCTB family B subunit proteins if they have a lysine at position 91, most preferably K91X.
For LTB and the LTB family proteins GI:3062900, 1169505, 1395122, 145833, 1648865, 223254, 408996, and 69630 wherein "X" is any amino acid that results in a protein with a reduced ability to conjugate at the mutant sites, K44X, KSSX, K64X, K83X, K84X, K90X, K102X, and KlOSX. For LTB family protein 494265 preferably K34X, K43X, K62X, K63X, K69X, K81X, K84X, and K91X. For all LTB family proteins if they have a lysine at position 91, most preferably For LT-IIa protein GI:146671 wherein "X" is any amino acid that results in a protein with a reduced ability to conjugate at the mutant sites, K47X, K48X, K89X, K100X, and K107X.
For LT-IIb protein GI:576584 wherein "X" is any amino acid that results in a protein with a reduced ability to conjugate at the mutant sites, K48X, K76X, and K89X.
For Shiga toxin beta subunit protein GI:152784 wherein "X" is any amino acid that results in a protein with a reduced ability to conjugate at the mutant sites, I<43X, K47X, and K73X.
For Shiga-like toxin from E.coli subunit B protein 61:4877349 wherein "X" is any amino acid that results in a protein with a reduced ability to conjugate at the mutant sites, K41X, K45X, and K71 X.
For pertussis toxin protein GI:144070 wherein "X" is any amino acid that results in a protein with a reduced ability to conjugate at the mutant sites subunit S2: K98X, K167X, K177X, K195X.
S3: K38X, K100X, K121X, K133X, and K196X. S4: KSOX, K61X, K78X, K96X, K99X, K127X, K134X, and K148X. S5: K42X, K52X, K54X, K56X, and K101X.
Lysine additions in rCTB family subunits The invention further contemplates the addition of amino acid residues throughout the amino acid sequence of the rCTB family, the LTB family, Shiga toxin, Shiga-like toxin, and pertussis toxin to direct conjugation of various bioactive compounds such as immunogens, immunomodulators, or drugs to specified sites. Any residue can be mutated to introduce amino acid residues that promotes acceptable conjugation events.
Hydrophobic coupling of rCTB
Although chemical coupling is an excellent way to produce Gm-1 targeted immunogens, it would be highly advantageous to alter rCTB in such a way that it no longer requires chemical coupling, but instead strongly binds to other proteins or immunogens non-covalently. As an example, if rCTB could be prenylated it would then display up to 5 hydrophobic isoprene tails per pentamer. It is expected that in the properly folded and assembled protein, these tails would be present on the surface of the protein in opposite orientation to the Gm-1 binding surfaces. The commonly occurring isoprene groups include farnesyl, geranyl, geranyl-geranyl;
all other IS prenylation or hydrophobic modification are considered to achieve the same outcome. Cholera toxin thus modified is expected to have an affinity for hydrophobic structures and surfaces.
Prenylated rCTB would bind to bacterial cell walls, cell membranes, virus membrane coats, and other hydrophobic structures such as hydrophobic proteins and hydrophobic phospholipids or adjuvants. The isoprene groups on rCTB would spontaneously insert into any lipid membrane, or hydrophobic miscelle, to non-covalently associate rCTB with the hydrophobic structure in such a manner as to present the ligand binding site of rCTB on the outer surface of the micelle. This concept could be applied to making conjugates between rCTB and vaccine antigens or to promote ganglioside specificity in microsome or liposome delivery systems.
Prenylation naturally occurs on selected proteins in eukaryotic cells, such as GTP binding proteins. The post-translational modification of proteins occurs at the C-Terminus, with a consensus sequence of CAAX (SEQ ID NO: 34) where C=cysteine, A=aliphatic amino acid, and X=any amino acid. The isoprenyl group is attached to the cysteine via a thioether link and after modification the cysteine becomes the last amino acid in the sequence. Other post-translational modifications such as modification of proteins with lipids, fatty acids, and glycosyl phospholipids also occur and could potentially serve the same purpose as prenylation.
In one embodiment, the gene for cholera toxin B is modified to include a prenylation signal that would permit in vitro prenylation. This may include a C-terminal cysteine, C-terminal CAAX box sequence (SEQ ID NO: 34), or any other sequence necessary or sufficient to achieve irr vitro or in vivo prenylation. A plasmid containing the mutant cholera toxin B
gene is transfected into a suitable host for expression. For example, a high expression rCTB
vector is used to express the mutated rCTB in bacteria. Once the mutated rCTB has been expressed and purified, it is used as a substrate for i~ vitro prenylation. In vitro prenylation is performed with the appropriate prenylation enzymes and substrates. The prenylated rCTB product is purified as necessary and used to produce the desired conjugated product. Alternatively, if the prenylation reactions permit, prenylation of rCTB is performed in the presence of the conjugation partner thus allowing immediate binding of the modified rCTB to the immunogen or vaccine. This may serve to stabilize prenylated rCTB or facilitate production and purification.
An alternative embodiment involves co-transfecting bacterial or eukaryotic cells to produce rCTB and the necessary proteins for prenylation. In this embodiment it may be necessary to construct the proteins for the special requirements of each system. For example, in any expression system both the rCTB and prenylation proteins may need to be targeted to the same compartment for efficient prenylation. This could be the cytoplasm, periplasm, or extracellular milieu of bacterial, or the cytoplasm, any of the secretory compartments or other organelles in eukaryotic expression systems.
Confirmation of hydrophobic coupling, purification, and Gm-1 binding assays would be performed essentially the same as chemically coupled rCTB, with variations in buffer and pH.
Vaccination would also be performed in essentially the same way.
Vaccines These concepts have been contemplated as methods for producing cholera toxin B
based vaccines. In particular, these prenyl-rCTB constructs lend themselves to whole cell, whole virus, or hydrophobic particle vaccine conjugates. Vaccines contemplated include influenza virus vaccines, both whole and split, because influenza virus acquires a membrane coat and is thus capable of binding prenyl-rCTB to the membrane coat. The split virus vaccines commonly contain the membrane coat protein hemagglutinin. This protein binds to prenyl-rCTB
through hydrophobic patches on its surface. Another suitable vaccine is whole cell pertussis, where prenyl-CTB could insert the hydrophobic groups into the outer membrane of B. pertussis. Also, hydrophobic particles such as water in oil emulsion based vaccines and liposome based vaccines would be attractive candidates for this technology.
Genetic fusion of rCTB with an immuno~en Another option for production of an rCTB coupled immunogen is genetic fusion.
Genetic fusion would occur using a vector that contains a promoter for expressing the fusion protein, the DNA sequence of the cholera toxin binding subunit rCTB, and an immunogenic peptide coding sequence. The rCTB and the immunogenic peptide coding sequence would be linked such that they were in the proper reading frame producing a fusion protein. The fusion protein would be expressed, secreted, and purified for use as a vaccine. rCTB fusion proteins are as shown in Table 2.
TABLE 2: CTB FUSION PROTEINS
Expression level Plasmid Bacterial Product Form Protein host (pg/m1) NH2-GST-linker 717 GST 1.10*XL-1 Inclusion 96 bodies # 1-A8V D4-C
NH2-GST-linker 717 GST2.9**XL-I Inclusion 58 bodies #2-A8V D4-CT
CTB with internal P55-64gp12***V. choleraSecreted 110 HIV epitope * Other antigenic sequences may be substituted for A8VD4. Linker is GAI'AS
(SEQ ID NO 34).
** Other antigenic sequences may be substituted for A8VD4. Linker is PGSTRAADRDGAPAS (SEQ ID
NO: 35).
*** HIV epitope is flanked by Kpnl and Mscl restriction enzyme sites, allowing easy insertion of other coding sequences into CTB.
rCTB vaccines Microorganisms which invade via mucosal membrane surfaces are the best targets for rCTB vaccines. However, it could be used for almost any type of vaccine.
Examples of diseases and antigens that could be coupled to rCTB for production of a vaccine are listed below in Table 3.
As mentioned above, larger, whole and killed cell vaccines or whole virus vaccines could be produced particularly using the hydrophobic coupling. Vaccines which couple the rCTB protein in some way to an immunogen of choice would be particularly useful for any type of disease which is targeted to mucosal surfaces.
Production of a specific vaccine involves the steps of 1 ) identifying an antigen or immunogen; 2) coupling the antigen or immunogen to rCTB in some way (chemically, hydrophobically, or genetically); 3) isolating the coupled rCTB/immunogen and confirming that it still binds to Gm-1; 4) identifying that it works in vivo by injecting it into a mouse or other model animal; and 5) testing it for efficacy in humans or other primates. Examples of vaccine targets are shown in Table 3 with potential antigens.
TABLE 3: HUMAN INFECTIOUS DISEASES AND VACCINE ANTIGENS
Oral/Intestinal Exemplary Infectious agent Diseases Antigen Urease, 50 kDa citrate synthatase H. pylori homologue protein, bacterial lysates, whole organisms E. coli LPS, enterotoxin type I, II, whole organisms v cholera Killed bacteria, avirulent live VP2, VP4, VP6, VP7, whole viral Rotavirus particles, VLPs Salmonella Whole or fragments of organism typhi Shigella dysenteriaWhole or fragments of organism Respiratory Diseases H. influenza Current vaccines are conjugates RSV F/G protein,whole viral particles, VLPs CorynebacteriaToxoid, whole or fragments of organism diphtheria Bordetella Toxoid, filamentous hemagglutinin, pertussis pilus, (Whooping cough)pe~actin, Sl subunits serotypes, whole or fragments of organism Polysaccharide ags (23) 23 most common Streptococcus serotypes of 90 capsular serotypes currently targeted. New vaccines target 7-I1 serotypes pneumonia bound to a protein carrier, whole or fragments of organism Killed, lysates, HA(hemagglutinin), NA
Influenza virus(neuraminidase), trivalent or more based on most common serotypes that year;
whole virus Anthrax Whole or fragments of organism Urogenital diseases (STD's) Gp4l, Gp120 env, Gp160env, Tat protein, HIV multiepitope polypeptide TAB9, Gag, Pol, and Env proteins Chlamydia Whole or fragments of organism Treponema 47 kDa antigen, whole or fragments of pallidum (Syphilis)organism Neisseria gonorrheawhole or fragments of organism Herpes ~ whole viral particles, VLPs, Tk Use of rCTB in treatment of autoimmunitv and the induction of tolerance Autoantigen specific peripheral T cell tolerance is induced by CTB-autoantigen conjugates. Peripheral tolerance suppresses autoinf7ammatory disease by down regulating Thl.
CTB-autoantigens can even reverse existing inflammatory cell proliferation in animals.
Autoimmune diseases considered for treatment using CTB include without limitation: rheumatoid arthritis, encephalomyelitis (or other neuron demyelinating diseases), diabetes, and female anti paternal immuno-contraception.
Reversal of inflammatory cell proliferation (thl tolerization) was shown in autoimmune models for diabetes in NOD mice (insulin-CTB conjugates; Bergerot et al. PNAS
1997 94:4610-14.). Additionally it was shown for rheumatoid arthritis (HSP 60, Haque et al.
1996 EurJImnZUnol 26:2650-2656; collagen type II conjugates) and experimental autoimmune encephalomyelitis (EAE) in Lewis rats (Sun et al., Myelin basic protein MBP-peptide CTB
conjugate, 1996 PNAS
93:7196-7201). These conjugates were fed as single doses to animals before and after induction of disease.
It is contemplated that the rCTB of the invention can be chemically, hydrophobically, or genetically coupled to the above-mentioned antigens and fed to animal models to test the efficacy.
It is believed that because such a treatment was effective in the above examples it will be as effective or more so using the advantageous rCTB of the invention.
Additionally, the rCTB
conjugates of the invention are easier to make, more likely to work because the site of conjugation can be controlled, and yield a higher percentage of conjugated products that in turn will induce both a systemic and mucosal response.
The rCTB or other B subunits of the invention can also be used to induce tolerance to infection. For example, tolerization may be induced by administering the Leshmania major produced immunodominant antigen LACK, which generates a CD4+ T cell dominant response and drives a th2 response to associated antigens. Th2 facilitates lesion development and leads to unresolved infection. LACK+ transgenic mice are tolerant of LACK and resolve infection. LACK
fed animals are tolerized and resolve infection. ( McSorley et al, Eur.J.Immunol. 1998, 28:424-32.) showed that CTB-LACK, fed or given nasally, down regulated the T cell proliferative response to LACK and allowed animals to resolve (fight off) disease more effectively.
Additionally, responses to diseases associated with the development of acute autoimmunity such as Reiter's syndrome or Lyme disease can be treated with tolerizing conjugates.
EXAMPLES
Expression and Purification of Mutant rCTB
Production of Recombinant CTB in Bacteria The expression plasmid MS-0 (see Figure 2) was used to express rCTB and variants. MS-0 containing the rCTB gene is named pML-CTBtacl. The plasmid pML-CTBtacl surprisingly generates up to five times the product which was generated by a comparable plasmid (SBL's vector pJS I 62). PML-CTBtac 1 was constructed by cloning a portion of the CTB
genomic region and the complete CTB coding region into plasmid MS-0 creating a 3.66 Kb expression plasmid. The PvuII
site in the polylinker was destroyed during cloning. The plasmid contains a tac promoter from pKK223, an EcoRI-BamHI polylinker fragment, and can be found at genbank accession No M77749.
The encoded protein is identical to the sequence from V. cholera strain 5698 (SEQ ID NO: 2). The signal sequence (SEQ ID NO: 3) is also from the CTB V. cholera classic strain 569B CTB gene. The complete nucleotide sequence of V. cholera strain 5698 CTB gene is shown in Figure 1 (SEQ ID
NO:1). The signal sequence for LTB (SEQ ID N0:15) is MNKVKCYVLFTALLSSLCAYG and can be used in the production of mutants or variants of LTB.
Measurement of Expression Level of rCTB mutant or variant It is advantageous to purify large quantities of the immunogen of interest quickly, easily and inexpensively. Accordingly, the ability to isolate milligram quantities of rCTB and rCTB variants for use in production of vaccines is discussed below.
A protocol for the isolation of rCTB and rCTB variants from shaker flasks is presented.
Surprisingly, is was possible to obtain up to 800 yg of rCTB per ml of culture supernatant. Many recombinant expression systems are considered very productive with yields exceeding 10 ~g/ml. The expression level of rCTB mutants thus far produced are moderately lower than wild type.
The concentration of all proteins tested is measured by comparison to a standard curve of rCTB at defined concentrations in the Gm-1 ELISA. The values recorded for a serial dilution of the unknown sample are then used to determine the sample concentration which is then multiplied by the dilution factor to obtain the correct concentration of the unknown sample.
One limitation of the Gm-1 ELISA is that it only identifies the relative binding concentrations of wild type vs. mutant rCTB. Thus, actual concentrations must be confirmed by .280 or by Lowry, Bradford, BCA or similar colorimetric protein assays known by those practiced in the art.
Any mutation to the rCTB sequence might result in an increase or decrease in receptor binding affinity for Gm-1 and other ligands (Backstrom et al. 1997 Mol Microbiol 24:489-497;
Merritt et al. 1995 Structure 3:561-570). Any significant change in receptor affinity of a newly created mutant rCTB for Gm-1 may cause the loss of binding in a Gm-1 ELISA and result an "apparent" decrease in concentration. In such case, each test protein is initially purified to homogeneity using methods discussed below. From these, the purity is demonstrated by comassie or silver stained polyacrylamide gel electrophoresis, a technique well known in the art. The relative concentration of each protein is determined by X280 and confirmed by protein concentration assays. Equivalent concentrations of each protein. sufficient to saturate the ganglioside moiety (e.g. ~50 pg/ml), are incubated in a Gm-1 ELISA plate. A
two-fold serial dilution of each mutant or unlabeled wild type protein is then incubated in solution with a constant concentration of horse radish peroxidase labeled wild type CTB (at concentrations which alone generate a maximum signal, usually >~10 ug/ml). From this assay, a standard curve for each mutant can be generated and compared to a similar curve for unlabeled wild type (positive standard curve control). Discrepancies from the positive standard curve control reflect significant changes in the affinity of the mutant rCTB for gm-1. The difference between curves can be quantified to determine the quantitative differences in affinity assuming the wild type affinity of 4.6x10-12M.
Purification of rCTB and rCTB variants A number of CTB purification protocols are available and known in the art.
Three purification methods are discussed below.
Ammonium Sulphate Precipitation of rCTB
This procedure worked well for cultures grown in baffled shaker flasks containing 100-500 pg/ml rCTB in the supernatant. Culture volumes between 50-250 ml have been successfully processed using this protocol. The supernatant was processed immediately after growth and clarification of the culture.
Briefly, the bacteria expressing rCTB or mutants of rCTB were grown in a shaker flask.
I S The supernatant was clarified by centrifuging the cells at 7000 x g (avg.) for 15 min at 4°C into a pellet. A step wise precipitation of protein with increasing concentrations of ammonium sultate results in highly purified rCTB product. Accordingly, ammonium sulfate was gradually added to the culture supernatant to bring the ammonium sulfate concentration up to 30%
(vol/vol) while stirring at room temperature. After 1 hour of precipitation without stirring, the sample was centrifuged at 14,000 x g (avg.) for 15 minutes at 4°C. The supernatant was removed and a concentrated ammonium sulfate solution was added to bring the concentration to 50% (vol/vol) while stirring. This mixture was allowed to stand at room temperature for 1 hour. The sample was again centrifuged at 14.000 x g (avg.) for 15 min at 4°C. A third precipitation step was performed, bringing the concentration up to 65% ( 101 g/L total volume). This mixture was again stirred and allowed to stand for 1 hour before centrifugation as before. The pellet of highly purified rCTB was then resuspended in a suitable buffer, for example, if additional purification by ion exchange chromatography is desired, the sample was brought up in 10 mM NaP04 buffer.
The sample was then placed in dialysis tubing (7000 MWCO). If the sample is not immediately used, it can be stored undialyzed for up to one month at 4°C until ready to use. When dialysis was performed, one-liter volumes of buffer were used for at least one hour each, changing the buffer three times.
Purification of rCTB by DEAE Ion-exchange Chromatography This part of the protocol applies specifically to ammonium sulfate precipitated rCTB. A
DEAE Sepharose Fast Flow gel of choice was packed on an Amersham Pharmacia Biotech column following the manufacturer's directions. 15 ml of a well-mixed gel slurry produced about 10 ml bed volume. The flow rate for packing was at least 4 ml/min. A column size of 1.5 cm (inner diameter) and 20 cm (length) with a bed volume of 10 ml bound approximately 30 mg of rCTB
from culture processed by ammonium sulfate precipitate. A flow rate adapter was used with the column. The column was washed with 1 M NaCI to activate the column bed, or 2 M
NaCI to regenerate a spent column bed. The flow rate for all washes did not exceed 75%
of the packing rate, or 3 ml/min. The column was extensively equilibrated with Buffer A (10 mM Sodium Phosphate Buffer, pH 7.5) to remove all salt. The sample containing rCTB was applied at a rate of 1-1.5 ml/min. Each fractions was tested for the presence of rCTB. Following sample application, the column was washed with Buffer A at a flow rate of 3 ml/min until the optical density at 1280 dropped below 0.02, confirming the removal of all non-specific and cationic species. The column was washed with Buffer A containing 50 mM NaCI, until the optical density at A280 dropped below 0.02. RCTB was eluted from the column with Buffer A containing 100 mM
NaCI. All fractions were collected and pooled. Approximately 80% of the total column bound rCTB was recovered in these fractions. The column was washed with Buffer A containing 1 M NaCI until the optical density at x.280 dropped belong 0.02. Before regeneration of the column, the DEAE bed was washed with 10 mM sodium phosphate, pH 7.5 to remove all of the salt.
Alternatively, CTB
bound to the DEAE column can be eluted with a salt gradient from 0.02M NaCI to 1 M NaCI in buffer A. Fractions containing rCTB are pooled, dialyzed or concentrated in the buffer of choice.
Detailed protocol for purification of rCTB using affinity chromatography on a ~anglioside-Affi~el column In this technique, clarified bacterial culture supernatant was directly poured onto the column. rCTB or rCTB mutants bound specifically to the immobilized gangliosides and the column was washed. rCTB was then eluted with 5M guanidine thiocyanite and dialyzed against a phosphate buffer. This technique was very easy and a high purity was achieved.
However, there was a limited capacity of approximately 7 mg rCTB per run and it required denatured protein to be able to fold properly, which may be a problem with some mutants.
The Ganglioside-Affigel columns were produced using Affigel (Pierce, Rockford, IL).
The smaller Ganglioside-Affigel column (0.5 ml bed volume) had the capacity to bind 1-2 mg of rCTB, while the larger (5 ml bed volume) will bind at least 7 mg. The following buffers were used: 0.1 M Na-phosphate buffer, pH 7.5; 0.1 M Na-phosphate buffer, pH 7.5, 0.5 M Na C1; 5 M
guanidine thiocyanite in DI water, freshly made in a 50 ml conical tube.
The culture supernatant was centrifuged at 10,000 rpm for 10 min (SS-34).
Particulate matter was avoided as it clogs the column. The column was equilibrated with 0.1 M Na-phosphate buffer, pH (2-5 column volumes). The sample containing rCTB was added and the flow through was collected and applied once more to allow quantitative binding to the column. The column was washed with 0.1 M Na-phosphate buffer, pH 7.5 until the X280 was close to 0, the column was washed again with 0.1 M Na-phosphate buffer, pH 7.5, 0.5 M NaCI until the A280 was close to 0.
The column was equilibrated with 0.1 M Na-phosphate buffer, pH 7.5 (2 column volumes). Fresh guanidine thiocyanite solution was prepared in 1 ml steps, 1 ml fractions were collected. The column was allowed to sit for 10 min after addition of the first two I ml additions of the elution buffer to the column. This ensured complete elution of rCTB from the ganglioside resin. The X280 containing fractions were pooled and dialyzed against 500 ml of 0.1 M Na-phosphate buffer, pH 7.4, with no stirring. A total of 4 buffer changes were performed with the last two in the desired buffer in which to store the protein.
Optionally, rCtB can be purified by canon exchange on a CM Sepharose Fast Flow ion exchange column. Briefly, NH4S04 salt precipitated or DEAE eluted rCTB can be dialyzed against 20 mM Tris-HC1, 10 mM NaCI, pH 8.4 and the dialysate applied to the column.
After washing, a highly purified rCtB product can be eluted with a continuous salt gradient of 10 mM to 300 mM NaCI in 20 mM Tris-HC1, pH 8.4.
This method resolves the remaining few contaminant products we see following DEAE
I S anion exchange chromatography.
Muta~enesis of rCTB
Mutagenesis was initially performed by oligonucleotide-directed in vitro mutagenesis according to Kunkel, TA, Roberts, J., and Zakour, R. "Rapid and efficient site-specific mutagenesis without phenotypic selection", Methods Enzymol., 154, 367-382, 1987.
Subsequently mutagenesis was performed essentially according to Nelson, M. and McClelland, M., Methods Enzymol. 216, 279-303, 1992. The results of the mutagenesis were confirmed by DNA
sequencing.
Lysine Mutation of rCTB
The following mutant rCTB proteins are made using the methods described in Example 2.
A lysine residue is inserted into the rCTB sequence of SEQ ID NO 2 to replace amino acid Asn 103. Asparagine's polarity comes from an amino side chain which is uncharged at neutral pH.
Replacement of Asn 103 with a lysine may prove to be an effective and novel conjugation site. A
lysine residue is inserted into the rCTB sequence of SEQ ID NO 2 to replace the amino-terminal amino acid Ala 102. A lysine residue is inserted at position Alal. A lysine residue is inserted at position Pro2. Although this mutant changes the structure of the amino terminus, Gm-I binding affinity and antigenicity of the resulting composition is not compromised by the mutation.
Amino acids 14-20 form a [3-sheet on the outer surface of rCTB with many of the side chains facing outward. Of the amino acid residues that form this structure, His 18, is particularly suitable for mutagenesis. Accordingly, a mutant rCTB protein is generated having the mutation H18K. Substitution of His 13 for any other amino acid may effect Zn+2 binding characterisitics of rCTB as well as pentamer-pentamer self association. Elimination of either of these characteristics might be desired for purposes of biochemical isolation of the mutant proteins.
Determining Immunoaenicity of rCTB Mutants Coupled to Immunogens Immunogenicity is determined by injection of the rCTB:Immunogen into balb/c mice. 1:1, 1:6, and 1:3 ratios of rCTB:immunogen conjugate are injected. Additionally, a control using immunogen alone is injected injected. After ten days, blood is drawn from the immunized mice and antibodies to the rCTB:immunogen conjugate are identified and measured via an antibody assaying protocol such as ELISA or any other suitable assay widely known by one of skill in the art.
Chemical Coupling of Mutant rCTB Proteins to an Immuno;~.,en Lysine residues Mutant CTB proteins CTB K91G and CTB-K62G, 63G, 91G were modified, expressed, and purified using the method described in Examples 1-2. Mutation of K91 was chosen as a site for substitution because of its proximity to the Gm-I binding site of CTB and it known interaction with the terminal glactose of Gm-1. Further, as discussed above, K91 is highly reactive with small molecular conjugates, such as FITC or SPDP. Accordingly, conjugations with heterobifunctional reagents are likely to create molecular complexes with diminished Gm-1 binding affinities. some important modifications to protocols which create a simpler, more efficient coupling reaction with SPDP. In brief, the pH of the conjugation must be > 8.0, and the SPDP (N-Succinimidyl 3-[2-pyridyldithio]propionate) modified rCTB and its associated molecule must be highly concentrated.
Employing these modifications, rCTB wild type was successfully coupled to bovine serum albumin (BSA) and to Diphtheria toxoid (Dt).
In contrast to established protocols, neither BSA nor Dt was SPDP modified prior to conjugation. These proteins were determined to have free sulfl~ydryl groups which will readily react with the SPDP modified rCTB.
Modification of rCTB using SPDP chemistry rCTB or variant rCTB was dialyzed into Borate-Phosphate buffer. Borate-Phosphate buffers: a lOX stock solution (2L) was made by adding 12.4 g. Boric acid, 175.3 g NaCI, and 136.09 g Potassium phosphate (monobasic) into 1.5 liters of water. The solution was adjusted to a pH of 6.6 with 5M KOH and then brought up to a final volume of 2 liters with water. The solution was filtered through 0.2 micron filter. The pH of a 1 X solution was 7Ø
Borate-Phosphate Buffer, pH 8.5 was 1X buffer adjusted with 5M KOH. The rCTB was modified using ten-fold molar excess of SPDP over rCTB. The SPDP was weighed and diluted to 5 mg/ml using anhydrous N,N-dimethylformamide (DMF), containing the molecular sieves (Grade 562, Type 3a, 4-8 mesh beads, Fisher Scientific, Tustin, CA). Thus, 25 p1 of 5 mg/ml SPDP would be added to a 2 mg rCTB/ml solution of rCTB. The SPDP and rCTB were incubated and allowed to react for at least 1 hour at room temperature.
Excess SPDP was removed by running a G-25 gel filtration column (1.5 cm x 9 cm bed volume is the minimum required to separate excess SPDP). 10 mM sodium phosphate buffer, pH
7.~ containing 50 mM NaCI was used for column running buffer. The SPDP
modified rCTB was concentrated by using Amicon centricon c-30 (30 kD cut-off) to a volume between 1-2 ml.
Coniu~ation of protein to SPDP modified rCTB
Unmodified protein (the immunogen - i.e. BSA or Dt) was dialyzed against 3 x volumes Borate-Phosphate buffer, pH 7Ø SPDP modified rCTB and unmodified protein (immunogen) were combined at selected molar ratios and incubated overnight.
The next the sample was concentrated using a Centricon 30 (30,000 MWCO Millipore, Bedford, MA).
Confirmation of Chemical Coupling The concentrated sample was separated into its component parts by gel electrophoresis on a 4-20% Tris-Glycine gel to confirm the formation of conjugates. A number of techniques can be used to confirm chemical coupling of the two proteins including: Gm-I ELISA
using immunogen-specific antibodies which recognize only immunogen when bound to rCTB, and molecular seive gel filtration.
Cysteine residues Mutant CTB proteins CTB-H18C and CTB-M101C were modified, expressed, and purified using the methods described in Examples 1-2. The rCTB proteins were treated with 100 mM DTT
for 2 hours at room temperature. DTT was removed by centrifugation for 2 min at 2000g through a I
ml spin column packed with Biogel P6 polyacrylamide gel (BioRad, Cambridge, MA), equilibrated with 25 mM sodium phosphate buffer pH 7.0/10 mM ethylenediaminetetraacetic acid (EDTA). The collected fraction was incubated for 2 hours at room temperature with maleimide-activated immunogen (i.e. immunogen functionalized with the cross-linker SMCC, Sigma).
The reaction was stopped by the addition of (3-mercaptoethanol ((3-me) to a final concentration of 1.5 mM and N-ethylmaleimide (NEM) suspended in N,N-dimethylformamide to a final concentration of 3 mM.
Confirmation of Chemical Coupling Conjugation of immunogen to rCTB was assessed by ELISA and Western blotting.
(I) ELISA: conjugates of Immunogen and rCTB were incubated with GLM1-coated microtitre plates and immobilized Immunogen was detected with the chromogenic substrate 3,3',5,5' tetramethylbenzidine (TMB, KPL). Detection of plate bound immunogen which was dependent on a coating of GM-I was interpreted as evidence that rCTB was physically linked to the Immunogen. (II) Western Blots:
conjugates were separated by electrophoresis on 7.5% SDS polyacrylamide gels and transferred to nitrocellulose. rCTB was detected with polyclonal anti-rCTB sera, followed by goat anti-mouse Ig alkaline phosphatase (A)(Amersham, Buckinghamshire, UK) and AP-specific substrate (BCIP/NBT, BioRad, Cambridge, MA). Immunogen was detected with antibodies specific to the immunogen, goat anti-mouse Ig-AP and BCIP/NBT.
Purification of immunogen-rCTB Conjugates Conjugates were purified by size exclusion chromatography based on the expected size of the conjugate. Additional purification was performed within a GM-1 or ganglioside affinity column to eliminate nonconjugated immunogen and within an antigen or immunogen specific column to eliminate residual free rCTB and rCTB-rCTB conjugates, respectively. This left only the bioactive conjugates which were assessed by SDS-PAGE and ELISA as described in Example 6.
Assaying Mutant rCTB Conjugated Complexes for Gm-1 Binding Relative to Wild Type rCTB
Maintenance of the ganglioside affinity by the GM-1 binding sites in mutant CTB, wild type CTB, or conjugates derived therefrom can be assayed by ELISA analysis. In the first example, the monosialoganglioside, GM-I, was used at a concentration of 0.3 nmol/ml PBS. One hundred microliters of ganglioside solution was added to each well of a 96 well microtiter plate and incubated overnight at 22°C. The following day, the plate was washed twice with PBS
utilizing a Bioplate Autowasher EL-404 (Bio-Tec Instruments, Winooski, VT).
All wells of the plate were then coated with 200 p1 of a 0.1% BSA in PBS solution for 30 minutes at 37°C. The plate was washed three times in PBS containing 0.05% tween-20 and evacuated of remaining solution. Al) wells, other than the initial test wells, received 100 ~I of a solution of 0.1% BSA, 0.05% tween-20 in PBS. Test wells then received 1 SO p1 of 15 pg CTB/ml test mutant, wild type, or conjugate. A three-fold serial dilution was then conducted across the plate, sequentially transferring and diluting 50 p1 from the second test well into 100 ~1 buffer in the third well and so on for up to twelve dilutions. The plate was incubated for 90 minutes at 22°C. The plate was then washed three times as described above. All wells then received either 100 p1 of a 1/20,000 dilution of mouse anti-rCTB antiserum or a pre-determined dilution of mouse anti-serum to the coupled compound. Wells were incubated one hour at 22°C and subsequently washed three times as above.
Test wells then received 100 ~l of a 1/3000 dilution of horseradish peroxidase conjugated goat anti-mouse IgG and were allowed to incubate one hour at 22°C. Plates were then washed again and incubated for 20 minutes with 100 p1 of a 1 mg/ml solution of othophenylenediamine dihydrochloride (OPD) and 0.01% H202 in 0.1 M sodium citrate buffer, pH 4.5.
50 p1 of a 3N
HC1 solution was then added to stop the enzymatic reaction. Plates were then read at 492 nm and 650 nm in a SpectroMax 250 microplate reader (Molecular Devices, Inc., Sunnyvale, CA). Results for mutants or conjugates thereof were reported as a function of endpoint dilution (apparent concentration) relative to wild type or conjugates thereof, respectively. The results indicated that mutated rCTB conjugated complexes retained their ability to bind to GM-1 binding sites.
SEQUENCE LISTING
<110> ACTIVE BIOTECH AB
HANDLEY, Harold H.
HAAPARANTA, Tapio EWALT, Karla L.
<120> AB5 TOXIN B SUBUNIT MUTANTS WITH ALTERED
CHEMICAL CONJUGATION CHARACTERISTICS
<130> ACTBI0.004VPC
<160> 31 <170> FastSEQ for Windows Version 4.0 <210> 1 <211> 373 <212> DNA
<213> Vibriocholera <220>
<221> CDS
<222> (1)...(373) <223> The gnalsequence V. olera c si from ch classi strain <400> 1 atg att ttaaaa tttggtgttttt tttacagtt ttacta tcttca 48 aaa Met Ile LeuLys PheGlyValPhe PheThrVal LeuLeu SerSer Lys gca tat catgga getectcaaaat attactgat ttgtgt gcagaa 96 gca Ala Tyr HisGly AlaProGlnAsn IleThrAsp LeuCys AlaGlu Ala tac cac acacaa atacatacgcta aatgataag atattt tcgtat 144 aac Tyr His ThrGln IleHisThrLeu AsnAspLys IiePhe SerTyr Asn aca gaa ctaget ggaaaaagagag atggetatc attact tttaag 192 tct Thr Glu LeuAla GlyLysArgGlu MetAlaIle IleThr PheLys Ser aat ggt actttt caagtagaagta ccaggtagt caacat atagat 240 gca Asn Gly ThrPhe GlnValGluVal ProGlySer GlnHis IleAsp Ala tca caa aaagcg attgaaaggatg aagaccgat ctgagg attgca 288 aaa Ser Gln LysAla IleGluArgMet LysThrAsp LeuArg IleAla Lys tat ett gaaget aaagtcgaaaag ttatgtgta tggaat aataaa 336 act Tyr Leu GluAla LysValGluLys LeuCysVal TrpAsn AsnLys Thr acg cct gcgatt gccgcaattagt atggcaaat t 373 cat Thr Pro AlaIle AlaAlaIleSer MetAlaAsn His <210> 2 <211> 124 <212> PRT
<213> Vibrio cholera <400> 2 Met Ile Lys Leu Lys Phe Gly Val Phe Phe Thr Val Leu Leu Ser Ser Ala Tyr Ala His Gly Ala Pro Gln Asn Ile Thr Asp Leu Cys Ala Glu Tyr His Asn Thr Gln Ile His Thr Leu Asn Asp Lys Ile Phe Ser Tyr Thr Glu Ser Leu Ala Gly Lys Arg Glu Met Ala I1e Ile Thr Phe Lys Asn Gly Ala Thr Phe Gln Val Glu Val Pro Gly Ser G1n His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Thr Asp Leu Arg Ile Ala Tyr Leu Thr Glu Ala Lys Val Glu Lys Leu Cys Val Trp Asn Asn Lys Thr Pro His Ala Ile Ala Ala Ile Ser Met Ala Asn <210> 3 <211> 28 <212> PRT
<213> Artificial Sequence <220>
<223> The signal sequence from V. cholera classic strain <900> 3 Met Asn Lys Val Lys Phe Tyr Val Leu Phe Thr Ala Leu Leu Ser Ser Leu Cys Ala His Gly Ala Pro Gly Tyr Ala His Gly <210> 4 <211> 124 <212> PRT
<213> Vibrio cholera <220>
<221> VARIANT
<222> (1)...(124) <223> CTB from variant NCBI gen bank number GI: 758351 <400> 4 Met Ile Lys Leu Lys Phe Gly Val Phe Phe Thr Val Leu Leu Ser Ser Ala Tyr Ala His Gly Thr Pro Gln Asn Ile Thr Asp Leu Cys Ala Glu Ser His Asn Thr Gln Ile Tyr Thr Leu Asn Asp Lys Ile Phe Ser Tyr Thr Glu Ser Leu Ala Gly Lys Arg Glu Met A1a I1e I1e Thr Phe Lys Asn Gly Ala Ile Phe Gln Val Glu Val Pro Ser Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Ala Tyr Leu Thr Glu Ala Lys Val Glu Lys Leu Cys Val Trp Asn Asn Lys Thr Pro His Ala Ile Ala Ala Ile Ser Met Ala Asn <210> 5 <211> 103 <212> PRT
~<213> Vibrio cholera <220>
<221> VARIANT
<222> (1)...(163) <223> CTB variant from NCBI gene bank GI: 1827850.
<400> 5 Thr Pro Gln Asn Ile Thr Asp Leu Cys Ala Glu Tyr His Asn Thr Gln Ile Tyr Thr Leu Asn Asp Lys Ile Phe Ser Tyr Thr Glu Ser Leu Ala Gly Lys Arg Glu Met Ala Ile Ile Thr Phe Lys Asn Gly Ala Ile Phe Gln Val Glu Val Pro Ser Ser Gln His Ile Asp Ser Gln Lys Lys Ala 5C 55 n0 Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Ala Tyr Leu Thr Glu Ala Lys Val Glu Lys Leu Cys Thr Trp Asn Asn Lys Thr Pro His Ala Ile Ala Ala Ile Ser Met Ala Asn <210> 6 <211> 124 <212> PRT
<213> Vibrio cholera <220>
<221> VARIANT
<222> (1)...(124) <223> CTB variant from NCBI gene bank GI: 808900.
<400> 6 Met Ile Lys Leu Lys Phe Gly Val Phe Phe Thr Val Leu Leu Ser Ser Ala Tyr Ala His Gly Thr Pro Gln Asn Ile Thr Asp Leu Cys Ala Glu Tyr His Asn Thr Gln Ile His Thr Leu Asn Asp Lys Ile Leu Ser Tyr Thr Glu Ser Leu Ala Gly Asn Arg Glu Met Ala Ile Ile Thr Phe Lys Asn Gly Ala Thr Phe Gln Val Glu Va1 Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Ala Tyr Leu Thr Glu Ala Lys Val Glu Lys Leu Cys Val Trp Asn Asn Lys Thr Pro His Ala Ile Ala Ala Ile Ser Met Ala Asn <210> 7 <211> 103 <212> PRT
<213> Vibrio cholera <220>
<221> VARIANT
<222> (1)...(103) <223> CTB variant from NCBI gene bank GI: 229616.
<400> 7 Thr Pro Glu Asn Ile Thr Asp Leu Cys Ala Glu Tyr His Asn Thr Gln Ile His Thr Leu Asn Asn Lys Ile Phe Ser Tyr Thr Glu Ser Leu Ala Gly Lys Arg Glu Met Ala Ile Ile Thr Phe Lys Asp Gly Ala Thr Phe Glu Val Glu Val Pro Gly Ser Glu His Ile Asp Ser Glu Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Ala Tyr Leu Thr Glu Ala Lys Val Glu Lys Leu Cys Val Trp Asn Asn Lys Thr Pro His Ala Ile g5 90 95 Ala Ala Ile Ser Met Ala Asn <210> 8 <211> 103 <212> PRT
<213> Vibrio cholera <220>
<221> VARIANT
<222> (1)...(103) <223> CTB variant from NCBI gene bank GI: 998409.
<400> 8 Thr Pro Gln Asn I1e Thr Asp Leu Cys Ala G1u Tyr His Asn Thr Gln Ile Tyr Thr Leu Asn Asp Lys Ile Phe Ser Tyr Thr Glu Ser Leu Ala Gly Lys Arg Glu Met Ala Ile Ile Thr Phe Lys Asn Gly Ala Ile Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Ala Tyr Leu Thr Glu Ala Lys Val Glu Lys Leu Cys Val Trp Asn Asn Lys Thr Fro His Ala Ile Ala Ala Ile Ser Met Ala Asn <210> 9 <211> 124 <212> PRT
<213> Vibrio cholera <220>
<221> VARIANT
<222> (1)...(124) <223> CTB variant from NCBI gene bank GI: 2144685.
<400> 9 Met Ile Lys Leu Lys Phe Gly Val Phe Phe Thr Val Leu Leu Ser Ser Ala Tyr Ala His Gly Thr Pro Gln Asn Ile Thr Asp Leu Cys Ala Glu Ser His Asn Thr Gln Ile Tyr Thr Leu Asn Asp Lys Ile Phe Ser Tyr Thr Glu Ser Leu Ala Gly Lys Arg G1u Met Ala Ile Ile Thr Phe Lys Asn Gly Ala Ile Phe Gln Val Glu Val Pro Ser Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Ala Tyr Leu Thr Glu Ala Lys Val Glu Lys Leu Cys Val Trp Asn Asn Lys Thr Pro His Ala Ile Ala Ala Ile Ser Met Ala Asn <210> 10 <211> 103 <212> PRT
<213> Vibrio cholera <220>
<221> VARIANT
<222> (1)...(103) <223> CTB variant from NCBI gene bank GI: 142I5ii.
<400> 10 Thr Pro Gln Asn Ile Thr Asp Leu Cys Ala Glu Tyr His Asn Thr Gln Ile His Thr Leu Asn Asp Lys Ile Phe Ser Tyr Thr Glu Ser Leu Ala Asp Lys Arg G1u Met Ala Ile Ile Thr Phe Lys Asn Gly Ala Thr Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Ala Tyr Leu Thr Glu A1a Lys Val Glu Lys Leu Cys Val Trp Asn Asn Lys Thr Fro His Ala Ile Ala Ala Ile Ser Met Ala Asn <210> 11 <211> 124 <212> PRT
<213> Vibrio cholera <220>
<221> VARIANT
<222> (1)...(129) <223> CTB variant from NCBI gene bank GI: 48890(classic 569B).
<900> 11 Met Ile Lys Leu Lys Phe Gly 'Jal Phe Phe Thr Val Leu Leu Ser Ser 1 5 10 i5 Ala Tyr Ala His Gly Thr Pro Gln Asn Ile Thr Asp Leu Cys Ala Glu Tyr His Asn Thr Gln Ile His Thr Leu Asn Asp Lys Ile Phe Ser Tyr Thr Glu Ser Leu Ala Gly Lys Arg Glu Met Ala Ile Ile Thr Phe Lys Asn Gly Ala Thr Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Ala Tyr Leu Thr Glu Ala Lys Val Glu Lys Leu Cys Val Trp Asn Asn Lys Thr Pro His Ala Ile Ala Ala Ile Ser Met Ala Asn <210> 12 <211> 105 <212> PRT
<213> Vibrio cholera <220>
<221> VARIANT
<222> (1)...(105) <223> CTB variant from NCBI gene bank GI: 2781121(Ogawa 41).
<400> 12 Met Thr Pro Gln Asn Ile Thr Asp Leu Cys Ala Glu Tyr His Asn Thr Gln Ile His Thr Leu Asn Asp Lys Ile Phe Ser Tyr Thr Glu Ser Leu Ala Gly Lys Arg Glu Met Ala Ile Ile Thr Phe Lys Asn Gly Ala Thr Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Ala Tyr Leu Thr Glu Ala Lys Val Glu Lys Leu Cys Val Trp Asn Asn Lys Thr Pro Ile Ile Ala Ile Ala Ala Ile Ser Met Ala Asn <210> 13 <211> 103 <212> PRT
<213> Vibrio cholera <220>
<221> VARIANT
<222> (1)...(103) <223> CTB variant from NCBI gene bank GI: 1421525(Ogawa 41 R35D).
<400> 13 Thr Pro Gln Asn Ile Thr Asp Leu Cys Ala Glu Tyr His Asn Thr Gln Ile His Thr Leu Asn Asp Lys Ile Phe Ser Tyr Thr Glu Ser Leu Ala Gly Lys Asp Glu Met Aia Ile Ile Thr Phe Lys Asn Gly Ala Thr Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Ala Tyr Leu Thr Glu Ala Lys Val Glu Lys Leu Cys Val Trp Asn Asn Lys Thr Pro His Ala Ile Ala Ala Ile Ser Met Ala Asn <210> 14 <211> 21 <212> PRT
<213> Artificial Sequence <220>
<223> The signal sequence from LTB.
<400> 14 Met Asn Lys Val Lys Cys Tyr Val Leu Phe Thr Ala Leu Leu Ser Ser Leu Cys Ala Tyr Gly <210> 15 <211> 125 <212> PRT
<213> Escherichia coli <220>
<221> VARIANT
<222> (1)...(125) <223> LTB variant from NCBI gene bank GI:3062900.
<400> 15 Met Asn Lys Val Lys Cys Tyr Val Leu Phe Thr Ala Leu Leu Ser Ser Leu Ala Cys Ala Tyr Gly Ala Pro Gln Ser Ile Thr Glu Leu Cys Ser Glu Tyr Arg Asn Thr Gln Ile Tyr Thr Ile Asn Asp Lys Ile Leu Ser Tyr Thr Glu Ser Met Ala Gly Lys Arg Glu Met Val Ile Ile Th r Phe Lys Ser Gly Ala Thr Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Thr Tyr Leu Thr Glu Thr Lys Ile Asp Lys Leu Cys Val Trp Asn Asn Lys Thr Pro Asn Ser Ile Ala Ala Ile Ser Met Glu Asn <210> 16 <211> 124 <212> PRT
<213> Escherichia coli <220>
<221> VARIANT
<222> (1)...(124) <223> LTB variant from NCBI gene bank GI:1169505.
<400> 16 Met Asn Lys Val Lys Cys Tyr Val Leu Phe Thr Ala Leu Leu Ser Ser Leu Tyr Ala His Gly Ala Pro Gln Thr Ile Thr G1u Leu Cys Ser Glu Tyr Arg Asn Thr Gln Ile Tyr Thr Ile Asn Asp Lys I~ie Leu Ser Tyr Thr Glu Ser Met Ala Gly Lys Arg Glu Met Val Ile Ile Thr Phe Lys Ser Gly Glu Thr Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Thr Tyr Leu Thr Glu Thr Lys Ile Asp Lys Leu Cys Val Trp Asn Asn Lys Thr Pro Asn Ser Ile Ala Ala Ile Ser Met Lys Asn <210> 17 <211> 123 <212> PRT
<213> Escherichia coli <220>
<221> VARIANT
<222> (1)...(123) <223> LTB variant from NCBI gene bank GI:1395122.
<400> 17 Met Asn Lys Val Lys Cys Tyr Val Leu Phe Thr Ala Leu Leu Ser Ser Leu Cys Ala Tyr Gly Ala Pro Gln Ser Ile Thr Glu Leu Cys Ser Glu Tyr Arg Asn Thr Gln Ile Tyr Thr Ile Asn Asp Lys Iie Leu Ser Tyr Thr Glu Ser Met Ala Gly Lys Arg Glu Met Val Ile Ile Thr Phe Lys Ser Gly Ala Thr Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Thr Tyr Leu Thr Glu Thr Lys Ile Asp Lys Leu Cys Val frp Asn Asn Lys Thr Pro Asn Ser Ile Ala Ala Ile Met Glu Asn <210> 18 <211> 124 <212> PRT
<213> Escherichia coli <220>
<221> VARIANT
<222> (1)...(124) <223> LTB variant from NCBI gene bank GI:145833.
<400> 18 Met Asn Lys Val Lys Cys Tyr Val Leu Phe Thr Ala Leu Leu Ser Ser Leu Tyr Ala His Gly Ala Pro Gln Thr Ile Thr Glu Leu Cys Ser Glu Tyr Arg Asn Thr Gln Ile Tyr Thr Ile Asn Asp Lys Ile Leu Ser Tyr Thr Glu Ser Met Ala Gly Lys Arg Glu Met Val Ile Ile Thr Phe Lys Ser G7_y Glu Thr Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Thr Tyr Leu Thr Glu Thr Lys Ile Asp Lys Leu Cys Val Trp Asn Asn Lys Thr Pro Asn Ser Ile Ala Ala Ile Ser Met Lys Asn <210> 19 <211> 124 <212> PRT
<213> Escherichia coli <220>
<221> VARIANT
<222> (1)...(124) <223> LTB variant from NCBI gene bank GI:1648865 (LT87).
<400> 19 Met Asn Lys Val Lys Phe Tyr Val Leu Phe Thr Ala Leu Leu Ser Ser Leu Cys Ala His Gly Ala Pro Gln Ser Ile Thr Glu Leu Cys Ser Glu Tyr His Asn Thr Gln Ile Tyr Thr Ile Asn Asp Lys Ile Leu Ser Tyr Thr Glu Ser Met Ala Gly Lys Arg Glu Met Val Ile Ile Thr Phe Lys Ser Gly Ala Thr Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Thr Tyr Leu Thr Glu Thr Lys Ile Asp Lys Leu Cys Val Trp Asn Asn Lys Thr Pro Asn Ser Ile Ala Ala Ile Ser Met Glu Asn <210> 20 <211> 123 <212> PRT
<213> Escherichia coli <220>
<221> VARIANT
<222> (1)...(123) <223> LTB variant from NCBI gene bank GI:223254.
_g_ <400> 20 Met Asn Lys Val Lys Cys Tyr Val Leu Phe Thr Ala Leu Leu Ser Ser Leu Tyr Ala His Gly Ala Pro Gln Thr Ile Thr Glu Leu Cys Ser Glu Tyr Arg Asn Thr Gln Ile Tyr Thr Asn Asp Lys Ile Leu Ser Tyr Thr Glu Ser Met Ala Gly Lys Arg Glu Met Val Ile Ile Thr Phe Met Ser Gly Glu Thr Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Thr Tyr Leu Thr Glu Thr Lys Ile Asp Lys Leu Cys Val Trp Asn Asn Lys Thr Pro Asn Ser Ile Ala Ala Ile Ser Met Lys Asn <210> 21 <211> 124 <212> PRT
<213> Escherichia coli <220>
<221> VARIANT
<222> (1)...(124) <223> LTB variant from NCBI gene bank GI:408996.
<400> 21 Met Asn Lys Val Lys Cys Tyr Val Leu Phe Thr Ala Leu Leu Ser Ser Leu Cys Ala Tyr Gly Ala Pro Gln Ser Ile Thr Glu Leu Cys Ser Glu Tyr Arg Asn Thr Gln Ile Tyr Thr Ile Asn Asp Lys Ile Leu Ser Tyr Thr Glu Ser Met Ala Gly Lys Arg Glu Met Val Ile Ile Thr Phe Lys Ser Gly Ala Thr Phe G1n Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Thr Tyr Leu Thr Glu Thr Lys Ile Asp Lys Leu Cys Val Trp Asn Asn Lys Thr Pro Asn Ser Ile Ala Ala Ile Ser Met Giu Asn <210> 22 <211> 103 <212> PRT
<213> Escherichia coli <220>
<221> VARIANT
<222> (1)...(1031 <223> LTB variant from NCBI gene bank GI:494265.
<400> 22 Ala Pro Gln Thr Ile Thr Glu Leu Cys Ser Glu Tyr Arg Asn Thr Gln Ile Tyr Thr Ile Asn Asp Lys Ile Leu Ser Tyr Thr Glu Ser Met Ala G1y Lys Arg Glu Met Val Ile Ile Thr Phe Lys Ser Gly Glu Thr Phe Gln Val Glu Va1 Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala _g_ Ile Glu Arg Met Lys Asp Thr Leu Arg I1e Thr Tyr Leu Thr Glu Thr Lys Ile Asp Lys Leu Cys Val Trp Asn Asn Lys Thr Pro Asn Ser Ile g5 90 95 Ala Ala Ile Ser Met Lys Asn <210> 23 <211> 124 <212> PRT
<213> Escherichia coli <220>
<221> VARIANT
<222> (1)...(124) <223> LTB variant from NCBI gene bank GI:69630.
<400> 23 Met Asn Lys Val Lys Cys Tyr Val Leu Phe Thr Ala Leu Leu Ser Ser Leu Tyr Ala His Gly Ala Pro Gln Thr Ile Thr Gln Leu Cys Ser Glu Tyr Arg Asn Thr Gln Ile Tyr Thr Ile Asn Asp Lys Ile Leu Ser Tyr Thr Glu Ser Met Ala Gly Lys Arg Glu Met Val Ile Ile Thr Phe Met Ser Gly Glu Thr Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Thr g5 90 95 Tyr Leu Thr Glu Thr Lys Ile Asp Lys Leu Cys Val Trp Asn Asn Lys Thr Pro Asn Ser Ile Ala Ala Ile Ser Met Lys Asn <210> 24 <211> 123 <212> PRT
<213> Escherichia coli <220>
<221> VARIANT
<222> (1)...(123) <223> LT-IIa from NCBI gene bank GI:146671.
<400> 24 Met Ser Ser Lys Lys Ile Ile Gly Ala Phe Val Leu Met Thr Gly Ile Leu Ser Gly Gln Val Tyr Ala Gly Val Ser Glu His Phe Arg Asn Ile Cys Asn Gln Thr Thr Ala Asp Ile Val Ala Gly Val Gln Leu Lys Lys Tyr Ile Ala Asp Val Asn Thr Asn Thr Arg Gly Ile Tyr Val Val Ser Asn Thr Gly Gly Val Trp Tyr Ile Pro Gly Gly Arg Asp Tyr Pro Asp Asn Phe Leu Ser Gly Glu Ile Arg Lys Thr Ala Met Ala Ala Ile Leu g5 90 95 Ser Asp Thr Lys Val Asn Leu Cys Ala Lys Thr Ser Ser Ser Pro Asn His Ile Trp Ala Met Glu Leu Asp Arg Glu Ser <210> 25 <211> 122 <212> PRT
<213> Escherichia coli <220>
<221> VARIANT
<222> (1)...(122) <223> LT-IIb LTB from NCBI gene bank GI:576584.
<400> 25 Met Ser Phe Lys Lys I1e Ile Lys Ala Phe Val Ile Met Ala Ala Leu Val Ser Val Gln Ala His Ala Gly Ala Ser Gln Phe Phe Lys Asp Asn Cys Asn Arg Thr Thr Ala Ser Leu Val Glu Gly Val Glu Leu Thr Lys Tyr Ile Ser Asp Ile Asn Asn Asn Thr Asp Gly Met Tyr Val Val Ser Ser Thr Gly Gly Val Trp Arg Ile Ser Arg Ala Lys Asp Tyr Pro Asp Asn Val Met Thr Ala Glu Met Arg Lys Ile Ala Met Ala Ala Val Leu Ser Gly Met Arg Val Asn Met Cys Ala Ser Pro Ala Ser Ser Pro Asn Val Ile Trp Ala Ile Glu Leu Glu Ala Glu <210> 26 <211> 88 <212> PRT
<213> Shigella dysenteriae type 1 <220>
<221> VARIANT
<222> (1)...(88) <223> Shiga toxin beta subunit from NCBI gene bank GI:152784.
<400> 26 Met Lys Lys Thr Leu Leu Ile Ala Ala Ser Leu Ser Phe Phe Ser Ala Ser Ala Leu Ala Thr Pro Asp Cys Val Thr Gly Lys Val Glu Tyr Thr Lys Tyr Asn Asp Asp Asp Thr Phe Thr Val Lys Val Gly Asp Lys Glu Leu Phe Thr Asn Arg Trp Asn Leu Gln Ser Leu Leu Leu Ser Ala Gln Ile Thr Gly Met Thr Val Thr Ile Lys Thr Asn Ala Cys His Asn Gly Gly Gly Phe Ser Val Ile Phe Arg <210> 27 <211> 89 <212> PRT
<213> Escherichia coli <220>
<221> VARIANT
<222> (1)...(89) <223> Shiga-like toxin from E.coli from NCBI gene bank GI:4877349.
<400> 27 Met Lys Lys Ile Phe Val Ala Ala Leu Phe Ala Phe Val Ser Val Asn Ala Met Ala Ala Asp Cys Ala Lys Gly Lys Ile Glu Phe Ser Lys Tyr Asn Glu Asn Asp Thr Phe Thr Val Lys Val Ala Gly Lys Glu Tyr Trp Thr Asn Arg Trp Asn Leu Gln Pro Leu Leu Gln Ser Ala Gln Leu Thr Gly Met Thr Val Thr Ile Lys Ser Asn Thr Cys Ala Ser Gly Ser Gly Phe A.la Glu Val Gln Phe Asn Asn Asp <210> 28 <211> 226 <212> PRT
<213> Bordetella pertussis <220>
<221> VARIANT
<222> (1)...(226) <223> Pertussis Toxin pentamer subunit S2.
<400> 28 Met Pro Ile Asp Arg Lys Thr Leu Cys His Leu Leu Ser Val Leu Pro 1 5 1~ 15 Leu Ala Leu Leu Gly Ser His -Jal Ala Arg Ala Ser Thr Pro Gly~° Iie Val Ile Pro Pro Gln Glu Gln Ile Thr Gln His Gly Ser Pro Tyr Gly Arg Cys Ala Asn Lys Thr Arg Ala Leu Thr Val Ala Glu Leu Arg Gly Ser Gly Asp Leu Gln Glu Tyr Leu Arg His Val Thr Arg Gly Trp Ser Ile Phe Ala Leu Tyr Asp Gly Thr Tyr Leu Gly Gly Glu Tyr Gly Gly Val Ile Lys Asp Gly Thr Pro Gly Gly Ala Phe Asp Leu Lys Thr Thr Phe Cys Ile Met Thr Thr Arg Asn Thr Gly Gln Pro Ala Thr Asp His Tyr Tyr Ser Asn Val Thr Ala Thr Arg Leu Leu Ser Ser Thr Asn Ser Arg Leu Cys Ala Val Phe Val Arg Ser Gly G1n Pro Val Ile Gly Ala Cys Thr Ser Pro Tyr Asp Gly Lys Tyr Trp Ser Met Tyr Ser Arg Leu Arg Lys Met Leu Tyr Leu Ile Tyr Val Ala Gly Ile Ser Val Arg Val His Val Ser Lys Glu Glu Gln Tyr Tyr Asp Tyr Glu Asp Ala Thr Phe Glu Thr Tyr Ala Leu Thr Gly Ile Ser Ile Cys Asn Pro Gly Ser Ser Leu Cys <210> 29 <211> 227 <212> PRT
<213> Bordetella pertussis <220>
<221> VARIANT
<222> (1)...(227) <223> Pertussis Toxin pentamer subunit S3.
<400> 29 Met Leu Ile Asn Asn Lys Lys Leu Leu His His Ile Leu Pro Ile Leu Val Leu Ala Leu Leu Gly Met Arg Thr Ala Gln Ala Val Ala Pro Gly Ile Val Ile Pro Pro Lys Ala Leu Phe Thr Gln Gln Gly Gly Ala Tyr Gly Arg Cys Pro Asn Gly Thr Arg Ala Leu Thr Val Ala Glu Leu Arg Gly Asn Ala Glu Leu Gln Thr Tyr Leu Arg Gln Ile Thr Pro Gly Trp Ser Ile Tyr Gly Leu Tyr Asp Gly Thr Tyr Leu Gly Gln Ala Tyr Gly Gly Ile Ile Lys Asp Ala Pro Pro G1y Ala Gly Phe I1e Tyr Arg Glu Thr Phe Cys Ile Thr Thr Ile Tyr Lys Thr Gly Gin Pro Ala Ala Asp His Tyr Tyr Ser Lys Val Thr Ala Thr Arg Leu Leu Ala Ser Thr Asn 130 i35 140 Ser Arg Leu Cys Ala Val Phe Val Arg Asp Gly Gln Ser Val Ile Gly Ala Cys Ala Ser Pro Tyr Glu Gly Arg Tyr Arg Asp Met Tyr Asp Ala Leu Arg Arg Leu Leu Tyr Met Ile Tyr Met Ser Gly Leu Ala Val Arg Val His Val Ser Lys Glu Glu Gln Tyr Tyr Asp Tyr Giu Asp Ala Thr Phe Gln Thr Tyr Ala Leu Thr Gly Ile Ser Leu Cys Asn Pro Ala Ala Ser Ile Cys <210> 30 <211> 152 <212> PRT
<213> Bordetella pertussis <220>
<221> VARIANT
<222> (1)...(152) <223> Pertussis Toxin pentamer subunit S4.
<400> 30 Met Leu Arg Arg Phe Pro Thr Arg Thr Thr Ala Pro Gly Gln Gly Gly Ala Arg Arg Ser Arg Val Arg Ala Leu Ala Trp Leu Leu Ala Ser Gly Ala Met Thr His Leu Ser Pro Ala Leu Ala Asp Va1 Pro Tyr Val Leu Val Lys Thr Asn Met Val Val Thr Ser Val Ala Met Lys Pro Tyr Glu Val Thr Pro Thr Arg Met Leu Val Cys Gly Ile Ala Ala Lys Leu Gly Ala Ala Ala Ser Ser Pro Asp Ala His Val Pro Phe Cys Phe Gly Lys Asp Leu Lys Arg Pro Gly Ser Ser Pro Met Glu Val Met Leu Arg Ala Val Phe Met Gln Gln Arg Pro Leu Arg Met Phe Leu Gly Pro Lys Gln Leu Thr Phe Glu Gly Lys Pro Ala Leu Glu Leu Ile Arg Met Va1 Glu Cys Ser Gly Lys Gln Asp Cys Pro <210> 31 <211> 133 <212> PRT
<213> Bordetella pertussis <220>
<221> VARIANT
<222> (1)...(133) <223> Pertussis Toxin pentamer subunit S5.
<400> 31 Met Gln Arg Gln Ala Gly Leu Pro Leu Lys Ala Asn Pro Met His Thr Ile Ala Ser Ile Leu Leu Ser Val Leu Gly Ile Tyr Ser Pro Ala Asp Val Ala Gly Leu Pro Thr His Leu Tyr Lys Asn Phe Thr Val Gln Glu Leu Ala Leu Lys Leu Lys Gly Lys Asn Gln Glu Phe Cys Leu Thr Ala Phe Met Ser Gly Arg Ser Leu Va1 Arg Ala Cys Leu Ser Asp Ala Gly His Glu His Asp Thr Trp Phe Asp Thr Met Leu Gly Phe Ala Ile Ser Ala Tyr Ala Leu Lys Ser Arg Ile Ala Leu Thr Val Glu Asp Ser Pro Tyr Pro Gly Thr Pro Gly Asp Leu Leu Glu Leu Gln Ile Cys Pro Leu Asn Gly Tyr Cys Glu
Amino acids 2-7 form a loop on the outer surface of rCTB. Residues Gln 3, Asn 4, Thr 6, and Asn7, all possess polar side chains which face out from the molecule.
These side chains can be replaced with another amino acid to introduce a chemically modifiable amino acid side chains into this region. Residues 10-14 are reported to form an amino acid sequence with ganglioside receptor affinity. Mutations to this site, particularly H13, might create a more hydrophobic rCTB
(Merritt et al. 1995. Structure 3:561-570). Amino acids 14-20 are thought to form a /.sheet on the outer surface of rCTB with many of the side chains facing outward. Among these amino acids are many polar side chain groups, particularly His 18, which may be amenable to lysine additions.
Residues 2l-25 of CTB form a surface loop on the surface of rCTB. The loop is comprised of Asn 21, an uncharged polar amine, Asp 22, an acidic side chain, and Lys 23, a basic amine. Each side group is thought to face outward from the surface of the protein. The orientation of this residue suggests that it may play some role in structural stability of the monomer. Amino acid residue Phe 25 also faces outward from the molecular surface with its uncharged, nonpolar benzyl ring and might be mutated to introduce a modifiable amino acid into the sequence of the protein. Residues 25-30 form a /pleated sheet within the CTB monomer that is not accessible to the molecular surface. Mutations to this site might be expected to disrupt the quaternary structure of rCTB. Residues 31-35 are referenced within the specification with regard to the Gm-1 receptor.
Residues 36-40 of CTB are thought to form an internal (3-pleated sheet as in 25-30.
Residues 41-44 form a surface exposed loop containing Lys 43 next to Asn 44.
Asn 44 may be a good candidate for lysine due to its location, charge, and side chain similarity to Lys 43.
Residues 45-55 are thought to form a (3-pleated sheet within the monomer.
Residues 55-64 are thought to form an insert permissive site. Lysines at positions 62 and 63 within this region may be deleted or mutated without apparent adverse effect on the ganglioside binding affinity of rCTB
mutants (Backstrom et al. 1995, Gene 165:163-171). Residues 60-78 form an internal hydrophobic a-helix in the homopentamer. Significant changes to this sequence, particularly to residues 65-78, might be expected to interfere with homopentamer formation.
Residues 79-85 of CTB form a loop on the surface of the CTB monomer. Within the loop, Lys 81 and Lys 84 face outward from the monomeric structure. Lys 81 and 84 would appear to be an optimal target residues for conjugation due to their position contralateral to the receptor and surface location within the monomer.
CTB residues 86-95 form internalized side chains and inferior loop contact points with Gm-I, encompass the Lys 91 successfully produced and claimed herein. CTB
residues 96-103 form an internal sheet which ends with an optimally positioned Asn 103. This Asn 103 is a key target for Lys insertion due to its similar charge, structure and on the molecule.
In view of the structural analysis discussed above, it is clear that a large number of mutations can result in a mutant CTB protein with altered conjugation characteristics. Some mutants will preserve, enhance, or at least not detrimentally reduce the Gm-1 binding affinity of the mutant CTB proteins described herein. On the other hand, some loss of Gm-1 affinity is tolerable given the extraordinarily high initial affinity (4.6 x 10-12) of the cholera toxin B for the Gm-1 receptor. Binding affinity of the mutant proteins can be determined using a number of assays well known in the art.
Mutants of Recombinant cholera Toxin Subunit B (rCTB) The invention contemplates mutations, substitutions, deletions, or insertions of one, two, three, four or more amino acid residues in the amino acid sequence of cholera toxin subunit B. The full length amino acid sequence of wild type rCTB is shown in FIGURE 1 (SEQ ID
NO: 2).
The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB without deleterious effect to the ganglioside (Gm-1 ) binding affinity of the recombinantly produced molecule.
Such mutations include: T1X, P2X, Q3 X, N4X, ISX, T6X, D7X, LBX, C9X, AlOX, E11X, Y12X, H13X, N14X, T15X, Q16X, I17X, H18X, T19X, L20X, N21X, D22X, K23X, I24X, F25X, S26X, Y27X, T28X, E29X, 530X, L31X, A32X, 633X, K34X, R35X, E36X, M37X, A38X, I39X, I40X, T41X, F42X, K43X, N44X, G45X, A46X, T47X, F48X, Q49X, VSOX, ES1X, V52X, P53X, G54X, SSSX, Q56X, H57X, I58X, D59X, S60X, Q61X, K62X, K63X, A64X, I65X, E66X, R67X, M68X, K69X, D70X, T71X, L72X, R73X, I74X, A75X, Y76X, L77X, T78X, E79X, A80X, K81X, V82X, E83X, K84X, L85X, C86X, V87X, W88X, N89X, N90X, K91X, T92X, P93X, H94X, A95X, I96X, A97X, A98X, I99X, S 100X, M 1 O1 X, A 102X, N 103X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
Lvsine Substitutions in rCTB
Conjugation of rCTB to immunogens derived from infectious diseases can create vaccines which induce protection following mucosal delivery. Classic conjugation chemistry targets are reactive amino acid side chain groups such as primary amines, carboxylic acids, aldehydes, or sulfhydryls. The primary reactive amino acids in rCTB are lysines (see Figure 3). The B subunit of cholera toxin contains nine (9) lysine amino acid residues. A number of these residues are contemplated to play a role in facilitating conjugation of bioactive compounds to the rCTB protein.
These lysine residues are distributed at various places throughout the CTB
sequence. Those lysine residues that are near the Gm-1 binding site (e.g. K91 ) can couple to a bioactive compound of interest in a conformation which interferes with ganglioside binding. Further, any lysine residues to which the bioactive compound is coupled may induce a conformational change upon conjugation, which prevents or disrupts the formation of the quaternary structure required for ganglioside binding.
Accordingly, a number of mutant rCTB proteins with increased or decreased numbers of conjugation sites as compared to the wild type form of the protein are disclosed herein.
The present approach involves directing the covalent linkage of an ABS B
subunit carrier and a bioactive molecule such that the bioactive molecule does not interfere with the ganglioside site of CTB. Site directed mutagenesis was employed to create a panel of mutations at Lys91 of the rCTB coding sequence. These mutations resulted in several mutants which produce levels of protein, in vitro, comparable to those of the wild type and which can effectively deliver bioactive CTB-immunogen complexes to the mucosal immune system.
Accordingly, one embodiment discussed herein articulates a number of mutant rCTB proteins with amino acid substitutions that replace the lysine residues found in the wild type rCtB protein. Of the 9 lysine residues present in wild type CTB, the invention contemplates recombinant CTB proteins with one or more of the following amino acid substitutions: K23X, K34X, K43X, K62X, K63X, K69X, K81X, K84X, and K91X; wherein "X" is any amino acid that results in a rCTB protein with a reduced ability to conjugate at the mutant sites. These mutants are also contemplated to maintain a substantial degree of Gm-1 binding affinity as compared to the wild type or unmutated form of the protein. Moreover, as mentioned before, some loss of affinity is allowable due to the extraordinarily high initial affinity (4.6 x 10-12) of the wild type CTB for the Gm-1 receptor.
There are a number of lysine residues that are thought to result in particularly deleterious conjugation events given the proximity of these residues to the Gm-1 binding site. These residues include K34, K62, K63, and K91. Mutation of these residues favors conjugation events that will not interfere with Gm-1 binding affinity.
The invention further contemplates mutating the lysine residue at K69 to eliminate conjugation at this position. Lysine 69 is thought to be distal from the Gm-I
binding site; however, conjugation to this residue might reduce rCtB homopentamer self assembly.
Incomplete quaternary structure formation is known to diminish Gm-1 affinity and likely also diminishes the bioactivity of a rCTB conjugated molecule.
The remaining lysine residues in CTB are K23, K43, K81, and K84. Each of these residues are contemplated as acceptable sites for conjugation. One or more of these residues can be mutated to reduce the total number of sites for conjugation.
McCann et al. (Biochem. 1997, 36:9169) demonstrated that Lys91 was the most reactive of all lysine residues in CTB when reacted with "small" (fluorescent) molecular probes. When CTB
is bound to Gm-l, Lys91 is positioned proximal to the terminal galactose residue of Gm-1.
Therefore, conjugation of large molecular weight bioactive molecules is likely to result in steric hinderance of the Gm-1 binding site of rCTB. Similarly, reaction of larger molecular weight compounds with Lys69, which is located within the hydrophobic core of the pentamer, would disfavor reformation of bioactive CTB homopentamers.
Lys91 possesses a basic amino side chain with which the hydroxylated galactose of Gm-1 may interact and facilitate the affinity of rCTB for Gm-1. A knockout of Lys91 might therefore be expected to significantly decrease the affinity of the mutant rCTB for Gm-l and effect a decrease in recombinant production levels.
sine additions in rCTB
The invention further contemplates the addition of amino acid residues throughout the amino acid sequence of rCTB to direct conjugation of immunogens, immunomodulators, drugs, or other bioactive molecules, to specified sites within rCTB. Any residue of rCTB can be mutated to introduce an amino acid residue that promotes acceptable conjugation events.
Examples of these mutations include Q3X, N4X, T6X, N7X, H18X, N21X, F25X, N44X, MlOlX, and N103X
wherein "X" is any amino acid that results in the addition of an acceptable conjugation site. Specific examples of suitable amino acids for use at these sites include lysine and cysteine.
Accordingly, one or more of the following mutations: Q3K, N4K, T6K, N7K, H18K, N21K, F25K, N44K, M101K, N103K, Q3C, N4C, T6C, N7C, H18C, N21C, F25C, N44C, M101C, and N103C are contemplated.
Alternative Chemical Cross-linking Moieties A further approach to specific chemical coupling or site-directed chemical coupling is to create a site for chemical coupling using a cysteine residue rather than a lysine residue. Accordingly, the following cysteine insertions are created: H18C and MIO1C. The site-directed mutagenesis is performed as in Examples 1-2. Example 5 provides techniques for chemically coupling these residues to an immunogen of interest.
Mutants in the N-terminus of rCTB
The wild type amino acid sequence of rCTB is shown in Figure 1. The invention contemplates various mutations throughout the rCTB amino acid sequence. In one embodiment, one or more mutations are introduced into the N-terminus of the protein sequence.
For example, in one embodiment, an alanine residue is introduced at the first position of the rCTB
amino acid sequence.
Introduction of this particular amino acid creates a defined signal sequence cleavage site, as opposed to the threonine residue at the amino terminus of the wild type form of rCTB.
This cleavage site can be important in post-translational modifications.
Mutants of other CTB family members identified by NCBI accession number The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GI:758351 without deleterious effect to the ganglioside (Gm-1) binding affinity of the recombinantly produced molecule. Such mutants include: M1X, I2X, K3X, L4X, KSX, F6X, G7X, V8X, F9X, F10X, T11X, V12X, L13X, L14X, S15X, S16X, A17X, Y18X, A19X, H20X, 621X, T22X, P23X, Q24X, N25X, I26X, T27X, D28X, L29X, C30X, A31X, E32X, 533X, H34X, N35X, T36X, Q37X, I38X, Y39X, T40X, L41X, N42X, D43X, K44X, I45X, F46X, 547X, Y48X, T49X, ESOX, SS1X, L52X, A53X, G54X, KSSX, R56X, E57X, M58X, A59X, 160X, I61X, T62X, F63X, K64X, N65X, G66X, A67X, I68X, F69X, Q70X, V71X, E72X, V73X, P74X, S75X, S76X, Q77X, H78X, 179X, D80X, S81X, Q82X, K83X, K84X, A85X, I86X, E87X, 888X, M89X, K90X, D91X, T92X, L93X, R94X, I95X, A96X, Y97X, L98X, T99X, E100X, AlOlX, K102X, V103X, E104X, K105X, L106X, C107X, V108X, W109X, N110X, N111X, K112X, T113X, P114X, H115X, A116X, I117X, A118X, A119X, I120X, S121X, M122X, A123X, N124X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB
GI:758351 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GI:1827850 without deleterious effect to the ganglioside (Gm-1) binding affinity of the recombinantly produced molecule. Such mutants include: T1X, P2X, Q3X, N4X, ISX, T6X, D7X, L8X, C9X, AlOX, E11X, Y12X, H13X, N14X, T15X, Q16X, 117X, Y18X, T19X, L20X, N21X, D22X, K23X, I24X, F25X, S26X, Y27X, T28X, E29X, S30X, L31X, A32X, G33X, K34X, R35X, E36X, M37X. A38X, I39X, I40X, T41X, F42X, K43X, N44X, G45X, A46X, 147X, F48X, Q49X, VSOX, E51X, V52X, P53X, S54X, SSSX, Q56X, H57X, I58X, D59X, S60X, Q61X, K62X, K63X, A64X, I65X, E66X, R67X, M68X, K69X, D70X, T71X, L72X, R73X, I74X, A75X, Y76X, L77X, T78X, E79X, A80X, K81X, V82X, E83X, K84X, L85X, C86X, T87X, W88X, N89X, N90X, K91X, T92X, P93X, H94X, A95X, I96X, A97X, A98X, I99X, 5100X, M101X, A102X, N103X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB GI: 1827850 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB 61:808900 without deleterious effect to the ganglioside (Gm-I) binding affinity of the recombinantly produced molecule. Such mutations include: M1X, I2X, K3X, L4X, KSX, F6X, 67X, V8X, F9X, F10X, T11X, V12X, L13X, L14X, S15X, S16X, A17X, Y18X, A19X, H20X, 621X, T22X, P23X, Q24X, N25X, I26X, T27X, D28X, L29X, C30X, A31X, E32X, Y33X, H34X, N35X, T36X, Q37X, I38X, H39X, T40X, L41X, N42X, D43X, K44X, 145X, L46X, S47X, Y48X, T49X, ESOX, SS1X, L52X, A53X, 654X, NSSX, R56X; E57X, M58X, A59X, I60X, I61X, T62X, F63X, K64X, N65X, 666X, A67X, T68X, F69X, Q70X, V71X, E72X, V73X, P74X, 675X, S76X, Q77X, H78X, I79X, D80X, S81X, Q82X, K83X, K84X, A85X, I86X, E87X, R88X, M89X, K90X, D91X, T92X, L93X, R94X, I95X, A96X, Y97X, L98X, T99X, E100X, AlOlX, K102X, V103X, E104X, KlOSX, L106X, C107X, V108X, W109X, N110X, N111X, K112X, T113X, P114X, H115X, A116X, I117X, A 118X, A 1 I 9X, I 120X, S 121 X, M 122X, A 123X, N 124X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB
GI:808900 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-I binding activity.
The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GI:229616 without deleterious effect to the ganglioside (Gm-1) binding affinity of the recombinantly produced molecule. Such mutations include: T1 X, P2X, E3X, N4X, ISX, T6X, D7X, LBX, C9X, AIOX, EI 1X, Y12X, H13X, N14X, T15X, Q16X, I17X, H18X, T19X, L20X, N21X, N22X, K23X, I24X, F25X, S26X, Y27X, T28X, E29X, S30X, L31X, A32X, 633X, K34X, R35X, E36X, M37X, A38X, I39X, I40X, T41X, F42X, K43X, D44X, 645X, A46X, T47X, F48X, E49X, VSOX, ES1X, V52X, P53X, 654X, SSSX, E56X, H57X, I58X, D59X, S60X, E61X, K62X, K63X, A64X, I65X, E66X, R67X, M68X, K69X, D70X, T71X, L72X, R73X, I74X, A75X, Y76X, L77X, T78X, E79X, A80X, K81X, V82X, E83X, K84X, L85X, C86X, V87X, W88X, N89X, N90X, K91X, T92X, P93X, H94X, A95X, I96X, A97X, A98X, I99X, S100X, MlOlX, A102X, N103X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB GI: 229616 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GI:998409 without deleterious effect to the ganglioside (Gill-1 ) binding affinity of the recombinantly produced molecule. Such mutations include: T1X, P2X, Q3X, N4X, ISX, T6X, D7X, LBX, C9X, AlOX, E1 IX, Y12X, H13X, N14X, T15X, Q16X, I17X, Y18X, T19X, L20X, N21X, D22X, K23X, I24X, F25X, 526X, Y27X, T28X, E29X, S30X, L31X, A32X, G33X, K34X, R35X, E36X, M37X, A38X, 139X, I40X, T41X, F42X, K43X, N44X, 645X, A46X, I47X, F48X, Q49X, VSOX, ES1X, V52X. P53X, G54X, SSSX, Q56X, I-I57X, I58X. D59X, S60X, Q61X, K62X, K63X, A64X, I65X, E66X. R67X, M68X, K69X, D70X, T71X, L72X, R73X. 174X. A75X, Y76X, L77X. T78X, E79X, A80X, K81X, V82X, E83X. K84X, L85X, C86X, V87X. W88X. N89X. N90X, K91X, T92X, P93X, H94X, A95X, I96X, A97X, A98X, I99X, S 100X, M 1 O 1 X, A 102X, N 103X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB GI: 998409 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GI:2144685 without deleterious effect to the ganglioside (Gm-I ) binding affinity of the recombinantly produced molecule: Such mutations include: MIX, I2X, K3X, L4X, KSX, F6X, G7X, VBX, F9X, F10X, T11X, V12X, L13X, L14X, S15X, S16X, A17X, Y18X, A19X, H20X, G21X, T22X, P23X, Q24X, N25X, I26X, T27X, D28X. L29X, C30X, A31X, E32X, S33X, H34X, N35X, T36X, Q37X, I38X, Y39X, T40X, L41 X, N42X, D43X, K44X, 145X, F46X, S47X, Y48X, T49X, ESOX, SS 1 X, L52X, A53X, G54X, KSSX, 856X, E57X, M58X, A~9X, 160X, 161 X, T62X. F63X. K64X, N65X, G66X, A67X, I68X, F69X, Q70X, V71X, E72X, V73X, P74X, S75X, S76X, Q77X, H78X, I79X, D80X, 581X, Q82X, K83X, K84X, A85X, I86X, E87X, R88X, M89X, K90X, D91X, T92X, L93X, R94X, 195X, A96X, Y97X, L98X, T99X, EIOOX, AIOIX, K102X, V103X, E104X, K105X, L106X, C107X, V108X, W109X, N110X, N111X, K112X, T113X, P114X, H115X, A116X, I117X, A118X, Al 19X, I120X, 5121X, M122X, A123X, N124X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB
GI:2144685 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GI:1421511 without deleterious effect to the ganglioside (Gm-1) binding affinity of the recombinantly produced molecule. Such mutations include: T1X, P2X, Q3X, N4X, ISX, T6X, D7X, LBX, C9X, AlOX, E11X, Y12X, H13X, N14X, T15X, Q16X, I17X, H18X, T19X, L20X, N21X, D22X, K23X, I24X, F25X, 526X, Y27X, T28X, E29X, 530X, L31X, A32X, D33X, K34X, R35X, E36X, M37X, A38X, I39X, I40X, T41X, F42X, K43X, N44X, 645X, A46X, T47X, F48X, Q49X, VSOX, ES1X, V52X, P53X, G54X, SSSX, Q56X, H57X, I58X, D59X, S60X, Q61X, K62X, K63X, A64X, I65X, E66X, R67X, M68X, K69X, D70X, T71X, L72X, R73X, I74X, A75X, Y76X, L77X, T78X, E79X, A80X, K81X, V82X, E83X, K84X, L85X, C86X, V87X, W88X, N89X, N90X, K91X, T92X, P93X, H94X, A95X, 196X, A97X, A98X, I99X, 5100X, MlOlX, A102X, N103X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB GI: 1421511 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GI:48890 (classic 569B) without deleterious effect to the ganglioside (Gm-1) binding affinity of the recombinantly produced molecule. Such mutations include: M1X, I2X, K3X, L4X, KSX, F6X, G7X, VBX, F9X, F10X, T11X, V12X, L13X, L14X, 515X, S16X, A17X, Y18X, A19X, H20X. G21X, T22X, P23X, Q24X, N25X, I26X, T27X, D28X, L29X, C30X, A31X, E32X, Y33X, H34X, N35X, T36X, Q37X, I38X, H39X, T40X, L41X, N42X, D43X, K44X, I45X, F46X, S47X, Y48X, T49X, ESOX, SS1X, L52X, A53X, G54X, KSSX, R56X, E57X, M58X, A59X, I60X, I61X, T62X, F63X, K64X, N65X, G66X, A67X, T68X, F69X, Q70X, V71X, E72X, V73X, P74X, G75X, S76X, Q77X, H78X, I79X, D80X, 581X, Q82X, K83X, K84X, A85X, I86X, E87X, R88X, M89X, K90X, D91X, T92X, L93X, R94X, I95X, A96X, Y97X, L98X, T99X, E100X, AlOIX, K102X, V103X, E104X, K105X, L106X, C107X, V108X, W109X, N110X, NI11X, K112X, T113X, P114X, H115X, Al 16X, I117X, A 118X, A 119X, I120X, S 121 X, M 122X, A 123X, N 124X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB
GI: 48890 (classic 569B) with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GI:2781121 (Ogawa 4l) without deleterious effect to the ganglioside (Gm-1) binding affinity of the recombinantly produced molecule. Such mutations include: M1X, T2X, P3X, Q4X, NSX, I6X, T7X, D8X, L9X, C10X, A11X, E12X, Y13X, H14X, N15X, T16X, Q17X, I18X, H19X, T20X, L21X, N22X, D23X, K24X, I25X, F26X, S27X, Y28X, T29X, E30X, S31X, L32X, A33X, 634X, K35X, R36X, E37X, M38X, A39X, I40X, I41X, T42X, F43X, K44X, N45X, G46X, A47X, T48X, F49X, Q50X, V51X, E52X, V53X, P54X, G55X, S55X, Q56X, H57X, I58X, D59X, 560X, Q61X, K62X, K63X, A64X, I65X, E66X, R67X, M68X, K69X, D70X, T71X, L72X, R73X, I74X, A75X, Y76X, L77X, T78X, E79X, A80X, K81X, V82X, E83X, K84X, L85X, C86X, V87X, W88X, N89X, N90X, K91 X, T92X, P93X, H94X, A95X, I96X, A97X, A98X, 199X, S 100X, M 1 O 1 X, A102X, N103X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid,. The "X"
represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB GI: 2781121 (Ogawa 41) with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rCTB GI:1421525 (Ogawa 41 R35D) without deleterious effect to the ganglioside (Gm-I ) binding affinity of the recombinantly produced molecule. Such mutations include: T1 X, P2X, Q3X, N4X, ISX, T6X, D7X, L8X, C9X, AIOX, E11X, Y12X, H13X, N14X, T15X, Q16X, I17X, H18X, T19X, L20X, N21X, D22X, K23X, I24X, F25X, S26X, Y27X, T28X, E29X, S30X, L31X, A32X, G33X, K34X, D35X, E36X, M37X, A38X, I39X, I40X, T41X, F42X, K43X, N44X, G45X, A46X, T47X, F48X, Q49X, V50X, ES1X, V52X, P53X, G54X, 555X, Q56X, H57X. I58X, D59X, S60X, Q61X, K62X, K63X, A64X, I65X, E66X, R67X, M68X, K69X, D70X, T71X, L72X, R73X, I74X, A75X, Y76X, L77X, T78X, E79X, A80X, K81X, V82X, E83X, K84X, L85X, C86X, V87X, W88X, N89X, N90X, K91X, T92X, P93X, H94X, A95X, I96X, A97X, A98X, I99X, S 100X, M 1 O1 X, A I 02X, N
103 X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rCTB GI: 1421525 (Ogawa 41 R35D) with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its Gm-1 binding activity.
Mutants of LTB and LTB family members identified by NCBI accession number The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GI:3062900 without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule. Such mutations include: M1X, N2X, K3X, V4X, KSX, C6X, Y7X, VBX, L9X. F10X, T11X, A12X, L13X, L14X, S15X, S16X, L17X, C18X, A19X, Y20X, 621X, A22X, P23X, Q24X, S25X, 126X, T27X, E28X, L29X, C30X, S31X, E32X, Y33X, R34X, N35X, T36X, Q37X, I38X, Y39X, T40X, I41X, N42X, D43X, K44X, I45X, L46X, S47X, Y48X, T49X, ESOX, SS1X, M52X, A53X, G54X, KSSX, 856X, E57X, M58X, V59X, I60X, I61X, T62X, F63X, K64X, S65X, G66X, A67X, T68X, F69X, Q70X, V71X, E72X, V73X, P74X, G75X, S76X, Q77X, H78X, I79X, D80X, S81X, Q82X, K83X, K84X, A85X, I86X, E87X, R88X, M89X, K90X, D91X, T92X, L93X, R94X, I95X, T96X, Y97X, L98X, T99X, EIOOX, T101X, K102X, I103X, D104X, K105X, L106X, C107X, V108X, W109X, N110X, Nl 11X, KI 12X. T113X, PI
14X, N115X, S116X, 1117X, A118X, A119X, I120X, S121X, M122X, E123X. N124X. wherein the first letter is the native amino acid appearing at the position of the indicated number. and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLTB GI:3062900 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside and glycosphingolipid binding activity.
The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GI:1169505 without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule. Such mutations include: MIX, N2X, K3X, V4X, KSX, C6X, Y7X, VBX, L9X, F10X, T11X, A12X, L13X, L14X, SISX, S16X, L17X, Y18X, A19X, H20X, G21X, A22X, P23X, Q24X, T25X, I26X, T27X, E28X, L29X, C30X, 531X, E32X, Y33X, R34X, N35X, T36X, Q37X, I38X, Y39X, T40X, I41X, N42X, D43X, K44X, I45X, L46X, 547X, Y48X, T49X, ESOX, SS1X, M52X, A53X, 654X, KSSX, R56X, E57X, M58X, V59X, I60X, I61X, T62X, F63X, K64X, S65X, 666X, E67X, T68X, F69X, Q70X, V71X, E72X, V73X, P74X, 675X, S76X, Q77X, H78X, I79X, D80X, 581X, Q82X, K83X, K84X, A85X, I86X, E87X, R88X, M89X, K90X, D91X, T92X, L93X, R94X, I95X, T96X, Y97X, L98X, T99X, E100X, T101X, K102X, I103X, D104X, K105X, L106X, C107X, V108X, W109X, N110X, N111X, Kl 12X, T113X, Pl 14X, N115X, 5116X, 1117X, A118X, A119X, I120X, 5121X, M122X, K123X, N124X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLTB GI:1169505 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside and glycosphingolipid binding activity.
The amino acid substitutions encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GI:1395122 without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule. Such mutations include: M1X, N2X, K3X, V4X, KSX, C6X, Y7X, VBX, L9X, FlOX, T11X, A12X, 1.13X, L14X, S15X, S16X, L17X, C18X, A19X, Y20X, G21X, A22X, P23X, Q24X, S25X, I26X, T27X, E28X, L29X, C30X, S31X, E32X, Y33X, R34X, N35X, T36X, Q37X, I38X, Y39X, T40X, I41X, N42X, D43X, K44X, 145X, L46X, S47X, Y48X, T49X, ESOX, SS1X, M52X, A53X, 654X, KSSX, R56X, E57X, M58X, V59X, 160X, I61X, T62X, F63X, K64X, 565X, 666X, A67X, T68X, F69X, Q70X, V71X, E72X, V73X, P74X, G75X, S76X, Q77X, H78X, I79X, D80X, S81X, Q82X, K83X, K84X, A85X, 186X, E87X, R88X, M89X, K90X, D91X, T92X, L93X, R94X, I95X, T96X, Y97X, L98X, T99X, E100X, T101X, K102X, I103X, D104X, K105X, L106X, C107X, V108X, W 109X, N 110X, N I 11 X, K I 12X, T113 X, P 114X, N I 15X, 5116X, 1117X, A l 18X, A l 19X, I 120X, M121X, E122X, N123X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLTB
GI:1395122 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside and glycosphingolipid binding activity.
The amino acid substitutions encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GI:145833 without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule. Such mutations include: MIX, N2X, K3X, V4X, KSX, C6X, Y7X, VBX, L9X, F10X, T11X, A12X, L13X, L14X, 515X, S16X, L17X, Y18X, A19X, H20X, G21X, A22X, P23X, Q24X, T25X, I26X, T27X, E28X, L29X, C30X, 531X, E32X, Y33X, R34X, N35X, T36X, Q37X, I38X, Y39X, T40X, 141X, N42X, D43X, K44X, I45X, L46X, S47X, Y48X, T49X, ESOX, SS1X, M52X, A53X, G54X, KSSX, R56X, E57X, M58X, V59X, I60X, I61X, T62X, F63X, K64X, S65X, G66X, E67X, T68X, F69X, Q70X, V71X, E72X, V73X, P74X, G75X, S76X, Q77X, H78X, I79X, D80X, 581X, Q82X, K83X, K84X, A85X, I86X, E87X, R88X, M89X, K90X, D91X, T92X, L93X, R94X, 195X, T96X, Y97X, L98X, T99X, E100X, TlOlX, K102X, I103X, D104X, K105X, L106X, C107X, V108X, W109X, N1 IOX, N111X, K112X, T113X, Pl 14X, N115X, 5116X, I117X, A118X, Al 19X, I120X, S121X, M122X, K123X, N124X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLTB GI:145833 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside and glycosphingolipid binding activity.
The amino acid substitutions encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GI:1648865 (LT87) without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule. Such mutations include: M1X, N2X, K3X, V4X, KSX, F6X, Y7X, VBX, L9X, F10X, T11X, A12X, L13X, L14X, SISX, S16X, L17X, C18X, A19X, H20X, G21X, A22X, P23X, Q24X, 525X, I26X, T27X, E28X, L29X, C30X, S31X, E32X, Y33X, H34X, N35X, T36X, Q37X, I38X, Y39X, T40X, I41X, N42X, D43X, K44X, I45X, L46X, 547X, Y48X, T49X, ESOX, SS1X, M52X, A53X, G54X, KSSX, R56X, E57X, M58X, V59X, I60X, I61X, T62X, F63X, K64X, S65X, G66X, A67X, T68X, F69X, Q70X, V71X, E72X, V73X, P74X, G75X, S76X, Q77X, H78X, 179X, D80X, S81X, Q82X, K83X, K84X, A85X, I86X, E87X, R88X, M89X, K90X, D91X, T92X, L93X, R94X, I95X, T96X, Y97X, L98X, T99X, E100X, T101X, K102X, I103X, D104X, K105X, L106X, C107X, V108X, W109X, N110X, N111X, K112X, T113X, P114X, N115X, Sl 16X, I117X, A118X, A119X, I120X, S121X, M122X, E123X, N124X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLTB GI:
1648865 (LT87) with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside and glycosphingolipid binding activity.
The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GI:223254 without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule. Such mutations include: M1X, N2X, K3X, V4X, KSX, C6X, Y7X, VBX, L9X, F10X, T11X, A12X, L13X, L14X, 515X, 516X, L17X, Y18X, A19X, H20X, 621X, A22X, P23X, Q24X, T25X, I26X, T27X, E28X, L29X, C30X, S31X, E32X, Y33X, R34X, N35X, T36X, Q37X, I38X. Y39X, T40X, I41X, N42X, D43X, K44X, I45X, L46X, S47X, Y48X, T49X, ESOX, SS1X, M52X, A53X, G54X, KSSX, R56X, E57X, M58X, V59X, I60X, I61X, T62X, F63X, M64X, S65X, G66X, E67X, T68X, F69X, Q70X, V71X, E72X, V73X, P74X, G75X, 576X, Q77X, H78X, I79X, D80X, 581X, Q82X, K83X, K84X, A85X, I86X, E87X, R88X, M89X, K90X, D91X, T92X, L93X, R94X, I95X, T96X, Y97X, L98X, T99X, E100X, T101X, K102X, I103X, D104X, K105X, L106X, C107X, V108X, W109X, N1 10X, N11 1X, K112X, T113X, Pl 14X, N115X, S 116X, I 117X, A 118X, A 119X, I 120X, S 121 X, M 122X, K 123 X, N 124X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLTB GI:223254 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside and glycosphingolipid binding activity.
The amino acid substitutions encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GI:408996 without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule. Such mutations include: M1X, N2X, K3X, V4X, KSX, C6X, Y7X, VBX, L9X, F10X, TI1X, A12X, L13X, L14X, S15X, S16X, L17X, C18X, A19X, Y20X, G21X, A22X, P23X, Q24X, 525X, I26X, T27X, E28X, L29X, C30X, 531X, E32X, Y33X, R34X, N35X, T36X, Q37X, I38X, Y39X, T40X, I41X, N42X, D43X, K44X, I45X, L46X, 547X. Y48X, T49X, E50X, S51X, M52X, A53X, 654X, K55X, R56X, E57X, M58X, V59X, I60X, I61X, T62X, F63X, K64X, S65X, G66X, A67X, T68X, F69X, Q70X, V71X, E72X, V73X, P74X, 675X, S76X, Q77X, H78X, I79X, D80X, 581X, Q82X, K83X, K84X, A85X, I86X, E87X, R88X, M89X, K90X, D91X, T92X, L93X, R94X, I95X, T96X, Y97X, L98X, T99X, E100X, T101X, K102X, I103X, D104X, K105X, L106X, C107X, V108X, W 109X, N l 1 OX, N 111 X, K 1 I 2X, T 113 X, P 114X, N 115 X, S 116X, I 117X, A 118X, A 119X, I 120X, 5121X, M122X, E123X, N124X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLTB GI:408996 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside and glycosphingolipid binding activity.
The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GI:494265 without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule. Such mutations include: A1 X, P2X, Q3 X, T4X, ISX, T6X, E7X, L8X, C9X, SIOX, E11X, Y12X, R13X, N14X, T15X, Q16X, I17X, Y18X, T19X, I20X, N21X, D22X, K23X, I24X, L25X, S26X, Y27X, T28X, E29X, S30X, M31X, A32X, G33X, K34X, R35X, E36X, M37X, V38X, I39X, I40X, T41X, F42X, K43X, 544X, 645X, E46X, T47X, F48X, Q49X, VSOX, E51X, V52X, P53X, G54X, S55X, Q56X, H57X, I58X, D59X, S60X, Q61X, K62X, K63X, A64X, I65X, E66X, R67X, M68X, K69X, D70X, T71X, L72X, R73X, I74X, T75X, Y76X, L77X, T78X, E79X, T80X, K81X, I82X, D83X, K84X, L85X, C86X, V87X, W88X, N89X, N90X, K91X, T92X, P93X, N94X, S95X, I96X, A97X, A98X, I99X, S100X, M101X, K102X, N103X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLTB 61:494265 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside and glycosphingolipid binding activity.
The amino acid substitutions encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLTB GI:69630 without deleterious effect to the ganglioside and glycosphingolipid binding affinity of the recombinantly produced molecule. Such mutations include: M1X, N2X, K3X, V4X, KSX, C6X, Y7X, V8X, L9X, F10X, T11X, A12X, L13X, L14X, 515X, S16X, L17X, Y18X, A19X, H20X, 621X, A22X, P23X, Q24X, T25X, I26X, T27X, Q28X, L29X, C30X, 531X, E32X, Y33X, R34X, N35X, T36X, Q37X, I38X, Y39X, T40X, I41X, N42X, D43X, K44X, I45X, L46X, S47X, Y48X, T49X, ESOX, SS1X, M52X, A53X, 654X, KSSX, R56X, E57X, M58X, V59X, I60X, I61X, T62X, F63X, M64X, S65X, 666X, E67X, T68X, F69X, Q70X, V71X, E72X, V73X, P74X, 675X, S76X, Q77X, H78X, 179X, D80X, S81X, Q82X, K83X, K84X, A85X, 186X, E87X, R88X, M89X, K90X, D91X, T92X, L93X, R94X, I95X, T96X, Y97X, L98X, T99X, E100X, T101X, K102X, I103X, D104X, K105X, L106X, C107X, V108X, W109X, N110X, N111X, K112X, T113X, P114X, N115X, S116X, I117X, A118X, A119X, I120X, 5121X, M122X, K123X, N124X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid,. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLTB GI:69630 with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside and glycosphingolipid binding activity.
Mutants of LT-IIa The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLT-IIa NCBI Accession No. 6I:146671 without deleterious effect to the ganglioside (GDI b, among others) binding affinity of the recombinantly produced molecule. Such mutations include: M1X, S2X, S3X, K4X, KSX, I6X, I7X, 68X, A9X, F 1 OX, V 11 X, L 12X, M 13 X, T 14X, G l SX, I 16X, L 17X, S
18X, G 19X, Q20X, V21X, Y22X, A23X, 624X, V25X, 526X, E27X, H28X, F29X, R30X, N31X, I32X, C33X, N34X, Q35X, T36X, T37X, A38X, D39X, I40X, V41X, A42X, 643X, V44X, Q45X, L46X, K47X, K48X, Y49X, ISOX, AS1X, D52X, V53X, N54X, TSSX, N56X, T57X, R58X, 659X, I60X, Y61X, V62X, V63X, S64X, N65X, T66X, G67X, G68X, V69X, W70X, Y71X, I72X, P73X, G74X, G75X, R76X, D77X, Y78X, P79X, D80X, N81X, F82X, L83X, S84X, G85X, E86X, I87X, R88X, K89X, T90X, A91X, M92X, A93X, A94X, I95X, L96X, S97X, D98X, T99X, KIOOX, V101X, N102X, L103X, C104X, AlOSX, K106X, T107X, 5108X, S109X, 5110X, P111X, N112X, H113X, I114X, W115X, A116X, M117X, El 18X, L119X, D120X, R121X, E122X, S123X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLT-IIa with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its GD1 b binding activity.
Mutants of LT-IIb The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of rLT-IIb NCBI accession no. GI:576584 without deleterious effect to the ganglioside (GDIa among others) binding affinity of the recombinantly produced molecule. Such mutations include: MIX, 52X, F3X, K4X, KSX, I6X, I7X, KBX, A9X, F I OX, V 11 X, I 12X, M I 3X, A 14X, A 1 SX, L 16X, V 17X, S
18X, V 19X, Q20X, A21X, H22X, A23X, 624X, A25X, S26X, Q27X, F28X, F29X, K30X, D31X, N32X, C33X, N34X, R35X, T36X, T37X, A38X, S39X, L40X, V41X, E42X, G43X, V44X, E45X, L46X, T47X, K48X, Y49X, ISOX, SS1X, D52X, I53X, N54X, NSSX, N56X, T57X, D58X, G59X, M60X, Y61X, V62X, V63X, 564X, S65X, T66X, G67X, 668X, V69X, W70X, R71X, I72X, S73X, R74X, A75X, K76X. D77X, Y78X, P79X, D80X, N81X, V82X, M83X, T84X, A85X, E86X, M87X, R88X, K89X, I90X, A91X, M92X, A93X. A94X, V95X, L96X, S97X, 698X, M99X, R100X, V101X, N102X, M103X, C104X, AlOSX, S106X, P107X, A108X, S109X, S110X, P111X, N112X, V113X, I114X, W115X, A116X, I117X, E118X, L119X, E120X, A121X, E122X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant rLT-IIb with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside GDIa binding activity.
Mutants of Shiya toxin Beta subunit The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of Shiga toxin Beta subunit NCBI Accession No. GI:152784 without deleterious effect to the carbohydrate binding affinity of the recombinantly produced molecule for Gal alpha 1----4Ga1 beta 1 ----4Glc and globotrioside trisaccharides. Such mutations include: M1X, K2X, K3X, T4X, LSX, L6X, I7X, ABX, A9X, SlOX, L11X, 512X, F13X, F14X, S15X, A16X, S17X, A18X, L19X, A20X, T21X, P22X, D23X, C24X, V25X, T26X, 627X, K28X, V29X, E30X, Y31 X, T32X, K33X, Y34X, N35X, D36X, D37X, D38X, T39X, F40X, T41X, V42X, K43X, V44X, 645X, D46X, K47X, E48X, L49X, F50X, T51X, N52X, R53X, W54X, N55X, L56X, Q57X, 558X, L59X, L60X, L61X, S62X, A63X, Q64X, I65X, T66X, G67X, M68X, T69X, V70X, T71X, I72X, K73X, T74X, N75X, A76X, C77X, H78X, N79X, .G80X, G81X, G82X, F83X, S84X, E85X, V86X, I87X, F88X, R89X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X'' represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant Shiga toxin Beta subunit with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its carbohydrate binding activity.
Mutants of verotoxin (Shiya-like toxin) beta subunit from E. coli The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of Shiga-like toxin Beta subunit from E. coli NCBI Accession No. G1:4877349 without deleterious effect to the carbohydrate binding affinity for globotriaosyl ceramide, Gb3 or blood group P1 antigenic trisaccharide of the recombinantly produced molecule. Such mutations include: M1X, K2X, K3X, I4X, FSX, V6X, A7X, ABX, L9X, F10X, AllX, F12X, V13X, 514X, V15X, N16X, A17X, M18X, A19X, A20X, D21X, C22X, A23X, K24X, G25X, K26X, I27X, E28X, F29X, S30X, K31X, Y32X, N33X, E34X, N35X, D36X, T37X, F38X, T39X, V40X, K41X, V42X, A43X, G44X, K45X, E46X, Y47X, W48X, T49X, N50X, R51 X, W52X, N53X, L54X, Q55X, P56X, L57X, L58X, Q59X, S60X, A61X, Q62X, L63X, T64X, 665X, M66X, T67X, V68X, T69X, I70X, K71X, S72X, N73X, T74X, C75X, A76X, S77X, G78X, S79X, G80X, FBIX, A82X, E83X, V84X, Q85X, F86X, N87X, N88X, D89X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X"
represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant Shiga-like toxin Beta subunit from E. coli with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its carbohydrate binding activity.
Mutants of ~ertussis toxin B subunits The amino acid substitutions contemplated in the invention encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of pertussis toxin S2 subunit NCBI Accession No. GI:144070 without deleterious effect to the ganglioside (sialoglycoproteins) binding affinity of the recombinantly produced molecule.
Such mutations include: MlX, P2X, I3X, D4X, RSX, K6X, T7X, LBX, C9X, H10X, L11X, L12X, S13X, V14X, L15X, P16X, L17X, A18X, L19X, L20X, 621X, S22X, H23X, V24X, A25X, 826X, A27X, 528X, T29X, P30X, 631X, I32X, V33X, I34X, P35X, P36X, Q37X, E38X, Q39X, I40X, T41X, Q42X, H43X, 644X, S45X, P46X, Y47X, 648X, 849X, CSOX, A51X, N52X, K53X, T54X, RSSX, A56X, L57X, T58X, V59X, A60X, E61X, L62X, 863X, 664X, S65X, 666X, D67X, L68X, Q69X, E70X, Y71X, L72X, 873X, H74X, V75X, T76X, 877X, 678X, W79X, S80X, I81X, F82X, A83X; L84X, Y85X, D86X, 687X, T88X, Y89X, L90X, 691X, 692X, E93X, Y94X, 695X, 696X, V97X, I98X, K99X, D 100X, G 1 O l X, T 102X, P 103 X, G 104X, G 105X, A
106X, F 107X, D108X, L109X, K110X, T111X, T112X, F113X, C114X, I115X, M116X, T117X, T118X, 8119X, N120X, T121X, 6122X, Q123X, P124X, A125X, T126X, D127X, H128X, Y129X, Y130X, S131X, N132X, V133X, T134X, A135X, T136X, 8137X, L138X, L139X, 5140X, 5141X, T142X, N143X, S144X, 8145X, L146X, C147X, A148X, V149X, FISOX, V151X, 8152X, S153X, 6154X, Q155X, P156X, V157X, I158X, 6159X, A160X, C161X, T162X, S163X, P164X, Y165X, D166X, 6167X, K 168X, Y 169X, W 170X, S 171 X, M 172X, Y 173 X, S 174X, 8175X, L 176X, 8177X, K 178X, M 179X, L 180X, Y 181 X, L I 82X, I 183X, Y 184X, V 185 X, A I 86X, G 187X, I
188X, S 189X, V 190X, R I 91 X, V 192X, H 193X, V 194X, S 195X, K 196X, E 197X, E 198X, Q 199X, Y200X, Y201 X, D202X, Y203X, E204X, D205X, A206X, T207X, F208X, E209X, T210X, Y211X, A212X, L213X, T214X, 6215X, I216X, S217X, I218X, C219X, N220X, P221X, 6222X, 5223X, S224X, L225X, C226X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant pertussis toxin S2 subunit with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside (sialoglycoproteins) binding activity.
The amino acid substitutions encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of pertussis toxin S3 subunit NCBI Accession No.
6I:144070 without deleterious effect to the ganglioside (sialoglycoproteins) binding affinity of the recombinantly produced molecule. Such mutations include: MIX, L2X, I3X, N4X, NSX, K6X, K7X, LBX, L9X, H10X, H11X, I12X, L13X, P14X, I15X, L16X, V17X, L18X, A19X, L20X, L21X, 622X, M23X, 824X, T25X, A26X, Q27X, A28X, V29X, A30X, P31X, 632X, I33X, V34X. I35X, P36X, P37X, K38X, A39X, L40X, F41X. T42X, Q43X, Q44X, 645X, 646X, A47X, Y48X, 649X, RS OX, CS1X, P52X, N53X, 654X, TSSX, 856X, A57X, L58X, T59X, V60X, A61X, E62X, L63X, 864X, 665X, N66X, A67X, E68X, L69X, Q70X, T71X, Y72X, L73X, 874X, Q75X, I76X, T77X, P78X, 679X, W80X, S81X, I82X, Y83X, 684X, L85X, Y86X, D87X, 688X, T89X, Y90X, L91X, 692X, Q93X, A94X, Y95X, 696X, 697X, I98X, I99X, K100X, DlOlX, A102X, P103X, P104X, 6105X, A106X, 6107X, F108X, I109X, Y110X, R111X, E112X, T113X, F114X, C115X, I116X, T117X, T118X, I119X, Y120X, K121X, T122X, 6123X, Q124X, P125X, A126X, A127X, D128X, H129X, Y130X, Y131X, S132X, K133X, V134X, T135X, A136X, T137X, R138X, L139X, L140X, A141X, S142X, T143X, N144X, 5145X, R146X, L147X, C148X, A149X, V150X, F151X, V152X, R153X, D154X, 6155X, Q156X, 5157X, V158X, I159X, 6160X, A161X, C162X, A163X, 5164X, P165X, Y166X, E167X, 6168X, R169X, Y170X, R171X, D172X, M173X, Y174X, D175X, A176X, L177X, R178X, R179X, L180X, L181X, Y182X, M183X, I184X, Y 185X, M I 86X, S 187X, G 188X, L I 89X, A 190X, V 19 I X, R 192X, V 193 X, H
194X, V 195X, S 196X, K196X, E197X, E198X, Q199X, Y200X, Y201X, D202X, Y203X, E204X, D205X, A206X, T207X, F208X, Q209X, T210X, Y211 X, A212X, L213X, T214X, 6215X, I216X, S217X, L218X, C219X, N220X, P221X, A222X, A223X, S224X, I225X, C226X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant pertussis toxin S3 subunit with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside (sialoglycoproteins) binding activity.
The amino acid substitutions further encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of pertussis toxin S4 subunit NCBI Accession No. 6I:144070 without deleterious effect to the ganglioside (sialoglycoproteins) binding affinity of the recombinantly produced molecule. Such mutations include: MIX, L2X, R3 X, R4X, FSX, P6X, T7X, RBX, T9X, T10X, Al IX, P12X, 63X, Q14X, 615X, 616X, A17X, R18X, R19X, S20X, R21X, V22X, R23X, A24X, L25X, A26X, W27X, L28X, L29X, A30X, S31X, 632X, A33X, M34X, T35X, H36X, L37X, S38X, P39X, A40X, L41X, A42X, D43X, V44X, P45X, Y46X, V47X, L48X, V49X, K50X, T51X, N52X, M53X, V54X, V55X, T56X, S57X, V58X, A59X, M60X, K61X, P62X, Y63X, E64X, V65X, T66X, P67X, T68X, R69X, M70X, L71X, V72X, C73X, 674X, I75X, A76X, A77X, K78X, L79X, 680X, A81X, A82X, A83X, S84X, 585X, P86X, D87X, A88X, H89X, V90X, P91X, F92X, C93X, F94X, 695X, K96X, D97X, L98X, K99X, R100X, P101X, 6102X, S103X, S104X, P105X, M106X, E107X, V108X, M109X, L110X, R111X, A112X, Vl 13X, F114X, M115X, Q116X, Q117X, R118X, P119X, L120X, R121X, M122X, F123X, L124X, 6125X, P126X, K127X, Q128X, L129X, T130X, F131X, E132X, 6133X, K134X, P135X, A136X, L137X, E138X, L139X, 1140X, R141X, M142X, V143X, E144X, C145X, S146X, 6147X, K148X, Q149X, DISOX, C151X, P152X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant pertussis toxin S4 subunit with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site, retains its ganglioside (sialoglycoproteins) binding activity.
The amino acid substitutions contemplated in the invention likewise encompass any such substitution, deletion, or insertion that selectively alters the conjugation characteristics of pertussis toxin SS subunit NCBI Accession No. 61:144070 without deleterious effect to the ganglioside (sialoglycoproteins) blildlllg affinity of the recombinantly produced molecule. Such mutations include: M1X, Q2X, R3X, Q4X, ASX, 66X, L7X, PBX, L9X, K10X, A11X, N12X, Pl3X, M14X, H15X, T16X, I17X, A18X, S19X, I20X, L21X, L22X, S23X, V24X, L25X, 626X, I27X, Y28X, S29X, P30X, A31X, D32X, V33X, A34X, 635X, L36X, P37X, T38X, H39X, L40X, Y41X, K42X, N43X, F44X, T45X, V46X, Q47X, E48X, L49X, ASOX, LSIX, K52X, L53X, K54X, GSSX, K56X, N57X, Q58X, E59X, F60X, C61X, L62X, T63X, A64X, F65X, M66X, 567X, 668X, R69X, S70X, L71 X, V72X, R73X, A74X, C75X, L76X, S77X, D78X, A79X, 680X, H81X, E82X, H83X, D84X, T85X, W86X, F87X, D88X, T89X, M90X, L91X, 692X, F93X, A94X, I95X, S96X, A97X, Y98X, A99X, L100X, KIO1X, S102X, R103X, 1104X, AIOSX, L106X, T107X, V108X, E109X, D110X, S111X, P112X, Y113X, P114X, GI15X, T116X, P117X, 6118X, D119X, L120X, L121X, E122X, L123X, Q124X, I125X, C126X, P127X, L128X, N129X, 6130X, Y131X, C132X, E133X, wherein the first letter is the native amino acid appearing at the position of the indicated number, and the last letter is the amino acid substituted for the native amino acid. The "X" represents the deletion or replacement of any amino acid residue that, when introduced in place of the wild type amino acid residue, results in a mutant or variant pertussis toxin SS subunit with altered characteristics for covalent modification or conjugation and, when coupled to bioactive compounds at that site. retains its ganglioside (sialoglycoproteins) binding activity.
Lysine Substitutions in the rCTB, rLTB, ShiQa, Shiga-like, and pertussis family Conjugation of members of the rCTB, rLTB, Shiga, Shiga-like, and pertussis family to immunogens derived from infectious diseases can create vaccines which induce protection following mucosal delivery. Classic conjugation chemistry targets are reactive amino acid side chain groups such as primary amines, carboxylic acids, aldehydes, or sulfllydryls. The lysine residues are distributed at various places throughout the sequence. Those lysine residues that are near the Gm-1 binding site can couple to the ligand in a conformation which interferes with ganglioside binding. Accordingly, the invention articulates a number of mutant conjugation characteristics, primarily at lysine residues found in the rCTB protein family.
Therefore, the present approach involves the idea of directing the covalent linkage of carrier and immunogen away from the ganglioside receptor of CTB family. Site directed mutagenesis is employed to create a panel of mutations at various lysines of the rCTB family coding sequences. These mutations will result in mutants which produce variable levels of protein, in vitro, comparable to those of the wild type and which can effectively deliver bioactive CTB-immunogen complexes to the mucosal immune system.
Accordingly, the invention articulates a number of mutant rCTB family proteins that with amino acid substitutions that replace the lysine residues found in the wild type rCTB family protein.
Preferably, the following amino acid substitutions are contemplated for rCTB
family proteins GI:758351, 808900, 2144685, and 48890 (wherein "X" is any amino acid that results in a rCTB
protein with a reduced ability to conjugate at the mutant sites): K44X, KSSX, K64X, K83X, K84X, K90X, K102X, K105X, and KI 12X. For rCTB family proteins 61:1827850, 998409, and 142151 l, preferably K34X, K43X, K62X, K63X, K69X, K81X, K84X, and K91X. For rCTB family proteins GI: 229616, preferably K43X, K63X, K69X, K81, K84X, and K91X. For rCTB family protein GI:
2781121, preferably K35X, K44X, K62X, K69X, K81X, K84X, and K91X. For rCTB
family protein GI:1421525. preferably K43X, K62X, K63X, K69X. K81X, K91X. For all rCTB family B subunit proteins if they have a lysine at position 91, most preferably K91X.
For LTB and the LTB family proteins GI:3062900, 1169505, 1395122, 145833, 1648865, 223254, 408996, and 69630 wherein "X" is any amino acid that results in a protein with a reduced ability to conjugate at the mutant sites, K44X, KSSX, K64X, K83X, K84X, K90X, K102X, and KlOSX. For LTB family protein 494265 preferably K34X, K43X, K62X, K63X, K69X, K81X, K84X, and K91X. For all LTB family proteins if they have a lysine at position 91, most preferably For LT-IIa protein GI:146671 wherein "X" is any amino acid that results in a protein with a reduced ability to conjugate at the mutant sites, K47X, K48X, K89X, K100X, and K107X.
For LT-IIb protein GI:576584 wherein "X" is any amino acid that results in a protein with a reduced ability to conjugate at the mutant sites, K48X, K76X, and K89X.
For Shiga toxin beta subunit protein GI:152784 wherein "X" is any amino acid that results in a protein with a reduced ability to conjugate at the mutant sites, I<43X, K47X, and K73X.
For Shiga-like toxin from E.coli subunit B protein 61:4877349 wherein "X" is any amino acid that results in a protein with a reduced ability to conjugate at the mutant sites, K41X, K45X, and K71 X.
For pertussis toxin protein GI:144070 wherein "X" is any amino acid that results in a protein with a reduced ability to conjugate at the mutant sites subunit S2: K98X, K167X, K177X, K195X.
S3: K38X, K100X, K121X, K133X, and K196X. S4: KSOX, K61X, K78X, K96X, K99X, K127X, K134X, and K148X. S5: K42X, K52X, K54X, K56X, and K101X.
Lysine additions in rCTB family subunits The invention further contemplates the addition of amino acid residues throughout the amino acid sequence of the rCTB family, the LTB family, Shiga toxin, Shiga-like toxin, and pertussis toxin to direct conjugation of various bioactive compounds such as immunogens, immunomodulators, or drugs to specified sites. Any residue can be mutated to introduce amino acid residues that promotes acceptable conjugation events.
Hydrophobic coupling of rCTB
Although chemical coupling is an excellent way to produce Gm-1 targeted immunogens, it would be highly advantageous to alter rCTB in such a way that it no longer requires chemical coupling, but instead strongly binds to other proteins or immunogens non-covalently. As an example, if rCTB could be prenylated it would then display up to 5 hydrophobic isoprene tails per pentamer. It is expected that in the properly folded and assembled protein, these tails would be present on the surface of the protein in opposite orientation to the Gm-1 binding surfaces. The commonly occurring isoprene groups include farnesyl, geranyl, geranyl-geranyl;
all other IS prenylation or hydrophobic modification are considered to achieve the same outcome. Cholera toxin thus modified is expected to have an affinity for hydrophobic structures and surfaces.
Prenylated rCTB would bind to bacterial cell walls, cell membranes, virus membrane coats, and other hydrophobic structures such as hydrophobic proteins and hydrophobic phospholipids or adjuvants. The isoprene groups on rCTB would spontaneously insert into any lipid membrane, or hydrophobic miscelle, to non-covalently associate rCTB with the hydrophobic structure in such a manner as to present the ligand binding site of rCTB on the outer surface of the micelle. This concept could be applied to making conjugates between rCTB and vaccine antigens or to promote ganglioside specificity in microsome or liposome delivery systems.
Prenylation naturally occurs on selected proteins in eukaryotic cells, such as GTP binding proteins. The post-translational modification of proteins occurs at the C-Terminus, with a consensus sequence of CAAX (SEQ ID NO: 34) where C=cysteine, A=aliphatic amino acid, and X=any amino acid. The isoprenyl group is attached to the cysteine via a thioether link and after modification the cysteine becomes the last amino acid in the sequence. Other post-translational modifications such as modification of proteins with lipids, fatty acids, and glycosyl phospholipids also occur and could potentially serve the same purpose as prenylation.
In one embodiment, the gene for cholera toxin B is modified to include a prenylation signal that would permit in vitro prenylation. This may include a C-terminal cysteine, C-terminal CAAX box sequence (SEQ ID NO: 34), or any other sequence necessary or sufficient to achieve irr vitro or in vivo prenylation. A plasmid containing the mutant cholera toxin B
gene is transfected into a suitable host for expression. For example, a high expression rCTB
vector is used to express the mutated rCTB in bacteria. Once the mutated rCTB has been expressed and purified, it is used as a substrate for i~ vitro prenylation. In vitro prenylation is performed with the appropriate prenylation enzymes and substrates. The prenylated rCTB product is purified as necessary and used to produce the desired conjugated product. Alternatively, if the prenylation reactions permit, prenylation of rCTB is performed in the presence of the conjugation partner thus allowing immediate binding of the modified rCTB to the immunogen or vaccine. This may serve to stabilize prenylated rCTB or facilitate production and purification.
An alternative embodiment involves co-transfecting bacterial or eukaryotic cells to produce rCTB and the necessary proteins for prenylation. In this embodiment it may be necessary to construct the proteins for the special requirements of each system. For example, in any expression system both the rCTB and prenylation proteins may need to be targeted to the same compartment for efficient prenylation. This could be the cytoplasm, periplasm, or extracellular milieu of bacterial, or the cytoplasm, any of the secretory compartments or other organelles in eukaryotic expression systems.
Confirmation of hydrophobic coupling, purification, and Gm-1 binding assays would be performed essentially the same as chemically coupled rCTB, with variations in buffer and pH.
Vaccination would also be performed in essentially the same way.
Vaccines These concepts have been contemplated as methods for producing cholera toxin B
based vaccines. In particular, these prenyl-rCTB constructs lend themselves to whole cell, whole virus, or hydrophobic particle vaccine conjugates. Vaccines contemplated include influenza virus vaccines, both whole and split, because influenza virus acquires a membrane coat and is thus capable of binding prenyl-rCTB to the membrane coat. The split virus vaccines commonly contain the membrane coat protein hemagglutinin. This protein binds to prenyl-rCTB
through hydrophobic patches on its surface. Another suitable vaccine is whole cell pertussis, where prenyl-CTB could insert the hydrophobic groups into the outer membrane of B. pertussis. Also, hydrophobic particles such as water in oil emulsion based vaccines and liposome based vaccines would be attractive candidates for this technology.
Genetic fusion of rCTB with an immuno~en Another option for production of an rCTB coupled immunogen is genetic fusion.
Genetic fusion would occur using a vector that contains a promoter for expressing the fusion protein, the DNA sequence of the cholera toxin binding subunit rCTB, and an immunogenic peptide coding sequence. The rCTB and the immunogenic peptide coding sequence would be linked such that they were in the proper reading frame producing a fusion protein. The fusion protein would be expressed, secreted, and purified for use as a vaccine. rCTB fusion proteins are as shown in Table 2.
TABLE 2: CTB FUSION PROTEINS
Expression level Plasmid Bacterial Product Form Protein host (pg/m1) NH2-GST-linker 717 GST 1.10*XL-1 Inclusion 96 bodies # 1-A8V D4-C
NH2-GST-linker 717 GST2.9**XL-I Inclusion 58 bodies #2-A8V D4-CT
CTB with internal P55-64gp12***V. choleraSecreted 110 HIV epitope * Other antigenic sequences may be substituted for A8VD4. Linker is GAI'AS
(SEQ ID NO 34).
** Other antigenic sequences may be substituted for A8VD4. Linker is PGSTRAADRDGAPAS (SEQ ID
NO: 35).
*** HIV epitope is flanked by Kpnl and Mscl restriction enzyme sites, allowing easy insertion of other coding sequences into CTB.
rCTB vaccines Microorganisms which invade via mucosal membrane surfaces are the best targets for rCTB vaccines. However, it could be used for almost any type of vaccine.
Examples of diseases and antigens that could be coupled to rCTB for production of a vaccine are listed below in Table 3.
As mentioned above, larger, whole and killed cell vaccines or whole virus vaccines could be produced particularly using the hydrophobic coupling. Vaccines which couple the rCTB protein in some way to an immunogen of choice would be particularly useful for any type of disease which is targeted to mucosal surfaces.
Production of a specific vaccine involves the steps of 1 ) identifying an antigen or immunogen; 2) coupling the antigen or immunogen to rCTB in some way (chemically, hydrophobically, or genetically); 3) isolating the coupled rCTB/immunogen and confirming that it still binds to Gm-1; 4) identifying that it works in vivo by injecting it into a mouse or other model animal; and 5) testing it for efficacy in humans or other primates. Examples of vaccine targets are shown in Table 3 with potential antigens.
TABLE 3: HUMAN INFECTIOUS DISEASES AND VACCINE ANTIGENS
Oral/Intestinal Exemplary Infectious agent Diseases Antigen Urease, 50 kDa citrate synthatase H. pylori homologue protein, bacterial lysates, whole organisms E. coli LPS, enterotoxin type I, II, whole organisms v cholera Killed bacteria, avirulent live VP2, VP4, VP6, VP7, whole viral Rotavirus particles, VLPs Salmonella Whole or fragments of organism typhi Shigella dysenteriaWhole or fragments of organism Respiratory Diseases H. influenza Current vaccines are conjugates RSV F/G protein,whole viral particles, VLPs CorynebacteriaToxoid, whole or fragments of organism diphtheria Bordetella Toxoid, filamentous hemagglutinin, pertussis pilus, (Whooping cough)pe~actin, Sl subunits serotypes, whole or fragments of organism Polysaccharide ags (23) 23 most common Streptococcus serotypes of 90 capsular serotypes currently targeted. New vaccines target 7-I1 serotypes pneumonia bound to a protein carrier, whole or fragments of organism Killed, lysates, HA(hemagglutinin), NA
Influenza virus(neuraminidase), trivalent or more based on most common serotypes that year;
whole virus Anthrax Whole or fragments of organism Urogenital diseases (STD's) Gp4l, Gp120 env, Gp160env, Tat protein, HIV multiepitope polypeptide TAB9, Gag, Pol, and Env proteins Chlamydia Whole or fragments of organism Treponema 47 kDa antigen, whole or fragments of pallidum (Syphilis)organism Neisseria gonorrheawhole or fragments of organism Herpes ~ whole viral particles, VLPs, Tk Use of rCTB in treatment of autoimmunitv and the induction of tolerance Autoantigen specific peripheral T cell tolerance is induced by CTB-autoantigen conjugates. Peripheral tolerance suppresses autoinf7ammatory disease by down regulating Thl.
CTB-autoantigens can even reverse existing inflammatory cell proliferation in animals.
Autoimmune diseases considered for treatment using CTB include without limitation: rheumatoid arthritis, encephalomyelitis (or other neuron demyelinating diseases), diabetes, and female anti paternal immuno-contraception.
Reversal of inflammatory cell proliferation (thl tolerization) was shown in autoimmune models for diabetes in NOD mice (insulin-CTB conjugates; Bergerot et al. PNAS
1997 94:4610-14.). Additionally it was shown for rheumatoid arthritis (HSP 60, Haque et al.
1996 EurJImnZUnol 26:2650-2656; collagen type II conjugates) and experimental autoimmune encephalomyelitis (EAE) in Lewis rats (Sun et al., Myelin basic protein MBP-peptide CTB
conjugate, 1996 PNAS
93:7196-7201). These conjugates were fed as single doses to animals before and after induction of disease.
It is contemplated that the rCTB of the invention can be chemically, hydrophobically, or genetically coupled to the above-mentioned antigens and fed to animal models to test the efficacy.
It is believed that because such a treatment was effective in the above examples it will be as effective or more so using the advantageous rCTB of the invention.
Additionally, the rCTB
conjugates of the invention are easier to make, more likely to work because the site of conjugation can be controlled, and yield a higher percentage of conjugated products that in turn will induce both a systemic and mucosal response.
The rCTB or other B subunits of the invention can also be used to induce tolerance to infection. For example, tolerization may be induced by administering the Leshmania major produced immunodominant antigen LACK, which generates a CD4+ T cell dominant response and drives a th2 response to associated antigens. Th2 facilitates lesion development and leads to unresolved infection. LACK+ transgenic mice are tolerant of LACK and resolve infection. LACK
fed animals are tolerized and resolve infection. ( McSorley et al, Eur.J.Immunol. 1998, 28:424-32.) showed that CTB-LACK, fed or given nasally, down regulated the T cell proliferative response to LACK and allowed animals to resolve (fight off) disease more effectively.
Additionally, responses to diseases associated with the development of acute autoimmunity such as Reiter's syndrome or Lyme disease can be treated with tolerizing conjugates.
EXAMPLES
Expression and Purification of Mutant rCTB
Production of Recombinant CTB in Bacteria The expression plasmid MS-0 (see Figure 2) was used to express rCTB and variants. MS-0 containing the rCTB gene is named pML-CTBtacl. The plasmid pML-CTBtacl surprisingly generates up to five times the product which was generated by a comparable plasmid (SBL's vector pJS I 62). PML-CTBtac 1 was constructed by cloning a portion of the CTB
genomic region and the complete CTB coding region into plasmid MS-0 creating a 3.66 Kb expression plasmid. The PvuII
site in the polylinker was destroyed during cloning. The plasmid contains a tac promoter from pKK223, an EcoRI-BamHI polylinker fragment, and can be found at genbank accession No M77749.
The encoded protein is identical to the sequence from V. cholera strain 5698 (SEQ ID NO: 2). The signal sequence (SEQ ID NO: 3) is also from the CTB V. cholera classic strain 569B CTB gene. The complete nucleotide sequence of V. cholera strain 5698 CTB gene is shown in Figure 1 (SEQ ID
NO:1). The signal sequence for LTB (SEQ ID N0:15) is MNKVKCYVLFTALLSSLCAYG and can be used in the production of mutants or variants of LTB.
Measurement of Expression Level of rCTB mutant or variant It is advantageous to purify large quantities of the immunogen of interest quickly, easily and inexpensively. Accordingly, the ability to isolate milligram quantities of rCTB and rCTB variants for use in production of vaccines is discussed below.
A protocol for the isolation of rCTB and rCTB variants from shaker flasks is presented.
Surprisingly, is was possible to obtain up to 800 yg of rCTB per ml of culture supernatant. Many recombinant expression systems are considered very productive with yields exceeding 10 ~g/ml. The expression level of rCTB mutants thus far produced are moderately lower than wild type.
The concentration of all proteins tested is measured by comparison to a standard curve of rCTB at defined concentrations in the Gm-1 ELISA. The values recorded for a serial dilution of the unknown sample are then used to determine the sample concentration which is then multiplied by the dilution factor to obtain the correct concentration of the unknown sample.
One limitation of the Gm-1 ELISA is that it only identifies the relative binding concentrations of wild type vs. mutant rCTB. Thus, actual concentrations must be confirmed by .280 or by Lowry, Bradford, BCA or similar colorimetric protein assays known by those practiced in the art.
Any mutation to the rCTB sequence might result in an increase or decrease in receptor binding affinity for Gm-1 and other ligands (Backstrom et al. 1997 Mol Microbiol 24:489-497;
Merritt et al. 1995 Structure 3:561-570). Any significant change in receptor affinity of a newly created mutant rCTB for Gm-1 may cause the loss of binding in a Gm-1 ELISA and result an "apparent" decrease in concentration. In such case, each test protein is initially purified to homogeneity using methods discussed below. From these, the purity is demonstrated by comassie or silver stained polyacrylamide gel electrophoresis, a technique well known in the art. The relative concentration of each protein is determined by X280 and confirmed by protein concentration assays. Equivalent concentrations of each protein. sufficient to saturate the ganglioside moiety (e.g. ~50 pg/ml), are incubated in a Gm-1 ELISA plate. A
two-fold serial dilution of each mutant or unlabeled wild type protein is then incubated in solution with a constant concentration of horse radish peroxidase labeled wild type CTB (at concentrations which alone generate a maximum signal, usually >~10 ug/ml). From this assay, a standard curve for each mutant can be generated and compared to a similar curve for unlabeled wild type (positive standard curve control). Discrepancies from the positive standard curve control reflect significant changes in the affinity of the mutant rCTB for gm-1. The difference between curves can be quantified to determine the quantitative differences in affinity assuming the wild type affinity of 4.6x10-12M.
Purification of rCTB and rCTB variants A number of CTB purification protocols are available and known in the art.
Three purification methods are discussed below.
Ammonium Sulphate Precipitation of rCTB
This procedure worked well for cultures grown in baffled shaker flasks containing 100-500 pg/ml rCTB in the supernatant. Culture volumes between 50-250 ml have been successfully processed using this protocol. The supernatant was processed immediately after growth and clarification of the culture.
Briefly, the bacteria expressing rCTB or mutants of rCTB were grown in a shaker flask.
I S The supernatant was clarified by centrifuging the cells at 7000 x g (avg.) for 15 min at 4°C into a pellet. A step wise precipitation of protein with increasing concentrations of ammonium sultate results in highly purified rCTB product. Accordingly, ammonium sulfate was gradually added to the culture supernatant to bring the ammonium sulfate concentration up to 30%
(vol/vol) while stirring at room temperature. After 1 hour of precipitation without stirring, the sample was centrifuged at 14,000 x g (avg.) for 15 minutes at 4°C. The supernatant was removed and a concentrated ammonium sulfate solution was added to bring the concentration to 50% (vol/vol) while stirring. This mixture was allowed to stand at room temperature for 1 hour. The sample was again centrifuged at 14.000 x g (avg.) for 15 min at 4°C. A third precipitation step was performed, bringing the concentration up to 65% ( 101 g/L total volume). This mixture was again stirred and allowed to stand for 1 hour before centrifugation as before. The pellet of highly purified rCTB was then resuspended in a suitable buffer, for example, if additional purification by ion exchange chromatography is desired, the sample was brought up in 10 mM NaP04 buffer.
The sample was then placed in dialysis tubing (7000 MWCO). If the sample is not immediately used, it can be stored undialyzed for up to one month at 4°C until ready to use. When dialysis was performed, one-liter volumes of buffer were used for at least one hour each, changing the buffer three times.
Purification of rCTB by DEAE Ion-exchange Chromatography This part of the protocol applies specifically to ammonium sulfate precipitated rCTB. A
DEAE Sepharose Fast Flow gel of choice was packed on an Amersham Pharmacia Biotech column following the manufacturer's directions. 15 ml of a well-mixed gel slurry produced about 10 ml bed volume. The flow rate for packing was at least 4 ml/min. A column size of 1.5 cm (inner diameter) and 20 cm (length) with a bed volume of 10 ml bound approximately 30 mg of rCTB
from culture processed by ammonium sulfate precipitate. A flow rate adapter was used with the column. The column was washed with 1 M NaCI to activate the column bed, or 2 M
NaCI to regenerate a spent column bed. The flow rate for all washes did not exceed 75%
of the packing rate, or 3 ml/min. The column was extensively equilibrated with Buffer A (10 mM Sodium Phosphate Buffer, pH 7.5) to remove all salt. The sample containing rCTB was applied at a rate of 1-1.5 ml/min. Each fractions was tested for the presence of rCTB. Following sample application, the column was washed with Buffer A at a flow rate of 3 ml/min until the optical density at 1280 dropped below 0.02, confirming the removal of all non-specific and cationic species. The column was washed with Buffer A containing 50 mM NaCI, until the optical density at A280 dropped below 0.02. RCTB was eluted from the column with Buffer A containing 100 mM
NaCI. All fractions were collected and pooled. Approximately 80% of the total column bound rCTB was recovered in these fractions. The column was washed with Buffer A containing 1 M NaCI until the optical density at x.280 dropped belong 0.02. Before regeneration of the column, the DEAE bed was washed with 10 mM sodium phosphate, pH 7.5 to remove all of the salt.
Alternatively, CTB
bound to the DEAE column can be eluted with a salt gradient from 0.02M NaCI to 1 M NaCI in buffer A. Fractions containing rCTB are pooled, dialyzed or concentrated in the buffer of choice.
Detailed protocol for purification of rCTB using affinity chromatography on a ~anglioside-Affi~el column In this technique, clarified bacterial culture supernatant was directly poured onto the column. rCTB or rCTB mutants bound specifically to the immobilized gangliosides and the column was washed. rCTB was then eluted with 5M guanidine thiocyanite and dialyzed against a phosphate buffer. This technique was very easy and a high purity was achieved.
However, there was a limited capacity of approximately 7 mg rCTB per run and it required denatured protein to be able to fold properly, which may be a problem with some mutants.
The Ganglioside-Affigel columns were produced using Affigel (Pierce, Rockford, IL).
The smaller Ganglioside-Affigel column (0.5 ml bed volume) had the capacity to bind 1-2 mg of rCTB, while the larger (5 ml bed volume) will bind at least 7 mg. The following buffers were used: 0.1 M Na-phosphate buffer, pH 7.5; 0.1 M Na-phosphate buffer, pH 7.5, 0.5 M Na C1; 5 M
guanidine thiocyanite in DI water, freshly made in a 50 ml conical tube.
The culture supernatant was centrifuged at 10,000 rpm for 10 min (SS-34).
Particulate matter was avoided as it clogs the column. The column was equilibrated with 0.1 M Na-phosphate buffer, pH (2-5 column volumes). The sample containing rCTB was added and the flow through was collected and applied once more to allow quantitative binding to the column. The column was washed with 0.1 M Na-phosphate buffer, pH 7.5 until the X280 was close to 0, the column was washed again with 0.1 M Na-phosphate buffer, pH 7.5, 0.5 M NaCI until the A280 was close to 0.
The column was equilibrated with 0.1 M Na-phosphate buffer, pH 7.5 (2 column volumes). Fresh guanidine thiocyanite solution was prepared in 1 ml steps, 1 ml fractions were collected. The column was allowed to sit for 10 min after addition of the first two I ml additions of the elution buffer to the column. This ensured complete elution of rCTB from the ganglioside resin. The X280 containing fractions were pooled and dialyzed against 500 ml of 0.1 M Na-phosphate buffer, pH 7.4, with no stirring. A total of 4 buffer changes were performed with the last two in the desired buffer in which to store the protein.
Optionally, rCtB can be purified by canon exchange on a CM Sepharose Fast Flow ion exchange column. Briefly, NH4S04 salt precipitated or DEAE eluted rCTB can be dialyzed against 20 mM Tris-HC1, 10 mM NaCI, pH 8.4 and the dialysate applied to the column.
After washing, a highly purified rCtB product can be eluted with a continuous salt gradient of 10 mM to 300 mM NaCI in 20 mM Tris-HC1, pH 8.4.
This method resolves the remaining few contaminant products we see following DEAE
I S anion exchange chromatography.
Muta~enesis of rCTB
Mutagenesis was initially performed by oligonucleotide-directed in vitro mutagenesis according to Kunkel, TA, Roberts, J., and Zakour, R. "Rapid and efficient site-specific mutagenesis without phenotypic selection", Methods Enzymol., 154, 367-382, 1987.
Subsequently mutagenesis was performed essentially according to Nelson, M. and McClelland, M., Methods Enzymol. 216, 279-303, 1992. The results of the mutagenesis were confirmed by DNA
sequencing.
Lysine Mutation of rCTB
The following mutant rCTB proteins are made using the methods described in Example 2.
A lysine residue is inserted into the rCTB sequence of SEQ ID NO 2 to replace amino acid Asn 103. Asparagine's polarity comes from an amino side chain which is uncharged at neutral pH.
Replacement of Asn 103 with a lysine may prove to be an effective and novel conjugation site. A
lysine residue is inserted into the rCTB sequence of SEQ ID NO 2 to replace the amino-terminal amino acid Ala 102. A lysine residue is inserted at position Alal. A lysine residue is inserted at position Pro2. Although this mutant changes the structure of the amino terminus, Gm-I binding affinity and antigenicity of the resulting composition is not compromised by the mutation.
Amino acids 14-20 form a [3-sheet on the outer surface of rCTB with many of the side chains facing outward. Of the amino acid residues that form this structure, His 18, is particularly suitable for mutagenesis. Accordingly, a mutant rCTB protein is generated having the mutation H18K. Substitution of His 13 for any other amino acid may effect Zn+2 binding characterisitics of rCTB as well as pentamer-pentamer self association. Elimination of either of these characteristics might be desired for purposes of biochemical isolation of the mutant proteins.
Determining Immunoaenicity of rCTB Mutants Coupled to Immunogens Immunogenicity is determined by injection of the rCTB:Immunogen into balb/c mice. 1:1, 1:6, and 1:3 ratios of rCTB:immunogen conjugate are injected. Additionally, a control using immunogen alone is injected injected. After ten days, blood is drawn from the immunized mice and antibodies to the rCTB:immunogen conjugate are identified and measured via an antibody assaying protocol such as ELISA or any other suitable assay widely known by one of skill in the art.
Chemical Coupling of Mutant rCTB Proteins to an Immuno;~.,en Lysine residues Mutant CTB proteins CTB K91G and CTB-K62G, 63G, 91G were modified, expressed, and purified using the method described in Examples 1-2. Mutation of K91 was chosen as a site for substitution because of its proximity to the Gm-I binding site of CTB and it known interaction with the terminal glactose of Gm-1. Further, as discussed above, K91 is highly reactive with small molecular conjugates, such as FITC or SPDP. Accordingly, conjugations with heterobifunctional reagents are likely to create molecular complexes with diminished Gm-1 binding affinities. some important modifications to protocols which create a simpler, more efficient coupling reaction with SPDP. In brief, the pH of the conjugation must be > 8.0, and the SPDP (N-Succinimidyl 3-[2-pyridyldithio]propionate) modified rCTB and its associated molecule must be highly concentrated.
Employing these modifications, rCTB wild type was successfully coupled to bovine serum albumin (BSA) and to Diphtheria toxoid (Dt).
In contrast to established protocols, neither BSA nor Dt was SPDP modified prior to conjugation. These proteins were determined to have free sulfl~ydryl groups which will readily react with the SPDP modified rCTB.
Modification of rCTB using SPDP chemistry rCTB or variant rCTB was dialyzed into Borate-Phosphate buffer. Borate-Phosphate buffers: a lOX stock solution (2L) was made by adding 12.4 g. Boric acid, 175.3 g NaCI, and 136.09 g Potassium phosphate (monobasic) into 1.5 liters of water. The solution was adjusted to a pH of 6.6 with 5M KOH and then brought up to a final volume of 2 liters with water. The solution was filtered through 0.2 micron filter. The pH of a 1 X solution was 7Ø
Borate-Phosphate Buffer, pH 8.5 was 1X buffer adjusted with 5M KOH. The rCTB was modified using ten-fold molar excess of SPDP over rCTB. The SPDP was weighed and diluted to 5 mg/ml using anhydrous N,N-dimethylformamide (DMF), containing the molecular sieves (Grade 562, Type 3a, 4-8 mesh beads, Fisher Scientific, Tustin, CA). Thus, 25 p1 of 5 mg/ml SPDP would be added to a 2 mg rCTB/ml solution of rCTB. The SPDP and rCTB were incubated and allowed to react for at least 1 hour at room temperature.
Excess SPDP was removed by running a G-25 gel filtration column (1.5 cm x 9 cm bed volume is the minimum required to separate excess SPDP). 10 mM sodium phosphate buffer, pH
7.~ containing 50 mM NaCI was used for column running buffer. The SPDP
modified rCTB was concentrated by using Amicon centricon c-30 (30 kD cut-off) to a volume between 1-2 ml.
Coniu~ation of protein to SPDP modified rCTB
Unmodified protein (the immunogen - i.e. BSA or Dt) was dialyzed against 3 x volumes Borate-Phosphate buffer, pH 7Ø SPDP modified rCTB and unmodified protein (immunogen) were combined at selected molar ratios and incubated overnight.
The next the sample was concentrated using a Centricon 30 (30,000 MWCO Millipore, Bedford, MA).
Confirmation of Chemical Coupling The concentrated sample was separated into its component parts by gel electrophoresis on a 4-20% Tris-Glycine gel to confirm the formation of conjugates. A number of techniques can be used to confirm chemical coupling of the two proteins including: Gm-I ELISA
using immunogen-specific antibodies which recognize only immunogen when bound to rCTB, and molecular seive gel filtration.
Cysteine residues Mutant CTB proteins CTB-H18C and CTB-M101C were modified, expressed, and purified using the methods described in Examples 1-2. The rCTB proteins were treated with 100 mM DTT
for 2 hours at room temperature. DTT was removed by centrifugation for 2 min at 2000g through a I
ml spin column packed with Biogel P6 polyacrylamide gel (BioRad, Cambridge, MA), equilibrated with 25 mM sodium phosphate buffer pH 7.0/10 mM ethylenediaminetetraacetic acid (EDTA). The collected fraction was incubated for 2 hours at room temperature with maleimide-activated immunogen (i.e. immunogen functionalized with the cross-linker SMCC, Sigma).
The reaction was stopped by the addition of (3-mercaptoethanol ((3-me) to a final concentration of 1.5 mM and N-ethylmaleimide (NEM) suspended in N,N-dimethylformamide to a final concentration of 3 mM.
Confirmation of Chemical Coupling Conjugation of immunogen to rCTB was assessed by ELISA and Western blotting.
(I) ELISA: conjugates of Immunogen and rCTB were incubated with GLM1-coated microtitre plates and immobilized Immunogen was detected with the chromogenic substrate 3,3',5,5' tetramethylbenzidine (TMB, KPL). Detection of plate bound immunogen which was dependent on a coating of GM-I was interpreted as evidence that rCTB was physically linked to the Immunogen. (II) Western Blots:
conjugates were separated by electrophoresis on 7.5% SDS polyacrylamide gels and transferred to nitrocellulose. rCTB was detected with polyclonal anti-rCTB sera, followed by goat anti-mouse Ig alkaline phosphatase (A)(Amersham, Buckinghamshire, UK) and AP-specific substrate (BCIP/NBT, BioRad, Cambridge, MA). Immunogen was detected with antibodies specific to the immunogen, goat anti-mouse Ig-AP and BCIP/NBT.
Purification of immunogen-rCTB Conjugates Conjugates were purified by size exclusion chromatography based on the expected size of the conjugate. Additional purification was performed within a GM-1 or ganglioside affinity column to eliminate nonconjugated immunogen and within an antigen or immunogen specific column to eliminate residual free rCTB and rCTB-rCTB conjugates, respectively. This left only the bioactive conjugates which were assessed by SDS-PAGE and ELISA as described in Example 6.
Assaying Mutant rCTB Conjugated Complexes for Gm-1 Binding Relative to Wild Type rCTB
Maintenance of the ganglioside affinity by the GM-1 binding sites in mutant CTB, wild type CTB, or conjugates derived therefrom can be assayed by ELISA analysis. In the first example, the monosialoganglioside, GM-I, was used at a concentration of 0.3 nmol/ml PBS. One hundred microliters of ganglioside solution was added to each well of a 96 well microtiter plate and incubated overnight at 22°C. The following day, the plate was washed twice with PBS
utilizing a Bioplate Autowasher EL-404 (Bio-Tec Instruments, Winooski, VT).
All wells of the plate were then coated with 200 p1 of a 0.1% BSA in PBS solution for 30 minutes at 37°C. The plate was washed three times in PBS containing 0.05% tween-20 and evacuated of remaining solution. Al) wells, other than the initial test wells, received 100 ~I of a solution of 0.1% BSA, 0.05% tween-20 in PBS. Test wells then received 1 SO p1 of 15 pg CTB/ml test mutant, wild type, or conjugate. A three-fold serial dilution was then conducted across the plate, sequentially transferring and diluting 50 p1 from the second test well into 100 ~1 buffer in the third well and so on for up to twelve dilutions. The plate was incubated for 90 minutes at 22°C. The plate was then washed three times as described above. All wells then received either 100 p1 of a 1/20,000 dilution of mouse anti-rCTB antiserum or a pre-determined dilution of mouse anti-serum to the coupled compound. Wells were incubated one hour at 22°C and subsequently washed three times as above.
Test wells then received 100 ~l of a 1/3000 dilution of horseradish peroxidase conjugated goat anti-mouse IgG and were allowed to incubate one hour at 22°C. Plates were then washed again and incubated for 20 minutes with 100 p1 of a 1 mg/ml solution of othophenylenediamine dihydrochloride (OPD) and 0.01% H202 in 0.1 M sodium citrate buffer, pH 4.5.
50 p1 of a 3N
HC1 solution was then added to stop the enzymatic reaction. Plates were then read at 492 nm and 650 nm in a SpectroMax 250 microplate reader (Molecular Devices, Inc., Sunnyvale, CA). Results for mutants or conjugates thereof were reported as a function of endpoint dilution (apparent concentration) relative to wild type or conjugates thereof, respectively. The results indicated that mutated rCTB conjugated complexes retained their ability to bind to GM-1 binding sites.
SEQUENCE LISTING
<110> ACTIVE BIOTECH AB
HANDLEY, Harold H.
HAAPARANTA, Tapio EWALT, Karla L.
<120> AB5 TOXIN B SUBUNIT MUTANTS WITH ALTERED
CHEMICAL CONJUGATION CHARACTERISTICS
<130> ACTBI0.004VPC
<160> 31 <170> FastSEQ for Windows Version 4.0 <210> 1 <211> 373 <212> DNA
<213> Vibriocholera <220>
<221> CDS
<222> (1)...(373) <223> The gnalsequence V. olera c si from ch classi strain <400> 1 atg att ttaaaa tttggtgttttt tttacagtt ttacta tcttca 48 aaa Met Ile LeuLys PheGlyValPhe PheThrVal LeuLeu SerSer Lys gca tat catgga getectcaaaat attactgat ttgtgt gcagaa 96 gca Ala Tyr HisGly AlaProGlnAsn IleThrAsp LeuCys AlaGlu Ala tac cac acacaa atacatacgcta aatgataag atattt tcgtat 144 aac Tyr His ThrGln IleHisThrLeu AsnAspLys IiePhe SerTyr Asn aca gaa ctaget ggaaaaagagag atggetatc attact tttaag 192 tct Thr Glu LeuAla GlyLysArgGlu MetAlaIle IleThr PheLys Ser aat ggt actttt caagtagaagta ccaggtagt caacat atagat 240 gca Asn Gly ThrPhe GlnValGluVal ProGlySer GlnHis IleAsp Ala tca caa aaagcg attgaaaggatg aagaccgat ctgagg attgca 288 aaa Ser Gln LysAla IleGluArgMet LysThrAsp LeuArg IleAla Lys tat ett gaaget aaagtcgaaaag ttatgtgta tggaat aataaa 336 act Tyr Leu GluAla LysValGluLys LeuCysVal TrpAsn AsnLys Thr acg cct gcgatt gccgcaattagt atggcaaat t 373 cat Thr Pro AlaIle AlaAlaIleSer MetAlaAsn His <210> 2 <211> 124 <212> PRT
<213> Vibrio cholera <400> 2 Met Ile Lys Leu Lys Phe Gly Val Phe Phe Thr Val Leu Leu Ser Ser Ala Tyr Ala His Gly Ala Pro Gln Asn Ile Thr Asp Leu Cys Ala Glu Tyr His Asn Thr Gln Ile His Thr Leu Asn Asp Lys Ile Phe Ser Tyr Thr Glu Ser Leu Ala Gly Lys Arg Glu Met Ala I1e Ile Thr Phe Lys Asn Gly Ala Thr Phe Gln Val Glu Val Pro Gly Ser G1n His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Thr Asp Leu Arg Ile Ala Tyr Leu Thr Glu Ala Lys Val Glu Lys Leu Cys Val Trp Asn Asn Lys Thr Pro His Ala Ile Ala Ala Ile Ser Met Ala Asn <210> 3 <211> 28 <212> PRT
<213> Artificial Sequence <220>
<223> The signal sequence from V. cholera classic strain <900> 3 Met Asn Lys Val Lys Phe Tyr Val Leu Phe Thr Ala Leu Leu Ser Ser Leu Cys Ala His Gly Ala Pro Gly Tyr Ala His Gly <210> 4 <211> 124 <212> PRT
<213> Vibrio cholera <220>
<221> VARIANT
<222> (1)...(124) <223> CTB from variant NCBI gen bank number GI: 758351 <400> 4 Met Ile Lys Leu Lys Phe Gly Val Phe Phe Thr Val Leu Leu Ser Ser Ala Tyr Ala His Gly Thr Pro Gln Asn Ile Thr Asp Leu Cys Ala Glu Ser His Asn Thr Gln Ile Tyr Thr Leu Asn Asp Lys Ile Phe Ser Tyr Thr Glu Ser Leu Ala Gly Lys Arg Glu Met A1a I1e I1e Thr Phe Lys Asn Gly Ala Ile Phe Gln Val Glu Val Pro Ser Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Ala Tyr Leu Thr Glu Ala Lys Val Glu Lys Leu Cys Val Trp Asn Asn Lys Thr Pro His Ala Ile Ala Ala Ile Ser Met Ala Asn <210> 5 <211> 103 <212> PRT
~<213> Vibrio cholera <220>
<221> VARIANT
<222> (1)...(163) <223> CTB variant from NCBI gene bank GI: 1827850.
<400> 5 Thr Pro Gln Asn Ile Thr Asp Leu Cys Ala Glu Tyr His Asn Thr Gln Ile Tyr Thr Leu Asn Asp Lys Ile Phe Ser Tyr Thr Glu Ser Leu Ala Gly Lys Arg Glu Met Ala Ile Ile Thr Phe Lys Asn Gly Ala Ile Phe Gln Val Glu Val Pro Ser Ser Gln His Ile Asp Ser Gln Lys Lys Ala 5C 55 n0 Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Ala Tyr Leu Thr Glu Ala Lys Val Glu Lys Leu Cys Thr Trp Asn Asn Lys Thr Pro His Ala Ile Ala Ala Ile Ser Met Ala Asn <210> 6 <211> 124 <212> PRT
<213> Vibrio cholera <220>
<221> VARIANT
<222> (1)...(124) <223> CTB variant from NCBI gene bank GI: 808900.
<400> 6 Met Ile Lys Leu Lys Phe Gly Val Phe Phe Thr Val Leu Leu Ser Ser Ala Tyr Ala His Gly Thr Pro Gln Asn Ile Thr Asp Leu Cys Ala Glu Tyr His Asn Thr Gln Ile His Thr Leu Asn Asp Lys Ile Leu Ser Tyr Thr Glu Ser Leu Ala Gly Asn Arg Glu Met Ala Ile Ile Thr Phe Lys Asn Gly Ala Thr Phe Gln Val Glu Va1 Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Ala Tyr Leu Thr Glu Ala Lys Val Glu Lys Leu Cys Val Trp Asn Asn Lys Thr Pro His Ala Ile Ala Ala Ile Ser Met Ala Asn <210> 7 <211> 103 <212> PRT
<213> Vibrio cholera <220>
<221> VARIANT
<222> (1)...(103) <223> CTB variant from NCBI gene bank GI: 229616.
<400> 7 Thr Pro Glu Asn Ile Thr Asp Leu Cys Ala Glu Tyr His Asn Thr Gln Ile His Thr Leu Asn Asn Lys Ile Phe Ser Tyr Thr Glu Ser Leu Ala Gly Lys Arg Glu Met Ala Ile Ile Thr Phe Lys Asp Gly Ala Thr Phe Glu Val Glu Val Pro Gly Ser Glu His Ile Asp Ser Glu Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Ala Tyr Leu Thr Glu Ala Lys Val Glu Lys Leu Cys Val Trp Asn Asn Lys Thr Pro His Ala Ile g5 90 95 Ala Ala Ile Ser Met Ala Asn <210> 8 <211> 103 <212> PRT
<213> Vibrio cholera <220>
<221> VARIANT
<222> (1)...(103) <223> CTB variant from NCBI gene bank GI: 998409.
<400> 8 Thr Pro Gln Asn I1e Thr Asp Leu Cys Ala G1u Tyr His Asn Thr Gln Ile Tyr Thr Leu Asn Asp Lys Ile Phe Ser Tyr Thr Glu Ser Leu Ala Gly Lys Arg Glu Met Ala Ile Ile Thr Phe Lys Asn Gly Ala Ile Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Ala Tyr Leu Thr Glu Ala Lys Val Glu Lys Leu Cys Val Trp Asn Asn Lys Thr Fro His Ala Ile Ala Ala Ile Ser Met Ala Asn <210> 9 <211> 124 <212> PRT
<213> Vibrio cholera <220>
<221> VARIANT
<222> (1)...(124) <223> CTB variant from NCBI gene bank GI: 2144685.
<400> 9 Met Ile Lys Leu Lys Phe Gly Val Phe Phe Thr Val Leu Leu Ser Ser Ala Tyr Ala His Gly Thr Pro Gln Asn Ile Thr Asp Leu Cys Ala Glu Ser His Asn Thr Gln Ile Tyr Thr Leu Asn Asp Lys Ile Phe Ser Tyr Thr Glu Ser Leu Ala Gly Lys Arg G1u Met Ala Ile Ile Thr Phe Lys Asn Gly Ala Ile Phe Gln Val Glu Val Pro Ser Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Ala Tyr Leu Thr Glu Ala Lys Val Glu Lys Leu Cys Val Trp Asn Asn Lys Thr Pro His Ala Ile Ala Ala Ile Ser Met Ala Asn <210> 10 <211> 103 <212> PRT
<213> Vibrio cholera <220>
<221> VARIANT
<222> (1)...(103) <223> CTB variant from NCBI gene bank GI: 142I5ii.
<400> 10 Thr Pro Gln Asn Ile Thr Asp Leu Cys Ala Glu Tyr His Asn Thr Gln Ile His Thr Leu Asn Asp Lys Ile Phe Ser Tyr Thr Glu Ser Leu Ala Asp Lys Arg G1u Met Ala Ile Ile Thr Phe Lys Asn Gly Ala Thr Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Ala Tyr Leu Thr Glu A1a Lys Val Glu Lys Leu Cys Val Trp Asn Asn Lys Thr Fro His Ala Ile Ala Ala Ile Ser Met Ala Asn <210> 11 <211> 124 <212> PRT
<213> Vibrio cholera <220>
<221> VARIANT
<222> (1)...(129) <223> CTB variant from NCBI gene bank GI: 48890(classic 569B).
<900> 11 Met Ile Lys Leu Lys Phe Gly 'Jal Phe Phe Thr Val Leu Leu Ser Ser 1 5 10 i5 Ala Tyr Ala His Gly Thr Pro Gln Asn Ile Thr Asp Leu Cys Ala Glu Tyr His Asn Thr Gln Ile His Thr Leu Asn Asp Lys Ile Phe Ser Tyr Thr Glu Ser Leu Ala Gly Lys Arg Glu Met Ala Ile Ile Thr Phe Lys Asn Gly Ala Thr Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Ala Tyr Leu Thr Glu Ala Lys Val Glu Lys Leu Cys Val Trp Asn Asn Lys Thr Pro His Ala Ile Ala Ala Ile Ser Met Ala Asn <210> 12 <211> 105 <212> PRT
<213> Vibrio cholera <220>
<221> VARIANT
<222> (1)...(105) <223> CTB variant from NCBI gene bank GI: 2781121(Ogawa 41).
<400> 12 Met Thr Pro Gln Asn Ile Thr Asp Leu Cys Ala Glu Tyr His Asn Thr Gln Ile His Thr Leu Asn Asp Lys Ile Phe Ser Tyr Thr Glu Ser Leu Ala Gly Lys Arg Glu Met Ala Ile Ile Thr Phe Lys Asn Gly Ala Thr Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Ala Tyr Leu Thr Glu Ala Lys Val Glu Lys Leu Cys Val Trp Asn Asn Lys Thr Pro Ile Ile Ala Ile Ala Ala Ile Ser Met Ala Asn <210> 13 <211> 103 <212> PRT
<213> Vibrio cholera <220>
<221> VARIANT
<222> (1)...(103) <223> CTB variant from NCBI gene bank GI: 1421525(Ogawa 41 R35D).
<400> 13 Thr Pro Gln Asn Ile Thr Asp Leu Cys Ala Glu Tyr His Asn Thr Gln Ile His Thr Leu Asn Asp Lys Ile Phe Ser Tyr Thr Glu Ser Leu Ala Gly Lys Asp Glu Met Aia Ile Ile Thr Phe Lys Asn Gly Ala Thr Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Ala Tyr Leu Thr Glu Ala Lys Val Glu Lys Leu Cys Val Trp Asn Asn Lys Thr Pro His Ala Ile Ala Ala Ile Ser Met Ala Asn <210> 14 <211> 21 <212> PRT
<213> Artificial Sequence <220>
<223> The signal sequence from LTB.
<400> 14 Met Asn Lys Val Lys Cys Tyr Val Leu Phe Thr Ala Leu Leu Ser Ser Leu Cys Ala Tyr Gly <210> 15 <211> 125 <212> PRT
<213> Escherichia coli <220>
<221> VARIANT
<222> (1)...(125) <223> LTB variant from NCBI gene bank GI:3062900.
<400> 15 Met Asn Lys Val Lys Cys Tyr Val Leu Phe Thr Ala Leu Leu Ser Ser Leu Ala Cys Ala Tyr Gly Ala Pro Gln Ser Ile Thr Glu Leu Cys Ser Glu Tyr Arg Asn Thr Gln Ile Tyr Thr Ile Asn Asp Lys Ile Leu Ser Tyr Thr Glu Ser Met Ala Gly Lys Arg Glu Met Val Ile Ile Th r Phe Lys Ser Gly Ala Thr Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Thr Tyr Leu Thr Glu Thr Lys Ile Asp Lys Leu Cys Val Trp Asn Asn Lys Thr Pro Asn Ser Ile Ala Ala Ile Ser Met Glu Asn <210> 16 <211> 124 <212> PRT
<213> Escherichia coli <220>
<221> VARIANT
<222> (1)...(124) <223> LTB variant from NCBI gene bank GI:1169505.
<400> 16 Met Asn Lys Val Lys Cys Tyr Val Leu Phe Thr Ala Leu Leu Ser Ser Leu Tyr Ala His Gly Ala Pro Gln Thr Ile Thr G1u Leu Cys Ser Glu Tyr Arg Asn Thr Gln Ile Tyr Thr Ile Asn Asp Lys I~ie Leu Ser Tyr Thr Glu Ser Met Ala Gly Lys Arg Glu Met Val Ile Ile Thr Phe Lys Ser Gly Glu Thr Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Thr Tyr Leu Thr Glu Thr Lys Ile Asp Lys Leu Cys Val Trp Asn Asn Lys Thr Pro Asn Ser Ile Ala Ala Ile Ser Met Lys Asn <210> 17 <211> 123 <212> PRT
<213> Escherichia coli <220>
<221> VARIANT
<222> (1)...(123) <223> LTB variant from NCBI gene bank GI:1395122.
<400> 17 Met Asn Lys Val Lys Cys Tyr Val Leu Phe Thr Ala Leu Leu Ser Ser Leu Cys Ala Tyr Gly Ala Pro Gln Ser Ile Thr Glu Leu Cys Ser Glu Tyr Arg Asn Thr Gln Ile Tyr Thr Ile Asn Asp Lys Iie Leu Ser Tyr Thr Glu Ser Met Ala Gly Lys Arg Glu Met Val Ile Ile Thr Phe Lys Ser Gly Ala Thr Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Thr Tyr Leu Thr Glu Thr Lys Ile Asp Lys Leu Cys Val frp Asn Asn Lys Thr Pro Asn Ser Ile Ala Ala Ile Met Glu Asn <210> 18 <211> 124 <212> PRT
<213> Escherichia coli <220>
<221> VARIANT
<222> (1)...(124) <223> LTB variant from NCBI gene bank GI:145833.
<400> 18 Met Asn Lys Val Lys Cys Tyr Val Leu Phe Thr Ala Leu Leu Ser Ser Leu Tyr Ala His Gly Ala Pro Gln Thr Ile Thr Glu Leu Cys Ser Glu Tyr Arg Asn Thr Gln Ile Tyr Thr Ile Asn Asp Lys Ile Leu Ser Tyr Thr Glu Ser Met Ala Gly Lys Arg Glu Met Val Ile Ile Thr Phe Lys Ser G7_y Glu Thr Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Thr Tyr Leu Thr Glu Thr Lys Ile Asp Lys Leu Cys Val Trp Asn Asn Lys Thr Pro Asn Ser Ile Ala Ala Ile Ser Met Lys Asn <210> 19 <211> 124 <212> PRT
<213> Escherichia coli <220>
<221> VARIANT
<222> (1)...(124) <223> LTB variant from NCBI gene bank GI:1648865 (LT87).
<400> 19 Met Asn Lys Val Lys Phe Tyr Val Leu Phe Thr Ala Leu Leu Ser Ser Leu Cys Ala His Gly Ala Pro Gln Ser Ile Thr Glu Leu Cys Ser Glu Tyr His Asn Thr Gln Ile Tyr Thr Ile Asn Asp Lys Ile Leu Ser Tyr Thr Glu Ser Met Ala Gly Lys Arg Glu Met Val Ile Ile Thr Phe Lys Ser Gly Ala Thr Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Thr Tyr Leu Thr Glu Thr Lys Ile Asp Lys Leu Cys Val Trp Asn Asn Lys Thr Pro Asn Ser Ile Ala Ala Ile Ser Met Glu Asn <210> 20 <211> 123 <212> PRT
<213> Escherichia coli <220>
<221> VARIANT
<222> (1)...(123) <223> LTB variant from NCBI gene bank GI:223254.
_g_ <400> 20 Met Asn Lys Val Lys Cys Tyr Val Leu Phe Thr Ala Leu Leu Ser Ser Leu Tyr Ala His Gly Ala Pro Gln Thr Ile Thr Glu Leu Cys Ser Glu Tyr Arg Asn Thr Gln Ile Tyr Thr Asn Asp Lys Ile Leu Ser Tyr Thr Glu Ser Met Ala Gly Lys Arg Glu Met Val Ile Ile Thr Phe Met Ser Gly Glu Thr Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Thr Tyr Leu Thr Glu Thr Lys Ile Asp Lys Leu Cys Val Trp Asn Asn Lys Thr Pro Asn Ser Ile Ala Ala Ile Ser Met Lys Asn <210> 21 <211> 124 <212> PRT
<213> Escherichia coli <220>
<221> VARIANT
<222> (1)...(124) <223> LTB variant from NCBI gene bank GI:408996.
<400> 21 Met Asn Lys Val Lys Cys Tyr Val Leu Phe Thr Ala Leu Leu Ser Ser Leu Cys Ala Tyr Gly Ala Pro Gln Ser Ile Thr Glu Leu Cys Ser Glu Tyr Arg Asn Thr Gln Ile Tyr Thr Ile Asn Asp Lys Ile Leu Ser Tyr Thr Glu Ser Met Ala Gly Lys Arg Glu Met Val Ile Ile Thr Phe Lys Ser Gly Ala Thr Phe G1n Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Thr Tyr Leu Thr Glu Thr Lys Ile Asp Lys Leu Cys Val Trp Asn Asn Lys Thr Pro Asn Ser Ile Ala Ala Ile Ser Met Giu Asn <210> 22 <211> 103 <212> PRT
<213> Escherichia coli <220>
<221> VARIANT
<222> (1)...(1031 <223> LTB variant from NCBI gene bank GI:494265.
<400> 22 Ala Pro Gln Thr Ile Thr Glu Leu Cys Ser Glu Tyr Arg Asn Thr Gln Ile Tyr Thr Ile Asn Asp Lys Ile Leu Ser Tyr Thr Glu Ser Met Ala G1y Lys Arg Glu Met Val Ile Ile Thr Phe Lys Ser Gly Glu Thr Phe Gln Val Glu Va1 Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala _g_ Ile Glu Arg Met Lys Asp Thr Leu Arg I1e Thr Tyr Leu Thr Glu Thr Lys Ile Asp Lys Leu Cys Val Trp Asn Asn Lys Thr Pro Asn Ser Ile g5 90 95 Ala Ala Ile Ser Met Lys Asn <210> 23 <211> 124 <212> PRT
<213> Escherichia coli <220>
<221> VARIANT
<222> (1)...(124) <223> LTB variant from NCBI gene bank GI:69630.
<400> 23 Met Asn Lys Val Lys Cys Tyr Val Leu Phe Thr Ala Leu Leu Ser Ser Leu Tyr Ala His Gly Ala Pro Gln Thr Ile Thr Gln Leu Cys Ser Glu Tyr Arg Asn Thr Gln Ile Tyr Thr Ile Asn Asp Lys Ile Leu Ser Tyr Thr Glu Ser Met Ala Gly Lys Arg Glu Met Val Ile Ile Thr Phe Met Ser Gly Glu Thr Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Thr g5 90 95 Tyr Leu Thr Glu Thr Lys Ile Asp Lys Leu Cys Val Trp Asn Asn Lys Thr Pro Asn Ser Ile Ala Ala Ile Ser Met Lys Asn <210> 24 <211> 123 <212> PRT
<213> Escherichia coli <220>
<221> VARIANT
<222> (1)...(123) <223> LT-IIa from NCBI gene bank GI:146671.
<400> 24 Met Ser Ser Lys Lys Ile Ile Gly Ala Phe Val Leu Met Thr Gly Ile Leu Ser Gly Gln Val Tyr Ala Gly Val Ser Glu His Phe Arg Asn Ile Cys Asn Gln Thr Thr Ala Asp Ile Val Ala Gly Val Gln Leu Lys Lys Tyr Ile Ala Asp Val Asn Thr Asn Thr Arg Gly Ile Tyr Val Val Ser Asn Thr Gly Gly Val Trp Tyr Ile Pro Gly Gly Arg Asp Tyr Pro Asp Asn Phe Leu Ser Gly Glu Ile Arg Lys Thr Ala Met Ala Ala Ile Leu g5 90 95 Ser Asp Thr Lys Val Asn Leu Cys Ala Lys Thr Ser Ser Ser Pro Asn His Ile Trp Ala Met Glu Leu Asp Arg Glu Ser <210> 25 <211> 122 <212> PRT
<213> Escherichia coli <220>
<221> VARIANT
<222> (1)...(122) <223> LT-IIb LTB from NCBI gene bank GI:576584.
<400> 25 Met Ser Phe Lys Lys I1e Ile Lys Ala Phe Val Ile Met Ala Ala Leu Val Ser Val Gln Ala His Ala Gly Ala Ser Gln Phe Phe Lys Asp Asn Cys Asn Arg Thr Thr Ala Ser Leu Val Glu Gly Val Glu Leu Thr Lys Tyr Ile Ser Asp Ile Asn Asn Asn Thr Asp Gly Met Tyr Val Val Ser Ser Thr Gly Gly Val Trp Arg Ile Ser Arg Ala Lys Asp Tyr Pro Asp Asn Val Met Thr Ala Glu Met Arg Lys Ile Ala Met Ala Ala Val Leu Ser Gly Met Arg Val Asn Met Cys Ala Ser Pro Ala Ser Ser Pro Asn Val Ile Trp Ala Ile Glu Leu Glu Ala Glu <210> 26 <211> 88 <212> PRT
<213> Shigella dysenteriae type 1 <220>
<221> VARIANT
<222> (1)...(88) <223> Shiga toxin beta subunit from NCBI gene bank GI:152784.
<400> 26 Met Lys Lys Thr Leu Leu Ile Ala Ala Ser Leu Ser Phe Phe Ser Ala Ser Ala Leu Ala Thr Pro Asp Cys Val Thr Gly Lys Val Glu Tyr Thr Lys Tyr Asn Asp Asp Asp Thr Phe Thr Val Lys Val Gly Asp Lys Glu Leu Phe Thr Asn Arg Trp Asn Leu Gln Ser Leu Leu Leu Ser Ala Gln Ile Thr Gly Met Thr Val Thr Ile Lys Thr Asn Ala Cys His Asn Gly Gly Gly Phe Ser Val Ile Phe Arg <210> 27 <211> 89 <212> PRT
<213> Escherichia coli <220>
<221> VARIANT
<222> (1)...(89) <223> Shiga-like toxin from E.coli from NCBI gene bank GI:4877349.
<400> 27 Met Lys Lys Ile Phe Val Ala Ala Leu Phe Ala Phe Val Ser Val Asn Ala Met Ala Ala Asp Cys Ala Lys Gly Lys Ile Glu Phe Ser Lys Tyr Asn Glu Asn Asp Thr Phe Thr Val Lys Val Ala Gly Lys Glu Tyr Trp Thr Asn Arg Trp Asn Leu Gln Pro Leu Leu Gln Ser Ala Gln Leu Thr Gly Met Thr Val Thr Ile Lys Ser Asn Thr Cys Ala Ser Gly Ser Gly Phe A.la Glu Val Gln Phe Asn Asn Asp <210> 28 <211> 226 <212> PRT
<213> Bordetella pertussis <220>
<221> VARIANT
<222> (1)...(226) <223> Pertussis Toxin pentamer subunit S2.
<400> 28 Met Pro Ile Asp Arg Lys Thr Leu Cys His Leu Leu Ser Val Leu Pro 1 5 1~ 15 Leu Ala Leu Leu Gly Ser His -Jal Ala Arg Ala Ser Thr Pro Gly~° Iie Val Ile Pro Pro Gln Glu Gln Ile Thr Gln His Gly Ser Pro Tyr Gly Arg Cys Ala Asn Lys Thr Arg Ala Leu Thr Val Ala Glu Leu Arg Gly Ser Gly Asp Leu Gln Glu Tyr Leu Arg His Val Thr Arg Gly Trp Ser Ile Phe Ala Leu Tyr Asp Gly Thr Tyr Leu Gly Gly Glu Tyr Gly Gly Val Ile Lys Asp Gly Thr Pro Gly Gly Ala Phe Asp Leu Lys Thr Thr Phe Cys Ile Met Thr Thr Arg Asn Thr Gly Gln Pro Ala Thr Asp His Tyr Tyr Ser Asn Val Thr Ala Thr Arg Leu Leu Ser Ser Thr Asn Ser Arg Leu Cys Ala Val Phe Val Arg Ser Gly G1n Pro Val Ile Gly Ala Cys Thr Ser Pro Tyr Asp Gly Lys Tyr Trp Ser Met Tyr Ser Arg Leu Arg Lys Met Leu Tyr Leu Ile Tyr Val Ala Gly Ile Ser Val Arg Val His Val Ser Lys Glu Glu Gln Tyr Tyr Asp Tyr Glu Asp Ala Thr Phe Glu Thr Tyr Ala Leu Thr Gly Ile Ser Ile Cys Asn Pro Gly Ser Ser Leu Cys <210> 29 <211> 227 <212> PRT
<213> Bordetella pertussis <220>
<221> VARIANT
<222> (1)...(227) <223> Pertussis Toxin pentamer subunit S3.
<400> 29 Met Leu Ile Asn Asn Lys Lys Leu Leu His His Ile Leu Pro Ile Leu Val Leu Ala Leu Leu Gly Met Arg Thr Ala Gln Ala Val Ala Pro Gly Ile Val Ile Pro Pro Lys Ala Leu Phe Thr Gln Gln Gly Gly Ala Tyr Gly Arg Cys Pro Asn Gly Thr Arg Ala Leu Thr Val Ala Glu Leu Arg Gly Asn Ala Glu Leu Gln Thr Tyr Leu Arg Gln Ile Thr Pro Gly Trp Ser Ile Tyr Gly Leu Tyr Asp Gly Thr Tyr Leu Gly Gln Ala Tyr Gly Gly Ile Ile Lys Asp Ala Pro Pro G1y Ala Gly Phe I1e Tyr Arg Glu Thr Phe Cys Ile Thr Thr Ile Tyr Lys Thr Gly Gin Pro Ala Ala Asp His Tyr Tyr Ser Lys Val Thr Ala Thr Arg Leu Leu Ala Ser Thr Asn 130 i35 140 Ser Arg Leu Cys Ala Val Phe Val Arg Asp Gly Gln Ser Val Ile Gly Ala Cys Ala Ser Pro Tyr Glu Gly Arg Tyr Arg Asp Met Tyr Asp Ala Leu Arg Arg Leu Leu Tyr Met Ile Tyr Met Ser Gly Leu Ala Val Arg Val His Val Ser Lys Glu Glu Gln Tyr Tyr Asp Tyr Giu Asp Ala Thr Phe Gln Thr Tyr Ala Leu Thr Gly Ile Ser Leu Cys Asn Pro Ala Ala Ser Ile Cys <210> 30 <211> 152 <212> PRT
<213> Bordetella pertussis <220>
<221> VARIANT
<222> (1)...(152) <223> Pertussis Toxin pentamer subunit S4.
<400> 30 Met Leu Arg Arg Phe Pro Thr Arg Thr Thr Ala Pro Gly Gln Gly Gly Ala Arg Arg Ser Arg Val Arg Ala Leu Ala Trp Leu Leu Ala Ser Gly Ala Met Thr His Leu Ser Pro Ala Leu Ala Asp Va1 Pro Tyr Val Leu Val Lys Thr Asn Met Val Val Thr Ser Val Ala Met Lys Pro Tyr Glu Val Thr Pro Thr Arg Met Leu Val Cys Gly Ile Ala Ala Lys Leu Gly Ala Ala Ala Ser Ser Pro Asp Ala His Val Pro Phe Cys Phe Gly Lys Asp Leu Lys Arg Pro Gly Ser Ser Pro Met Glu Val Met Leu Arg Ala Val Phe Met Gln Gln Arg Pro Leu Arg Met Phe Leu Gly Pro Lys Gln Leu Thr Phe Glu Gly Lys Pro Ala Leu Glu Leu Ile Arg Met Va1 Glu Cys Ser Gly Lys Gln Asp Cys Pro <210> 31 <211> 133 <212> PRT
<213> Bordetella pertussis <220>
<221> VARIANT
<222> (1)...(133) <223> Pertussis Toxin pentamer subunit S5.
<400> 31 Met Gln Arg Gln Ala Gly Leu Pro Leu Lys Ala Asn Pro Met His Thr Ile Ala Ser Ile Leu Leu Ser Val Leu Gly Ile Tyr Ser Pro Ala Asp Val Ala Gly Leu Pro Thr His Leu Tyr Lys Asn Phe Thr Val Gln Glu Leu Ala Leu Lys Leu Lys Gly Lys Asn Gln Glu Phe Cys Leu Thr Ala Phe Met Ser Gly Arg Ser Leu Va1 Arg Ala Cys Leu Ser Asp Ala Gly His Glu His Asp Thr Trp Phe Asp Thr Met Leu Gly Phe Ala Ile Ser Ala Tyr Ala Leu Lys Ser Arg Ile Ala Leu Thr Val Glu Asp Ser Pro Tyr Pro Gly Thr Pro Gly Asp Leu Leu Glu Leu Gln Ile Cys Pro Leu Asn Gly Tyr Cys Glu
Claims (44)
1. A recombinant AB5 B subunit protein comprising at least one mutation, wherein said mutation alters the number of amino acid residues available for chemical modification as compared to a wild type AB5 B subunit protein, and wherein said recombinant protein retains an effective target ligand binding affinity.
2. The recombinant AB5 B subunit protein of Claim 1, wherein said mutation increases the number of amino acid residues available for chemical modification.
3. The recombinant AB5 B subunit of Claim 1, wherein said mutation decreases the number of amino acid residues available for chemical modification.
4. The recombinant AB5 B subunit of Claim 1, wherein said amino acid residues available for chemical modification are selected from the group consisting of lysine, cysteine, and histidine.
5. The recombinant AB5 B subunit of Claim 1, wherein said mutation is selected from the group consisting of an amino acid insertion, an amino acid deletion, and an amino acid substitution.
6. The recombinant AB5 B subunit protein of Claim 1, wherein said recombinant AB5 B subunit protein is in chemical association with a compound selected from the group consisting of drugs, immunogens, immunomodulatory molecules, adjuvants, and other bioactive molecules.
7. The recombinant AB5 B subunit protein of Claim 1, wherein said AB5 B
subunit protein is selected from the group consisting of cholera toxin B protein (CTB), E. coli heat labile toxin B protein (LTB), LT type IIa B protein, LT type IIb B protein, Shiga toxin B protein, Shiga-like toxin B protein, and pertussis toxin B protein.
subunit protein is selected from the group consisting of cholera toxin B protein (CTB), E. coli heat labile toxin B protein (LTB), LT type IIa B protein, LT type IIb B protein, Shiga toxin B protein, Shiga-like toxin B protein, and pertussis toxin B protein.
8. The recombinant AB5 B subunit protein of Claim 1- wherein said AB5 B
subunit protein is cholera toxin B (CTB) subunit protein.
subunit protein is cholera toxin B (CTB) subunit protein.
9. The recombinant cholera toxin B (CTB) subunit protein of Claim 8, wherein said recombinant protein retains an effective Gm-1 binding affinity.
10. The recombinant cholera toxin B subunit protein of Claim 8, wherein said mutation is selected from the group consisting of T1X, P2X, Q3X, N4X, I5X, T6X, D7X, L8X, C9X, A10X, E11X, Y12X, H13X, N14X, T15X, Q16X, I17X, H18X, T19X, L20X, N21X, D22X, K23X, I24X, F25X, S26X, Y27X, T28X, E29X, S30X, L31X, A32X, G33X, K34X, R35X, E36X, M37X, A38X, I39X, I40X, T41X, F42X, K43X, N44X, G45X, A46X, T47X, F48X, Q49X, V50X, E51X, V52X, P53X, G54X, S55X, Q56X, H57X, I58X, D59X, S60X, Q61X, K62X, K63X, A64X, I65X, E66X, R67X, M68X, K69X, D70X, T71X, L72X, R73X, I74X, A75X, Y76X, L77X, T78X, E79X, A80X, K81X, V82X, E83X, K84X, L85X, C86X, V87X, W88X, N89X, N90X, K91X, T92X, P93X, H94X, A95X, I96X, A97X, A98X, I99X, S100X, M101X, A102X, N103X, wherein "X" represent any amino acid residue that alters the number of covalent modification sites within the recombinant CTB protein.
11. The recombinant cholera toxin B (CTB) subunit of Claim 10, wherein said amino acid residues available for chemical modification are selected from the group consisting of lysine, cysteine, and histidine.
12. The recombinant cholera toxin B (CTB) subunit of Claim 10, wherein said mutation is selected from the group consisting of an amino acid insertion, an amino acid deletion, and an amino acid substitution.
13. The recombinant cholera toxin B (CTB) subunit of Claim 10, wherein "X"
represents an amino acid that decreases the number of amino acid residues available for chemical modification.
represents an amino acid that decreases the number of amino acid residues available for chemical modification.
14. The recombinant cholera toxin B subunit protein of Claim 11, wherein said at least one mutation is selected from the group consisting of K91G, K91Q, K91S, K91P, and K91Y.
15. The recombinant cholera toxin B subunit protein of Claim 11, wherein said at least one mutation is selected from the group consisting of K34G, K35G, K62G, K63G, and K91G.
16. The recombinant cholera toxin B subunit protein of Claim 11, comprising the mutations K34G, and K91G.
17. The recombinant cholera toxin B subunit protein of Claim 11, comprising the mutations K62G, K63G, and K91G.
18. The recombinant cholera toxin B (CTB) subunit protein of Claim 10, wherein "X"
represents an amino acid that increases the number of amino acid residues available for chemical modification.
represents an amino acid that increases the number of amino acid residues available for chemical modification.
19. The recombinant cholera toxin B subunit protein of Claim 18, wherein said protein comprises at least one mutation selected from the group consisting of A1K, P2K, Q3K, N4K, T6K, N7K, H18K, N21K, F25K, N44K, M101K, N103K, Q3C, N4C, T6C, N7C, H18C, N21C, F25C, N44C, M101C, and N103C.
20. The recombinant AB5 B subunit protein of Claim 1, wherein said mutations comprises:
at least one modification decreasing mutation, resulting in said recombinant AB5 B subunit protein having a decreased number of amino acid residues available for modification as compared to a wild type AB5 B subunit protein; and at least one modification increasing mutation, wherein said modification increasing mutation introduces an amino acid capable of chemical modification into a site within said recombinant AB5 B subunit protein previously incapable of chemical modification.
at least one modification decreasing mutation, resulting in said recombinant AB5 B subunit protein having a decreased number of amino acid residues available for modification as compared to a wild type AB5 B subunit protein; and at least one modification increasing mutation, wherein said modification increasing mutation introduces an amino acid capable of chemical modification into a site within said recombinant AB5 B subunit protein previously incapable of chemical modification.
21. The recombinant AB5 B subunit protein of Claim 20, wherein said AB5 B
subunit protein is selected from the group consisting of cholera toxin B protein (CTB), E. coli heat labile toxin B protein (LTB), LT type IIa B protein, LT type IIb B protein, Shiga toxin B protein, Shiga-like toxin B protein, and pertussis toxin B protein.
subunit protein is selected from the group consisting of cholera toxin B protein (CTB), E. coli heat labile toxin B protein (LTB), LT type IIa B protein, LT type IIb B protein, Shiga toxin B protein, Shiga-like toxin B protein, and pertussis toxin B protein.
22. The recombinant AB5 B subunit protein of Claim 20, wherein said AB5 B
subunit protein is cholera toxin B protein (CTB).
subunit protein is cholera toxin B protein (CTB).
23. The recombinant AB5 B subunit protein of Claim 20, wherein said amino acid residues available for chemical modification are selected from the group consisting of lysine, cysteine, and histidine.
24. A method of making a recombinant AB5 B subunit gene encoding the recombinant AB5 B subunit protein of Claim 1, comprising:
providing an AB5 B subunit gene encoding an AB5 B subunit protein;
selecting codons encoding amino acid residues involved in covalent modification of the AB5 B subunit protein; and mutating said codons such that the resulting amino acids are either incapable of covalent modification or possess enhanced modification capabilities.
providing an AB5 B subunit gene encoding an AB5 B subunit protein;
selecting codons encoding amino acid residues involved in covalent modification of the AB5 B subunit protein; and mutating said codons such that the resulting amino acids are either incapable of covalent modification or possess enhanced modification capabilities.
25. The method of Claim 24, wherein said AB5 B subunit protein is selected from the group consisting of cholera toxin B protein (CTB), E. coli heat labile toxin B
protein (LTB), LT
type IIa B protein, LT type IIb B protein, Shiga toxin B protein, Shiga-like toxin B protein, and pertussis toxin B protein.
protein (LTB), LT
type IIa B protein, LT type IIb B protein, Shiga toxin B protein, Shiga-like toxin B protein, and pertussis toxin B protein.
26. The method of Claim 24, wherein said amino acid residues available for chemical modification are selected from the group consisting of lysine, cysteine, and histidine.
27. A method for producing the recombinant AB5 B subunit protein of Claim 1 comprising the steps of:
obtaining a gene encoding the recombinant AB5 B subunit;
adding to said gene a promoter, thereby producing an expression cassette;
introducing said expression cassette into a suitable host cell, and cultivating said host cell under conditions whereby said expression cassette is translated into protein.
obtaining a gene encoding the recombinant AB5 B subunit;
adding to said gene a promoter, thereby producing an expression cassette;
introducing said expression cassette into a suitable host cell, and cultivating said host cell under conditions whereby said expression cassette is translated into protein.
28. The method of Claim 27, wherein said AB5 B subunit protein is selected from the group consisting of cholera toxin B protein (CTB), E. coli heat labile toxin B
protein (LTB), LT
type IIa B protein, LT type IIb B protein, Shiga toxin B protein. Shiga-like toxin B protein, and pertussis toxin B protein.
protein (LTB), LT
type IIa B protein, LT type IIb B protein, Shiga toxin B protein. Shiga-like toxin B protein, and pertussis toxin B protein.
29. The method of Claim 27, wherein said AB5 B subunit protein is cholera toxin B
protein (CTB).
protein (CTB).
30. A gene construct for producing the recombinant AB5 B subunit of Claim 1, comprising:
a promoter and a DNA sequence which encodes the recombinant AB5 B subunit, operably linked in the proper reading frame.
a promoter and a DNA sequence which encodes the recombinant AB5 B subunit, operably linked in the proper reading frame.
31. The gene construct of Claim 30, wherein said AB5 B subunit protein is selected from the group consisting of cholera toxin B protein (CTB), E. coli heat labile toxin B protein (LTB), LT type IIa B protein, LT type IIb B protein, Shiga toxin B protein, Shiga-like toxin B
protein, and pertussis toxin B protein.
protein, and pertussis toxin B protein.
32. The gene construct of Claim 30, wherein said AB5 B subunit protein is cholera toxin B protein (CTB).
33. A method for producing the recombinant AB5 B subunit of Claim 1, comprising:
expressing the gene construct of Claim 30. in a suitable host cell; and recovering recombinant AB5 B subunit.
expressing the gene construct of Claim 30. in a suitable host cell; and recovering recombinant AB5 B subunit.
34. A method of generating an immune response to a recombinant AB5 B subunit, comprising:
providing the recombinant AB5 B subunit protein of Claim 1 or Claim 20;
covalently modifying said protein with a dimeric cross-linking reagent with a first and a second functional groups, wherein said first functional group is in chemical association with the recombinant AB5 B subunit protein of Claim 1 or Claim 20:
covalently modifying said second functional group with a compound; and administering said modified protein to a host until said immune response is generated.
providing the recombinant AB5 B subunit protein of Claim 1 or Claim 20;
covalently modifying said protein with a dimeric cross-linking reagent with a first and a second functional groups, wherein said first functional group is in chemical association with the recombinant AB5 B subunit protein of Claim 1 or Claim 20:
covalently modifying said second functional group with a compound; and administering said modified protein to a host until said immune response is generated.
35. The method of Claim 34, wherein said immune response is an antibody response.
36. The method of Claim 34, wherein said AB5 B subunit protein is selected from the group consisting of cholera toxin B protein (CTB), E. coli heat labile toxin B
protein (LTB), LT
type IIa B protein, LT type IIb B protein, Shiga toxin B protein, Shiga-like toxin B protein, and pertussis toxin B protein.
protein (LTB), LT
type IIa B protein, LT type IIb B protein, Shiga toxin B protein, Shiga-like toxin B protein, and pertussis toxin B protein.
37. The method of Claim 34, wherein said AB5 B subunit protein is cholera toxin B
protein (CTB).
protein (CTB).
38. The method of Claim 34, wherein said immune response is a cellular immune response.
39. The method of Claim 34, wherein the covalently modified protein is mixed with an immunogen to produce a hydrophobically coupled protein prior to administering said protein to said host to generate said immune response.
40. The method of Claim 39 wherein said AB5 toxin B protein is selected from the group consisting of: cholera toxin B protein (CTB), E. coli heat labile toxin B protein (LTB), LT
type IIa B protein, LT type IIb B protein, Shiga toxin B protein, Shiga-like toxin B protein, pertussis toxin B protein.
type IIa B protein, LT type IIb B protein, Shiga toxin B protein, Shiga-like toxin B protein, pertussis toxin B protein.
41. The method of Claim 39 wherein said AB5 toxin B subunit protein is cholera toxin B protein (CTB).
42. An expression vector comprising:
a promoter and a gene encoding for the AB5 B subunit protein of Claim 1, wherein said AB5 toxin B protein is selected from the group consisting of: cholera toxin B protein (CTB), E. coli heat labile toxin B protein (LTB), LT type IIa B protein, LT
type IIb B
protein, Shiga toxin B protein, Shiga-like toxin B protein, pertussis toxin B
protein.
a promoter and a gene encoding for the AB5 B subunit protein of Claim 1, wherein said AB5 toxin B protein is selected from the group consisting of: cholera toxin B protein (CTB), E. coli heat labile toxin B protein (LTB), LT type IIa B protein, LT
type IIb B
protein, Shiga toxin B protein, Shiga-like toxin B protein, pertussis toxin B
protein.
43. The expression vector of Claim 42, wherein said expression vector is a gene fusion vector, further comprising:
an immunogenic peptide coding sequence, wherein said AB5 toxin B subunit protein and said immunogenic peptide coding sequences are operably linked in the proper reading frame, whereby a gene fusion protein results; and said gene fusion protein is expressed and secreted.
an immunogenic peptide coding sequence, wherein said AB5 toxin B subunit protein and said immunogenic peptide coding sequences are operably linked in the proper reading frame, whereby a gene fusion protein results; and said gene fusion protein is expressed and secreted.
44. The gene fusion vector of Claim 43, wherein said AB5 toxin B subunit protein is cholera toxin B protein (CTB).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15856199P | 1999-10-08 | 1999-10-08 | |
US60/158,561 | 1999-10-08 | ||
PCT/US2000/027607 WO2001027144A2 (en) | 1999-10-08 | 2000-10-05 | Ab5 toxin b subunit mutants with altered chemical conjugation characteristics |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2385172A1 true CA2385172A1 (en) | 2001-04-19 |
Family
ID=22568704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002385172A Abandoned CA2385172A1 (en) | 1999-10-08 | 2000-10-05 | Ab5 toxin b subunit mutants with altered chemical conjugation characteristics |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1222202A2 (en) |
JP (1) | JP2003511061A (en) |
AU (1) | AU7865900A (en) |
CA (1) | CA2385172A1 (en) |
IL (1) | IL149009A0 (en) |
NZ (1) | NZ518342A (en) |
WO (1) | WO2001027144A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0115382D0 (en) * | 2001-06-22 | 2001-08-15 | Univ Bristol | Mutant |
MXPA04005134A (en) | 2001-11-30 | 2004-08-11 | Ca Nat Research Council | Self-assembly molecules. |
US7455843B2 (en) | 2003-09-25 | 2008-11-25 | Research Foundation Of State University Of New York, The | Adjuvant activities of mutants of LT-IIa and LT-IIb enterotoxin lacking binding to ganglioside |
WO2007042169A2 (en) * | 2005-10-07 | 2007-04-19 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Matrix metalloproteinase 11 vaccine |
KR101303282B1 (en) | 2010-11-08 | 2013-09-03 | 한국생명공학연구원 | Bacterial mutants devoid of AB type exotoxin by causing deficiency of toxin B-subunit and use thereof |
MX2015012461A (en) | 2013-03-15 | 2016-08-08 | Bioven 3 Ltd | Self-assembling synthetic proteins. |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2636842B1 (en) * | 1988-09-27 | 1994-06-10 | Liege Universite Etat | FUSION PROTEIN OF A SEQUENCE DERIVED FROM CHOLERIC TOXIN B SUBUNIT B AND A HETEROLOGOUS ANTIGEN HAVING IMMUNOGENIC PROPERTIES, RECOMBINANT NUCLEIC ACID CONTAINING VACCINE COMPOSITIONS CONTAINING NUCLEOTIDITE CODING SEQUENCE |
JPH02115129A (en) * | 1988-10-21 | 1990-04-27 | Kokuritsu Yobou Eisei Kenkyusho | Antiviral |
US5834246A (en) * | 1989-09-18 | 1998-11-10 | Vitec Aktiebolag | Recombinant systems for expression of cholera B-subunit with the aid of foreign promoters and/or leader peptides |
-
2000
- 2000-10-05 AU AU78659/00A patent/AU7865900A/en not_active Abandoned
- 2000-10-05 WO PCT/US2000/027607 patent/WO2001027144A2/en not_active Application Discontinuation
- 2000-10-05 EP EP00968795A patent/EP1222202A2/en not_active Withdrawn
- 2000-10-05 CA CA002385172A patent/CA2385172A1/en not_active Abandoned
- 2000-10-05 NZ NZ518342A patent/NZ518342A/en unknown
- 2000-10-05 JP JP2001530362A patent/JP2003511061A/en not_active Withdrawn
- 2000-10-05 IL IL14900900A patent/IL149009A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2001027144A3 (en) | 2002-01-17 |
AU7865900A (en) | 2001-04-23 |
IL149009A0 (en) | 2002-11-10 |
NZ518342A (en) | 2004-04-30 |
JP2003511061A (en) | 2003-03-25 |
EP1222202A2 (en) | 2002-07-17 |
WO2001027144A2 (en) | 2001-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4840745B2 (en) | Conjugates formed from heat shock proteins and oligosaccharides or polysaccharides | |
US9603923B2 (en) | Universal carrier for targeting molecules to GB3 receptor expressing cells | |
JP3253327B2 (en) | Polynucleotide having nucleotide sequence encoding meningococcal outer membrane protein and vaccine composition | |
US5917017A (en) | Diphtheria toxin vaccines bearing a mutated R domain | |
CA2190494C (en) | Heterodimer polypeptide immunogen carrier composition and method | |
US20050244425A1 (en) | Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability | |
JP2001511122A (en) | Novel drug targeting epithelial tissue | |
JP4081140B2 (en) | Hybrid molecule of non-heat-stable enterotoxin and cholera toxin B subunit | |
CA2385172A1 (en) | Ab5 toxin b subunit mutants with altered chemical conjugation characteristics | |
CA2069106A1 (en) | Chimeric proteins | |
FI104496B (en) | Overexpression systems for cholera B subunit expression by foreign promoters and leader peptides | |
JP4820000B2 (en) | Verotoxin B subunit for immunization | |
TW528760B (en) | Peptide repeat immunogens | |
JP2001503981A (en) | Secretory immunoglobulin A as a mucosal vaccine delivery system | |
WO2022263574A1 (en) | Crm197 protein carrier | |
WO2001000839A1 (en) | Tetanus toxin polypeptides | |
JP2008289480A (en) | Moraxella (branhamella) catarrhalis antigen | |
CN115724940A (en) | Targeted STAT3 protein Tyr705 phosphorylation peptide and application thereof | |
EP2915543B1 (en) | Polypeptides derived from Enterococcus and their use for vaccination and the generation of therapeutic antibodies | |
HOUSTON et al. | Sommaire du brevet 2190494 | |
WO2004104044A1 (en) | Process for producing antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |